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Synthetic lethal genetic interactions are re-emerging as an important con-
cept in the post-genomics era due to their potential for use in precision
medicine against cancers. Synthetic lethal drug design exploits the func-
tional redundancy of genes disrupted in cancers (including tumour suppres-
sors) to develop specific treatments against them. CDH1, which encodes
E-cadherin, is a tumour supressor gene with loss of function in breast and
stomach cancers. Experimental screens have identified candidate synthetic
lethal interactions with CDH1, which can be further supported with bioin-
formatics analysis. Furthermore, gene expression data enables investigation
of synthetic lethal pathways and the structure of synthetic lethal genes.
Methods
A computational methodology, the Synthetic Lethal Prediction Tool (SLIPT)
was developed to detect synthetic lethal interactions in gene expression
data. The application of this methodology is demonstrated on interactions
with CDH1 in breast and stomach cancer data from The Cancer Genome
Atlas (TCGA) project. Synthetic lethal genes and pathways were fur-
ther investigated with unsupervised clustering, gene set over-representation
analysis, metagenes, and permutation resampling. In particular, analyses
focused on comparing SLIPT gene candidates to an experimental short in-
terfering RNA (siRNA) screen. Network analysis methods were applied to
the most supported pathways to test for pathway structure between syn-
thetic lethal candidates. Simulation and modelling was used to assess the
statistical performance of SLIPT, including simulated data with correlation
structures from graph structures.
iii
Results
Many candidate synthetic lethal partners of CDH1 were detected in TCGA
breast cancer. These genes clustered into several distinct groups, with dis-
tinct biological functions and elevated expression in different clinical sub-
types. While the number of genes detected by both SLIPT and siRNA was
not significant, these contained significantly enriched pathways. In particu-
lar, Gαi signalling, cytoplasmic microfibres, and extracellular fibrin clotting
were robustly supported by both approaches, which is consistent with the
known cytoskeletal and cell signalling roles of E-cadherin. Many of these
pathways were replicated in stomach cancer data. The pathways supported
only by SLIPT included regulation of immune signalling and translation,
which were not expected to be detected in an isogenic cell line model but
are still candidates for further investigation.
Synthetic lethal candidates detected by SLIPT and siRNA were compared
within the graph structures of the candidate synthetic lethal pathways.
SLIPT genes had lower centrality and were consistently upstream of siRNA
candidates, specifically in the Gαi signalling pathway.
A statistical model of synthetic lethality was used to simulate gene ex-
pression data with known synthetic lethal partners for a gene. The SLIPT
methodology had high statistical performance when detecting few synthetic
lethal partners, which diminished with more synthetic lethal partners or
lower sample size. The SLIPT methodology performed better than Pear-
son correlation or the χ2-test. In particular, it performed well with high
specificity for datasets containing thousands of genes, or genes positively
correlated with the query gene (as expected to occur in gene expression
data). SLIPT was robust across correlation structures, including those de-
rived from complex pathway structures, and often distinguished synthetic
lethal genes from those positively or negatively correlated with them.
Thus this thesis has developed, evaluated, and applied a bioinformatics
approach for the discovery of synthetic lethal genes from gene expression
data. This approach has been demonstrated to detect biologically informa-
tive and clinically relevant candidate synthetic lethal partners for CDH1 in
breast and stomach cancers.
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Chapter 1
Introduction and Literature Review
This thesis presents research into genetic interactions using genomics data and bioin-
formatics approaches. Chapter 1 introduces recent developments in genomics and
bioinformatics, particularly in their application to cancer research. Studies of syn-
thetic lethal interactions, which have fundamental importance in genetics in model
organisms and renewed relevance in cancer biology specifically, will be discussed and
reviewed in detail. A bioinformatic approach to synthetic lethal interactions enables
a wider exploration of the function of genes and proteins in cancer cells, in contrast
with candidate gene and experimental screening approaches. Synthetic lethal drug
design aims to develop treatments with specificity against loss of function mutations
in tumour suppressor genes, such as CDH1 (which encodes E-cadherin) and was the
focus of the analysis in this thesis. The role of CDH1 in cellular and cancer biology is
therefore also briefly reviewed.
1.1 Cancer Research in the Post-Genomic Era
Genomic technologies which capture molecular data from genes throughout the genome
are expected to significantly impact on the clinical treatment of cancers, along with
wider applications of genetics (Goodwin et al., 2016; Roychowdhury and Chinnaiyan,
2016). These technologies enable focused genetic investigations on candidate genes
selected from bioinformatic analyses of genomic data. Facilitated by rapidly developing
technologies, large-scale projects have investigated populations (1000 Genomes, 2010),
cancers (Dickson, 1999; Zhang et al., 2011), and functional genomics (Kawai et al.,
2001; ENCODE, 2004). However, genomic technologies such as microarrays or genome
sequencing have yet to be widely adopted in healthcare or oncology (Roychowdhury
and Chinnaiyan, 2016; Waldron, 2016). Bioinformatics analysis for interpretation of
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genomic data is one of the main approaches to address this disparity (Goodwin et al.,
2016). Here, I outline the cancer genomics projects and findings which have led to the
availability of genomics data used in this thesis, and recent findings in cancer research
which demonstrate potential applications of using this data.
1.1.1 Cancer is a Global Health Issue
Cancers are the second leading cause of death globally (WHO, 2017), with an estimated
annual incidence of 14.1 million cases and annual mortality of 8.2 million people (Ferlay
et al., 2015). Breast and stomach cancers are among the most prevalent cancers. Breast
cancer is the most common cancer in women and has an estimated annual incidence
of 1.6 million cases and mortality of 520,000 people. Stomach cancer has an estimated
annual incidence of 950,000 cases and a mortality of 723,000 people. Cancer is also a
major health concern here in New Zealand, with 19,100 people (including 2500 cases
of breast cancer and 370 cases of stomach cancer) diagnosed annually (Hanna, 2003).
New Zealand has among the highest incidence (age-standardised per capita) of cancer
in the world (Ferlay et al., 2015).
While environmental factors often play a role, genetics is an important contribu-
tor to cancer risk. Most cancers occur more frequently with age and family history.
Cancers arise from dysregulated cellular growth or differentiation. These can occur
through genetic mutations or alterations in gene regulation or expression which gen-
erally accumulate as the disease develops. Therefore, early diagnosis is important to
ensure patient survival and quality of life. Identification of patients with genetic vari-
ants or family histories at a high-risk of particular cancers is an important health issue.
These high-risk individuals are regularly monitored for some cancers and are sometimes
offered preventative surgery (Guilford et al., 2010; Scheuer et al., 2002).
Chemotherapy is a treatment for many advanced stage cancers, designed to inhibit
rapidly growing cells. However, this approach often has severe adverse effects, a narrow
therapeutic window, and is not suitable for chemopreventative application in many
cases (Kaelin, Jr, 2009). Patients at high-risk of cancers are offered surveillence and
preventative surgery but these approaches are not completely effective at preventing
cancers and can severely impact on quality of life (Guilford et al., 2010). Alternative
chemoprevention and treatment strategies based on molecular biology and other fields
are being investigated, including targeted molecular therapeutics (Bozovic-Spasojevic
et al., 2012).
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1.1.1.1 The Genetics and Molecular Biology of Cancers
Cancers involve dysregulation of genes, including somatic and hereditary mutations,
which may predispose individuals to high-risk cancers and familial cancer syndromes
(American Cancer Society, 2017; Guilford et al., 1998; Stratton et al., 2009; NCI, 2015;
Vogelstein et al., 2013). The occurrence of somatic mutations throughout our lifespan
increases the risk of cancer with age. An association of cancer incidence with the stem
cell divisions in which mutations could occur across tissue types, suggests that cancers
may be inseparably coupled with aging (Tomasetti and Vogelstein, 2015).
Hanahan and Weinberg (2000) proposed the “hallmarks of cancer”, molecular and
cellular traits shared across cancers. These form the basis of a rational approach to
categorising the complex changes that occur in cancer. These traits include limitless
replication potential, signals for indefinite growth, and invasive or metastatic capabil-
ities. Cancers also evade apoptosis and the immune system, and sustain angiogenesis
and energy metabolism (Hanahan and Weinberg, 2011). To achieve this, cancer cells
change their genomes and the tumour microenvironment. Genomic instability has a
role in the survival and proliferation of cancer cells and the progression of disease, as
these malignant characteristics are acquired. Identifying the genetic mechanisms in-
volved in the acquisition of these traits is important for understanding and effectively
inhibiting cancer.
1.1.2 The Genomics Revolution in Cancer Research
Genomic technologies have transformed genetics research, including the study of health
and disease (Goodwin et al., 2016; Lander, 2011). Genomics enables systematic, unbi-
ased studies across all of the genes in the genome. Cancer genomics investigations have
been widely applied to different tissues across molecular profiles (Bamford et al., 2004;
Weinstein et al., 2013; Zhang et al., 2011). Genome sequencing technologies continue
to improve and become feasible in a wider range of applications.
Genomics has been used in many investigations (Goodwin et al., 2016) but relatively
few of the potential applications in healthcare have been realised yet (Roychowdhury
and Chinnaiyan, 2016; Tran et al., 2012). Cancer genomics, in particular, could have
numerous benefits across diagnostics, prognosis, management, and treatment (Roy-
chowdhury and Chinnaiyan, 2016). For instance, patient outcome and quality of life
could be more improved by more precise diagnosis of tumour subtype or tailored treat-
ment based on molecular diagnosis, including targeted therapeutics with fewer adverse
effects (Kaelin, Jr, 2005; O’Neil et al., 2017). While direct impact of genomics on the
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clinic has been limited thus far, the cancer genes and therapeutic targets identified
have begun to be introduced in the clinic (Stratton et al., 2009).
1.1.2.1 High-Throughput Technologies
These investigations have been enabled by recent developments in genomics technolo-
gies, including microarrays and more recently “Next-Generation Sequencing” (NGS),
which can both be used to generate high-throughput expression data. Microarray are
a high-throughput molecular technique, reducing the cost, time, and labour required
to study genes at the “genome” scale (Schena, 1996). Microarray can detect geno-
type or expression across many genes, making it feasible to perform on a statistically
informative number of samples. Microarray are manufactured with probes which mea-
sure binding of nucleotides which either detect the presence of a sequence such as a
single nucleotide polymorphism (SNP) or quantify sequences for DNA copy number,
gene expression, or DNA CpG methylation. In addition to being more versatile, with
higher-throughput than polymerase chain reaction (PCR) based techniques, microar-
rays are considered cost-effective, particularly when scaled up to a large number of
probes.
The introduction of massively parallel sequencing technologies has further expanded
high-throughput molecular studies and the availability of genomics data. NGS enables
rapid de novo genome and transcriptome sequencing, in addition to quantifying gene
expression (Goodwin et al., 2016). However, the cost of sequencing for gene expression
studies is still considerably higher than a microarray study, limiting feasible sample
sizes, and NGS studies have large compute requirements to handle the raw data. In
many cases, the benefits of NGS technologies outweigh the additional cost. NGS tech-
nologies have the advantage of greater potential accuracy and sensitivity than microar-
rays. NGS has a wider dynamic range than microarrays and are not limited to genes
with an already characterised sequence or functions (Tarazona et al., 2011).
NGS is highly adaptable to different applications, including DNA sequencing (ob-
taining the base sequence for the exome or whole genome) or RNA-Seq (Goodwin
et al., 2016; Tran et al., 2012; Waldron, 2016). RNA-Seq of the transcriptome is a
common adaptation where RNA is reverse transcribed and sequenced from the result-
ing complementary DNA (cDNA). This is utilised to quantify the levels of RNA and
identify which regions of DNA are expressed. Subsets of the nucleic acid may be ex-
tracted for sequencing such as the coding regions of DNA (for the “exome”), mRNA, or
micro RNA. These “’omics” technologies (Roychowdhury and Chinnaiyan, 2016; Wal-
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dron, 2016) are applicable across a wide range of biomolecules to generate “molecular
profiles” of a cell or sample (Perou et al., 2000).
NGS technologies continue to be refined (Goodwin et al., 2016) with Illumina (the
platform used to generate data in this project) and competitors continuing to im-
prove products and decrease costs. As such, RNA-Seq for examining transcriptomes
or expression studies is a growing field and will continue to be generated for a range
of samples. The technology may yet improve (Goodwin et al., 2016) with develop-
ments in speed and accuracy (e.g., semi-conductor platforms) or long reads, single
molecule sequences (e.g., Pacific Biosciences, Oxford Nanopore, and Quantum Biosys-
tems Japan). Due to the benefits of sequencing and the availability of public data, this
thesis has focused on gene expression data generated by RNA-Seq. RNA-Seq data is
publicly available from large-scale cancer genomics projects and the methods anlaysis
developed for RNA-Seq data could be applied to future genomics technologies.
1.1.2.2 Bioinformatics and Genomic Data
Genomic technologies have generated data at a scale which requires computational,
mathematical, and statistical expertise to handle this data effectively (Markowetz,
2017; Tran et al., 2012), in addition to an understanding of the biological context and
research questions. The interdisciplinary field of “bioinformatics”, which draws upon
these skills, focuses specifically on making inferences from genomics data or developing
the tools to do so. Gene expression analysis is the focus of many bioinformatics research
groups, drawing upon statistical approaches to appropriately handle microarray and
RNA-Seq data along with making biological inferences from a large number of statistical
tests.
Bioinformatics is often confused with the broader field “computational biology”
(Markowetz, 2017), which focuses on modelling and simulating aspects of biology and
is not necessarily limited to genetics or data analysis. In practice, many researchers
identify with both bioinformatics and computational biology or use techniques in both
fields. This thesis uses many of these approaches, mainly in bioinformatics, to address
biological research questions pertaining to synthetic lethal interactions.
1.1.3 Genomics Projects
Genomic projects have also been applied to various organisms, functional genetics
(Kawai et al., 2001; ENCODE, 2004), and human populations focusing on variability
between individuals and health or disease risk (HapMap, 2003; 1000 Genomes, 2010).
International projects and consortiums have begun to release data gathered using com-
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mon agreed upon protocols across laboratories. These include many genomics projects
including cancer genomics projects discussed below. The quality, consistency, and
accessibility of these international projects is appealing, particularly for gene expres-
sion datasets where the more recent, larger projects have switched from microarray to
RNA-Seq technologies.
1.1.3.1 The Cancer Genome Project
The cancer genome project was among the first genomics investigations into cancer
(Dickson, 1999), using the human genome sequence (Collins and Barker, 2007; Lan-
der et al., 2001), the cancer research literature, and sequencing the genes of cancers
themselves. The main aim of the Cancer Genomes Project was to discover “cancer
genes”, which are frequently mutated in cancers by comparing cancer and normal
tissue samples. These include both “oncogenes” (which drive cancer growth) and “tu-
mour suppressors” (which protect against cancers) that are functionally activated and
inactivated in cancers respectively. This project is ongoing and continues to main-
tain the Catalogue Of Somatic Mutations In Cancer (COSMIC), a database of cancer
genes (COSMIC, 2016). It includes 1,257,487 samples with 4,175,8787 gene mutations
curated from 23,870 publications, including 29,112 whole genomes (COSMIC, 2016).
1.1.3.2 The Cancer Genome Atlas Project
The Cancer Genome Atlas (TCGA) network initially set out to demonstrate utility in a
pilot project on brain (McLendon et al., 2008), ovarian (Bell et al., 2011), and squamous
cell lung (Hammerman et al., 2012) cancers. The project then expanded, aiming to
analyse 500 samples each for 20-25 tumour tissue types. TCGA has since exceeded that
goal, with data available for 33 cancer types including 10 “rare” cancers, a total of over
10,000 samples (TCGA, 2017). The TCGA projects set out to generate a molecular
“profile” of the tumour (and some matched normal tissue) samples: genotype, somatic
mutations, gene expression, micro RNA, DNA copy number, DNA methylation, and
protein levels. Data which cannot be used to identify the patients are publicly available
The Cancer Genome Atlas pilot projects (Bell et al., 2011; Hammerman et al.,
2012; McLendon et al., 2008) serve to demonstrate the power of applying genomic
technologies to cancer research at such a scale. TCGA demonstrated the potential
discovery of the molecular basis of cancer with these tissues, including describing the
recurrently mutated genes in each cancer, identifying differentially methylated regions,
and proposing transcriptional subtypes for ovarian cancers. The molecular aberrations
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in each cancer represent potential therapeutic targets in some cases and some were
shown to have an impact on patient survival.
The TCGA breast cancer analysis (Koboldt et al., 2012) consisted of 802 samples
with exomes, copy number variants, RPPA protein quantification, and DNA methyla-
tion, mRNA, and micro RNA arrays, with 97 whole genomes sequenced. Four main
molecular classes were identified to subtype the samples, despite considerable hetero-
geneity between samples. Recurrent mutations across more than 10% of samples were
identified in the TP53, PIK3CA, and GATA3 genes. In a further analysis of 817
breast cancer samples including 127 invasive lobular breast and 88 mixed type samples
(Ciriello et al., 2015), 3 molecular subtypes of lobular breast cancer were identified.
Lobular breast cancer was also characterised by recurrent mutations in the CDH1,
PTEN, TBX2, and FOXA1 genes.
TCGA stomach cancer analysis of 295 samples (Bass et al., 2014) identified molecu-
lar subtypes of stomach cancers characterised by: the Epstein-Barr virus, microsatellite
instability, genomic instability, and chromosomal instability. Abberrations in PD-L1,
PIK3CA, and JAK2 were also identified in stomach cancers which may present thera-
peutic targets.
TCGA has identified various genes as recurrent, driver mutations across cancer
types which are likely to have a role in driving the development of these cancers and
present a molecular target that could be applied across tissue types. In addition to
disregarding the tissue-based distinction between colon and rectal cancers based on
molecular similarlity (Muzny et al., 2012), TCGA has observed differences within tu-
mour types and proposed molecular subtyping for breast, clear cell renal, papillary
renal, stomach, skin, bladder, and prostate cancers (Abeshouse et al., 2015; Akbani
et al., 2015; Bass et al., 2014; Ciriello et al., 2015; Creighton et al., 2013; Hammerman
et al., 2012; Koboldt et al., 2012; Linehan et al., 2016; Muzny et al., 2012; Weinstein
et al., 2014).
The “Pan Cancer” TCGA project (Hoadley et al., 2014; Weinstein et al., 2013)
analysed 3527 samples across 12 tissue types. This project performed a comprehensive
analysis of molecular data across cancer types to identify molecular simliarities and
differences. These included recurrent TP53, BRCA1 and BRCA2 mutations, HER2
over-expression, and microsatellite instability across cancer types. The Pan Cancer
project has identified 11 molecular subtypes across these tissues, with only 5 of these
corresponding to tissue cancer types due to molecular similarities shared across cancer
types (Hoadley et al., 2014) . The project further supports the genomic stratification
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of cancer patients, demonstrated in breast cancer (Parker et al., 2009; Pereira et al.,
2016; Perou et al., 2000), and there being core molecular characteristics across cancers
(Hanahan and Weinberg, 2000, 2011).
While these findings contribute to further understanding cancer biology within and
across tissue types, the main objective of such projects is to publicly release data to
analyse in future investigations (McLendon et al., 2008; TCGA, 2017; Weinstein et al.,
2013). These serve as a vast resource of common and rare cancer types and are publicly
available for further analysis (cBioPortal, 2017; TCGA, 2017; Zhang et al., 2011).
1.1.4 Genomic Cancer Medicine
Cancer genomics has substantial potential for impacts in cancer medicine: from diag-
nosis to treatment (Roychowdhury and Chinnaiyan, 2016; Tran et al., 2012). Beyond
direct use of genomes or RNA-Seq in clinical laboratories to more precisely diagnose
cancers based on molecular features, genomic studies also generate prognostic biomark-
ers to better predict patient outcomes and inform development of novel treatments such
as targeted therapeutics. These are likely to have a more immediate patient benefit
considering the cost of routine genomes sequencing for diagnostics.
1.1.4.1 Cancer Genes and Driver Mutations
There are two main classes of “cancer genes” (Futreal et al., 2001). Oncogenes are acti-
vated in cancers either by gain of function mutations in proto-oncogenes, amplification
of DNA, or elevated gene expression. Their normal functions are typically to regulate
stem cells or to promote cellular growth, with recurrent mutations that are typically
concentrated to particular gene regions (“hotspots”). Conversely, tumour suppressor
genes are those inactivated in cancer either by loss of function mutations, deletion of
DNA copies, or reduced gene expression, including hypermethylation. Their normal
functions are typically to regulate cell division (e.g., TP53 ), DNA repair (e.g., BRCA1
and BRCA2 ), and cell signalling (e.g., ESR1, PIK3CA and PTEN ). Detecting these
cancer genes has accelerated with genomic technologies, as demonstrated by COSMIC
and TCGA (COSMIC, 2016; Weinstein et al., 2013). Recurrent mutations, DNA copy
number variants, differential gene expression, or differential DNA methylation are all
indicative of cancer genes (Mattison et al., 2009), which can be detected in genomics
data (Pereira et al., 2016; Weinstein et al., 2013).
Distinguishing important “driver” mutations in cancer genes from “passenger mu-
tation” mutations is challenging due to patient variation, tumour heterogeneity, and
genomic instability producing many variant gene sequences (Stratton et al., 2009; Tran
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et al., 2012). Driver mutations can be identified by whether they co-occur or are mutu-
ally exclusive with mutations in other genes in cancers, are recurrently mutated across a
significant proportion of samples for a specific tissue type, or if mutations are recurrent
across different cancer tissue types (cBioPortal, 2017; Pereira et al., 2016; COSMIC,
2016; Weinstein et al., 2013; Zhang et al., 2011). Approximately 140 driver mutations
have been identified, including many novel genes in particular cancers from genomic
studies, with 2–8 typically occurring in each tumour usually affecting cell fate, survival,
or genomes maintenance (Vogelstein et al., 2013). There remains a need to translate
the identification of many cancer genes and driver mutations to patient benefit by
repurposing or designing of therapeutic interventions against these molecular targets.
1.1.4.2 Precision Cancer Medicine
The importance of genomics is emphasised in translational cancer research in contrast
with current strategies of healthcare based on what works well for the majority of the
population. Cancers could eventually be treated by their genomic features (Benstead-
Hume et al., 2017; Roychowdhury and Chinnaiyan, 2016), particularly grouping pa-
tients by the mutation, expression, or DNA methylation profiles of their cancers, which
is already done in part (Parker et al., 2009). Identifying actionable molecular targets
is a key aspect of “precision medicine”, the rationale to target molecular subtypes with
separate treatment strategies (Glaire et al., 2017). To this end many driver mutations
and gene expression signatures for distinguishing cancers have been identified. Some
oncogenic driver mutations have effective pharmacological inhibitors designed against
them (such as vemurafenib against BRAFV600E and herceptin against ERRB2 /HER2
but there remain many cancer genes and mutations, particularly tumour suppressors,
for which there is not yet a targeted therapy.
1.1.4.3 Molecular Diagnostics and Pan-Cancer Medicine
Molecular features such as mutations or gene expression signatures have been proposed
to diagnose tumour subtypes. In breast cancer, several distinct “intrinsic subtypes”
have been identified, distinguished by molecular mechanisms, with differences in ma-
lignancy and patient outcome (Parker et al., 2009; Perou et al., 2000). Conversely,
common molecular mechanisms may be shared between cancers across tissue types
as discovered by the “Pan Cancer” TCGA project, which combined molecular pro-
files across tissue types (Weinstein et al., 2013). Molecular subtypes could feasibly
be included in clinical testing as a panel of biomarkers for diagnosis, monitoring drug
response, or predicting risk of recurrence. As these molecular subtypes and genetic
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aberrations specific to cancers have been identified, there is an increasingly clear need
for further development of treatments that target them.
Gene expression can be used to characterise breast cancers. The “intrinsic sub-
types” identified were characterised by estrogen receptor, HER2, and basal, epithelial
signalling (Perou et al., 2000). The expression profiles were similar across independent
samples of the same tumour or the same patient and therefore represent the molecular
state of a tumour The molecular intrinsic subtypes “luminal A”, “luminal B”, “HER2-
enriched”, “basal-like”, and “normal-like” have been replicated across microarray stud-
ies (Hu et al., 2006), with their relevance to prognosis demonstrated, and a 50-gene
subtype predictor developed (Parker et al., 2009; Sørlie et al., 2001). Despite specific
differences in subtyping, there is widespread agreement that distinguishing luminal,
HER2-enriched, and triple negative tumours has prognostic importance for patients
(Dai et al., 2015). The “Pan Cancer” The Cancer Genome Atlas project (discussed in
Section 1.1.3.2) demonstrates the importance of molecular similarities and differences
between cancers across cancer tissue types (Weinstein et al., 2013).
Gatza et al. (2010) used gene signatures for 18 cellular pathways in breast cancer
to define subtypes with distinct molecular pathway activity. A “metagene” is a mea-
sure of pathway activation (derived from eigenvectors or principal components) which
gives a consistent signal of gene expression (Anjomshoaa et al., 2008; Huang et al.,
2003; Nagalla et al., 2013). Unsupervised hierarchical clustering defined subtypes with
common pathway activity, despite variation in mutations. These intrinsic subtypes
and provide finer molecular stratification with a functional basis (Gatza et al., 2014;
Parker et al., 2009). The subtypes with shared pathway activity have similar molecular
characteristics (e.g., DNA copy number) and clinical properties including prognosis.
1.1.4.4 Targeted Therapeutics and Pharmacogenomics
Targeted therapies with specificity against a molecular target are examples of precision
cancer medicine. Molecular targets can be tested in laboratory conditions with RNA
interference (RNAi) or pharmacological agents (Fece de la Cruz et al., 2015). Identi-
fication of molecular targets is important for developing novel anti-cancer treatments
along with validation and drug testing. For oncogenic mutations, the recurrent mu-
tant variant or over-expressed gene can be directly inhibited, however, oncogenes with
high homology to other genes or tumour suppressor genes are not amenable to direct
targeting (Kaelin, Jr, 2009). Targeted anticancer therapeutics can exploit complex in-
teractions to distinguish normal and cancerous cells which may benefit from studies of
gene regulation or interaction networks (Hopkins, 2008). Targeted therapeutics have
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already been successfully applied as monoclonal antibodies against oncogenes, such as
HER2 in breast cancer (Miles, 2001).
1.1.5 Systems and Network Biology
Driver mutations in oncogenes and tumour suppressor genes do not occur in isolation.
Genetic interactions, regulatory and cellular signalling, and metabolic reactions are
inter-related and may each be perturbed by aberrations in gene function occurring in
cancers. These relationships can be represented by biological networks of connected
pairs of genes with a relationship. Due to the complexity of a cell, these molecu-
lar networks are very large, consisting of thousands of nodes comprised by genes or
proteins.
The properties of large networks were first studied by constructing random networks
by randomly linking a fixed number of nodes (Erdős and Rényi, 1959, 1960). Despite
the random nature of these networks, properties such as their connectivity were well
characterised. The vertex degree (number of partners for each node) of their random
networks followed a Poisson distribution, however this property does not hold in nature.
Thus natural networks are non-random or not formed in this way (Barabási and Oltvai,
2004).
This work formed the foundation for studying complex networks (van Steen, 2010),
which model features of observed networks not found in Erdő and Rényi‘s random
networks (Erdős and Rényi, 1959, 1960). The small world property, made popular by
findings in social networks (Travers and Milgram, 1969), is the remarkably short path
lengths between any nodes in a network. A small world network is well-connected
with a characteristic path length (the average length of shortest paths between all
pairs of nodes) proportional to the logarithm of the number of nodes. Watts and
Strogatz (1998) developed a model of random rewiring of a regular network to construct
random networks with the small world property and a high clustering coefficient. While
these properties are more representative of networks occurring in nature, their model
was limited by the degree distribution which converges to a Poisson distribution as
it is rewired (Barrat and Weigt, 2000). The vertex degree distribution of naturally
occurring networks often follows a power law distribution with most nodes having far
fewer connections than average and a small subset of highly connected network ‘hubs’
(Barabási and Albert, 1999).
Barabási and Albert (1999) constructed a network model in an entirely different way
to randomly generate scale-free networks which have a power law degree distribution.
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They constructed random networks by preferential attachment, modelling growth of a
network by sequentially adding nodes with links to existing nodes. The scale-free nature
of the random networks was ensured by adding new nodes with an increasing probability
of attachment to an existing node if it had a higher degree. These networks successfully
captured the scale-free nature of many observed networks with short characteristic path
length and low eccentricity resulting in super small worlds (Barabási and Albert, 1999).
High-throughput technologies such as siRNA screens, two-hybrid screens, microar-
rays and massively parallel sequencing have generated genome-scale data and enabled
analysis of biological networks (Barabási and Oltvai, 2004; Boone et al., 2007; Good-
win et al., 2016). Molecular networks are biological networks consisting of biological
molecules including genes, transcripts (with non-coding and micro RNAs), or pro-
teins related by known interactions and gene regulatory or metabolic pathways. Many
types of molecular networks can be constructed, depending on the biological appli-
cation (Barabási and Oltvai, 2004). Synthetic genetic interactions occurring between
mutations in different genes are relatively unexplored within molecular networks and
may lead to better understanding of the role of gene functions in cellular function and
disease. High-throughput screens in humans, mammals, and non-model organisms are
costly and labour-intensive (Fece de la Cruz et al., 2015). Computational approaches
with effective predictive models are therefore a more feasible alternative to study the
connectivity of a biological network in a complex metazoan cell at the genome-scale.
1.2 Synthetic Lethal Cancer Medicine
Synthetic lethality has vast potential to improve cancer medicine by expanding appli-
cation of targeted therapeutics to include inactivation of tumour suppressors and genes
that are difficult to target directly. Synthetic lethal interactions are also studied for
gene function and drug mode-of-action in model organisms. This Section introduces the
concept of synthetic lethality as it was originally conceived and how it has been adopted
conceptually in cancer research. Detecting these interactions at scale and interpreting
them is the focus of this thesis, hence I start with an overview of the concepts involved,
initial work on the interaction, and the rationale for applications to cancer. Specific
investigations into synthetic lethality in cancer, detection by experimental screening,
and prediction by computational analysis will then be reviewed.
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1.2.1 Synthetic Lethal Genetic Interactions
Genetic interactions are a core concept of molecular biology, discovered among earliest
investigations of Mendelian genetics, and have received revived interest with new tech-
nologies and potential applications. Biological epistasis is the effect of an allele at one
locus “masking” the phenotype of another locus (Bateson and Mendel, 1909). Statisti-
cal epistasis is where there is significant disparity between the observed and expected
phenotype of a double mutant, compared to the respective phenotypes of single mutant
and the wild-type (Fisher, 1919). Fisher’s definition lends itself to quantitative traits
and more broadly encompasses synthetic genetic interactions (SGIs). These have be-
come popular for studies in yeast genetics and cancer drug design (Boone et al., 2007;
Kaelin, Jr, 2005).
SGIs are substantial deviations of growth or viability from the expected null
mutant phenotype (of an organism or cell) assuming additive (deleterious) effects of
the single mutant. The double mutant does not necessarily have either of the single
mutant phenotypes (as shown for cellular growth phenotypes in Figure 1.1). Most
SGIs are more viable than either single mutant or less viable than the expected double
mutant. Mutations are “synergistic” in negative SGI with more deviation from the
wild-type than expected. Formally, “synthetic sick” (SSL) and “synthetic lethal” (SL)
interactions are negative SGIs giving growth inhibition and complete inviability re-
spectively. In cancer research, synthetic lethality more broadly describes any negative
SGI with specific inhibition of a mutant cell, including SSL interactions. Mutations
are “alleviating” in positive SGI with less deviation from the wild-type than expected.
For viability, “suppression” (SS) and “rescue” (SR) are positive SGIs giving at least
partial restoration of wild-type growth from single mutant with growth impairment
and lethal phenotypes respectively. Negative SGIs were markedly more common than
positive SGIs in a number of studies in model systems (Boucher and Jenna, 2013; Tong
et al., 2004).
1.2.2 Synthetic Lethal Concepts in Genetics
Synthetic lethal genes are generally regarded to arise due to functional redundancy
(Boone et al., 2007). Due to the functional level of SGIs, synthetic lethal genes do not
need to directly interact, nor be expressed in the same cell or at the same developmental
stage: serving related functions is sufficient to affect cell (or organism) viability and
be relevant to drug-mode-of-action cancer biology. Combined loss of genes performing


















































0.7 x 0.5 = 0.35
Figure 1.1: Synthetic genetic interactions. Impact of various negative and positive
SGIs: negative interactions involve deleterious (sick) or inviable (lethal) phenotypes whereas
positive interactions involve restoring viability by masking or suppressing the other mutation
or complete rescue of thewild-type phenotype. Figure adapted from (Costanzo et al., 2011)
concerning growth viability fitness in yeast.
gene pairs are therefore pairwise essential with “induced essentiality”: each synthetic
lethal gene becomes essential to the cell upon loss of the other (Ashworth et al., 2011;
Kaelin, Jr, 2005).
Since synthetic lethal gene partners can be affected by extracellular stimuli such as
chemicals, essentiality of synthetic lethal genes can be induced by the environment of
a cell. An environmental stress condition may inhibit one or the other synthetic lethal
gene, such as exposure to chemicals, in which case the synthetic lethal partner gene
is “conditionally essential” (Hillenmeyer, 2008). Thus the evolutionary rationale for
the abundance of SGIs (compared to the surprisingly low number of essential genes) in
Eukaryotic genomes can be attributed to genetic functional redundancy and network
robustness of a cell which are advantageous to survival.
Biological functions are typically performed by a pathway of genes (or their prod-
ucts). Synthetic lethal genes occur within the same biological pathway and between
them (Boone et al., 2007; Costanzo et al., 2010; Kelley and Ideker, 2005). Many genes
of the same pathway may be interchangable as synthetic lethal partners of a particular
gene. Therefore biological pathways can exhibit induced essentiality with loss of the
synthetic lethal partner gene and synthetic lethality may occur at pathway level or in
a gene regulation network.
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1.2.3 Synthetic Lethality in Model Systems
Genetic high-throughput screens have identified unexpected, functionally informative,
and clinically relevant synthetic lethal interactions. Synthetic lethal partners of genes
recurrently mutated in cancer or attributed to familial early-onset cancers are partic-
ularly important for their clinical applications (Lord et al., 2015). The interactions
between BRCA1 and BRCA2 with PARP1 in breast cancer (Bryant et al., 2005;
Farmer et al., 2005) have demonstrated that synthetic lethality can be applied to de-
velop specific treatments against cancers with few adverse effects (McLachlan et al.,
2016) as discussed in Section 1.2.5.
While screening presents an appealing strategy for synthetic lethal discovery, com-
putational approaches are becoming popular as an alternative or complement to ex-
perimental methods to overcome inherent bias and limitations of experimental screens.
An array of recently developed computational methods (Jerby-Arnon et al., 2014; Lu
et al., 2015; Tiong et al., 2014; Wang and Simon, 2013; Wappett, 2014) show the need
for synthetic lethal discovery in the fundamental genetics and translational cancer re-
search community. However, many existing computational methods are not suitable
for queries of genomic data for interacting partners of a particular gene, as (1) they
have been applied pairwise across the genomes, (2) they do not have software released
to apply the methodology, or (3) they lack statistical measures of error for further anal-
ysis. A robust prediction of gene interactions is an effective and practical approach at
a scale of the entire genome for ideal translational applications, analysis of biological
systems, and constructing functional gene networks.
1.2.3.1 Synthetic Lethal Pathways and Networks
SGIs are common in genomes, four-fold more interactions were detected with synthetic
gene array (SGA) mating screens than protein-protein interactions detected with yeast-
2-hybrid (Tong et al., 2004). The SGI network was scale-free and had a low average
shortest path length, as expected for a complex biological network (Barabási and Olt-
vai, 2004). Highly connected “hub” genes with the highest number of links (vertex
degree) are functionally important with many negative SGI hubs involved in cell cycle
regulation, and many positive SGI hubs involved in translation (Baryshnikova et al.,
2010b; Costanzo et al., 2010). Negative SGIs were far more common than positive
SGIs, with synthetic gene loss being more likely to be deleterious to cell than advan-
tageous, which indicates that synthetic lethality may be comparably easier to detect
than other SGIs.
15
Essential pathways are highly buffered, with five-fold more interactions than other
SGIs, consistent with strong selection for survival, as found with conditional and partial
mutations in essential genes (Davierwala et al., 2005). This SGI network had scale-free
topology and rarely shared interactions with the protein-protein interaction network.
These networks are related by an “orthogonal” relationship: shared partners in one
network tend to be themselves connected directly in the other network. Essential
genes were likely to have closely related functions, whereas non-essential networks were
relatively more inclined to have SGIs between distinct biological pathways.
1.2.3.2 Evolution of Synthetic Lethality
There is poor conservation of specific SGIs between S. cerevisiae and S. pombe with
29% of the interactions tested in both distantly related species being conserved be-
tween them (Dixon et al., 2008). The remaining interactions show high species-specific
differences, however, many of the species-specific interactions were still conserved be-
tween biological pathways, protein complexes, or protein-protein interaction modules.
Similarly, conservation of pathway redundancy was also found between Eukaryotes (S.
cerevisiae) and prokaryotes (E. coli) (Butland et al., 2008). Negative SGIs were more
likely to be conserved between biological pathways, whereas positive SGIs were more
likely to be conserved within a pathway or protein complex (Roguev et al., 2008).
A modest 5% of interactions were conserved between unicellular (S. cerevisiae) and
multicellular (C. elegans) organisms. However, the nematode SGI network had similar
scale-free topology and modularity despite differences in methodology: metazoan syn-
thetic lethal screens with RNA interference (RNAi) are incomplete knockouts, whereas
screening null mutations is feasible in yeast (Bussey et al., 2006). The nematode SGI
screen identified network hubs with important interactions to orthologues of known
human disease genes (Lehner et al., 2006). Despite the lack of direct conservation of
SGIs between yeasts and nematode worms, genetic redundancy was consistent with an
“induced essentiality” model of SGIs where gene functions are conserved with network
restructuring over evolutionary change (Tischler et al., 2008).
While nematode models are more closely related to human cells which are also
screened with RNAi, cancer cells can present growth and viability phenotypes more
comparable to yeast models. Therefore findings from both SGA and RNAi models
are relevant to understanding human and cancer cells. RNAi has also been applied to
human and mouse cancer cells with short interfering RNA (siRNA) in cell culture and
genetic screening experiments. These findings suggest that SGI network “rewiring”
is a concern for identifying specific synthetic lethal interactions in cancer as specific
16
synthetic lethal genes may vary between genetic backgrounds. Thus it is expected at
a pathway approach will be more robust in the context of evolution, patient variation,
tumour heterogeneity, or disease progression.
1.2.4 Synthetic Lethality in Cancer
Loss of function occurs in many genes in cancers, including tumour suppressors, yet
few interventions target such mutations compared to targeted therapies for gain of
function mutation in oncogenes (Kaelin, Jr, 2005). Synthetic lethality is a powerful
design strategy for therapies selective against loss of gene function with potential for
application against a range of genes and diseases (Fece de la Cruz et al., 2015; Kaelin,
Jr, 2009). When genes are disrupted in cancers, the induced essentiality of synthetic
lethal partners presents a vulnerability that may be exploited for anti-cancer therapy.
Since synthetic lethality affects cellular viability by indirect functional relationships
between genes, it is suitable for indirectly targeting mutations in cancers via synthetic
lethal partners with targeted therapeutics. These treatments could be highly specific
against cancer cells (with the target mutation) over non-cancer cells (with a functional
compensating gene). Analogous to “oncogene addiction”, where cancer cells adapt
to particular oncogenic growth signals and become reliant on them to remain viable
(Luo et al., 2009; Weinstein, 2000), synthetic lethal partners of inactivated tumour
suppressors are required to maintain cancer cell viability and proliferation. As such
cancers are subject to “non-oncogene addiction” and these genes are feasible anti-cancer
drug targets.
The synthetic lethal approach to cancer medicine is most amenable to loss of func-
tion mutations in tumour suppressor genes, where it would feasibly be effective against
any loss of function mutation across the tumour suppressor with a viable synthetic
lethal partner gene (as shown in Figure 1.2). However, the approach may also be suit-
able for cases where cancer cells have mutations where the normal function of the gene
is disrupted such as if it were over-expressed (“synthetic dosage lethality”) or if an
oncogenic mutation interfered with the function of the proto-oncogene. Thus synthetic
lethality makes it feasible to target a range of cancer-specific mutations with targeted
therapeutic, including inactivated tumour suppressor genes. synthetic lethality may
also enable distinguishing highly homologous oncogenes by functional differences by
targeting their synthetic lethal partners.
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Figure 1.2: Synthetic lethality in cancer. Rationale of exploiting synthetic lethality for
specificity against a tumour suppressor gene (e.g., CDH1 ) while other cells are spared under
the inhibition of a partner gene.
1.2.5 Clinical Impact of Synthetic Lethality in Cancer
The synthetic lethal interaction of BRCA1 or BRCA2 with PARP1 in breast cancer
is an example of how gene interactions are important in cancer and these discovery
of these interactions has lead to translation to the clinic. These genetic interactions
enable specific targeting of mutations in BRCA1 or BRCA2 tumour suppressor genes
with PARP inhibitors by inducing synthetic lethality in breast cancer (Farmer et al.,
2005). PARP inhibitors were one of the first targeted therapeutic against a tumour
suppressor mutation to exhibit success in clinical trials.
BRCA1 /BRCA2 and PARP1 genes demonstrate the application of the synthetic
lethal approach to cancer therapy (Ashworth, 2008; Kaelin, Jr, 2005). BRCA1 and
BRCA2 are homologous DNA repair genes, widely known as tumour suppressors; mu-
tation carriers have substantially increased risk of breast (risk by age 70 of 57% for
BRCA1 and 59% for BRCA2 ) and ovarian (risk by age 70 of 40% for BRCA1 and 18%
for BRCA2 ) cancers (Chen and Parmigiani, 2007). The BRCA1 or BRCA2 genes,
which usually repair DNA or destroy the cell if it cannot be repaired, have inactivating
somatic mutations in some familial and sporadic cancers. Poly-ADP-ribose polymerase
(PARP) genes are tumour suppressor genes involved in base excision DNA repair. Loss
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of PARP activity results in single-stranded DNA breaks. However, PARP1−/− knock-
out mice are viable and healthy indicating low toxicity from PARP inhibition (Bryant
et al., 2005).
Bryant et al. (2005) showed that BRCA2 cells were sensitive to PARP inhibition
by siRNA of PARP1 or drug inhibition (which targets PARP1 and PARP2 ) using
Chinese hamster ovary cells, MCF7 and MDA-MB-231 breast cell lines. This effect
was sufficient to kill mouse tumour xenografts and showed high specificity to BRCA2
deficient cells in culture and xenografts. Farmer et al. (2005) replicated these results
in embryonic stem cells and showed that BRCA1 cells were also sensitive to PARP
inhibition relative to the wild-type with siRNA and drug experiments in cell culture
and drug activity against BRCA1 or BRCA2 deficient embryonic stem cell mouse
xenografts. They found evidence that PARP inhibition causes DNA lesions, usually
repaired in wild-type cells, which lead to chromosomal instability, cell cycle arrest, and
induction of apoptosis in BRCA1 or BRCA2 deficient cells. The combined loss of DNA
repair pathways gives a plausible mechanism for an effective anti-cancer treatment.
Thus PARP inhibitors could be applied with clinical use against BRCA1 or BRCA2
mutations in both hereditary and sporadic cancers (Ashworth, 2008; Kaelin, Jr, 2005).
PARP inhibition has been found to be effective in ovarian cancer patients carrying
BRCA1 or BRCA2 mutations and some patients without these mutations, suggesting
synthetic lethality between PARP and other DNA repair pathways (Ström and Helle-
day, 2012). This supports the potential for PARP inhibition as a chemopreventative
alternative to prophylactic surgery for high-risk individuals with BRCA1 or BRCA2
mutations (Ström and Helleday, 2012). Hormone-based therapy has also been sug-
gested as a chemopreventative in such high-risk individuals and aromatase inhibitors
have completed phase I clinical trials for this purpose (Bozovic-Spasojevic et al., 2012).
Ström and Helleday (2012) also postulate increased efficacy of PARP inhibitors in the
hypoxic DNA-damaging tumour micro-environment.
A PARP inhibitor, olaparib, showed fewer adverse effects than cytotoxic chemother-
apy and anti-tumour activity in various clinical trials against BRCA1 or BRCA2 de-
ficient familial or sporadic breast, ovarian, and prostate cancers (Audeh et al., 2010;
Fong et al., 2009, 2010; Tutt et al., 2010). This treatment has a favourable therapeutic
window and similarly low toxicity between mutation carriers of BRCA1 or BRCA2 mu-
tations and sporadic cases. These PARP inhibitors have been FDA approved for some
cancers (McLachlan et al., 2016), are effective against germline and sporadic BRCA1 or
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BRCA2 mutations, and are a potential prevention alternative to prophylactic surgery
for high-risk mutation carriers Ström and Helleday (2012).
This demonstrates the clinical impact of a well characterised system of synthetic
lethality with known cancer risk genes. Synthetic lethality has the benefit of being
effective against inactivation of tumour suppressor genes by any means, broader than
targeting a specific oncogenic mutation (Kaelin, Jr, 2005). The targeted therapy is
effective in both sporadic and hereditary BRCA1 or BRCA2 deficient tumours acting
against an oncogenic molecular aberration across several tissues.
1.2.6 High-throughput Screening for Synthetic Lethality
RNA interference (RNAi) technologies have enabled extensive investigations of genetic
redundancy in mammalian experimental models including testing experimentally for
synthetic lethality (Fraser, 2004). Synthetic lethal RNAi screens are performed, using
short interfering RNA (siRNA) or short hairpin RNA (shRNA) to target specific genes
is isogenic cells. Identifying synthetic lethality is crucial for studying gene function,
drug mechanisms, and to design novel therapies (Lum et al., 2004). Candidate selection
of synthetic lethal gene pairs relevant to cancer has shown some success but is limited
because interactions are difficult to predict; they can occur between seemingly unrelated
pathways in model organisms (Costanzo et al., 2011). While biologically informed
hypotheses have had some success in synthetic lethal discovery (Bitler et al., 2015;
Bryant et al., 2005; Farmer et al., 2005), interactions occurring indirectly between
distinct pathways would be missed (Boone et al., 2007; Costanzo et al., 2011). Scanning
the entire genomes for interactions against a clinically relevant gene is an emerging
strategy being explored with high-throughput screens (Fece de la Cruz et al., 2015)
and computational approaches (Boucher and Jenna, 2013; van Steen, 2012).
Experimental screening for synthetic lethality is an appealing strategy for wider
discovery of functional interactions in vivo despite many potential sources of error
which must be considered (Fece de la Cruz et al., 2015; O’Neil et al., 2017). The syn-
thetic lethal concept has both genetic and pharmacological screening applications to
cancer research. Genetic screens, with RNAi to discover the specific genes involved,
inform development of targeted therapies with a known mode of action, anticipated
mechanisms of resistance, and biomarkers for treatment response. RNAi is a transient
knockdown of gene expression more similar to the effect of drugs than complete gene
loss and is more representative of disease than model organisms (Bussey et al., 2006).
The RNAi gene knockdown process has inherent toxicity to some cells, potential off-
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target effects, and issues with a high false positive rate. Therefore, it is important to
validate any candidates in a secondary screen and replicate knockdown experiments
with a number of independent shRNAs. Genetic screens have potential for quantita-
tive gene disruption experiments to selectively target over-expressed genes in cancer
via synthetic dosage lethality. While powerful for understanding fundamental cellular
function, analysis of isogenic cell lines is inherently limited by assuming only a single
mutation differs between them and cannot account for diverse genetic backgrounds or
tumour heterogeneity (Fece de la Cruz et al., 2015). Genetic screens can thus identify
targets to develop, or can repurpose targeted therapies for disease, but alone will not
directly identify a lead compound to develop for the market or for clinical translation.
Chemical screens are immediately applicable to the clinic, as they are directly
screening for selective lead compounds with suitable pharmacological properties. How-
ever, chemical screens lack a known mode of action, may affect many targets, and
screen a narrow range of genes with existing drugs. With either approach there are
still many challenges to translating candidates into the clinic. Identifying specific tar-
get genes may contribute to overcoming such challenges, which can be approached
with genetic screens and computational alternatives. Screening methods have proven
a fruitful area of research, despite being costly, laborious, and having many different
sources of error. These limitations suggest a need for complementary computational
approaches to synthetic lethal discovery.
1.2.6.1 Synthetic Lethal Screens
Synthetic lethal screens have been conducted for cancer genes in a variety of cancers.
These have found synthetic lethality of PIM1 over-expression with PLK1 inhibition in
prostate cells (van der Meer et al., 2014), FH null mutations (involved in hereditary
leiomyomatosis and renal cell cancer ) with inhibition of adenylate cyclases (Boettcher
et al., 2014), and WEE1 inhibitor treatment with knockdown of checkpoint kinases,
Fanconi anaemia, and homologous recombination in colorectal cells (Aarts et al., 2015).
These results include genes that have been found to be co-expressed in cancers, are
consistent with those identified in the literature, and that were successfully validated
with RNAi and drug experiments. These findings demonstrate that synthetic lethal
screening can identify partner genes with clinical relevance as biomarkers, therapeu-
tic targets, or conferring sensitivity to existing treatments. These are of particular
importance for familial cancer syndromes where treatments with adverse effects are
unsuitable for outwardly healthy patients with high cancer risk (Boettcher et al., 2014;
Telford et al., 2015).
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Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome involving predispo-
sition to early-onset malignant stomach and breast cancers that has been attributed to
inactivating mutations in E-cadherin, encoded by CDH1 (as discussed in Section 1.3).
Telford et al. (2015) performed an RNAi screen on MCF10A breast cells for synthetic
lethality with CDH1. This screen was performed in isogenic cell lines as described in
Section 1.3.3 and consisted of a primary siRNA screen of four pooled siRNAs for each
gene followed by a secondary screen on those with the highest ratio of viability between
CDH1 wild-type and null mutant cells of each of the independently targeting siRNAs
to reduce false-positives due to off-target effects. Synthetic lethal candidates with spe-
cific inhibition of CDH1 null cells were identified from the primary screen based on
thresholds of viability ratio and wild-type viability under siRNA treatment. In con-
junction with a drug compound screen, inhibitors of JAK, HDAC, PI3K, aurora kinase,
and tyrosine kinases were demonstrated to be synthetic lethal with CDH1. Therefore
the synthetic lethal strategy shows potential to achieve clinical impact against HDGC
by the identification of compounds suitable for use in chemoprevention.
The examples above show that high-throughput screens are an effective approach
to discover synthetic lethality in cancer. Screens have the power to test mode of action
of drugs, find unexpected synthetic lethal interactions between pathways, or identify
effective treatment strategies without prior knowledge of a mechanism. However, syn-
thetic lethal screens are costly, labour-intensive, error-prone, and biased towards genes
with effective RNAi knockdown libraries. Off-target effects and inconsistent replication
synthetic lethality across different cell lines, tissues, or laboratories, are also problem-
atic. Therefore there is a need for replication, validation, and alternative approaches to
identify synthetic lethal candidates. In addition, varied conditions across experimental
screens and differences between RNAi and drug screens makes meta-analysis extremely
challenging.
Genome-scale synthetic lethal experiments (across gene pairs) are not feasible, even
in model organisms, and these studies typically focus on specific gene candidates or the
partners of a gene of interest. Therefore a computational approach is more suitable for
this task and may also augment existing experimental screens.
1.2.7 Computational Prediction of Synthetic Lethality
1.2.7.1 Bioinformatics Approaches to Genetic Interactions
Prediction of gene interaction networks is a feasible alternative to high-throughput
screening, and has both biological importance and clinical relevance. There are many
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existing methods to predict gene networks (Benstead-Hume et al., 2017; Boucher and
Jenna, 2013; van Steen, 2012), as shown in Table 1.1. However, many of these methods
have limitations, including the requirement for existing SGI data, several data inputs,
and reliability of gene function annotation. Many of the existing methods also assume
conservation of individual interactions between species, which has been found not to
hold in yeast studies (Dixon et al., 2008). Tissue specificity is important in gene regula-
tion and gene expression, which are used as predictors of genetic interaction. However,
tissue specificity of genetic interactions cannot be explored in yeast studies and has not
been considered in many studies of multicellular model organisms, human networks, or
cancers. Similarly, investigation into tissue specificity of PPIs, an important predictor
of genetic interactions, is difficult given that high-throughput two-hybrid screens occur
out of cellular context for multicellular organisms (Brückner et al., 2009).
Table 1.1: Methods for predicting genetic interactions
Method Input Data Species Source Tool Offered
Between Pathways Model PPI, SGI S. cerevisiae Kelley and Ideker (2005)
Within Pathways Model PPI, SGI S. cerevisiae Kelley and Ideker (2005)
Decision Tree PPI, expression, phenotype S. cerevisiae Wong et al. (2004) 2 Hop
Logistic Regression SGI, PPI, co-expression, phenotype C. elegans Zhong and Sternberg (2006) Gene Orienteer
Network Sampling SGI, PPI, GO S. cerevisiae
Le Meur and Gentleman (2008)
Le Meur et al. (2014)
SLGI(R)
Random Walk GO, PPI, expression
S. cerevisiae
C. elegans
Chipman and Singh (2009)
Shared Function Co-expression, PPI, text mining, phylogeny C. elegans Lee et al. (2010b) WormNet
Logistic Regression Co-expression, PPI, phenotype C. elegans Lee et al. (2010a) GI Finder
Jaccard Index GO, SGI, PPI, phenotype Eukarya Hoehndorf et al. (2013)
Machine Learning Pandey et al. (2010) MNMC







Güell et al. (2014)
There are existing computational methods for predicting synthetic lethal gene pairs
in humans, with a specific emphasis on cancer (shown in Table 1.2). While these
demonstrate the power and need for predictions of synthetic lethality in human and
cancer contexts, limitations of previous methods could be met with a different approach.
Existing computational approaches to synthetic lethal prediction are often difficult to
interpret or replicate for new genes, or are reliant on data types not available for a
wider range of genes to test.
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Table 1.2: Methods for predicting synthetic lethality in cancer
Method Input Data Source Tool Offered




Wang and Simon (2013)
Comparative Genomic
Chemical-Genomic
Yeast synthetic gene interactions
Homology
Heiskanen and Aittokallio (2012)
Comparative Genomic
Yeast synthetic gene interactions
Homology
Deshpande et al. (2013)
Machine Learning
Discussed by Babyak (2004)
and Lee and Marcotte (2009)
Differential Expression Expression Tiong et al. (2014)




Wu et al. (2014) MetaSL
Pathway Analysis Zhang et al. (2015)




Somatic mutation and DNA CNV
siRNA in cell lines
Jerby-Arnon et al. (2014)










Lu et al. (2013)






Wappett et al. (2016)




Kelly, S. T., Guilford, P. J., and Black, M. A.
Honours Dissertation (Kelly, 2013) and developed here
SLIPT
1.2.7.2 Comparative Genomics
A comparative genomic approach by Deshpande et al. (2013) used the results of well
characterised high-throughput mutation screens in S. cerevisiae as candidates for syn-
thetic lethality in humans (Baryshnikova et al., 2010a; Costanzo et al., 2010, 2011;
Tong et al., 2001, 2004). Yeast synthetic lethal partners were compared to human or-
thologues to find cancer relevant synthetic lethal candidate pairs with direct therapeutic
potential. Proposed as a complementary approach to siRNA screens, approximately
24,000 of the 116,000 negative SGI in yeast (Costanzo et al., 2011) were matched to
human orthologues, with over 500 involving a cancer gene (Futreal et al., 2004). Under
strict criteria of one-to-one orthologues, large effect size and significant interaction in
yeast data, 1522 interactions were identified with 70 involving cancer genes. Of the
21 gene interactions tested with pairs of siRNA in IMR1 fibroblast cells, 6 exhibited
synthetic lethal effects. The two strongest interactions (SMARCB1 with PSMA4 and
ASPSCR1 with PSMC2 ) were successfully validated by protein analysis of human cells
and replication with tetrad analysis for yeast orthologues.
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Another approach to systematic synthetic lethality discovery specific to human can-
cer (in contrast to the plethora of yeast synthetic lethality data) was to build a database
as done by Li et al. (2014). In their relational database, called “Syn-lethality”, they
have curated both known experimentally discovered synthetic lethal pairs in humans
(113 pairs) from the literature and those predicted from synthetic lethality between
orthologous genes in S. cerevisiae yeast (1114 pairs). This knowledge-based database
is the first dedicated to human cancer synthetic lethal interactions and integrates gene
function annotation, pathway and molecular mechanism data with experimental and
predicted synthetic lethal gene pairs. This combination of data sources is intended to
tackle the trade-off between more conclusive synthetic lethal experiments in yeast and
more clinically relevant synthetic lethal experiments in human cancer models, such as
RNAi, especially when high-throughput screens are costly and prone to false positives
in either system and are difficult to replicate across gene backgrounds. This database
centralises a wealth of knowledge scattered in the literature including cancer relevant
genes, including the previously mentioned interactions of BRCA1 and BRCA2 with
PARP1, and TP53 with WEE1 and PLK1, although the computational methodology
was not released and was limited to 647 human genes. Their future directions were
promising, such as constructing networks of known synthetic lethality, applying known
synthetic lethality to cancer treatment, data mining, replicating the approach for syn-
thetic lethality in model organisms, signalling pathways, and developing a complete
global network in human cancer or yeast (both of which are still incomplete with ex-
perimental data), some of which has been implemented in “SynLethDB” (Guo et al.,
2016).
Machine learning approaches have also been explored for synthetic lethal discovery
(Babyak, 2004; Lee and Marcotte, 2009). Due to concerns that these may be subject to
overfitting or noise, Wu et al. (2014) developed a meta-analysis method. They focused
on synthetic lethal gene pairs relevant to developing selective drugs against human can-
cer, building upon their previous database (Li et al., 2014). Their “metaSL” approach
utilises genomic, proteomic and annotation data and had a high statistical performance
in yeast data with an area under receiver operating characteristic (AUROC) of 0.871
(as described in Section 2.3.5.1). They predicted orthologous synthetic lethal partners
in human data that were not experimentally validated but some were relevant to cancer
such as EGFR with PRKCZ.
Computational approaches scale-up across the genome at a lower cost than experi-
mental screens (Wu et al., 2014). Wu et al. (2014) provided their most supported inter-
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actions online but the method is not available for analysis of other genes. Syn-Lethality
(Li et al., 2014) and MetaSL (Wu et al., 2014) demonstrate the value of computational
approaches to synthetic lethality but omitted many genes of importance in cancer, such
as CDH1. Accordingly, there remains a need to enable biological researchers to query
further genes and do so in a particular tissue or genetic background.
There is also concern for analyses based on yeast data that many synthetic lethal
interactions may not be conserved between species (Dixon et al., 2009), although in-
teractions between pathways may be more comparable. It is unsurprising that many of
the interactions identified were not experimentally validated. There have been many
gene duplications in the separate evolutionary histories of humans and yeast which
may lead to differences in genetic redundancy. Yeast cells are not an ideal human
cancer model because they do not have tissue specificity, multicellular gene regulation,
or orthologues to several known cancer genes such as p53 (Guaragnella et al., 2014).
Although these studies have tried to anticipate these issues with stringent criteria such
as requiring one-to-one orthologues (Deshpande et al., 2013; Heiskanen and Aittokallio,
2012; Kranthi et al., 2013), there remains the possibility that changes in gene function
may affect whether these are solely redundant such as if functions had co-evolved with-
out sequence homology. Many genes will also be excluded since they lack homologues
in yeast, the corresponding experimental data, or having paralogues in either species.
Thus conservation of yeast interactions is not an ideal strategy and analysis of human
data directly for comparison with human experimental data will be the focus of this
thesis.
1.2.7.3 Analysis and Modelling of Protein Data
Kranthi et al. (2013) took a network approach to discovery of synthetic lethal candi-
date selection applying the concept of “centrality” to a human PPI network involving
interacting partners of known cancer genes. The effect of removing pairs of genes on
connectivity of the network was used as a surrogate for viability which is supported by
observations that the PPI and synthetic lethal networks are orthogonal in S. cerevisiae
studies (Tong et al., 2004). They showed that the human cancer protein interaction
network derived protein interactions and cancer gene databases (Futreal et al., 2004;
Higgins et al., 2007; Keshava Prasad et al., 2009), consisting of 1539 proteins and
6471 interactions, exhibits the power law distribution expected of a scale-free synthetic
lethal network with high connectivity (average vertex degree of 23.67 and network ef-
ficiency of 0.2952). Their top 100 candidate interactions included interactions of the
tumour suppressor TP53 with BRCA1, CDKNA1, CDKNA2, MET, and RB1 which
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have been detected by prior studies. The gene pairs were often observed to be in the
same or a plausible compensatory pathway. This demonstrated that network structure
is important in the biological functions of cancers and could be exploited for targeting
TP53 loss of function mutations.
However, the approach of Kranthi et al. (2013) was limited to known cancer genes
and is not applicable to genes that do not have PPI data. Other nucleotide sequencing
data types are more commonly available for cancer studies at a genomic scale. Of
further concern is that the results were enriched for p53 synthetic lethal partners,
which is relevant to many cancers but this genome-wide approach did not detect many
other cancer genes due to the extent of multiple testing. This enrichment may be
due to the known drastic effect of removing p53 itself from the network as a highly
connected, master regulator, and cancer driving tumour suppressor gene. The focus
on cancer genes is useful for translation into therapeutics but does not account for
variable genetic backgrounds or effect of removing an individual protein on the cellular
network.
Focusing on the potential for synthetic lethality to be an effective anti-cancer drug
target, Zhang et al. (2015) used modelling of signalling pathways to identify synthetic
lethal interactions between known drug targets and cancer genes by simulating gene
knockdowns. A computational approach was applied to avoid the limitations of exper-
imental RNAi screens such as scale, instability of knockdown, and off-target effects.
This ‘hybrid’ method of a data-driven model and known signalling pathways showed
potential to predict cell death in single and combination gene knockouts. They used
time series protein phosphorylation data (Lee et al., 2012) for 28 signalling proteins
and Gene Ontology (GO) pathways (Ashburner et al., 2000; Blake et al., 2015). This
approach successfully detected many known essential genes in the human gene essen-
tiality database, known synthetic lethal partners in the Syn-Lethality database (Li
et al., 2014), and predicted novel synthetic lethal gene pairs.
These novel results contained many TP53 and AKT synthetic lethal partners
(Zhang et al., 2015), genes known to be important in many cancers a known bias
in some approaches (O’Neil et al., 2017). However, these genes also have a severe
impact on the signalling pathways in an essentiality analysis of single gene disrup-
tions and large phenotypic changes in cancer (Zhang et al., 2015). This approach is
amenable to detect functionally related pathways and protein complexes across the
molecular function, cellular component, and biological process annotations provided
by Gene Ontology. The results were consistent with the experimental results in the
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literature but the novel synthetic lethal interactions have yet to be validated. While
the mathematical reasoning and algorithms are given, the code was not released to
replicate the findings or apply the methodology beyond the signalling pathways anal-
ysed by Zhang et al. (2015). While this is an interesting approach, the analysis of
this thesis will focus on gene expression and RNAi data, the widespread availability of
which allows testing of a broader range of candidate gene pairs.
1.2.7.4 Differential Gene Expression
Differential gene expression has been explored to predict synthetic lethal pairs in cancer
which would be widely applicable due to the availability of public gene expression data
for many samples and cancer types. Wang and Simon (2013) found differentially ex-
pressed genes (by the t-test, adjusted by False discovery rate (FDR)) between tumours
with or without functional p53 mutations in TCGA (McLendon et al., 2008) and Can-
cer Cell Line Encyclopaedia (CCLE) (Barretina et al., 2012) RNA-Seq gene expression
data as candidate synthetic lethal partner pathways of p53. They identified 2, 8, and
21 candidate synthetic lethal partner genes in 3 microarray datasets from the NCI60
cell lines, 31 partner genes from the CCLE RNA-Seq data (Barretina et al., 2012), and
50 in TCGA RNA-Seq data (Muzny et al., 2012). PLK1 was replicated across 4 of
these analyses and 17 other genes were replicated across 2 analyses (including MTOR,
PLK4, MAST2, MAP3K4, AURKA, BUB1 and 6 CDK genes) with many playing a
role in cell cycle regulation. This was supported by a drug sensitivity experiment on
the NCI60 cell lines which found that cells lacking functional p53 were more sensitive to
paclitaxel (which targets PLK1, AURKA, and BUB1 ). This demonstrated the poten-
tial of gene expression as a surrogate for gene function, and the use of public genomic
data to predict synthetic lethal gene pairs in cancer. Wang and Simon (2013) advo-
cated for pre-screening of expression profiles to augment future RNAi screens, however,
their analyses were limited to kinase genes and focused on currently druggable targets,
lacking wider application of synthetic lethal prediction methodology. This approach
may not be feasible or applicable in cancer genes with a lower mutation rate than p53.
Tiong et al. (2014) also investigated gene expression as a predictor of synthetic
lethal pairs with colorectal cancer microarrays from a Han Chinese population with
a sample size of 70 tumours and 12 normal tissue samples. Simultaneously differen-
tial expressed “tumour dependent” gene pairs (which includes co-expression) between
cancer and normal tissue were used to rank 663 candidate synthetic lethal interactions
identified in cell line siRNA experiments. Of the top 20 gene pairs, 17 were tested for
differential expression at the protein level with immunohistochemistry staining and cor-
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relation with clinical characteristics, with 11 pairs exhibiting synergistic effects. Some
of the predicted synthetic lethal pairs were consistent with the literature (including
TP53 with S6K1 and partners of KRAS, PTEN, BRCA1, and BRCA2 ) and two novel
synthetic lethal interactions (TP53 with CSNK1E and CTNNB1 ) were validated in
pre-clinical models. This serves as a valuable proof-of-concept for integration of in
silico approaches to synthetic lethal discovery in cancer, demonstrating its utility to
triage and identify synthetic lethal partners of p53 applicable to colorectal tissues. Al-
though the experimental work was the focus of the paper, these findings show that
bioinformatically identified synthetic lethal candidates can be validated in patient tis-
sue samples to find those applicable to colorectal cancers (including in a non-Caucasian
population).
1.2.7.5 Data Mining and Machine Learning
Recognising the utility of synthetic lethality to drug inhibition and specificity of anti-
cancer treatments, Jerby-Arnon et al. (2014) also saw the need for effective prediction
of gene essentiality and synthetic lethality to augment experimental studies. They de-
veloped the “DAta mIning SYnthetic lethal identification pipeline” (DAISY), a data-
driven approach for genome-wide analysis of synthetic lethality in public cancer ge-
nomics data from TCGA and CCLE (Barretina et al., 2012). DAISY is intended to
predict the candidate synthetic lethal partners of a query gene such as genes recurrently
mutated in cancer.
Jerby-Arnon et al. (2014) combined a computational approach to triage candidates
with a conventional RNAi screen to validate synthetic lethal partners. They screened
a selection of computationally predicted candidates and randomly selected genes with
RNAi against VHL loss of function mutation in RCC4 renal cell lines. The computa-
tional method had a high AUROC of 0.779 and predictions were enriched 4-fold for
validated RNAi hits over randomly selected genes. This approach detected known syn-
thetic lethal pairs such as BRCA1 or BRCA2 genes with PARP1, and MSH2 with
DHFR. The synthetic lethal candidates identified with both RNAi screening and com-
putational prediction formed an extensive network of 2077 genes with 2816 synthetic
lethal interactions, and a similar network of 3158 genes with 3635 synthetic dosage
lethal interactions (for synthetic lethality with over-expression). Each network was
scale-free, as expected of a biological network, and was enriched for known cancer
genes and for essential genes in mice which could be harnessed for predicting prognosis
and drug response.
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The DAISY methodology (Jerby-Arnon et al., 2014) compares the results of analy-
sis of several data types to predict synthetic lethality, namely: DNA copy number and
somatic mutation for TCGA patient samples and CCLE cell lines. The cell lines were
also analysed with gene expression and gene essentiality (shRNA screening) profiles.
Genes were classed as inactivated by copy number deletion, somatic loss of function
mutation, or low expression and tested for synthetic lethal gene partners which are
either essential in screens or not deleted with copy number variants. Co-expression is
also used for synthetic lethality prediction based on studies in yeast (Costanzo et al.,
2010; Kelley and Ideker, 2005). Copy number, gene expression, and essentiality anal-
yses were stringently compared by adjusting each for multiple tests with Bonferroni
correction and only taking candidates identified in all analyses. The predictions per-
formed well and an RNAi screen, for the example of VHL in renal cancer, validated
predicted synthetic lethal partners of VHL demonstrating the feasibility of combining
approaches to synthetic lethal discovery in cancer and using computational predictions
to enable more efficient high-throughput screening. While DAISY performed well sta-
tistically, co-expression and shRNA functional examination contributed less to this
than the mutation and copy number analysis (AUROC 0.683 alone). However, this
methodology was very stringent, missing potentially valuable synthetic lethal candi-
dates. Additionally, the software for the procedure has not been publicly released for
replication.
Although the DAISY procedure performed well and has been well received by the
scientific community (Crunkhorn, 2014; Lokody, 2014; Ryan et al., 2014), showing a
need for such methodology, there has not yet been widespread adoption of this ap-
proach. Co-expression analysis may exclude some synthetic lethal interactions, where
inverse correlation could occur (Lu et al., 2015). In the interests of a large sample size,
tissue types were not tested separately despite tissue-specific synthetic lethality being
likely since gene function (and by extension expression, isoforms, and clinical charac-
teristics) in cancers may often be tissue-dependent. Some data forms and analyses
used, such as gene essentiality, may not be available for all cancers, genes, or tissues,
and may not be reproduced.
Lu et al. (2015) propose an alternative computational prediction of synthetic lethal-
ity based on machine learning methods and a “cancer genome evolution” hypothesis.
Using DNA copy number and gene expression data from TCGA patient samples, a
cancer genomes evolution model assumes that synthetic lethal gene pairs behave in
two distinct ways in response to an inactive synthetic lethal partner gene, either a
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“compensation” pattern where the other synthetic lethal partner is overactive or a
“co-loss underrepresentation” pattern where the other synthetic lethal partner is less
likely to be lost, since loss of both genes would cause death of the cancer cell. During
the genomes evolution of cancers, the cell becomes addicted to the remaining syn-
thetic lethal partner due to induced gene essentiality. These patterns would explain
why DAISY detects only a small number of synthetic lethal pairs, compared to the
large number expected based on model organism studies (Boone et al., 2007), and the
disparity between screening and computationally predicted synthetic lethal candidates
due to testing different classes of synthetic lethal gene pairs.
Lu et al. (2015) compared a genome-wide computational model of genomes evo-
lution and gene expression patterns to the experimental data (Laufer et al., 2013;
Vizeacoumar et al., 2013). This more simple model performed well, with an AUROC
of 0.751 (lower than DAISY), and did not rely on data from cell lines which may not
represent patient disease. Lu et al. (2015) predicted 591,000 human synthetic lethal
partners with a probability score threshold of 0.81, giving a precision of 67% and 14-
fold enrichment of synthetic lethal true positives compared to randomly selected gene
pairs. Discovery of such a vast number of cancer-relevant synthetic lethal interactions
in humans would not be feasible experimentally and is a valuable resource for research
and clinical applications. These predictions are not limited by assuming co-expression
of synthetic lethal partners or evolutionary conservation with model organisms enabling
wider synthetic lethal discovery. However, there remains a lack of basis for an expec-
tation of how many synthetic lethal partners a particular gene will have, how many
pairs there are in the human genomes, and whether pathways or correlation structure
would influence predicted synthetic lethal partners.
Large scale, computational approaches have yet to determine whether synthetic
lethal interactions are tissue-specific, since Lu et al. (2015) used pan cancer data for
14136 patients with 31 cancer types. Experimental data used for comparison was a
small training dataset specific to colorectal cancer, and based on screens for other
phenotypes, which may limit performance of the model or application to other can-
cers. Proposed expansion of the computational approach to mutation, micro RNA,
or epigenetic modulation of gene function and tumour micro-environment or hetero-
geneity suggests that synthetic lethal discovery could be widely applied to the current
challenges in cancer genomics. This approach was also based on machine learning
methodology and was not supported by a software release for the community to de-
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velop, contribute to, or reproduce beyond the gene pairs given in the supplementary
results.
1.2.7.6 Mutual Exclusivity and Bimodality
Wappett et al. (2016) demonstrated a multi-omic approach to identify synthetic lethal-
ity in cancer with a strategy to detect bimodal patterns in molecular profiles. They
released this solution as the BiSEp R package (Wappett, 2014) which aims to detect
subtle bimodal and non-normal patterns in expression data. Since loss of gene func-
tion is not consistently genetic, Wappett et al. (2016) advocate for the use of gene
expression (loss of mRNA) and deletion (loss of copy number) data in addition to
mutations. The BiSEp procedure was demonstrated on an analysis of 881 cell lines
from CCLE (Barretina et al., 2012), 442 cell lines from COSMIC (Forbes et al., 2015),
and RNA-Seq by Expectation Maximization (RSEM) normalised RNA-Seq data for
178 TCGA lung patient samples (Collisson et al., 2014). BiSEp was demonstrated to
have significant enrichment of validated tumour suppressor, synthetic lethal gene pairs
(detecting 76 experimentally supported gene pairs) and was improved (detecting 420)
with expression data, rather than relying on detecting loss of gene function by muta-
tion or deletion. Wappett et al. (2016) identified interactions with genes relevant to
cancer with support in experimental screens including ERCC4 with XRCC1, BRCA1
with PARP3, and SMARCA1 with SMARCA4.
Wappett et al. (2016) demonstrated that analysis of genomics data, particularly
expression data, is relevant to augment the identification of synthetic lethal interac-
tions with screening experiments. They further showed that this is applicable in both
genetically homogeneous cell lines and heterogeneous cell population from patient sam-
ples. These approaches are limited however, to genes that exhibit bimodal expression
patterns which does not commonly occur, particularly in normalised gene expression
data. Other approaches may need to be considered for gene, such as CDH1 which were
not identified by BiSEp.
Srihari et al. (2015) used a computational analysis to identify synthetic lethal can-
didate genes from mutually exclusive alterations in cancers. This analysis focused on
synthetic lethality with “DNA damage response genes” in cancers, including CDH1,
using TCGA expression and copy number data across several cancers. The 718 genes
that were identified as frequently altered in cancer were enriched among essential genes
in cell lines deficient in DNA damage response genes which demonstrates “induced es-
sentiality” in a cancer model. These were tested by underMutExSL, a hypergeometric
test, for synthetic lethality. Of the DNA damage response genes examined, CDH1
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exhibited the most mutually exclusive alterations with other frequently altered genes
in breast cancers, including related genes in focal adhesion such as PTK2. These re-
sults indicate that CDH1 may be particularly subject to “non-oncogene addiction” in
breast cancers and that computational analysis is valuable to rationally identify these
putative synthetic lethal genes. These results were limited to frequently altered genes
in cancer and could be improved with an approach that expands to consider synthetic
lethal genes that are not themselves altered in cancers or further investigation into
synthetic lethal pathways.
1.2.7.7 Rationale for Further Development
Many of the approaches discussed here aimed to identify the strongest synthetic lethal
pairs across the yeast or human genomes (Deshpande et al., 2013; Lu et al., 2015; Wap-
pett et al., 2016; Wu et al., 2014), which may not be an ideal strategy to identify inter-
actions in particular functions or relevance to particular cancers. These demonstrate
a need for computational approaches to prioritise candidate gene pairs for validation.
This thesis will focus on the interactions with CDH1 with importance in breast and
stomach cancers, although these partners may be applicable in other cancers. As such,
this thesis presents a query-based method, amenable to identification of candidate
partners for a selected gene of functional or translational importance such as CDH1.
I have previously conducted an Honours project (Kelly, 2013) into synthetic lethal-
ity in microarray cancer gene expression datasets from the cancer genome altas (We-
instein et al., 2013) and a breast cancer cohort (Soon et al., 2011). Many synthetic
lethal interactions were identified for CDH1 and this was shown to be typical across
genes tested rather than specific to CDH1. This project successfully identified known
synthetic lethal interactions between BRCA1 and PARP1 ; BRCA2 and PARP1 ; and
CDH1 and JAK2 (Bryant et al., 2005; Farmer et al., 2005; Telford et al., 2015). The
methodology used in the Honours project has been refined to be more stringent and
the analysis that will be presented in this thesis will analyse synthetic lethality with
CDH1 with a focus on biological pathways and RNA-Seq gene expression data.
1.3 E-cadherin as a Synthetic Lethal Target
E-cadherin is a transmembrane protein (encoded by CDH1 ) with several well-characterised
functions in the cytoskeleton and cell-to-cell signalling. Here I outline the characterised
functions of E-cadherin and its importance in cancer biology. CDH1 is a tumour sup-
pressor gene, with loss of function occurring in both familial (germline mutations) and
sporadic (somatic mutations) cancers. As such, CDH1 inactivation is a prime example
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of a genetic event that could be targeted by synthetic lethality. Drugs against CDH1 -
deficient cancers would be applicable for chemoprevention of HDGC and treatment of
sporadic cancers carrying somatic CDH1 mutations.
1.3.1 The CDH1 gene and its Biological Functions
CDH1 is implicated in hereditary and sporadic lobular breast cancers and diffuse gastric
cancers (Berx et al., 1996; Berx and van Roy, 2009; De Leeuw et al., 1997; Guilford
et al., 1998; Masciari et al., 2007; Semb and Christofori, 1998; Vos et al., 1997). E-
cadherin is normally expressed in epithelial tissues and loss of CDH1 function has been
implicated in breast cancer progression and metastasis (Becker et al., 1994; Berx et al.,
1995; Christofori and Semb, 1999).
The primary function of CDH1 is cell-cell adhesion at the adherens junction. E-
cadherin is transmembrane signalling protein which maintains the cytoskeleton and
mediating molecular signals between cells (Chen et al., 2014; Tunggal et al., 2005).
The function of the adherens complex is particularly important for cell structure and
regulation because it interacts with actin and microtubule cytoskeletons. The cy-
toskeletal role of E-cadherin includes maintaining cellular polarity (Jeanes et al., 2008).
E-cadherin is not essential to cellular viability but loss in epithelial cells does lead to
defects in cytoskeletal structure and proliferation. In addition to a central role in the
adherens complex, E-cadherin is involved in many other cellular functions and thus
CDH1 is regarded as a highly pleiotropic gene (Kroepil et al., 2012).
E-cadherin also interacts with the extracellular environment and regulates of epithe-
lial tissues by intercellular communication (Jeanes et al., 2008). The signals mediated
by adherens junctions are also passed on to intracellular signalling pathways . One such
example is the regulation of β-catenin which interacts with both the actin cytoskeleton
and acts as a transcription factor via the WNT pathway (Jeanes et al., 2008). Sim-
ilarly, the Hippo and PI3K/AKT pathways are also mediated in part by E-cadherin
(De Santis et al., 2009; Kim et al., 2011). E-cadherin shares several downstream path-
ways with cell-surface proteins, such as integrins, and thus indirectly interacts with
them.
The key roles of E-cadherin in maintaining cellular structure and regulating growth
are consistent with CDH1 being a tumour suppressor gene. E-cadherin loss in breast
cancers has been shown to cause increased proliferation, lymph node invasion, and
metastasis with poor cell-cell contact (Berx and van Roy, 2009). Thus the CDH1 gene is
an established invasion suppressor, with a key role in the epithelial-mesenchymal transi-
34
tion (EMT), an established mechanism of cancer progression (Hanahan and Weinberg,
2011). EMT is important during development and wound healing but such changes in
cellular differentiation also occur in cancers.
1.3.2 Hereditary Diffuse Gastric (and Lobular Breast) Cancer
CDH1 loss of function mutations also cause familial cancers, including diffuse gastric
cancer and lobular breast cancer (Graziano et al., 2003; Guilford et al., 2010, 1999;
Oliveira et al., 2009). Individuals carrying a null mutation in CDH1 have a syndromic
predisposition to early-onset of these cancers, including hereditary diffuse gastric cancer
(HDGC) (Guilford et al., 1998). Due to carrying a dysfunctional allele, these individ-
uals are prone to carcinogenic lesions in the breast or stomach when the remaining
functional allele is inactivated. Thus familial cancers occur more frequently and at an
earlier age than in individuals with two functional CDH1 alleles. The loss of the sec-
ond allele is most often through hypermethylation suppressing expression rather than
mutation (Grady et al., 2000; Graziano et al., 2003; Machado et al., 2001; Oliveira
et al., 2009), although loss of heterozygousity may also occur (Guilford et al., 2010).
HDGC is an autosomal dominant cancer syndrome with incomplete penetrance.
The “lifetime” (until age 80 years) risk for mutation carriers of diffuse gastric cancer is
70% in males and 56% in females (Hansford et al., 2015; van der Post et al., 2015). In
addition, the lifetime risk of lobular breast cancer is 42% in female mutation carriers
(Hansford et al., 2015). HDGC represents less than 1% of gastric cancers (Ferlay
et al., 2015), however, it is a serious health issue for several hundred families globally.
E-cadherin is also mutated in 13% of sporadic gastric cancers (Ferlay et al., 2015).
While diagnostic testing for CDH1 genotype has enabled more effective manage-
ment of HDGC and improved patient outcomes, there are still limited options for clini-
cal interventions (Guilford et al., 2010). Individuals with a family history of HDGC are
recommended to be tested for CDH1 mutations in late adolescence and are offered pro-
phylactic stomach surgery at the age of 20 years. Another option is annual endoscopic
screening to diagnose early stage stomach cancers with surgical intervention once they
are detected (Oliveira et al., 2013). However, these early stage cancers are difficult to
detect and may be missed in regular screening. Thus patients carrying germline CDH1
mutations either have surgery which has a significant impact on quality of life and risk
of complications or remain at risk of developing stomach cancer. There are similar
concerns for female mutations carriers for the management of high-risk lobular breast
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cancer. An effective treatment against CDH1 mutant cancers would potentially have
significant therapeutic and preventative applications for many patients.
1.3.3 Cell Line Models of CDH1 Null Mutations
Previous work published by members of our research group used a model of homozygous
CDH1−/− null mutation in non-malignant MCF10A breast cells to show that loss of
CDH1 alone was not sufficient to induce EMT (Chen et al., 2014). However, CDH1 -
deficient cells did manifest changes in morphology, migration, and weaker cell adhesion
(Chen et al., 2014). This CDH1−/− MCF10A model has been used in a genome-wide
screen of 18,120 genes using siRNA and a complementary drug screen using 4057 known
drugs to identify synthetic lethal partners to E-cadherin (Telford et al., 2015). One
of the most supported pathways from the siRNA screen was the G protein coupled
receptor (GPCR) signalling cascades, which were highly enriched in a Gene Ontology
(GO) analysis validated with Pertussis toxin which targets Gαi signalling (Clark, 2004).
1.4 Summary and Research Direction of Thesis
Genomic technologies have immense potential for understanding of genetics and im-
proving healthcare, including the identification of cancer genes for diagnosis, biomark-
ers, and therapeutic targets. This has been demonstrated by the identification of many
driver genes, tumour subtypes, and the development of targeted therapies against onco-
genes (e.g., BRAFV600E) and tumour suppressors (e.g., BRCA1 ). Synthetic lethality is
important for studying cellular functions and exploiting them for biomarker identifica-
tion and cancer treatment. Synthetic lethal interactions present a means to target loss
of function mutations and dysregulation of tumour suppressor genes via interacting
partners with redundant (or compensating) functions.
Discovery of synthetic lethal partners of CDH1 could identify molecular mechanisms
driving the growth of CDH1 -deficient tumours and therapeutic targets or chemopre-
ventative agents for management of HDGC. The clinical potential of the synthetic
lethal approach has been demonstrated by the use of olaparib against BRCA1 and
BRCA2 mutations (Lord et al., 2015; McLachlan et al., 2016). There is still a need to
systematically identify synthetic lethal partners for other genes, such as CDH1.
Effective screening and prediction of synthetic lethal interactions are crucial for
developing precision cancer medicines. Therefore, I will develop a computational sta-
tistical procedure to identify synthetic lethal interactions. This will assist the devel-
opment of novel precision medicine targeted to particular molecular aberrations. To
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address the concerns raised by recent computational approaches to synthetic lethal
discovery in cancer (Jerby-Arnon et al., 2014; Lu et al., 2015; Wappett et al., 2016),
this query-based method uses gene expression data that is widely available for many
samples in different cancers. To further determine the limitations and implications of
synthetic lethal predictions, modelling and simulation was performed upon the statisti-
cal behaviour of synthetic lethal gene pairs in genomics data. Comparison of synthetic
lethal gene candidates from public data analysis and experimental candidates, pathway
analysis, and networks structure will also be presented to investigate the relationships
between synthetic lethal candidates. Release of the R code used for simulation, predic-
tion, and analysis will enable adoption of the methodology by the research community
and comparison to existing methods.
1.4.1 Thesis Aims
This thesis aims to develop and demonstrate a method to identify synthetic lethal
gene pairs using public gene expression data. Chapter 3 describes this synthetic lethal
detection methodology (SLIPT), the methods developed to evaluate it, and the release
of R software packages. This chapter also documents the simulation procedures and
network analysis that were developed to support the use of SLIPT and perform analyses
throughout this thesis.
To demonstrate the SLIPT methodology for analysis of RNA-Seq gene expression
data, an analysis was performed in Chapter 4 to identify candidate synthetic lethal gene
partners of CDH1 in public breast and stomach cancer data (Bass et al., 2014; Koboldt
et al., 2012). This analysis demonstrates the biological relevance of candidate synthetic
lethal partners by identifying synthetic lethal pathways and makes comparisons to an
experimental siRNA screen (Telford et al., 2015).
To assess the importance of synthetic lethal genes within pathways, network anal-
ysis was also performed using graph structures in Chapter 5. Chapter 5 also used
pathway structure to identify directional relationships between SLIPT and siRNA syn-
thetic lethal candidates and explore the disparity between them. The SLIPT method-
ology was supported by simulation-based investigations in Chapters 3 and 6 to evaluate
performance of SLIPT with known synthetic lethal genes in simulated data. Graph
structures were used in Chapter 6 to investigate the effect of pathway correlation struc-
tures on synthetic lethal detection with SLIPT in simulated data, including complex





In this Chapter, I will outline the various existing resources and methods that were used
throughout this project. This includes public data repositories, stable and development
releases of software packages (primarily using the R programming environment), and
custom implementation of bioinformatic methods and statistical concepts with Shell
or R scripts developed for this purpose. The methods and packages that have been
developed specifically for this project will be covered in Chapter 3 with supporting
data and demonstration of their use .
2.1 Bioinformatics Resources for Genomics Research
2.1.1 Public Data and Software Packages
Various bioinformatics resources, such as databases and methods, have become integral
parts of genetics and genomics research. Reference genomes, genotyped variants, gene
expression, and epigenetics profiles are among the most commonly used resources.
Gene expression data, in particular, is widely available from microarray and RNA-Seq
projects, driven by data sharing, data mining, and the wider initiatives for publicly
available data for enabling the scientific community to further utilise the data generated
beyond a single research group or consortium (Rung and Brazma, 2013). These datasets
are a valuable resource to examine the changes in gene expression occurring in cancers
and the variation between samples. The potential for integrating findings from publicly
available genomic data with experimental investigations has expanded with RNA-Seq
datasets, including large-scale cancer genomics projects (Zhang et al., 2011). This
thesis presents such an investigation, enabled by the release of these datasets and tools
developed to handle them.
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It is now common practice for bioinformatics researchers to release open-source code
or provide software packages to enable replication of the findings or further applications
of the methods (Stajich and Lapp, 2006). This is part of a wider movement in software
and data analysis, including the development of Linux and the R programming envi-
ronment (R Core Team, 2016). In addition to the R packages hosted on comprehensive
R archive network (CRAN) (CRAN, 2017), many packages specifically developed for
applications in bioinformatics are hosted on the Bioconductor repositories (Gentleman
et al., 2004), and numerous packages in various stages of development are hosted on
GitHub (https://github.com/). Packages from each of these resources have been
used throughout this project and are cited wherever possible. Several R packages have
been developed during this thesis project and publicly released on GitHub or will be
released in conjunction with a publication.
2.1.1.1 Cancer Genome Atlas Data
Molecular profile data for normal and tumour samples were downloaded from pub-
licly available sources, using the TCGA (TCGA, 2017) and the International Cancer
Genome Consortium (ICGC) web portals (Zhang et al., 2011). These include gene
expression (RNA-Seq), somatic mutations, and clinical data. The versions were down-
loaded on the 6th of August 2015 (Release 19) and the 2nd of May 2016 (Release
20) for breast and stomach cancer respectively via the ICGC data portal (https:
//dcc.icgc.org/).
The TCGA project (Koboldt et al., 2012) used widely adopted tools: “Bowtie” for
alignment (Langmead et al., 2009), “mapslice” to detect splice sites (Wang et al., 2010),
and the RSEM approach to quantify reads as a measure of gene expression (Li et al.,
2010). These are widely acceptable tools for processing RNA-Seq data which were used
to produce the raw counts of mapped reads (tier 1) and normalised expression data
(tier 3) publicly downloaded from ICGC and TCGA respectively.
Raw count and RSEM normalised TCGA expression data from Illumina RNA-
Seq protocols were downloaded for 1177 breast samples (113 normal, 1057 primary
tumour, and 7 metastases) for 20,501 genes. TCGA breast somatic mutation data
for 981 samples (976 primary tumours and 5 metastases) across 25,836 genes were
downloaded. These included 969 samples (964 primary tumours and 5 metastases)
with corresponding RNA-Seq expression data and 19,166 genes mapped from Ensembl
identifiers to gene symbols. Of these genes, 16,156 had corresponding gene expression
information. Unless otherwise stated, the raw counts were used for further processing
rather than the RSEM normalised data (provided by TCGA tier 3). Somatic mutations
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were reported if there were non-synonymous substitutions, frameshifts, or truncations
(by premature stop codons) detected which would likely disrupt the wild-type gene
function.
Raw count TCGA expression data (TCGA tier 1) from Illumina RNA-Seq was
downloaded for 450 stomach samples (35 normal, 415 primary tumour) for 20,501
genes. TCGA stomach mutation data was also used for 289 samples across 25,807
genes, corresponding to 19,436 genes with expression data.
2.1.1.2 Reactome and Annotation Data
Pathway analysis was performed for human pathway annotation from the Reactome
database (version 52) with pathway gene sets derived from the reactome.db R pack-
age. The overlap between these pathways is shown in Appendix Figure A.1. Entrez
identifiers were mapped to gene symbols or aliases to match to TCGA expression and
mutation data using the org.Hs.eg.db R package. Gene expression for breast cancer
from Gatza and colleagues were also used (Gatza et al., 2011; Gatza et al., 2014). The
gene symbols for each pathway were matched to the expression data and to construct
a matrix of category membership using the safe R package (Barry, 2016).
2.2 Data Handling
2.2.1 Normalisation
Apart from the Prediction Analysis of Microarray 50 (PAM50) subtyping procedure
(Parker et al., 2009), which required RSEM normalised data (J.S. Parker personal
communication), the analysis of the RNA-Seq data presented here was based on raw
read count data. After some samples were removed for consistency (based on a Eu-
clidean distance correlation matrix as described in Section 2.2.2), raw read counts were
log-scaled and the final dataset was normalised as Counts per Million mapped reads
(CPM), weighted by variance modelling, using the voom function (Law et al., 2014) in
the limma R package (Ritchie et al., 2015). This procedure adjusts the data to account
for differences in read count by sequencing depth between samples and length between
genes.
2.2.2 Sample Triage
The TCGA breast RNA-Seq data were assessed for batch effects using a correlation
matrix of the log-transformed raw counts for which a heatmap (Euclidean distance,
complete linkage) is shown in Appendix Figure A.2. While no major batch effects
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were detectable between the samples, 9 samples were excluded due to poor correlation
with the remaining samples, as detailed in Table 2.1. These samples showed unusual
density plots compared to the rest of the dataset, and exhibited low mean read count
in Figures 2.1 and 2.2. A heatmap showing key clinical properties of these excluded
samples and their correlation with the remainder of the samples is shown in Appendix
Figure A.3, and a full correlation heatmap (Figure A.2) shows these samples as rela-
tively poorly correlated outliers in the bottom rows and left columns. In addition to
the clustering analysis (in Appendix A.2), replicate tumour samples were also exam-
ined for sample quality in Appendix A.3. After removal of these samples, the TCGA
dataset used for analysis consisted of the remaining 1168 samples (from 1040 patients):
1049 tumour samples, 112 normal tissue for matched samples, and 7 metastases.
(a) Raw counts (log-scale) (b) Voom normalised
Figure 2.1: Read count density. Sample density plots of raw counts on log-scale and
voom normalised showing samples removed due to quality concerns.
Similarly, a correlation matrix of log-transformed raw counts was used to evaluate
sample quality for TCGA stomach RNA-Seq. A tumour sample (patient 4294) was
removed due to similar quality concerns leaving a final dataset for 449 samples (from
417 patients): 414 tumour samples and 35 normal tissue samples.
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(a) Mean raw counts (log-scale) (b) Mean voom normalised
Figure 2.2: Read count sample mean. Boxplots of sample means for raw counts on
log-scale and voom normalised show removed tumour samples with low mean read count.
Table 2.1: Excluded samples by batch and clinical characteristics.
Tissue Source Type Batch Plate Patient Samples p53 Subtype Treatment (History) Clinical Subtypes (Stage)
A7 Christiana Tumour 47 A227 A0DB 1 of 3 NA Luminal A Mastectomy (no) ER+ Ductal (2)
A7 Christiana Tumour 96 A220 A13D 1 of 3 Wildtype Luminal A Mastectomy (no) ER+ Ductal (2)
A7 Christiana Tumour 96 A227 A13E 1 of 3 NA Basal Lumpectomy (no) ER− Ductal (2)
A7 Christiana Tumour 142 A277 A26E 1 of 3 NA Basal Lumpectomy (no) ER+ Ductal (2)
A7 Christiana Tumour 47 A277 A0DC 1 of 2 NA Luminal A Mastectomy (yes) ER+ Lobular (3)
A7 Christiana Tumour 142 A220 A26I 1 of 2 Mutant Basal Lumpectomy (yes) ER− Ductal (2)
AC Intl Genom Tumour 177 A18M A2QH 2 of 2 Mutant Basal Radical Mastectomy (no) ER− Metaplastic (2)
AC Intl Genom Tumour 177 A220 A2QH 2 of 2 Mutant Basal Radical Mastectomy (no) ER− Metaplastic (2)
GI ABS IUPUI Normal 177 A16F A2C8 1 of 1 NA Luminal A
Radical Mastectomy
and Neoadjuvant
(no) ER+ Ductal (2)
2.2.3 Metagenes and the Singular Value Decomposition
A “metagene” offers a one-dimensional summary of pathway (expression) activation or
inactivation by dimension reduction of a matrix, avoiding negatively correlated genes
averaging out the signal of a mean-based centroid (Huang et al., 2003). Constructing
pathway metagenes used gene sets for Reactome and the Gatza signatures (Gatza et al.,
2011, 2014) as specified above (in Section 2.1.1.2). The singular-value decomposition
(X = UTDV ) was performed on a data matrix X of m genes (in the gene set) ×
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n samples, U an m × m matrix of eigenvectors of the matrix XXT which gives an
eigenvector for each gene, D is a rectangular diagonal matrix of “singular values” which
weight the eigenvectors, and V is an n× n matrix of eigenvectors of the matrix XTX
which gives an eigenvector for each sample. The leading eigenvector (first column of
V ) corresponding to the largest singular value was used as a metagene for the pathway
gene set. To ensure consistent directionality of metagene signals, the median of the
gene set in each sample was calculated and correlated against the metagene with the
(arbitrary) metagene sign adjusted as needed to conform with the majority of the gene
set (i.e., positive correlation between metagene and the median-based centroid). To
ensure that genes and pathways were weighted equally, metagenes were derived from a
z-transformed (mean 0, standard deviation 1) dataset of gene expression and samples
were scaled (by fractional ranking) for each metagene so that they were comparable on
a [0, 1] scale.
2.2.4 Candidate Triage and Integration with Screen Data
Candidate triage in combination with the experimental data was intended to integrate
findings of the SLIPT analysis (a synthetic lethal detection methodology developed
in this thesis and described Section 3.1) with an ongoing experimental project (Chen
et al., 2014; Telford et al., 2015). The first procedure to compare the SLIPT gene
candidates for CDH1 with an siRNA experimental screen (Telford et al., 2015) was
a direct comparison of the overlapping candidates, presented in a Venn diagram and
tested with the χ2 test. Since these candidates modestly overlapped at the gene level
(even when excluding genes not contained in both datasets), further gene set over-
representation analysis was performed for pathways specific to each detection approach
and the intersection of the two.
The pathway composition of the intersection was further verified by a permuta-
tion resampling analysis (as described in Section 2.3.6): the same number of genes
detected by SLIPT were sampled randomly from the universe of genes tested by both
approaches. These samplings were performed over 1 million iterations and the path-
way over-representation was compared for each of the 1652 Reactome pathways. These
over-representation scores (χ2) were compared the observed over-representation in the
intersection of the SLIPT candidates, with the proportion of resamplings with higher
χ2 values used for empirical p-values of pathway composition. The χ2 test was used as
an appropriation of Fisher’s exact test on a hypergeometric distribution for resampling
to computationally scale pathway over-representation tests across iterations. Path-
44
ways for which no resamplings were occurred as high as the observed were reported
as p < 10−6. These empirical p-values were adjusted for multiple comparisons (FDR).
Intersection size was not assumed to be constant during resampling so that it could
also be used to evaluate significance of enrichment or depletion (of siRNA candidate
among SLIPT candidate genes).
2.3 Techniques
Various statistical, computational, and bioinformatics techniques were performed through-
out this thesis. This Section describes these techniques and gives the parameters used
unless otherwise specified. Where relevant, the R package implementation which pro-
vided the technique will be acknowledged.
2.3.1 Statistical Procedures and Tests
As described in Sections 2.3.4 and 2.2.3, the z-transform has been used to generate z-
scores in various analyses in this thesis. Each row (i) of the dataset (xi) was transformed





This generates data where each row (gene) has a mean of 0 and standard deviation of
1. Where plotted as a heatmap, any data more than 3 standard deviations above or
below the mean was plotted as 3 or −3 respectively.
Where specified, the Fisher’s exact test, χ2 test, and correlation were used to mea-
sure associations between variables, as implemented in the stats R package (R Core
Team, 2016). Unless otherwise specified, Pearson correlation was used for correlation
analyses (r) and coefficient of determination (R2). Where these comparisons are dis-
cussed in more detail, Fisher’s exact test and χ2 tests are supported by a table or Venn
diagram, rendered with the limma R package (Ritchie et al., 2015). In some analyses,
correlation is further supported by a scatter plot and a line of best fit derived by least
squares linear regression.
The t.test function (R Core Team, 2016) has also been used to implement the
t-test to compare pairs of data. Where relevant, an analysis of variance (ANOVA) has
been performed to report significance of multivariate predictors of outcomes, or least
squares linear regression performed for the adjusted coefficient of determination (R2)
and F-statistic p-value to evaluate the fit of the predictor variables. For some analyses
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these are supported by boxplot or violin plot visualisation (Adler, 2005), rendered in
R (R Core Team, 2016).
Multiple comparisons were accounted for with the Benjamini-Hochberg procedure
to control the FDR unless otherwise specified (Benjamini and Hochberg, 1995). This
procedure adjusts p-values to achieve an average of the proportion of false-positives
among significant tests below a threshold, α. The more stringent Holm-Bonferroni
(Holm) procedure (Holm, 1979) was also applied in some cases to adjust for multiple
comparisons and control the family-wise error rate which adjusts p-values so that the
probability that any one of the tests is a false-positive (type-1 error) below a threshold,
α.
2.3.2 Gene Set Over-representation Analysis
Gene set enrichment over-representation analysis was performed to test whether there
was an enrichment of a gene set (e.g., a biological pathway) among a group of input
genes. Such input genes may be predicted synthetic lethal candidates or a subset
defined by clustering (in Section 2.3.3) or comparison with experimental candidates
(in Section 2.2.4). Initially, these tests were performed using the GeneSetDB web tool
(Araki et al., 2012) hosted by the University of Auckland on the Reactome pathways
(Croft et al., 2014). Since the GeneSetDB tool used an older version of Reactome
(version 40), it was difficult to directly compare with the results of other analysis (in
Sections 2.2.4 and 2.3.6) performed on version 52 (as described in Section 2.1.1.2).
Thus an implementation of the hypergeometric test in R (R Core Team, 2016) was
used to test for over-representation against Reactome (version 52) pathways. Pathways
containing less than 10 genes or more than 500 (as performed in GeneSetDB by Araki
et al., 2012) were excluded before adjusting for multiple comparisons. Therefore 1050
of the 1642 Reactome pathways were analysed. These pathways overlap as shown in
Appendix Figure A.1 and so adjusting for multiple testing is very stringent since some
statistical tests were not independent.
2.3.3 Clustering
The clustering analysis used unsupervised hierarchical clustering with complete link-
age (distance calculated from the furthest possible pairing). For correlation matrices
or multivariate normal parameters (e.g., Σ), the distance metric used was Euclidean
distance. For empirical or simulated gene and pathway expression data correlation dis-
tance was used, calculated by distance = 1−cor(t(x)) where cor is Pearson correlation
and t(x) is the transpose of the expression matrix.
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2.3.4 Heatmap
Standardised z-scores of the data were used to plot heatmaps on an appropriate scale.
Raw (log-scale) read counts or voom normalised counts per gene (as specified) were
plotted as normalised z-scores on a [−3,+3] blue-red scale. Similarly, correlations
were plotted on a [−1,+1] blue-red scale. Heatmap dendrograms were generated us-
ing the linkage method and distance specified for the clustering performed in Sec-
tion 2.3.3. The gplots R package (Warnes et al., 2015) was used to generate many of
the heatmaps throughout this thesis, along with a customised heatmap function (re-
leased as heatmap.2x, detailed in Table 2.4 and Section 3.5.2). Where clearly specified,
data have been split into subsets with clustering performed separately on each subset
with these plotted alongside each other.
2.3.5 Modelling and Simulations
Statistical modelling and simulations were used to test various synthetic lethal detec-
tion procedures on simulated data. This involved constructing a statistical model of
how synthetic lethality would appear in (continuous normally distributed) gene expres-
sion data. Where presented (in Section 3.2.1), the assumptions of the model are stated
clearly. The model allows sampling from a multivariate normal distribution (using the
mvtnorm R package (Genz and Bretz, 2009; Genz et al., 2016)) to generate simulated
data with known underlying synthetic lethal partners (detailed in Section 3.2.2). I can
test whether statistical procedures, including those developed in this thesis (presented
in Section 3.1), are capable of detecting synthetic lethal partners within the simulated
data. This multivariate normal simulation procedure also enables the inclusion of cor-
relation structure which is either given as correlated blocks of genes or derived from
pathway structures (as detailed in Section 3.4.2).
When this multivariate normal distribution is sampled once and the procedure to
add known synthetic lethal partners is performed, it generates a simulated dataset.
Performing this simulation procedure and testing with a synthetic lethal detection
procedure iteratively, these simulations can be used to assess the statistical performance
of the detection procedure. The number of iterations (Reps) will be given for each
simulation result. Typically, these are performed 1000 or 10,000 times depending on
the computational feasibility of doing so on larger datasets.
Several measures of statistical performance were used to assess the simulations. The
following measures used the final classification of the detection procedure, statistical
significance for χ2, significance and directional criteria met for SLIPT (in Section 3.1),
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and an arbitrary threshold: r < −0.2 and r > +0.2 for negative correlation and correla-
tion respectively. The significance thresholds (of FDR adjusted p < 0.05) were applied
for SLIPT and χ2 as used throughout thesis. The thresholds for correlation were used
to classify a meaningful number of genes (several hundred) to test the methodology.
This threshold does not affect the statistical performance from which the main conclu-
sions are drawn. Sensitivity (or “true positive rate”) was measured as the proportion of
known synthetic lethal partners predicted to be synthetic lethal. Specificity (or “true
negative rate”) was measured as the proportion of known non-synthetic lethal partners
predicted not to be synthetic lethal. The “false positive rate” was measured here as the
proportion of known non-synthetic lethal partners out of all putative partners predicted
by the detection procedure. Statistical “accuracy” is the proportion of true predictions
for a detection procedure, which is both the correctly predicted known synthetic lethal
partners and correctly negative known non-synthetic lethal partners.
2.3.5.1 Receiver Operating Characteristic Curves
A more general procedure to measure the statistical performance of a simulation is the
receiver operating characteristic (ROC) curve which does not assume a threshold for
classification of synthetic lethality but demonstrates the achievable range of sensitivity
and specificity for a model (Akobeng, 2007; Fawcett, 2006; Zweig and Campbell, 1993).
These curves (implemented with the ROCR R package (Sing et al., 2005)) plot the
true positive rate (sensitivity) against the false positive rate (1−specificity) as the
prediction threshold is varied. An ideal detection method will have a true positive
rate of 1 and a false positive rate of 0, hence the Area Under the ROC curve (AUC
or area under receiver operating characteristic (AUROC)) is a measure of statistical
performance for a detection procedure accounting for this trade-off. AUROC values
typically range from 0.5 (the value expected by random chance) to 1 for an optimal
detection method, however it is possible for an AUROC below 0.5 for a poor detection
method that performs worse than random chance. In cancer biology, it has been
suggested that an AUROC of approximately 0.8 is a predictive biomarker suitable for
publication (Hajian-Tilaki, 2013) but predictors with lower AUROC values may still
be informative depending on the context. In this thesis, the AUROC values varied
widely across simulation parameters and were primarily used for comparisons across




Resampling analyses (e.g., “permutation” analysis) are used to statistically test the sig-
nificance of an observation without assuming the underlying distribution of expected
test statistics (Collingridge, 2013). Instead these are derived from randomly shuffling
test statistics or randomly sampling predicted candidates. For the purposes of this
thesis, this involved randomly sampling genes from those tested to be analysed as
putative synthetic lethal candidates. This was performed both for testing the signif-
icance of pathway composition in the intersection with experimental gene candidates
(Section 2.2.4) and for assessing the significance of pathway structure among synthetic
lethal candidates (Section 3.4.1.1).
These were analysed to compare the observed synthetic lethal genes against values
derived from randomly sampling the same number of genes as were observed to be
synthetic lethal from among the genes tested. Sampling iteratively across many resam-
pling procedures, these resampling-based values form a null distribution that could be
expected if the null hypothesis were true. Thus the proportion of resampling-based
values across these iterations that are greater than or equal to that observed, forms an
empirically derived p-value to test significance.
Resampling was performed for comparison (in Section 2.2.4) with fixed experimental
screen candidates (Telford et al., 2015) both resampling the number of genes overlap-
ping with the screen candidates and test statistics for pathway enrichment. Resampling
analysis was also applied to shortest paths and network metrics (in Section 3.4.1.1) to
test significance of directional relationships between synthetic lethal candidate genes
within pathway structures.
The number of iterations determines the accuracy of these p-values. For path-
way composition (in Section 2.2.4), a million iterations were performed using high
performance computing (as detailed in Section 2.5.3) to provide sufficient accuracy af-
ter adjusting for multiple comparisons across pathways. For the purposes of network
analysis (in Section 3.4.1.1), a thousand iterations were sufficient to reject the null hy-
pothesis for the majority of pathways tested before adjusting for multiple comparisons,
and thus further iterations were not performed.
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2.4 Pathway Structure Methods
2.4.1 Network and Graph Analysis
Networks are important in considering the structure of relationships in molecular bi-
ology, including gene regulation, kinase cellular signalling, and metabolic pathways
(Barabási and Oltvai, 2004). Network theory is an interdisciplinary field which com-
bines the approaches of computer science with the metrics and fundamental principles
of graph theory, an area of pure mathematics dealing with relationships between sets
of discrete elements. The vast amounts of molecular and cellular data from high-
throughput technologies have enabled the application of network-based and genomes-
wide bioinformatics analysis to examine the complexity of a cell at the molecular level
and understand aberrations in cancer. This thesis uses various metrics and analysis
procedures developed in Graph and Network theory to analyse graph structure of bi-
ological pathways. Where feasible, these have been implemented using the igraph R
package with such procedures described below (Csardi and Nepusz, 2006). Custom R
functions were used to perform more complex analysis and visualisation of iGraph data
(as described in Section 3.5.3).
Graph theory is a branch of pure mathematics which deals with the properties of sets
of discrete objects (referred to as a ‘node’ or ‘vertex‘) with some pairs are joined (by a
‘link’ or an ‘edge‘). While a seemingly reductionist abstraction to mathematically study
relationships, graph theory has applications in a wide range of fields, including the life
sciences. Graph theory has been applied to analysis of social networks (Milgram, 1967),
protein-protein interactions (Kranthi et al., 2013), disease transmission (Barabási and
Oltvai, 2004), and multi-target compounds in pharmacology (Hopkins, 2008). Network
theory is the sub-discipline of graph theory that deals with networks, which has become
popular due to the vast potential for applications of networks (van Steen, 2010).
Applications vary depending on the situation modelled, particularly in how the
edges between vertices are defined, whether they are directed or weighted, and whether
multiple redundant edges between a pair of vertices (referred to as ‘parallel edges‘)
or edges connecting a vertex to itself (referred to as ‘loops‘) are permitted in the
model. Networks are defined such that the edges represent a relationship between the
vertices and may be directed, weighted, or contain parallel edges or loops depending
on the application (van Steen, 2010). Unless otherwise stated, graph structures and
networks in this thesis will be unweighted and have no parallel edges or loops. Where
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a directional relationship is known or modelled, it will be represented with a directed
edge in a directed graph.
2.4.2 Sourcing Graph Structure Data
Pathway Commons interaction data was sourced using the Biological PAthway eX-
change (BioPAX) with the paxtools-4.3.0 Java application on October 6th 2015 (Cerami
et al., 2011; Demir et al., 2013). This utility was used to import‘sif’ format interaction
data into R (R Core Team, 2016) and extract the human Reactome (version 52) dataset
of interactions was imported (Croft et al., 2014), matching those used for pathway en-
richment analysis. These interactions were used to construct an adjacency matrix (Aij
for row i and column j) for the Reactome network and subnetworks corresponding to
each relevant biological pathway.
Aij =
1 if genes i and j are adjacent0 otherwise
2.4.3 Constructing Pathway Subgraphs
Subgraphs for each relevant pathway were constructed by matching the nodes in the
complete Reactome network to the pathway gene sets (as derived in Section 2.1.1.2).
A subgraph with adjacent nodes was constructed by adding nodes which have an edge
with a gene in the pathway gene set. The pathways these adjacent nodes belong to
were added to form a “meta-pathway” to account for the possibility for nodes within
the pathway being linked by the surrounding graph structure.
2.4.4 Network Analysis Metrics
The existing network analysis measures applied in this thesis (as described below)
used an implementation in the igraph R package to compute vertex degree, shortest
paths, and centrality (Csardi and Nepusz, 2006). Additionally, custom features were
developed for analysis of iGraph objects in R and released as igraph.extensions (as
described in Section 3.5.3).
Vertex degree is the number of edges a node has and is a fundamental measure
of the importance and connectivity of a network (van Steen, 2010). More connected
nodes, such as network hubs, will have a higher vertex degree relative to other nodes.
For the purposes of this thesis, vertex degree ignored edge direction with loops (edges
with itself) and double edges to the same node excluded.
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A fundamental concept in network analysis is a “shortest path”, that is the shortest
route via edges between any two particular nodes in a network. These are computed
by Dijstra’s algorithm (Dijkstra, 1959) in the igraph R package (Csardi and Nepusz,
2006). Where applicable paths will only use directed edges in a particular direction.
Shortests paths are a useful measure of how close nodes are in a network. This is used
to compute information centrality, and for further analysis of pathway structure (as
described in Section 3.4.1).
Network centrality is an alternative measure of the importance or influence of a node
to the graph structure (Borgatti, 2005). Various strategies are used to derive centrality,
typically based on how connected the node is or the impact of node removal on the
connectivity of the network. One of the most notable is the “PageRank” algorithm, a
refinement of eigenvector centrality based on the eigenvectors of the adjacency matrix
(Brin and Page, 1998). This is implemented in the igraph R package (Csardi and
Nepusz, 2006).
Another network centrality measure that has been previously applied to biological
protein interaction networks (Kranthi et al., 2013) is the “information centrality”.
The information centrality of a node is the relative impact on efficiency (transmission
of information via shortest paths) of the network when the node is removed. The





where G′ is the subgraph with the node removed and E is the efficiency (Latora and








The efficiency of a network can be derived from shortest paths using the igraph R
package and the network centrality computation for each node has been released as an
R package (info.centrality) and included in the igraph.extensions package.
2.5 Implementation
2.5.1 Computational Resources and Linux Utilities
Several computers were used to process and store data during this thesis (as summarised
in Appendix Table B.1), running different versions of Linux operating systems, includ-
ing a personal laptop computer, laboratory desktop machine, departmental server, and
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the New Zealand eScience Infrastructure Intel Pan high-performance computing clus-
ter (a supercomputer based at the University of Auckland). Each of these systems
support a 64-bit architecture. Current workflows on local machines use Elementary
OS (based on the Ubuntu versions given in Appendix Table B.1) and the ZSH shell.
However, Ubuntu OS and the Bash were used at the inception of this project and Bash
continues to be used for running scripts. Various Linux applications and command-
line utilities were used on these machines (shown in Appendix Table B.2). As such,
the workflows developed in this project should be backwards-compatible with Ubuntu
Linux (and other derivatives). The majority of novel methodology and implementa-
tions were performed in R which is a cross-platform language, packages developed in
R will be available for users of Linux, Mac, and Windows machines.
2.5.2 R Language and Packages
The R programming language has been used for the majority of this thesis. Current R
installations across the machines used are given in Table 2.2. Local machines currently
run the latest version of the R (at the time of writing) and remote machines run the
versions and modules as managed by the system administrator.
Various scripts and packages in this thesis were developed or run in previous versions
of RStudio and R but these run without error in the current version of R (and the older
versions on remote machines). The R packages which were used throughout this thesis
(as detailed in Table 2.3 with versions specified) were installed from the comprehensive
R archive network (CRAN) (CRAN, 2017), Bioconductor (Gentleman et al., 2004,
version 3.4; BiocInstaller 1.24.0), or GitHub (https://github.com/). These packages
were not updated when they would change the functionality of scripts or functions in
packages. In particular, imported data from annotation packages (used to define gene
sets) have been saved as local files to continue using stable versions of these pathway
data (across machines).
This is a summary of the key packages which (in addition to their dependencies)
have been used throughout this project. Where a package implementation has been
central to the methods applied, they are described in more detail in the relevant Section.
A full table of packages used in this thesis can be found in Appendix Table B.3. The R
packages developed during this thesis are given in Table 2.4 with the relevant Sections
describing their implementation and use where appropriate, in addition to further
details on these functions in Section 3.5.
Table 2.3: R Packages used during thesis
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Package Version Used Built Repository
colorspace 1.3-2 3.3.1 CRAN
curl 2.3 3.3.1 CRAN
data.table 1.9.6 3.3.1 CRAN
dendextend 1.4.0 3.3.2 CRAN
DBI 0.5-1 3.3.1 CRAN
devtools 1.12.0 3.3.1 CRAN
dplyr 0.5.0 3.3.1 CRAN
ggplot2 2.2.1 3.3.1 CRAN
git2r 0.18.0 3.3.1 CRAN
gplots 3.0.1 3.3.1 CRAN
gtools 3.5.0 3.3.1 CRAN
igraph 1.0.1 3.3.1 CRAN
matrixcalc 1.0-3 3.3.1 CRAN
mclust 5.2.2 3.3.1 CRAN
mvtnorm 1.0-6 3.3.1 CRAN
org.Hs.eg.db 3.1.2 3.1.2 Bioconductor
openssl 0.9.6 3.3.1 CRAN
plyr 1.8.4 3.3.1 CRAN
purrr 0.2.2 3.3.1 CRAN
reactome.db 1.52.1 3.2.1 Bioconductor
RColorBrewer 1.1-2 3.3.1 CRAN
Rcpp 0.12.9 3.3.1 CRAN
ROCR 1.0-7 3.3.1 CRAN
roxygen2 6.0.1 3.3.2 CRAN
shiny 1.0.0 3.3.1 CRAN
snow 0.4-2 3.3.1 CRAN
testthat 1.0.2 3.3.2 CRAN
tidyr 0.6.1 3.3.2 CRAN
tidyverse 1.1.1 3.3.2 GitHub (hadley)
sm 2.2-5.4 3.3.1 CRAN
Unicode 9.0.0-1 3.3.2 CRAN
vioplot 0.2 3.3.1 CRAN
viridis 0.3.4 3.3.2 CRAN
xml2 1.1.1 3.3.2 CRAN
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xtable 1.8-2 3.3.1 CRAN
zoo 1.7-14 3.3.1 CRAN
graphics 3.3.2 3.3.2 base
grDevices 3.3.2 3.3.2 base
cluster 2.0.5 3.3.1 base
Matrix 1.2-8 3.3.1 base
stats 3.3.2 3.3.2 base
2.5.3 High Performance and Parallel Computing
Another enabling technology for bioinformatics is parallel computing, performing in-
dependent operations using separate central processing unit (CPU) cores: this “mul-
tithreading” is widely used to decrease the time to compute results. Bioinformatics is
particularly amenable to this since performing multiple iterations of a simulation or
testing separate genes is often “embarrassingly parallel”, as CPUs completely indepen-
dent of each other.
The New Zealand eScience Infrastructure (NeSI) is a High Performance Computing
(HPC) organisation providing the Intel Pan cluster or “supercomputer” at the Univer-
sity of Auckland (NeSI, 2017). The cluster was used throughout this thesis project to
optimise and perform computations which would have otherwise been infeasible. High
performance computing on the Pan cluster was used extensively in this project in-
cluding for resampling analysis (in Sections 2.3.6 and 3.4.1.1), calculating information
centrality (in Section 2.4.4), and in simulations (in Sections 2.3.5, 3.2, and 3.4.2)
Scripts and data were transferred between the Pan cluster and University of Otago
computing resources by rsync or the Globus file transfer service (Globus, 2017). R
scripts (R Core Team, 2016) were run in parallel with the “simple network of work-
stations” snow R package Tierney et al. (2015). This utilised the “message passing
interface” (Yu, 2002) when it was feasible with memory requirements to run in parallel
across multiple compute nodes, otherwise Socket Secure (SOCKS) was used to access
multiple cores within an instance of R and pass input data to them. R jobs were sub-
mitted to queue for available resources and run on the Pan cluster via the Simple Linux
Utility for Resource Management (Slurm) workload manager (Slurm, 2017). Slurm ar-
ray job submission and independent running of different parameters (with arguments
passed to R from the shell) were used to run memory-intensive job or scripts across
many parameters simultaneously. In some cases, this submission was automated across
a range of parameters with Bash scripts.
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Table 2.2: R installations used during thesis










Programming R 3.3.2 3.3.2 3.3.1 3.3.0-intel (module)
Development RStudio 1.0.136 1.0.136 1.0.136 (server)
Table 2.4: R packages developed during thesis
Package Name Description and GitHub Repository Section
slipt




Customised violin plots (based on vioplot)
https://github.com/TomKellyGenetics/vioplotx
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Methods Developed During Thesis
In this Chapter, I outline the rationale and development of various methods used
throughout this thesis to examine synthetic lethality in gene expression data, graph
structures, models and simulations. Firstly, the Synthetic Lethal Interaction Prediction
Tool (SLIPT), a bioinformatics approach to triage synthetic lethal candidate genes,
will be described. This is one of the main research outputs of this thesis project
and is supported by comparisons to an experimental screen from a related project and
evaluation of performance on simulated data. These supporting findings will be covered
in further chapters but simulation data is included to support the use and design of
SLIPT. This includes the construction of a statistical model of synthetic lethality in
(continuous multivariate Gaussian) gene expression data, which enables testing SLIPT
upon simulated data with known synthetic lethal partners. Another key component
of this simulation pipeline is the generation of simulated data from a known graph
structure or simulated biological pathway (as applied in Chapter 6). The development
of this simulation procedure and other statistical treatment of graph and network
structures will also be covered. Various R packages have been developed to support this
project, including the slipt package to implement the SLIPT methodology. Additional
R packages for handling graph structures, simulations, and custom plotting features
will be described as research outputs of this thesis, methods applied throughout, and
contributions of open-source software.
3.1 A Synthetic Lethal Detection Methodology
The SLIPT methodology identifies gene expression patterns consistent with synthetic
lethal interactions, between a query gene and a panel of candidate interacting partners.
Gene expression is scored “low”, “medium”, or “high”, sorting samples by tertiles (1/3-
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quantiles) for each gene. Genes with insufficient expression across all samples are
excluded by requiring that the first tertile of raw counts is above zero. A χ2 test is
then performed between the query gene and each candidate partner. The p-values for
the χ2 test are corrected for multiple testing using False discovery rate (FDR) error
control to reduce false positives (Benjamini and Hochberg, 1995). Significance is called
for FDR adjusted p < 0.05. A synthetic lethal interaction is predicted (as shown in
Figure 3.1) when (i) the χ2 test is significant; (ii) observed low-query, low-candidate
samples are less frequent than expected; and (iii) observed low-query, high-candidate
and high-query, low-candidate samples are more frequent than expected.
The synthetic lethal prediction procedure has also been performed with somatic
mutation data for the query gene. This is intended for a known query gene which is
recurrently mutated, with the majority of mutations disrupting gene function (e.g.,
null or frameshift mutations). A synthetic lethal interaction is predicted (as shown
in Figure 3.2) when (i) the χ2 test is significant; (ii) observed mutant-query, low-





























Figure 3.1: Framework for synthetic lethal prediction. SLIPT was designed to identify
candidate interacting genes from gene expression data using the χ2 test against a query gene.
Samples are sorted into low, medium, and high expression quantiles for each gene to test for a
directional shift. A sample being low in both genes of a synthetic lethal pair is unlikely, since
loss of both genes will be deleterious, and is expected to be statistically under-represented in
a gene expression dataset. It is expected for there to be a corresponding (symmetric) increase
in frequency of sample with low-high gene pairs. Synthetic lethal candidate partners of a gene
were identified by running this procedure on all possible partner genes, selecting those with
an FDR-adjusted χ2-derived p < 0.05, and meeting the directional criteria. Since synthetic
lethal genes are partners of each other, commutatively, the symmetric direction criteria were




























Figure 3.2: Synthetic lethal prediction adapted for mutation. SLIPT was also
adapted to identify candidate interacting genes using (somatic) mutation data of the query
gene in the χ2 test. Samples are sorted into low, medium, and high expression quantiles for
each candidate gene and tested for a directional shift against mutation status of the query
gene. A sample having low expression or mutation for the synthetic lethal pair is expected
to be unlikely with a corresponding increase in frequency of sample with mutant-high or
wild-type-low gene pairs. Synthetic lethal (mtSLIPT) candidate partners of a gene were
identified from running this procedure on all possible partner genes, selecting those with an
FDR-adjusted χ2-derived p < 0.05, and meeting the directional criteria.
high-candidate and wild-type-query, low-candidate samples are more frequent than
expected. This modified methodology will be referred to as mtSLIPT.
The SLIPT methodology can be performed on expression data, including pathway
metagenes (as generated in Section 2.2.3). The application of the SLIPT methodology
on public gene expression data will be supported with simulation results (in Section 3.3
and Chapter 6), including comparison to other statistical methods. SLIPT results for
CDH1 were compared to the experimental screen results in a breast cell line (Telford
et al., 2015). Primary screen results are discussed in Section 4.2 and secondary screen
results are presented in Section 4.2.4.
3.2 Synthetic Lethal Simulation and Modelling
A statistical model of synthetic lethality was developed to generate simulated data and
to evaluate the SLIPT procedure. This Section describes the synthetic lethal model
and the simulation procedure for generating gene expression data with known syn-
thetic lethal partners. Simulation results, to support usage of the SLIPT methodology
throughout this thesis, will be presented in Section 3.3. The simulation procedure will
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also be applied in Chapter 6, including in combination with simulations from graph
structures (as described in Section 3.4.2).
3.2.1 A Model of Synthetic Lethality in Expression Data
A conceptual model of synthetic lethality was devised (as shown in Figure 3.3), which
was used to build a statistical model of synthetic lethal gene expression and to simulate
expression data for assessing various potential synthetic lethal prediction methods,
including SLIPT. In the model, synthetic lethality occurs between genes with related
functions leading to a cell death phenotype when these functions are inactivated.
This model suggests that synthetic lethality is detectable in measures of gene inacti-
vation across a sample population, namely mutation, DNA copy number, DNA methy-
lation, and expression levels. While any of these mechanisms of gene inactivation could
lead to synthetic lethality, expression data is readily available and changes in other
mechanisms are likely to impact on the amount of expressed RNA that is detectable.
Functional relationships between genes could manifest in expression data in several
ways, including coexpression, mutual exclusivity and directional shifts. Co-expression
is overly simplistic (Lu et al., 2015) and has previously performed poorly as a predictor
of synthetic lethality with an AUROC of 0.623 (Jerby-Arnon et al., 2014), although
this will still be tested with correlation measures in later simulations. The alternative
hypothesis is that synthetic lethality will result in a detectable shift in the number
of samples which exhibit low or high expression of either gene. This model does not
preclude mutual exclusivity, compensating expression, or co-loss under-representation
which may occur between synthetic lethal genes (Lu et al., 2015; Wappett et al., 2016).
The first condition of the synthetic lethal model is that if there are only two syn-
thetic lethal genes (e.g., CDH1 and one SL partner), then they will not both be non-
functional in the same sample (in an ideal model). Gene function is thus determined
for each sample in a model of synthetic lethality with the proportion of samples which
are functional or non-functional for a gene being arbitrary. Whether a gene is func-
tional can similarly be modelled by an arbitrary threshold of continuous and normally
distributed gene expression data to define gene function (as shown in Figure 3.4). For
the purposes of modelling synthetic lethality in cancer expression data, a threshold
of the 30th percentile of the expression levels was used because approximately 30% of
samples analysed had CDH1 inactivation (mutations) in breast cancer (Koboldt et al.,
2012). This was generalised for a model of the proportion of samples inactivated for
each gene. The threshold of the 0.3 quantile was used in simulations derived from this
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Figure 3.3: A model of synthetic lethal gene expresion. A conceptual model of
synthetic lethal interactions between a Query gene and partner gene (GX). Genes that are
synthetic lethal may not both be non-functional in the same sample without another gene
compensating for the loss of function. This is most likely to be detectable as low gene
expression, whether they are lost by mutation, deletion, DNA methylation, or suppressing
regulatory signals. This could manifest as coexpression, mutual exclusivity, or directional
shifts in sample frequency. Thus the alternative hypothesis (HA) is that synthetic lethal
genes will have a reduced frequency of co-loss samples while the null hypothesis (H0) is
that non-synthetic lethal gene pairs would show no such relationship, even if they may be
correlated for other means such as pathway relationships. In this model synthetic lethal genes
may compensate for the loss of each other but this is not assumed, only that loss of both is
unfavourable to cell viability and probability of detecting samples with combined gene loss.
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Figure 3.4: Modelling synthetic lethal gene expression. When modelling synthetic
lethal interactions between a Query gene and partner genes (GX and GY ) above, cellular
viability requires that at least of genes is not inactivated. As a model of loss of function,
genes are regarded as non-functional with expression below a threshold for the purposes of
modelling synthetic lethality. Tumour suppressor genes with loss of function also have cancer
specific phenotypes (although these thresholds are not assumed to be the same). Expression
is modelled by normally (Gaussian) distributed continuous data, such as (log-scale) data from
RNA (microarray or RNA-Seq), protein, or pathway metagenes. This rationale generalises
to several genes on a multivariate normal distribution.
model throughout this thesis. In this ideal case, no samples lowly expressing both of
these genes are expected to be observed. While this was not the case, that is to be
expected as it is unlikely that only two genes will have an exclusive synthetic lethal
partnership.
A synthetic lethal pair of genes is unlikely to act in isolation, therefore higher-order
synthetic lethal interactions (i.e., 3 or more genes) must be considered in the model as
shown in Figure 3.5. Even when testing pairwise interactions, it is important to model
higher level interactions that may interfere. If there are additional synthetic lethal
partners, there are two possibilities for adding these: 1) that they are independent
partners of the query genes interacting pairwise (and not with each other) or 2) that
an additional partner gene interacts with both of the synthetic lethal genes already in
the system and any of the three (or more) are required to be functional for the cell to
survive.
The signal (in terms of gene expression data) will be weaker for this latter case
and this model has the more stringent assumption that all synthetic lethal partner
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Under the synthetic lethal model, all SL partners can not be inactivated
but inactive pairs may be detected at lower frequency than expected
Figure 3.5: Synthetic lethality with multiple genes. Higher order synthetic lethal inter-
actions may occur between 3 or more genes, affecting the simulated expression (or synthetic
lethal predictions) even if undetected when observed pairwise. Consider interactions between
a Query gene and two partner genes (GX and GY ). They may interact with the Query
pairwise (inviable when either gene pair is lost) or form a higher-order interaction such as
the “synthetic lethal triplet” if any of the genes provide an essential function (inviable only
when all are lost). Either is plausible with the potential pathway structures. A synthetic
lethal triple has 8 potential combinations of gene function but one is not expected to be
observed (due to inviability), however pairwise inactivation may be observed if additional
partner genes are functional. The proportion of these combinations varies depending on the
functional threshold.
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the model of synthetic lethality. In this model, any of the synthetic lethal genes in
a higher-order interaction are able to perform the essential function of the others,
allowing for higher-level synthetic lethal partners to compensate for loss of a synthetic
lethal gene pair. While samples that express low levels of the synthetic lethal gene
pairs will be under-represented, they may not be completely absent from the dataset,
due to these higher-level interactions. In the example of three synthetic lethal genes
(shown in Figure 3.5), only one of the genes involved in the higher-order synthetic
lethal interaction is required for cell viability. For synthetic lethal pairs, only a subset
of these samples will be inviable (i.e., removed from simulated data), leading to an
under-representation.
Samples were not actually removed from a simulated dataset, rather the expression
and function of the query gene is generated across samples separately from the pool
of potential partner genes. The query gene data was matched to simulated samples
(as shown in Figure 3.7) satisfying the synthetic lethal condition with the procedure
described in Section 3.2.2. This was performed to maintain a comparable sample size
across simulations and to preserve the (multivariate) normal distribution of the data.
3.2.2 Simulation Procedure
Simulations were developed to generate normal distributions of expression data and
define gene function with a threshold cut-off. While gene function was used as an
intermediary step in modelling synthetic lethal genes in expression data, the normal
distribution was sampled for simulated data to represent normalised empirical gene
expression data for which SLIPT (and other methods) will be applicable.
Sampling a distribution for expression profiles has the advantage of enabling sim-
ulating correlation structures with the multivariate normal distribution, using the
mvtnorm R package (Genz and Bretz, 2009; Genz et al., 2016). The parameter Σ,
the covariance matrix (Σij = σXiXj), defines the correlation structure between the sim-




= 1), this Σ matrix simulates genes with a standard deviation of one and
the covariance parameters between them are the correlations between each gene. In
Figure 3.6, an example of such a simulated multivariate normal dataset is shown with
the functional threshold applied.
Once a simulated dataset has been generated, the samples were compared by gene
function (as derived from a functional threshold). The known underlying synthetic
lethal partners were selected within the dataset and a query gene was generated by
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(a) Simulated expression matrix (b) Corresponding gene function calls
Figure 3.6: Simulating gene function. A simulated dataset with samples (columns) and
genes A–I (rows) was transformed from a continuous (coloured blue–red) scale to a discrete
matrix of gene function (black for functional levels and grey for non-functional).
(a) Simulated gene function with SL genes (b) Query gene added with SL condition
Figure 3.7: Simulating synthetic lethal gene function. In a discrete simulated gene
function dataset (shaded for functional levels and pale otherwise) with samples (columns)
and genes (rows), genes A and I were SL partners of a “Query” gene. A partner was selected
(highlighted in green) randomly in each sample for simulating synthetic lethality, then ordered
such that the query gene or an SL partner were functional in each sample.
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sampling from the normal distribution. These were matched (as shown for two synthetic
lethal partners in Figure 3.7) such that the synthetic lethal condition was met: at
least one of the synthetic lethal partner genes and the query gene are functional in
any particular cell. The samples are ordered by functional data (without assuming
correlation of underyling expression values) with the query gene in one direction and
the remaining dataset ordered by the selected synthetic lethal partner.
(a) Initial expression matrix (b) Simulated synthetic lethal dataset
Figure 3.8: Simulating synthetic lethal gene expression. A simulated continuous
expression dataset (blue–red scale) with samples (columns) and genes A–I (rows) was matched
to a query gene such that at least one synthetic lethal partner was above a functional threshold
when the query gene was below it which satisfied the synthetic lethal model.
This procedure produces a simulated dataset where samples with a non-functional
query gene have at least one functional partner gene. Similarly, the query gene is func-
tional in all samples where all of the synthetic lethal partner genes are non-functional.
In this procedure, a dataset has been generated with known synthetic lethal partners
(as shown in Figure 3.8) with few assumptions about the relationships between the each
synthetic lethal pair (allowing compensating functions from higher-order interactions).
This procedure has been designed to have the most stringent (least detectable) syn-
thetic lethal relationships, where higher-order interactions are possible for the purposes
of testing pairwise detection procedures such as SLIPT.
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3.3 Detecting Simulated Synthetic Lethal Partners
The synthetic lethal detection methodology (SLIPT), as described in Section 3.1, was
evaluated with simulated data containing known synthetic lethal partners, generated
using the procedure described in Section 3.2.2. Simulations were performed to demon-
strate the methodology and support its use throughout this thesis. These simulations
were performed by sampling from statistical distributions, including the multivariate
normal distribution with correlated blocks of genes, generated by Σ matrices such as
those shown. A more complex multivariate normal sampling procedure based on path-
way graph structures, as described in Section 3.4.2, was used for further investigations
in Chapter 6.
3.3.1 Binomial Simulation of Synthetic Lethality
The synthetic lethal simulation procedure (described in Section 3.2.2) initially used
gene function, sampled directly from a binomial distribution using the binomial prob-
ability of observing functional gene levels (p = 0.3) in one observation (n = 1) for each
samples:
X ∼ Binomial(n, p)
for a binary matrix X of gene function with n trials and a probability of p. Once a
query gene with synthetic lethal partners has been added, these functional levels were
passed directly into SLIPT as “low” and “high” samples.
The simulation procedure was performed with 20,000 total genes (as occurs in ex-
pression datasets) with a variable number of true synthetic lethal partners and 500,
1000, 2000, or 5000 samples. Each ROC curve was derived from the results of 10,000
replicate simulations. The statistical performance (as shown in Figure 3.9) of the χ2-
derived p-value declined towards random predictions (an AUROC of 0.5) with more
underlying synthetic lethal partners to detect. However, increased sample size some-
what mitigated this decline, as expected with a statistical predictor, particularly for
moderate numbers of synthetic lethal partners.
Simulations using this binomial model of synthetic lethality were simplistic but
informed the development of more complex simulations including expression and cor-
relation structures. It did not represent the data that SLIPT will be applied to but the
binomial simulations demonstrated that SLIPT is able to distinguish small numbers
of synthetic lethal partners in a simulated system with behaviours expected with re-
spect to sample size. This supported further development of the synthetic lethal model
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Figure 3.9: Performance of binomial simulations. Gene function was simulated by bi-
nomial sampling and tested for synthetic lethality by SLIPT. Statistical performance declined
with additional synthetic lethal partners and lower sample sizes.
Figure 3.10: Comparison of statistical performance. Binomial simulation of synthetic
lethality (in colour) in comparison to multivariate normal simulations (in greyscale), in which
SLIPT consistently had higher performance across parameters.
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and simulation pipeline (as described in Section 3.2) using the multivariate normal
distribution.
The multivariate normal simulation procedure more closely recapitulates the (nor-
malised) expression data that SLIPT was intended for and enables the methodology
procedure to be tested without requiring modifications (in Section 3.3.2). Sampling
continuous expression values from a normal distribution enabled the expression thresh-
old for gene function to differ from the categorical “low” and “high” expression binning
performed by SLIPT (as discussed in Section 3.2.1). The SLIPT procedure does not
assume a known threshold for expression and instead uses expression as an estimate
of gene function which does not compromise the statistical performance of the SLIPT
in the multivariate normal simulation. The performance was an improvement over the
binomial simulation procedure (shown in Figure 3.10) across simulation parameters
in an equivalent simulation (without correlation structure). This multivariate normal
model is also more refined since it defines the synthetic lethal condition, to ensure that
at least one synthetic lethal partner was active in query-deficient samples, without
disrupting the proportion of samples with each gene being functional.
3.3.2 Multivariate Normal Simulation of Synthetic Lethality
The multivariate normal simulation procedure was initially performed using the mvtnorm
R package (Genz and Bretz, 2009; Genz et al., 2016) (as described in Section 3.2) with-
out correlation structure. Expression data (X) was sampled from multivariate normal
distribution with a mean (µ = 0), standard deviation (σ = 1), and no correlation
between genes (r = 0):
X ∼ Normal(µ̄,Σ).
Once a query gene with synthetic lethal partners has been added, the simulated ex-
pression values were tested by SLIPT, as described in Section 3.1.
The statistical accuracy of SLIPT as a binary classifier was high across simulations
of a full dataset of 20,000 genes (shown in Figure 3.11a). Using the χ2-derived p-value
as a threshold for prediction, this was largely due to high specificity: the majority
of non-synthetic lethal genes were distinguished from the underlying synthetic lethal
genes. Thus the SLIPT methodology performed better with larger datasets with more
expected negatives and the results of simulations of smaller numbers of genes (e.g., the
graph structures analysed in Section 6.2.1) can be applied to larger datasets, where
they are expected to perform comparably or better with a lower false negative rate
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(a) Statistical evaluation (b) ROC curves
(c) Statistical performance (AUROC)
Figure 3.11: Performance of multivariate normal simulations. Simulation of syn-
thetic lethality was performed by sampling from a multivariate normal distribution (without
correlation structure). Performance of SLIPT declined with increasing numbers of synthetic
lethal partners and lower sample sizes (in darker colours). This occurred as the sensitivity
decreased with a greater number of true positives to detect, which lead to a trade-off in
accuracy as seen in a trough for false positive rate and the ROC curves.
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(as shown in Sections 6.2.4 and 6.3.2). Accordingly, key results will be supported by
replication with larger numbers of non-synthetic lethal genes added to the simulations.
The sensitivity of SLIPT as a binary classifier of synthetic lethality (as shown in
Figure 3.11a) declined with higher numbers of synthetic lethal genes to detect, although
this is somewhat mitigated by higher sample sizes. The minority of true synthetic
lethal partners are more difficult to distinguish when there are more of them (with
a weaker expression signal from each). While a reduction of the false positive rate
could be achieved for moderate numbers of underlying synthetic lethal partners, the
number of partners to be detected in analyses of expression data is unknown. However,
this simulation procedure is amenable to assessing the performance of SLIPT across
simulation parameters, graph structures, and comparisons to other approaches (as
presented in Chapter 6).
Not all of the genes detected by SLIPT were true synthetic lethal genes but they
were among the strongest candidates and SLIPT had higher performance with fewer
underlying synthetic lethal genes to detect. These results support a focus on pathway
analyses, in particular, the selection of pathways for further investigation. Pathway
over-representation analysis was performed to detect functional groups recurrently de-
tected by SLIPT since individually detected gene candidates were not necessarily syn-
thetic lethal. The detection of functionally related genes (in Chapter 4) supports the
role of a pathway in synthetic lethal relationships. The use of pathway metagenes
can reduce the number of potential pathways, compared to genes, to help identify
synthetic lethality. These approaches were both applied in Chapter 4 to identify the
synthetic lethal pathways of CDH1. Pathways are also more likely to replicate across
experimental models, as demonstrated by Dixon et al. (2008).
The ROC curves showed that SLIPT is subject to a near equal trade-off between
sensitivity and specificity across threshold values (as shown in Figure 3.11b). The lower
sensitivity and higher specificity with a binary classification (as shown in Figure 3.11a)
results from stringent testing by SLIPT with FDR adjusted p-values. The area under
these curves (AUROC) was used to compare statistical performance (as shown in Fig-
ure 3.11c), which had lower performance for more underlying synthetic lethal partners,
and higher performance for larger sample size in multivariate normal simulations.
3.3.2.1 Multivariate Normal Simulation with Correlated Genes
Correlation structures were added to the simulation procedure (with the Σ matrix, as
discussed in Section 3.2), using correlated blocks of genes (as shown in Figure 3.12a).






















































(d) Simulated gene function
Figure 3.12: Simulating expression with correlated gene blocks. A Σ matrix (a)
was used to generate 100 genes with a multivariate normal distribution, including correlated
blocks of genes (r = 0.8) with correlation (b) similar to Σ, on a red–to–green scale. The
annotation for genes gives the χ2 (in blue for in the direction of SLIPT or red otherwise)
and the gene category (blue for query, cyan for query-correlated, red for SL, orange for
SL-correlated, forest green for non-synthetic lethal-correlated, and green for non-synthetic
lethal). The simulated gene expression (c) and function (d) generated were ordered by χ2























































(d) Simulated gene function
Figure 3.13: Simulating expression with correlated gene blocks. Using the Σ ma-
trix (a), sampling 1000 genes from a multivariate normal distribution produced (b) correlated
blocks of genes (correlated by r = 0.8) on a red–to–green scale. The simulated gene expression
(c) and function (d) generated were ordered by χ2 and SLIPT direction show that synthetic
lethal genes are among the strongest SLIPT results with high specificity against many po-
tential false positives. These are annotated for log-χ2 (on a red–to–green scale) and category
(blue for query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green
for non-synthetic lethal-correlated, and green for non-synthetic lethal) for each gene.
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or shared membership of biological pathways. The example (as shown in Figure 3.12)
shows four synthetic lethal genes (out of 100), each with five correlated genes that are
not themselves synthetic lethal partners of the query gene. These simulations address
whether synthetic lethal genes are distinguishable from correlated partners. The Σ
matrix produced a similar correlation structure (Figure 3.12b) and expression profiles
(Figure 3.12c). Apart from correlated blocks of genes (r = 0.8), the remaining genes
had small variations due to random sampling. The structure of the dataset, particu-
larly between synthetic lethal genes and the query, was evident in the simulated gene
expression (Figure 3.12c) and function (Figure 3.12d). When these genes were ordered
by the SLIPT results, the synthetic lethal genes were highly ranked and the majority
of them were distinguishable from highly correlated genes.
The use of correlation structure was applied to larger datasets, such as the 1000
genes shown in Figure 3.13. Synthetic lethal genes were highly ranked by SLIPT
and were often distinguishable from correlated genes. As previously discussed in Sec-
tion 3.3.2, these synthetic lethal genes were still detectable among a larger number
of non-synthetic lethal genes, and the SLIPT methodology performed better on large
datasets.
These plots (Figures 3.12 and 3.13) used similar correlated blocks with a non-
synthetic lethal gene (true negative) and the query gene (which is not synthetic lethal
with itself). Neither of these were synthetic lethal but they could potentially affect per-
formance methodology, particularly the specificity, as correlated non-synthetic lethal
genes may be distinguishable from synthetic lethal genes. The non-synthetic lethal
correlated block of genes had no impact on synthetic lethal detection but the query
correlated genes were important (as shown in Sections 3.3.2.2 and and 6.1.1.1).
The simulations of gene expression data (with 100 genes) with correlations structure
were used to examine the variation between detection in different samples and varying
the number of underlying synthetic lethal partners. A small number of simulations
(10 for each) are shown to demonstrate the variation between replicate simulations
from iterative sampling from the same multivariate normal distribution (as shown
in Figure 3.14). These simulations showed that synthetic lethal genes were highly
ranked by SLIPT when there are few of them and these were relatively consistent
across replicate simulations. However, they were less consistent for higher numbers of
synthetic lethal partners to detect and were more difficult to distinguish from other
genes, particularly those correlated with them. Similarly, the χ2 values showed clear
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(a) Gene category in simulations







































































































































(b) Corresponding χ2 values
Figure 3.14: Synthetic lethal prediction across simulations. The gene category (a)
ordered by χ2 and the SLIPT directional condition is shown across simulations (blue for
query, cyan for query-correlated, red for SL, orange for SL-correlated, forest green for non-
synthetic lethal-correlated, and green for non-synthetic lethal). For each number (1–10) of
synthetic lethal partners, 10 simulations show that the increasing numbers of synthetic lethal
partners became harder detect (i.e., red cells become interspersed in the columns of (a)). The
log-χ2 values on a blue–red scale (b) showed a threshold for synthetic lethal and correlated
genes when there are fewer of them, distinguishable from correlated genes in this case.
thresholds for synthetic lethal and correlated genes in simple simulations but these
were more gradual for higher numbers of synthetic lethal partners.
While the synthetic lethal genes were detected in simple simulations (as shown in
Figure 3.14), ROC analysis was performed to determine whether they were robustly
detectable and to make further comparisons. These results (as shown in Figure 3.15)
were similar to simulations without correlation structure. As a binary classifier, SLIPT
had low sensitivity for higher numbers of synthetic lethal partners to detect and high
specificity with the vast majority of non-synthetic lethal genes (for 20,000 genes). This
was reflected in a similar reduction in statistical performance for higher numbers of
synthetic lethal partners and a higher performance with higher sample size. Overall,
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(a) Statistical evaluation (b) ROC curves
(c) Statistical performance (AUROC)
Figure 3.15: Performance with correlations. Simulation of synthetic lethality was per-
formed by sampling from a multivariate normal distribution (with correlation structure).
Performance of SLIPT declines for more synthetic lethal partners but this is mitigated by
increased sample sizes (darker colours). This generally occurs as the sensitivity decreases for
a greater number of true positives to detect, leading to a trade-off in accuracy as seen in a
trough for false positive rate and the ROC curves.
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Figure 3.16: Comparison of statistical performance with correlation structure.
Multivariate simulation of synthetic lethality with correlation structure (in colour) has com-
parable performance to simulation without correlations (in greyscale) with known synthetic
lethal partners across parameters.
the statistical performance was no different to simulations without correlation structure
(as shown in Figure 3.16).
SLIPT was robust across correlation structures and is applicable to gene expression
data, with pathway structures and correlations. These correlation structures were not
intended to model specific biological pathways or represent them but showed potential
impact of correlation structure on the performance of SLIPT using highly correlated
(r = 0.8) gene blocks. More complex correlation structures, such as genes positively
correlated with the query gene and derived from pathway graph structures (as described
in 3.4.2) were examined further in Sections 3.3.2.2 and 6.2.1 respectively.
In particular, genes correlated with true synthetic lethal genes had little impact
on the performance of SLIPT detection: synthetic lethal genes were as distinguishable
from correlated genes as they are from true negative genes. Genes correlated with
synthetic lethal partners did not interfere with the detection of true synthetic lethal
genes, although they were often ranked next below them and may support synthetic
lethal pathways by having related gene functions.
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(a) Statistical evaluation (b) ROC curves
(c) Statistical performance (AUROC)
Figure 3.17: Performance with query correlations. Simulation of synthetic lethality
was performed by sampling from a multivariate normal distribution (with correlation struc-
ture including correlated genes with non-synthetic lethal and query genes). Performance of
SLIPT declined for more synthetic lethal partners and is mitigated by increased sample sizes
(darker colours) but the sensitivity remains higher for a greater number of true positives with
corresponding improvements in ROC curves.
78
(a) χ2 testing without direction (b) SLIPT with directional criteria
Figure 3.18: Statistical evaluation of directional criteria. A simulated multivariate
normal dataset of 20,000 genes with correlation structures was tested by SLIPT with the
directional condition and the χ2 test. SLIPT exhibited a consistently higher sensitivity and
lower false positive rate.
3.3.2.2 Specificity with Query-Correlated Pathways
Correlation structures were also considered for non-synthetic lethal genes that were
(positively) correlated genes with the query gene. Specifically, five highly correlated
(r = 0.8) with the query gene were added (as described in Section 3.3.2.1). These
simulations had similar performance (as shown in Figure 3.17) to those without these
correlations with a higher specificity and a lower false positive rate (shown in Fig-
ure 3.17a).
The directional criteria of the SLIPT procedure was important in this case, enhanc-
ing its performance, particularly in distinguishing positively correlated non-synthetic
lethal genes. The multivariate normal simulations were performed, with 20,000 genes,
including all of the correlation structures discussed (with synthetic lethal, non-synthetic
lethal, and query correlated genes). These simulations were compared for the direction
SLIPT and the χ2 testing. There was a considerably higher statistical performance
with SLIPT, particularly increased sensitivity and lower false positive rate (as shown
in Figure 3.18).
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(a) χ2 testing without direction (b) SLIPT with directional criteria
(c) Statistical performance (AUROC)
Figure 3.19: Performance with directional criteria. A simulated multivariate normal
dataset of 20,000 genes with correlation structures was tested by SLIPT and χ2 test. SLIPT
had higher performance across simulation parameters, clearly differing from random (grey
diagonal) in ROC curves up to 100 SL genes (b). The performance (c) of SLIPT (in greyscale)
was consistently higher than the χ2 test (in color).
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These results show that the performance of SLIPT is appropriate for the analysis
of expression datasets, where positively correlated genes commonly occur, with the
directional condition robustly improving the performance of SLIPT across simulation
parameters (compared to the χ2 test). Without assuming the underlying number of
synthetic lethal genes, SLIPT will performed than the χ2 test alone, irrespective of
the significance threshold as shown by ROC analysis (as shown in Figure 3.19). The
directional SLIPT methodology outperformed the χ2 test at detecting synthetic lethal
partners with even up to 100 synthetic lethal genes.
Together these simulation results support the application of the SLIPT method-
ology as it has been performed throughout Chapters 4 and 5. The methodology and
simulation procedure were explored further in Chapter 6, with comparison to other
synthetic lethal detection approaches and the inclusion of graph structures.
3.4 Graph Structure Methods
Graph structures have been used in several ways in this project, including novel ap-
proaches to analysis and simulations. Procedures were developed for statistical and
network analysis of gene states in pathway structures. Specifically, the relationships
between siRNA and SLIPT genes were tested within biological pathways in Chapter 5.
These graph structures were also used in Chapter 6 to derive correlation structure
between simulated gene expression profiles to represent biological pathways.
3.4.1 Upstream and Downstream Gene Detection
Comparison of experimental and computational candidate synthetic lethal partner
genes within pathway structures was performed to determine whether these sets of
genes were related by pathway structure. Considering the differences in how these
candidates were generated, it was unsurprising that they did not detect some identical
genes within the candidate biological pathways. However, they could still be related
by being upstream or downstream of each other.
Using the Reactome version 52 (Croft et al., 2014), as described in Section 2.4.2,
genes detected by each synthetic lethal discovery approach were mapped to the graph
structure for each candidate pathway identified in Chapter 4 (with graphs defined as
described in Section 2.4.3). To test whether siRNA candidate genes were upstream of
SLIPT candidate genes, shortest paths were traced between each pair of these genes
in a directed network. The paths where the siRNA candidate was upstream (“up”)
and downstream (“down”) of a SLIPT candidate were scored. This procedure yielded
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the total number of shortest paths which indicated that siRNA genes were upstream
or downstream of the SLIPT genes and measured the difference between these to de-
termine if there was an imbalance in a particular direction. While this difference was
indicative of the number of paths between the gene candidate groups in either direc-
tion, it was not sufficient to statistically verify structure or relationships between siRNA
and SLIPT genes. It was then combined with a permutation resampling procedure (as
described in Section 3.4.1.1) to test for directional relationships.
Initially, this procedure excluded genes that were detected by both approaches
since they would count in both directions. Upon further consideration, these genes
were restored to accounted for that they may contribute unequally to each gene set if
there are unequal numbers of genes above or below them in the pathway structure.
3.4.1.1 Permutation Analysis for Statistical Significance
A permutation procedure was developed to randomly assign members of the pathway
to siRNA and/or SLIPT groups, with the same number of each candidate partner gene
set as observed in the pathway. These permuted genes were measured for pathway
structure between the permuted gene groups as performed for the observed candidates
(as performed in Section 3.4.1). A distribution of pathway structure relationships
expected by chance was generated by permuting iteratively over these pathways. The
resulting null distribution was compared to the observed counts of relationships (in
either direction). This procedure yielded a permutation p-value as the proportion of
permutations which had a value greater than the observed value. The null hypothesis
was that there was no relationship between these gene groups compared to genes that
had been selected at random. Thus both the alternate hypotheses that the siRNA
genes were either upstream of the SLIPT genes or that they are downstream of them
were testable.
The permutation procedure does not assume the underlying distribution of the data
under the null hypothesis and accounts for the total number of nodes, edges, siRNA,
and SLIPT genes in each graph or networkpathway structure. The number of genes
detected by both siRNA and SLIPT was not accounted for under the initial shortest
path counts procedure that excluded them. Once they were included, it was ensured
that the number of intersecting genes was equal to the number observed to test for
pathway structure without changing the intersection size, the subject of prior analyses.
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3.4.2 Simulating Gene Expression from Graph Structures
The simulation procedure was refined to generate expression data with correlation
structure from a known graph structure. This enabled modelling of synthetic lethal
partners within a biological pathway and the investigation of the impact of pathway
structure on synthetic lethal prediction. Firstly, a simulated pathway was constructed
as a graph structure, with the igraph R package Csardi and Nepusz (2006), with the
state of the edges (i.e, whether they activate or inhibit downstream pathway members).
This simulation procedure was intended for biological pathway members with correlated
gene expression (higher than the background of genes in other pathways) but it may
also be applicable to modelling protein levels (e.g, in a kinase regulation cascade) or
substrates and products (e.g., in a metabolic pathway).
The graph structure was constructed to be used to simulate data by sampling a
multivariate normal distribution using the mvtnorm R package (Genz and Bretz, 2009;
Genz et al., 2016). Throughout this Section, the simulation procedure will be demon-
strated with the relatively simple constructed graph structure shown in Figure 3.20.
This graph structure visualisation was specifically developed for (directed) iGraph ob-
jects in R and has been released in the plot.igraph package and igraph.extensions
library (in Table 2.4 and Section 3.5.3). The plot directed function enabled customi-
sation of plot parameters for each node or edge and mixed (directed) edge types for
indicating activation or inhibition. These inhibition links (which occur frequently in
biological pathways) were demonstrated in Figure 3.20b.
The simulation procedure was designed to use such graph structures to inform
development of a “Sigma” variance-covariance matrix (Σ) for sampling from a mul-
tivariate normal distribution (using the mvtnorm R package). This procedure uses a
graph structure (or adjacency matrix Aij), such as Figure 3.21a.
Aij =
1 if genes i and j are adjacent0 otherwise
A relation matrix Rij was calculated based on distance such that nearer nodes are given
higher weight than farther nodes. Throughout this thesis, a geometrically decreasing
(relative) distance weighting was used
Rij =

1 if genes i and j are adjacent
(1/2)dij if a path can be found between genes i and j
0 if no path exists between genes i and j
83
(a) Activating pathway structure (b) Pathway structure with inhibitions
Figure 3.20: Simulated graph structures. A constructed graph structure used as an
example to demonstrate the simulation procedure. Activating links are denoted by blue
arrows and inhibiting links by red edges. Nodes have been coloured accordingly to the
simulation results presented in Section 6.2.3 and Appendix J.2.
where dij is the shortest path length between genes i and j in graph G. Thus with
each more distant node being related by 1/2 compared to the next nearest, as shown
in Figure 3.21b. An arithmetically decreasing (absolute) distance weighting is also
supported in the graphsim R package release of this procedure.
Rij =

1 if genes i and j are adjacent
1− dij
diam(G)
if a path can be found between genes i and j
0 if no path exists between genes i and j
A Σ matrix can be derived from this distance weighting matrix
Σij =
1 if i = j so a gene is correlated with itselfcorrelation×Rij otherwise
creating a matrix (with a diagonal of 1) where each node has a variance and standard
deviation of 1. Thus covariances between adjacent nodes were assigned by a correlation
parameter and the remaining matrix based on weighting these correlations by the
geometrically weighted distance matrix (or the nearest “positive definite” matrix for Σ
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(a) Activating pathway structure (b) Distance matrix
(c) Σ (expected correlation) (d) Simulated correlation
(e) Simulated expression data (f) Simulated gene function calls
Figure 3.21: Simulating expression from a graph structure. An example graph struc-
ture that was used to derive a correlation structure from the relative distances between nodes
and simulate continuous gene expression (coloured blue–red) with sampling from the multi-
variate normal distribution.
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(a) Inhibiting pathway structure (b) Distance matrix
(c) Σ (expected correlation) (d) Simulated correlation
(e) Simulated expression data (f) Simulated gene function calls
Figure 3.22: Simulating expression from graph structure with inhibitions. An
example graph structure that was used to derive a correlation structure from the relative
distances between nodes and simulate continuous gene expression (coloured blue–red) with
sampling from the multivariate normal distribution.
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weighted for negatively correlated inhibitions). Computing the nearest positive definite
matrix was necessary to ensure that the variance-covariance matrix could be inverted
when used as a parameter in multivariate normal simulations. Matrices that could
not be inverted occurred rarely with the graph structures used but was included for
robustly applicable functions in the R software release. The nearest positive definite
matrix was computed using the nearPD function of the Matrix R package (Bates and
Maechler, 2016) to perform Higham’s algorithm (Higham, 2002), a procedure designed
for variance-covariance matrices.
Throughout this thesis, the correlation parameter was 0.8, unless otherwise specified
(as used for the example in Figure 3.21c). This Σ matrix was then used to sample
from a multivariate normal distribution such that each gene had a mean of 0, standard
deviation 1, and covariance within the range [0, 1] such that they are correlations. This
procedure generated a simulated (continuous normally distributed) expression profile
for each node (as shown in Figure 3.21e) with corresponding correlation structure
(Figure 3.21d). The simulated correlation structure closely resembled the expected
correlation structure (Sigma in 3.21c) even for the relatively modest sample size (N =
100) illustrated in 3.21. Once a simulated gene expression dataset has been generated
(as in Figure 3.21e), then a discrete matrix of gene function was constructed with a
functional threshold quantile to simulate functional relationships of synthetic lethality
(as shown in Figure 3.4). Throughout this thesis, this threshold is the 0.3 quantile (as
discussed in Section 3.2.1) which generates functional discrete matrices such as those
used for synthetic lethal simulation in Section 3.2.2 (as shown Figure 3.21f).
The simulation procedure (depicted in Figure 3.21) can be used for pathways con-
taining inhibition links (as shown in Figure 3.22) with several refinements. With the in-
hibition links (as shown in Figure 3.22a), distances were calculated in the same manner
as before (Figure 3.22b) with inhibitions accounted for by iteratively multiplying down-
stream nodes by −1 to form blocks of negative correlations (as shown in Figures 3.22c
and 3.22d). A multivariate normal distribution with these negative correlations can be
sampled to generate simulated data (as shown in Figures 3.22e and 3.22f).
These simulated datasets could then be used for simulating synthetic lethal partners
of a query gene within a graph network. The query gene was assumed to be separate
from the graph network pathway and was added to the dataset using the procedure
in Section 3.2.2. Thus I can simulate known synthetic lethal partner genes within a
synthetic lethal partner pathway structure.
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3.5 Customised Functions and Packages Developed
Various R packages (R Core Team, 2016) have been developed throughout this thesis
using devtools (Wickham and Chang, 2016) and roxygen (Wickham et al., 2017)
to enable reproducibility of customised analysis and visualisation. Many of these
have been documented, demonstrated in vignettes, and released on GitHub (https:
//github.com/TomKellyGenetics) to enable the research community to utilise them
in their own analysis. These are summarised in Table 2.4, with the corresponding
urls for their GitHub repository which contains instructions for installation with the
devtools R package (Wickham and Chang, 2016) and links the relevant vignette(s).
3.5.1 Synthetic Lethal Interaction Prediction Tool
The statistical methodology for detection of synthetic lethality in gene expression data
(SLIPT) is one of the main novel procedures developed in this thesis, as described in
Section 3.1. The slipt R package has been prepared for release to accompany a pub-
lication demonstrating the applications of the methodology for identifying candidate
interacting genes and pathways with CDH1 in breast cancer (Koboldt et al., 2012).
SLIPT can be used for analysis of any effectively continuous measure of gene activ-
ity (e.g., microarray, RNA-Seq, protein abundance, or pathway metagenes). Execut-
ing slipt is straightforward: the prep data for SL function scores samples as “low”,
“medium”, or “high” for each gene, then the detect SL function tests a given query
gene against all potential partners by performing the chi-squared test and directional
conditions. This function returns a table summarising the observed and expected sam-
ple numbers used for the directional criteria, the χ2 values, and corresponding p-values
including adjusting for multiple comparisons. The count of SL and table of SL func-
tions serve to facilitate summary and extraction of the positive SLIPT hits, respectively,
from the table of predictions of synthetic lethal partners.
The SLIPT methodology in this package release was used in later analyses rather
than the corresponding source R code, including use on remote machines and upon
simulated data. In particular, the functions in the package facilitate alterations to
parameters, such as the proportion of samples called as exhibiting low or high gene
activity (as shown in Section 6.1.1). This release supports reproducible research and
enables wider use of SLIPT in future investigations into other disease genes.
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3.5.2 Data Visualisation
Customised data visualisations in R (R Core Team, 2016) were developed to present
data throughout this thesis. The vioplotx package provides an alternative visualisa-
tion (of continuous variables against categories) to the more familiar boxplot, showing
variability of the data by the width of the plots. As demonstrated in Figure 3.23,
this version enables separate plotting parameters for each violin with vector inputs for
colour, shape, and size of various elements of the median point, central boxplot, bor-
ders, and fill colour for the violin. Scaling violin width to adjust violin area and splitting
data by a second categorical variable is also enabled. This function is intended to be
backwards compatible with the vioplot package (Adler, 2005) (applying scalar inputs
across all violins) and boxplot (by enabling formula inputs as an S3 method). Each
of these features has been demonstrated with examples in respective vignettes on the
package GitHub repository (https://github.com/TomKellyGenetics/vioplotx).
The heatmap.2x function provides extensions for annotation colour bars for both
the rows and columns (as shown in Figure 3.24). Multiple bars are enabled on both
axes with matrix inputs (rather than single vector for heatmap.2 (Warnes et al., 2015))
which facilitates additional plotting of gene and sample characteristics for comparison
with correlation matrices, expression profiles, or pathway metagenes. The annotation
bar inputs correspond to their orientation on the plot, each colour bar is provided as a
column for the row annotation on the left of the heatmap and as a row for the column
annotation on top of the heatmap. Row and column annotation bars are labelled
with the column or row names respectively. Additional parameters enable resizing of
these annotation bar labels and control of reordering columns for when samples have
been ordered in advance (e.g., ranked by a metagene or split into groups clustered
separately). These features were used through this thesis and have been provided in a
package GitHub repository (https://github.com/TomKellyGenetics/heatmap.2x).
3.5.3 Extensions to the iGraph Package
The following features were developed during this thesis using “iGraph” data objects,
building upon the igraph package (Csardi and Nepusz, 2006). These have been re-
leased as separate packages for each respective procedure and can be installed to-
gether as a collection of extensions to the igraph package (https://github.com/
TomKellyGenetics/igraph.extensions).
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(a) Customised violin plot
(b) Split violin plot
Figure 3.23: Demonstration of violin plots with custom features. An example of the
iris dataset is plotted to show the custom features of the vioplotx package including (a)
individual colour, shape and size parameters of each violin, scaling violin widths by area, and
(b) splitting violins to compare subsets of data.
3.5.3.1 Sampling Simulated Data from Graph Structures
The graphsim package implements the procedure for simulating gene expression from
graph structures (as described in Section 3.4.2). By default, this derives a matrix with
a geometrically decreasing weighting by distance (by shortest paths) between each
pair of nodes. An absolute decreasing weighting is also available with the option to
derive correlation structures from adjacency matrices or the number of links common
partners (i.e., size of the shared “neighbourhood” (Hell, 1976)) between each pair
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Figure 3.24: Demonstration of annotated heatmap. The example heatmap depicts the
additional row and column annotation bars enabled by heatmap.2x, extending the features
of gplots with backwards compatible inputs.
of nodes. Functions to compute these are called directly by passing parameters to
them when running the generate expression or make sigma mat commands. This
package enables simulating expression data directly from a graph structure (with the
intermediate steps automated) or generating Σ parameters for mvtnorm from graph
structures or matrices derived from them. These functions support assignment of
activating or inhibiting relationships to each edge (with a state parameter).
3.5.3.2 Plotting Directed Graph Structures
The plot.igraph package provides the plot directed function, specifically developed
for directed graph structures, to plot activating or inhibiting for each edge (as described
in Section 3.4.2). As shown in Figure 3.25, this function supports separate plotting
parameters for each node, node label, and edge. This includes colours of node fill,
border, label text, and edges and size of nodes, edge widths, arrowhead lengths, and
font size of labels. The state parameter for assigning activating or inhibiting to each
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edge determines whether edges were depicted with 30° or 90° arrowheads. Colours
are assigned separately so they may be customised. Vectorised parameters are applied
across each node or edge, whereas scalar parameters apply the same plotting parameters
across them. The default layout function is layout.fruchterman.reingold but any
layout function supported by plot function in igraph (Csardi and Nepusz, 2006) was
compatible, such as layout.kamada.kawai used to implement the Kamada–Kawai
algorithm (Kamada and Kawai, 1989) for graph plots throughout this thesis.
Figure 3.25: Simulating graph structures. An example graph structure which has been
used throughout demonstrating the simulation procedure from graph structures. Activating
links are denoted by blue arrows and inhibiting links by red edges.
3.5.3.3 Computing Information Centrality
The shortest paths of a network were computed by the igraph package (Csardi and
Nepusz, 2006) which can be extended to calculate the network efficiency but was
not provided by the package itself (ss described in Section 2.4.4). The “information
centrality” of a vertex is computed as the relative change in the network efficiency
when the vertex is removed. Information centrality is calculated iteratively for each
node and the sum of information centrality for each vertex is the information cen-
trality for the network. These metrics were released in the info.centrality package
(https://github.com/TomKellyGenetics/info.centrality).
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3.5.3.4 Testing Pathway Structure with Permutation Testing
A network-based procedure was developed to compare siRNA and SLIPT candidate
genes in a pathway structure. Such pathway structure relationships were tested by com-
puting the number of shortest paths between two different groups of nodes in either
direction within a graph . This pathway relationship metric was implemented in the
pathway.structure.permutation package (https://github.com/TomKellyGenetics/
pathway.structure.permutation) with permutation testing (as described in Sec-
tions 3.4.1 and 3.4.1.1).
3.5.3.5 Metapackage to Install iGraph Functions
These features may be installed together with igraph.extensions, which can be ac-
cessed from a GitHub repository (https://github.com/TomKellyGenetics/igraph.
extensions). This meta-package installs igraph (Csardi and Nepusz, 2006) and the
packages described in Section 3.5.3 including their dependencies for matrix operations
and statistical procedures: Matrix, matrixcalc, and mvtnorm (Bates and Maechler,




Synthetic Lethal Analysis of Gene
Expression Data
Having developed a statistical synthetic lethal detection methodology, SLIPT, it was
next applied to publicly available cancer gene expression datasets. The analysis pre-
sented in this Chapter focuses on breast cancer for which TCGA expression data
(Koboldt et al., 2012) from a patient cohort and siRNA screen data, from experiments
conducted in MCF10A cells (Telford et al., 2015), were available. Stomach cancer
data (Bass et al., 2014) was used to replicate findings in an independent dataset, with
this cancer chosen because it also occurs in syndromic HDGC patients. The TCGA
data also has the advantages of having other clinical and molecular profiles, including
somatic mutation across many of the same samples, in addition to a considerable sam-
ple size for RNA-Seq expression data generated with common TCGA procedures to
minimise batch effects.
Synthetic lethal candidate partners for CDH1 were identified at both the gene and
pathway level. SLIPT gene candidates were analysed by cluster analysis for common
expression profiles across samples and relationships with clinical factors and mutations
in key breast cancer genes. These genes were also compared to the gene candidates
from primary and secondary (validation) screens conducted by Telford et al. (2015)
on isogenic cell lines. For comparison, the SLIPT methodology was also applied us-
ing mutation data for CDH1 against expression of candidate partners (as described
in Section 3.1) which may better represent the null mutations in HDGC patients and
the experimental cell model (Chen et al., 2014). Pathways were analysed by over-
representation analysis (with resampling for comparisons with siRNA data) and sup-
ported by a metagene analysis of pathways gene signatures. The pathways metagene
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expression profiles were used to replicate known relationships between clinical and
molecular characteristics for breast cancer and to demonstrate application of SLIPT
directly on metagenes to detect synthetic lethal pathways.
4.1 Synthetic Lethal Genes in Breast Cancer
The SLIPT methodology (as described in Section 3.1) was applied to the normalised
TCGA breast cancer gene expression dataset (n = 1168). As shown in Table 4.1,
the most significant of the 5165 genes had strong evidence of expression-based asso-
ciation with CDH1 (high χ2 values) with fewer samples exhibiting low expression of
both genes than expected statistically. Eukaryotic translation genes were among the
highest scoring gene candidates, including initiation factors, elongation factors, and
ribosomal proteins. These are clearly necessary for cancer cells to grow and proliferate,
with sustained gene expression needed to maintain growth signalling pathways and
resist apoptosis or immune factors, translation genes may be subject to non-oncogene
addiction for CDH1 -deficient cells.
While these are among the strongest synthetic lethal candidates, translational genes
are crucial to the viability of healthy cells and dosing for a selective synthetic lethal
effect against these may be difficult compared to other biological functions which may
also be supported among the SLIPT candidate genes. Furthermore, few known bio-
logical functions of CDH1 were among the strongest SL candidates, so the remaining
candidate genes may also be informative since they are likely to contain these expected
functions in addition to novel relationships for CDH1. Thus further pathway level
analyses were also conducted to examine biological functions over-represented among
synthetic candidate genes and to identify synthetic lethal pathways.
The modified mtSLIPT methodology (as described in Section 3.1) was also applied
to the normalised TCGA breast cancer gene expression dataset, against somatic loss
of function mutations in CDH1. As shown in Table 4.2, the most significant genes also
had strong evidence of expression associated with CDH1 mutations (high χ2 values)
with fewer samples with CDH1 exhibiting low expression each candidate gene than
expected statistically. These genes were not as strongly supported as the expression
analysis (in Table 4.1), however, nor were as many genes detected. This is perhaps
unsurprising due to the lower sample size with matching somatic mutation data and
the lower frequency of CDH1 mutations compared to low expression defined by 1/3
quantiles.
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Table 4.1: Candidate synthetic lethal gene partners of CDH1 from SLIPT
Gene Observed* Expected* χ2 value p-value p-value (FDR)
TRIP10 62 130 162 5.65× 10−34 1.84× 10−31
EEF1B2 56 130 158 3.10× 10−33 9.45× 10−31
GBGT1 61 131 156 1.08× 10−32 3.14× 10−30
ELN 81 130 149 3.46× 10−31 8.82× 10−29
TSPAN4 78 130 146 1.63× 10−30 3.79× 10−28
GLIPR2 72 130 146 1.68× 10−30 3.86× 10−28
RPS20 73 131 145 1.89× 10−30 4.28× 10−28
RPS27A 80 130 143 5.53× 10−30 1.18× 10−27
EEF1A1P9 63 130 141 1.91× 10−29 3.74× 10−27
C1R 73 130 141 2.05× 10−29 3.97× 10−27
LYL1 73 130 140 2.99× 10−29 5.74× 10−27
RPLP2 71 130 139 4.88× 10−29 9.07× 10−27
C10orf10 73 130 138 6.72× 10−29 1.20× 10−26
DULLARD 74 131 138 9.29× 10−29 1.61× 10−26
PPM1F 64 130 136 1.61× 10−28 2.65× 10−26
OBFC2A 69 130 136 2.49× 10−28 3.93× 10−26
RPL11 70 130 136 2.56× 10−28 3.97× 10−26
RPL18A 70 130 135 3.08× 10−28 4.70× 10−26
MFNG 76 131 133 7.73× 10−28 1.12× 10−25
RPS17 77 131 133 8.94× 10−28 1.29× 10−25
MGAT1 73 130 132 1.44× 10−27 2.03× 10−25
RPS12 72 130 128 8.57× 10−27 1.12× 10−24
C10orf54 73 130 127 1.37× 10−26 1.75× 10−24
LOC286367 72 130 126 2.20× 10−26 2.70× 10−24
GMFG 70 130 126 2.20× 10−26 2.70× 10−24
Strongest candidate synthetic lethal partners for CDH1 of 5165 genes detected by
SLIPT (with FDR p-value < 0.05) in TCGA breast cancer expression data
* Observed and expected numbers of samples which had low expression of both genes
The mtSLIPT candidates had more genes involved in cell and gene regulation,
particularly DNA and RNA binding factors. The strongest candidates also included
microtubule (KIF12 ), microfibril (MFAP4 ), and cell adhesion (TENC1 ) genes con-
sistent with the established cytoskeletal role of CDH1. The elastin gene (ELN ) was
notably strongly supported by both expression and mutation SLIPT analysis of CDH1
supporting interactions with extracellular proteins and the tumour microenvironment.
4.1.1 Synthetic Lethal Pathways in Breast Cancer
Translational pathways were strongly over-represented in SLIPT partners, as shown
in Table 4.3. The Reactome pathways analysed here include those which overlap as
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Table 4.2: Candidate synthetic lethal gene partners of CDH1 from mtSLIPT
Gene Observed* Expected* χ2 value p-value p-value (FDR)
TFAP2B 8 36.7 89.5 3.60× 10−20 8.37× 10−17
ZNF423 15 36.7 78.8 7.89× 10−18 1.22× 10−14
CALCOCO1 11 36.7 76.8 2.09× 10−17 2.59× 10−14
RBM5 13 36.7 75.7 3.65× 10−17 4.00× 10−14
BTG2 7 36.7 71.7 2.72× 10−16 1.81× 10−13
RXRA 6 36.7 70.5 5.00× 10−16 2.97× 10−13
SLC27A1 11 36.7 70.3 5.42× 10−16 2.97× 10−13
MEF2D 12 36.7 69.6 7.86× 10−16 3.95× 10−13
NISCH 12 36.7 69.6 7.86× 10−16 3.95× 10−13
AVPR2 9 36.7 69.2 9.36× 10−16 4.58× 10−13
CRY2 13 36.7 68.9 1.07× 10−15 4.98× 10−13
RAPGEF3 13 36.7 68.9 1.07× 10−15 4.98× 10−13
NRIP2 10 36.7 68.2 1.58× 10−15 7.18× 10−13
DARC 12 36.7 66.4 3.76× 10−15 1.54× 10−12
SFRS5 12 36.7 66.4 3.76× 10−15 1.54× 10−12
NOSTRIN 5 36.7 65.1 7.40× 10−15 2.70× 10−12
KIF13B 12 36.7 63.4 1.69× 10−14 5.16× 10−12
TENC1 10 36.7 62.5 2.67× 10−14 7.40× 10−12
MFAP4 12 36.7 60.5 7.17× 10−14 1.67× 10−11
ELN 13 36.7 59.7 1.07× 10−13 2.32× 10−11
SGK223 14 36.7 59 1.51× 10−13 3.05× 10−11
KIF12 11 36.7 58.8 1.74× 10−13 3.34× 10−11
SELP 11 36.7 58.8 1.74× 10−13 3.34× 10−11
CIRBP 9 36.7 58.7 1.83× 10−13 3.41× 10−11
CTDSP1 9 36.7 58.7 1.83× 10−13 3.41× 10−11
Strongest candidate synthetic lethal partners for CDH1 of 3743 genes detected by
mtSLIPT (with FDR p-value < 0.05) in TCGA in breast cancer expression and
mutation data
* Observed and expected numbers of CDH1 mutant TCGA breast tumours with low
expression of partner genes
shown in Appendix Figure A.1. These pathways include ribosomal subunits, initi-
ation, peptide elongation, and termination. Regulatory processes involving mRNA
including 3’ untranslated region (UTR) binding, L13a-mediated translational silenc-
ing, and nonsense-mediated decay were also implicated. These are consistent with
protein translation being subject to “non-oncogene addiction” (Luo et al., 2009), as a
core process that is dysregulated to sustain cancer proliferation and survival (Gao and
Roux, 2015).
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Immune pathways, including the adaptive immune system and responses to infec-
tious diseases were also strongly implicated as synthetic lethal with loss of E-cadherin.
This is consistent with the alterations of immune response being a hallmark of cancer
Hanahan and Weinberg (2000), since evading the immune system is necessary for cancer
survival. Either of these systems are potential means to target CDH1 -deficient cells,
although these were not detected in an isolated cell line experimental screen (Telford
et al., 2015) and the differences between the findings in patient data are described in
more detail in Section 4.2.5.
Table 4.3: Pathways for CDH1 partners from SLIPT
Pathways Over-represented Pathway Size SL Genes p-value (FDR)
Eukaryotic Translation Elongation 86 81 1.3× 10−207
Peptide chain elongation 83 78 5.6× 10−201
Eukaryotic Translation Termination 83 77 1.2× 10−196
Viral mRNA Translation 81 76 1.2× 10−196
Formation of a pool of free 40S subunits 93 81 3.7× 10−194
Nonsense Mediated Decay independent of the Exon Junction Complex 88 77 5.3× 10−187
L13a-mediated translational silencing of Ceruloplasmin expression 103 82 9.6× 10−183
3’ -UTR-mediated translational regulation 103 82 9.6× 10−183
GTP hydrolysis and joining of the 60S ribosomal subunit 104 82 1.9× 10−181
Nonsense-Mediated Decay 103 80 6.2× 10−176
Nonsense Mediated Decay enhanced by the Exon Junction Complex 103 80 6.2× 10−176
Adaptive Immune System 412 167 6.5× 10−174
Eukaryotic Translation Initiation 111 82 5.7× 10−173
Cap-dependent Translation Initiation 111 82 5.7× 10−173
SRP-dependent cotranslational protein targeting to membrane 104 79 2.0× 10−171
Translation 141 91 6.1× 10−170
Infectious disease 347 146 1.6× 10−166
Influenza Infection 117 81 1.9× 10−163
Influenza Viral RNA Transcription and Replication 108 77 1.9× 10−160
Influenza Life Cycle 112 77 2.5× 10−156
The most significant pathways from gene set over-representation analysis (hypergeometric test) for Reactome pathways in
SLIPT partners for CDH1.
It is also notable that the pathways over-represented in SLIPT candidate genes
have strongly significant over-representation of Reactome pathways based on the hy-
pergeometric test (as described in Section 2.3.2). Even after adjusting stringently for
multiple testing, biologically related pathways were supported together. These path-
ways are further supported by testing for synthetic lethality against CDH1 mutations
(mtSLIPT) with many of these pathways also among the most strongly supported
in this analysis (shown in Appendix Table C.1). This mutation-based analysis more
closely represents the null CDH1 mutations in HDGC (Guilford et al., 1998) and the
experimental MCF10A cell model (Chen et al., 2014). There was still support for
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translational and immune pathways not detected in the isolated experimental system.
GPCRs also among the most strongly supported pathways, supporting the experimen-
tal findings of Telford et al. (2015) for these intracellular signalling pathways already
being targeted for other diseases.
4.1.2 Expression Profiles of Synthetic Lethal Partners
Due to the sheer number of gene candidates (e.g., 5165 for SLIPT), investigations pro-
ceeded into correlation structure and pathways over-representation. These analyses
also examined expression patterns of synthetic lethal gene candidates. This serves to
explore the functional similarity of the synthetic lethal partners of CDH1, with the
eventual aim to assess their utility as drug targets. As shown in Figure 4.1 (which
clusters CDH1 lowly expressing samples separately), there were several large clusters
of genes among the expression profiles of the CDH1 synthetic lethal candidate part-
ners. The clustering suggests co-regulation of genes or pathways correlation between
partner gene candidates. A number of candidates from an experimental RNAi screen
study performed by Telford et al. (2015) were also identified by this approach. In
addition, novel gene candidates were also identified, which had not been observed to
affect viability in isogenic cell line experiments.
In these expression profiles, a gene with a moderate or high signal across samples
exhibiting low CDH1 expression would represent a potential drug target. However,
it appears that several molecular subtypes of cancer have elevation of different clus-
ters of synthetic lethal candidates in samples with low CDH1. This clustering (shown
by red correlated blocks of genes in Figure 4.1) suggests that different targets (or
combinations) could be effective in different patients, suggesting potential utility for
stratification. In particular, ER negative, basal-like subtype, and “normal-like” tu-
mours (Dai et al., 2015; Eroles et al., 2012; Parker et al., 2009) have elevation of genes
specific to particular clusters, indicative of some synthetic lethal interactions being
specific to a particular molecular subtype or genetic background. Thus synthetic lethal
drug therapy against these subtypes may be ineffective if it were designed against genes
in another cluster.
A similar correlation structure was observed among the candidates tested against
CDH1 mutation (mtSLIPT), as shown in Appendix Figure C.1. This clustering analy-
sis similarly identified several major clusters of putative synthetic lethal partner genes.
In this case, many partner genes had consistently high expression across most of the
(predominantly lobular subtype) CDH1 breast cancer samples. However, a major ex-
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Figure 4.1: Synthetic lethal expression profiles of analysed samples. Gene expression
profile heatmap (correlation distance, complete linkage) of all samples (separated by the 1/3
quantile of CDH1 expression) analysed in TCGA breast cancer dataset for gene expression of
5165 candidate partners of E-cadherin (CDH1 ) from SLIPT prediction (with FDR adjusted
p < 0.05). Deeply clustered, inter-correlated genes form several main groups, each containing
genes that were SL candidates or lethal in an siRNA screen (Telford et al., 2015). Screen
results for synthetic lethal (SL), the reverse effect (RSL), or lethal cell viability are shown
as reported by Telford et al. (2015). Clusters had different sample groups highly expressing
the synthetic lethal candidates in CDH1 low samples, notably ‘normal-like’, ‘basal-like’, and
Estrogen receptor (ER) negative samples have elevated expression in one or more distinct
clusters showing complexity and variation among candidate synthetic lethal partners. CDH1
low samples also contained most of samples with CDH1 mutations (shown in black). Negative
values for mutation and screen data are shown in light grey, with missing data in white.
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ception to this in the CDH1 expression analysis were the normal tissue samples which
were excluded from the mutation data (as they were not tested for tumour-specific geno-
types). This supports synthetic lethal interventions being more applicable to CDH1
mutant tumours. There was still considerable correlation structure, particularly among
CDH1 wild-type samples, sufficient to distinguish gene clusters. In contrast, the pre-
dominantly ductal CDH1 wild-type basal-like subtype and ER negative samples had
depleted expression among most candidate synthetic lethal partners. This is consistent
with synthetic lethal interventions only being effective in lobular ER positive breast
cancers in which they are a more common, as recurrent (driver) mutation. However,
the remaining samples are still informative for synthetic lethal analysis (by SLIPT) as
it requires highly expressing CDH1 samples for comparison.
The CDH1 mutant samples (as shown in Figure 4.1) were predominantly among
the low CDH1 expressing samples, clustering throughout them with similar expression
profiles to other samples exhibiting low CDH1 expression. Thus the molecular pro-
files of CDH1 low samples were indistinguishable from CDH1 mutant samples, with
the exception of normal samples (that do not have somatic mutation data available).
Many of the CDH1 mutant samples (in Appendix Figure C.1) had among the lowest
CDH1 expression, and some of the synthetic lethal partners were also highly expressed
in low expressing CDH1 wild-type samples, despite these not being considered as “in-
activated” by mtSLIPT analysis.
Together these results support the use of low CDH1 expression as a strategy for
detecting CDH1 inactivation. This has the benefit of increasing sample size (including
samples such as normal tissue which do not have somatic mutation data available)
and increasing the expected number of mutually inactive (low-low) samples for the
directional criteria of (mt)SLIPT which enables it to better distinguish significant de-
viations below this (as discussed in Section 6.1). This also circumvents the assumption
that all (detected) mutations are inactivating (although synonymous mutations were
excluded from the analysis), which may not be the case for several highly express-
ing CDH1 mutant samples that do not cluster together in Figure 4.1 or Appendix
Figure C.1. One of these exhibits among the lowest expression for many predicted syn-
thetic lethal partners and would not be vulnerable to inactivation of these genes. As
such, correctly genotyping inactivating mutations will be essential in clinical practice
for synthetic lethal targeting of tumour suppressor genes, particularly for other genes
such as TP53 where oncogenic and tumour suppressor mutations (with different molec-
ular consequences) are both common. Using expression as a measure of gene function
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also avoids the assumption that mutations are somatic, rather than germline, and that
gene inactivation occurs by detectable mutations, rather than other mechanisms, such
as epigenetic changes. These factors may also account for some of the lowly expressing
CDH1 wild-type samples clustering with similar profiles to mutant samples.
4.1.2.1 Subgroup Pathway Analysis
Synthetic lethal gene candidates for CDH1 from SLIPT analysis of RNA-Seq gene
expression data were also used for pathway over-representation analyses (as described
in Section 2.3.2). The correlation structure in the expression of candidates synthetic
lethal genes in CDH1 low tumours (lowest 1/3rd quantile of expression) was examined
for distinct biological pathways in subgroups of genes elevated in different clusters of
samples. These genes were highly expressed in different samples with their clinical
factors including ER status and intrinsic subtypes, from the PAM50 procedure (Parker
et al., 2009) shown in Figure 4.1.
As shown by the most over-represented pathways in Table 4.4, each correlated
cluster of candidate synthetic lethal partners of CDH1 contains functionally different
genes. Cluster 1 contains genes with less evidence of over-represented pathways than
other clusters, corresponding to less correlation between genes within the cluster, and
to it being a relatively small group. While there is some indication that collagen
biosynthesis, microfibril elastic fibres, extracellular matrix, and metabolic pathways
may be over-represented in Cluster 1, these results are mainly based on small pathways
containing few synthetic lethal genes. Genes in Cluster 2 exhibited low expression in
normal tissue samples compared to tumour samples (as shown in Figure 4.1) and show
compelling evidence of over-representation of post-transcriptional gene regulation and
protein translation processes. Similarly, Cluster 3 has over-representation of immune
signalling pathways (including chemokines, secondary messenger, and TCR signalling)
and downstream intracellular signalling cascades such as GPCR and Gαi signalling
events. While pathways over-representation was weaker among genes in Cluster 4,
they contained intracellular signalling pathways and were highly expressed in normal
samples (in contrast to Cluster 2). Cluster 4 also involved extracellular factors and
stimuli such as extracellular matrix, platelet activation, ligand receptors, and retinoic
acid signalling.
Based on these results, potential synthetic lethal partners of CDH1 include pro-
cesses known to be dysregulated in cancer, such as translational, cytoskeletal, and
immune processes. Intracellular signalling cascades such as the GPCRs and extracel-
103
Table 4.4: Pathways for clusters of CDH1 partners from SLIPT
Pathways Over-represented in Cluster 1 Pathway Size Cluster Genes p-value (FDR)
Collagen formation 67 10 4.0× 10−11
Extracellular matrix organisation 238 21 1.8× 10−9
Collagen biosynthesis and modifying enzymes 56 8 1.8× 10−9
Uptake and actions of bacterial toxins 22 5 9.5× 10−9
Elastic fibre formation 37 6 1.9× 10−8
Muscle contraction 62 7 2.4× 10−7
Fatty acid, triacylglycerol, and ketone body metabolism 117 10 4.9× 10−7
XBP1(S) activates chaperone genes 51 6 6.6× 10−7
IRE1alpha activates chaperones 54 6 1.2× 10−6
Neurotoxicity of clostridium toxins 10 3 1.3× 10−6
Retrograde neurotrophin signalling 10 3 1.3× 10−6
Assembly of collagen fibrils and other multimeric structures 40 5 1.9× 10−6
Collagen degradation 58 6 2.0× 10−6
Arachidonic acid metabolism 41 5 2.1× 10−6
Synthesis of PA 26 4 3.0× 10−6
Signalling by NOTCH 80 7 3.3× 10−6
Signalling to RAS 27 4 3.7× 10−6
Integrin cell surface interactions 82 7 4.2× 10−6
Pathways Over-represented in Cluster 2 Pathway Size Cluster Genes p-value (FDR)
Eukaryotic Translation Elongation 86 75 1.1× 10−181
Viral mRNA Translation 81 72 9.8× 10−179
Peptide chain elongation 83 72 1.9× 10−175
Eukaryotic Translation Termination 83 72 1.9× 10−175
Formation of a pool of free 40S subunits 93 75 1.9× 10−171
Nonsense Mediated Decay independent of the Exon Junction Complex 88 72 9.9× 10−168
L13a-mediated translational silencing of Ceruloplasmin expression 103 75 3.0× 10−159
3’ -UTR-mediated translational regulation 103 75 3.0× 10−159
Nonsense-Mediated Decay 103 75 3.0× 10−159
Nonsense Mediated Decay enhanced by the Exon Junction Complex 103 75 3.0× 10−159
SRP-dependent cotranslational protein targeting to membrane 104 75 3.2× 10−158
GTP hydrolysis and joining of the 60S ribosomal subunit 104 75 3.2× 10−158
Eukaryotic Translation Initiation 111 75 4.5× 10−151
Cap-dependent Translation Initiation 111 75 4.5× 10−151
Influenza Infection 117 75 1.4× 10−145
Influenza Viral RNA Transcription and Replication 108 72 5.7× 10−145
Translation 141 81 8.0× 10−143
Influenza Life Cycle 112 72 2.3× 10−141
Pathways Over-represented in Cluster 3 Pathway Size Cluster Genes p-value (FDR)
Adaptive Immune System 412 90 6.1× 10−61
Chemokine receptors bind chemokines 52 27 6.7× 10−56
Generation of second messenger molecules 29 21 6.5× 10−55
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 64 29 6.5× 10−55
TCR signalling 62 27 8.9× 10−51
Peptide ligand-binding receptors 161 40 1.5× 10−45
Translocation of ZAP-70 to Immunological synapse 16 14 3.1× 10−43
Costimulation by the CD28 family 51 22 4.0× 10−43
PD-1 signalling 21 15 4.0× 10−41
Class A/1 (Rhodopsin-like receptors) 258 50 6.7× 10−41
Phosphorylation of CD3 and TCR zeta chains 18 14 1.3× 10−40
Interferon gamma signalling 74 24 5.0× 10−39
GPCR ligand binding 326 57 1.8× 10−38
Cytokine Signalling in Immune system 268 48 8.9× 10−37
Downstream TCR signalling 45 18 1.8× 10−35
Gαi signalling events 167 33 2.2× 10−33
Cell surface interactions at the vascular wall 99 21 1.3× 10−26
Interferon Signalling 164 28 1.7× 10−26
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Table 4.4: Pathways for clusters of CDH1 partners from SLIPT
Pathways Over-represented in Cluster 4 Pathway Size Cluster Genes p-value (FDR)
Extracellular matrix organisation 238 48 8.0× 10−41
Class A/1 (Rhodopsin-like receptors) 258 47 2.8× 10−36
GPCR ligand binding 326 54 2.1× 10−34
Gαs signalling events 83 22 1.4× 10−31
GPCR downstream signalling 472 68 1.1× 10−29
Haemostasis 423 61 3.3× 10−29
Platelet activation, signalling and aggregation 180 31 7.1× 10−28
Binding and Uptake of Ligands by Scavenger Receptors 40 14 9.9× 10−27
RA biosynthesis pathways 22 11 2.5× 10−26
Response to elevated platelet cytosolic Ca2+ 82 19 3.0× 10−26
Developmental Biology 420 57 3.5× 10−26
Gαi signalling events 167 28 7.3× 10−26
Platelet degranulation 77 18 1.6× 10−25
Gastrin-CREB signalling pathways via PKC and MAPK 171 28 2.5× 10−25
Muscle contraction 62 16 4.7× 10−25
Gαq signalling events 150 25 3.2× 10−24
Retinoid metabolism and transport 34 12 5.0× 10−24
Phase 1 - Functionalisation of compounds 67 16 6.5× 10−24
Pathway over-representation analysis for Reactome pathways with the number of genes in each pathways (Pathway Size),
number of genes within the pathways identified (Cluster Genes), and the pathway over-representation p-value (adjusted by
FDR) from the hypergeometric test.
lular stimuli for these pathways were also implicated in potential synthetic lethality
with CDH1.
Similar translational, cytoskeletal, and immune processes were identified among
SLIPT partners with respect to CDH1 mutation, shown in Appendix Table C.2. While
GPCR signalling was replicated in mtSLIPT analysis, there was also stronger over-
representation for NOTCH, ERBB2, and PI3K/AKT signalling in mutation analysis
consistent with these signals being important for proliferation of CDH1 -deficient tu-
mours. The GCPR and PI3K/AKT pathways are of particular interest as pathways
with oncogenic mutations that can be targeted and downstream effects on transla-
tion (a strongly supported process across analyses). Extracellular matrix pathways
(e.g., elastic fibre formation) were also supported across analyses (in Table 4.4 and
Appendix Table C.2) consistent with the established cell-cell signalling role of CDH1
and the importance of the tumour microenvironment for cancer proliferation.
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4.2 Comparing Synthetic Lethal Gene Candidates
4.2.1 Primary siRNA Screen Candidates
Gene candidates were compared between computational (SLIPT in TCGA breast can-
cer data) and experimental (the primary siRNA screen performed by Telford et al.
(2015)) approaches in Figure 4.2. The number of genes detected by both methods did
not produce a significant overlap but these may be difficult to compare due to vast dif-
ferences between the detection methods. There were similar issues in the comparison
of mtSLIPT genes tested against CDH1 mutations (in Appendix Figure C.2), despite
excluding genes not tested by both methods in either test. However, these intersecting
genes may still be functionally informative or amenable to drug triage as they were
replicated across both methods and pathways over-representation differed between the
sections of the Venn diagram (as shown in Figure 4.2).
4.2.2 Comparison with Correlation
Another potential means to triage drug target candidates is by correlation of expression
profiles with CDH1. Correlation with CDH1 was compared to SLIPT and siRNA
results in Figure 4.3. As expected, the genes not detected by SLIPT (including siRNA
candidates) were distributed around a correlation of zero. Genes with higher correlation
with CDH1 (either direction) were more significant. The majority of SLIPT candidates
had negative correlations, particularly genes detected by both approaches, although
these were typically weak correlations and are unlikely to be sufficient to detect such
genes on their own. This is supported by simulation results in Section 6.1.
There were not many strong positive correlations with CDH1 among siRNA can-
didates, consistent with previous findings that co-expression was not predictive of syn-
thetic lethality (Jerby-Arnon et al., 2014; Lu et al., 2015). Negative correlation may
not be indicative of synthetic lethality either as many siRNA candidates also had pos-
itive correlation with CDH1 . The SLIPT methodology has therefore been shown to
detect genes with both positive and negative correlations, although it does appear to
preferentially detect negatively correlated genes to some extent. These findings were
replicated with the mtSLIPT approach against CDH1 mutation (in Appendix Fig-
ure C.3), although the range of the χ2 p-values differs due to lower sample size for
mutation analysis.
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Figure 4.2: Comparison of SLIPT with siRNA. Testing the overlap of gene candidates
for E-cadherin synthetic lethal partners between computational (SLIPT) and experimental
screening (siRNA) approaches. The χ2 test suggests that the overlap is no more than would
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Figure 4.3: Comparison of SLIPT and siRNA genes with correlation. The χ2 p-
values for genes tested by SLIPT (in TCGA breast cancer) expression analysis were compared
against Pearson correlation of gene expression with CDH1. Genes detected by SLIPT or
siRNA are coloured according to the legend.
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The apparent tendency for genes detected by SLIPT or siRNA to have negative cor-
relations with CDH1 expression was not due to the smaller number of genes in these
groups. The distribution of CDH1 correlations differed across these gene groups (as
shown by Figure 4.4 and Appendix Figure C.4) and tended to be lower in SLIPT can-
didates (as supported by analysis of variance (ANOVA) in Table 4.5). However, these
are relatively weak correlations and further triage of gene candidates by correlation is
not suitable. The genes detected both SLIPT and siRNA did not differ from SLIPT
genes and the number of positively correlated SLIPT genes was very small.The use of
correlation itself is also less effective than SLIPT to predict synthetic lethal partners






































Figure 4.4: Comparison of SLIPT and siRNA genes with correlation. Genes de-
tected as candidate synthetic lethal partners by SLIPT (in TCGA breast cancer) expression
analysis and experimental screening (with siRNA) were compared against Pearson correlation
of gene expression with CDH1. There were significant differences in correlation between gene
groups (as shown in Table 4.5).
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Table 4.5: ANOVA for synthetic lethality and correlation with CDH1
DF Sum Squares Mean Squares F-value p-value
siRNA 1 0.027 0.027 2.8209 0.09306
SLIPT 1 134.603 134.603 14115.9824 <0.0001
siRNA×SLIPT 1 7.14× 10−5 9.54× 10−3 0.0073 0.93212
Analysis of variance for correlation with CDH1 against synthetic lethal detection
approaches (with an interaction term). Only genes tested by both methods were
included in this analysis.
4.2.3 Comparison with Primary Screen Viability
A similar comparison of SLIPT results was made with the viability ratio (CDH1−/−
mutant to wild-type) of MCF10A cells in the primary siRNA screen performed by
Telford et al. (2015). The significance and viability thresholds used for SLIPT and
siRNA detection of synthetic lethal candidate partners of CDH1 are shown in Fig-
ure 4.5. Not all of the genes below the viability thresholds were necessarily selected
to be candidate partners, however, as additional criteria were used in each case: di-
rectional criteria as for SLIPT (in Section 3.1) and minimum wild-type viability for
siRNA (Telford et al., 2015).
There does not appear to be a clear relationship between SLIPT and siRNA can-
didates. The genes detected by one approach but not the other were numerous in
Figure 4.2 and Appendix Figure C.2. The genes detected by one approach are not
necessarily near the thresholds for the other. In this respect, the SLIPT approach
with patient data and the siRNA cell line experiments are independent means to iden-
tify synthetic lethal candidates. While genes detected by both approaches were not
necessarily more strongly supported by either, the genes with a viability closer to 1
(no synthetic lethal effect) in siRNA included those with more significant SLIPT p-
values, whereas more extreme viability ratios tended to be less significant (as shown
by Figure 4.5). However, it should be noted that genes with more moderate viabil-
ity ratios were more common and SLIPT was capable (despite adjusting for multiple
testing) of detecting significant genes with extreme viability ratios, particularly those
considerably lower than 1. Lower viability ratios were used by Telford et al. (2015)
to detect synthetic lethal candidates in the primary screen. However, there was little
support for SLIPT candidates differing with respect to viability ratio (as shown in
Figures 4.6 and C.5) and the vast majority of SLIPT candidate genes did not have
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Figure 4.5: Comparison of SLIPT and siRNA genes with screen viability. The
χ2 p-values (log-scale) for genes tested by SLIPT (in TCGA breast cancer) were compared
against the viability ratio of CDH1 mutant and wild-type cells in the primary siRNA screen.
Genes detected by SLIPT or siRNA are coloured according to the legend. Lines show the
thresholds of significance with SLIPT (p < 0.05) and of viability (ratio < 0.75 or < 0.85)




























Figure 4.6: Comparison of SLIPT genes with siRNA screen viability. Genes detected
as candidate synthetic lethal partners by SLIPT (in TCGA breast cancer) expression analysis
were compared against the viability ratio of CDH1 mutant and wild-type cells in the primary
siRNA screen. The genes identified by SLIPT had a higher viability ratio (by t-test: t =
2.1553, p = 0.03117), although the effect size was relatively small (mean SLIPT− 1.029, mean
SLIPT+ 1.037).
110
4.2.4 Comparison with Secondary siRNA Screen Validation
It should be noted that genes with a lower viability ratio were not necessarily the most
strongly supported by experimental screening. The primary screen (with 4 pooled siR-
NAs for each gene) has been used for the majority of comparisons in this thesis because
the genome-wide panel of target genes screened enables a large number of genes to be
compared with SLIPT results from gene expression and somatic mutation analysis. A
secondary screen was also performed by Telford et al. (2015) on the isogenic MCF10A
breast cell lines to validate the individual (i.e., non-pooled) siRNAs separately, with the
strongest candidates being those exhibiting synthetic lethal viability ratios replicated
across independently targeting siRNAs. The strongest candidates from the primary
screen were subject to a further secondary screen for validation by independent repli-
cation with 4 gene knockdowns with different targeting siRNAs. This was performed
for the top 500 candidates (with the lowest viability ratio) from the primary screen:
482 of these genes were also tested by SLIPT in breast cancer.
The secondary screen results show that SLIPT candidate genes were significantly
(p = 7.49 × 10−3 by Fisher’s exact test) more likely to be validated with detection
by more independently targeting siRNAs in the secondary screen. Gene detected by
SLIPT are thus informative of more robust partner genes, in addition to providing sup-
port that these interactions are consistent with expression profiles from heterogeneous
patient samples across genetic backgrounds. As shown in Table 4.6, there is significant
association between SLIPT candidates and stronger validations of siRNA candidates.
Since there were more SLIPT− genes among those not validated and more SLIPT+
genes among those validated with several siRNAs, this supports the use of SLIPT as a
synthetic lethal discovery procedure which may augment such screening experiments.
While the individual genes detected by either approach do not necessarily match
(and are potentially false-positives), the biological functions important in CDH1 -
deficient cancers and potential mechanisms for specific targeting of them can be further
supported by pathways analysis of the genes detected by either method. The genes
detected by both approaches may therefore be more informative at the pathway level,
where it is less likely for a pathway to be consistently detected by chance. As the
SLIPT candidates differ from the siRNA candidates (in addition to those detected by
both approaches which were more likely to be validated), they can provide information
about additional mechanisms by which CDH1 -deficient cancers proliferate, and vul-
nerabilities that may be exploited against them by using the synthetic lethal pathways.
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Table 4.6: Comparison of SLIPT genes against secondary siRNA screen
Secondary Screen
siRNAs* 0/4 1/4 2/4 3/4 4/4 Total
Observed 70 46 31 8 2
SLIPT+
Expected 85 44 10 4 2
157
Observed 190 90 31 10 4
SLIPT−
Expected 175 91 42 12 4
325
Total 280 136 52 18 6 482
* Number of siRNAs (targeting the same gene) to successfully
reproduce synthetic lethality in MCF10A cells (Telford et al.,
2015)
4.2.5 Comparison to Primary Screen at Pathway Level
These pathway over-representation analyses (performed as described in Section 2.3.2)
correspond to genes separated into SLIPT or siRNA screen candidates unique to either
method, or detected by both (Table 4.7). The SLIPT-specific gene candidates were
involved most strongly with translational and immune regulatory pathways, although
extracellular matrix pathways were also supported. These pathways were largely con-
sistent with those identified in Table 4.3 and in the clustering analysis (Table 4.4).
The genes detected only by the siRNA screen had over-representation of cell sig-
nalling pathways, including many containing genes known to be involved in cancer
(e.g., MAPK, PDGF, ERBB2, and FGFR), with the detection of Class A GPCRs
supporting the independent analyses by Telford et al. (2015). The intersection of com-
putational and experimental synthetic lethal partners of CDH1 had stronger evidence
for over-representation of GPCR pathways and more specific subclasses, such as visual
phototransduction (p = 6.9× 10−10) and Gαs signalling events (p = 1.7× 10−7), than
other signalling pathways.
The pathways analysis for mtSLIPT against CDH1 mutations (in Table C.3) had
similar results to SLIPT, particularly for mtSLIPT-specific pathways. The specific
pathways composition of the intersection of these analyses differed from SLIPT against
low CDH1 expression. However, signalling pathways were also detected, including
GPCRs, NOTCH, EERB2, PDGF, and SCF-KIT. These findings indicate the sig-
nalling pathways are among the most suitable vulnerability to exploit in targeting
CDH1 -deficient tumours as they can be detected in both a patient cohort (with TCGA
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Table 4.7: Pathways for CDH1 partners from SLIPT and siRNA
Predicted only by SLIPT (4025 genes) Pathway Size Genes Identified p-value (FDR)
Eukaryotic Translation Elongation 80 75 1.5× 10−182
Peptide chain elongation 77 72 2.9× 10−176
Viral mRNA Translation 75 70 4.9× 10−172
Eukaryotic Translation Termination 76 70 5.9× 10−170
Formation of a pool of free 40S subunits 87 74 9.5× 10−166
Nonsense Mediated Decay independent of the Exon Junction Complex 81 70 1.2× 10−160
L13a-mediated translational silencing of Ceruloplasmin expression 97 75 3.8× 10−155
3’ -UTR-mediated translational regulation 97 75 3.8× 10−155
GTP hydrolysis and joining of the 60S ribosomal subunit 98 75 6.0× 10−154
Nonsense-Mediated Decay 96 73 5.2× 10−150
Nonsense Mediated Decay enhanced by the Exon Junction Complex 96 73 5.2× 10−150
SRP-dependent cotranslational protein targeting to membrane 97 73 7.8× 10−149
Eukaryotic Translation Initiation 105 75 4.7× 10−146
Cap-dependent Translation Initiation 105 75 4.7× 10−146
Translation 133 83 4.0× 10−142
Influenza Viral RNA Transcription and Replication 102 71 2.9× 10−137
Influenza Infection 111 74 3.7× 10−137
Influenza Life Cycle 106 71 2.3× 10−133
Infectious disease 326 125 4.2× 10−120
Extracellular matrix organisation 189 77 5.4× 10−95
Detected only by siRNA screen (1599 genes) Pathway Size Genes Identified p-value (FDR)
Class A/1 (Rhodopsin-like receptors) 282 44 1.3× 10−27
GPCR ligand binding 363 52 5.8× 10−26
Gαq signalling events 159 26 6.7× 10−23
Gastrin-CREB signalling pathways via PKC and MAPK 180 27 2.0× 10−21
Gαi signalling events 184 27 5.3× 10−21
Downstream signal transduction 146 23 7.6× 10−21
Signalling by PDGF 172 25 4.0× 10−20
Peptide ligand-binding receptors 175 25 8.5× 10−20
Signalling by ERBB2 146 22 1.3× 10−19
DAP12 interactions 159 23 2.6× 10−19
DAP12 signalling 149 22 2.7× 10−19
Organelle biogenesis and maintenance 264 33 5.5× 10−19
Signalling by NGF 266 33 8.2× 10−19
Downstream signalling of activated FGFR1 134 20 1.1× 10−18
Downstream signalling of activated FGFR2 134 20 1.1× 10−18
Downstream signalling of activated FGFR3 134 20 1.1× 10−18
Downstream signalling of activated FGFR4 134 20 1.1× 10−18
Signalling by FGFR 146 21 1.3× 10−18
Signalling by FGFR1 146 21 1.3× 10−18
Signalling by FGFR2 146 21 1.3× 10−18
Intersection of SLIPT and siRNA screen (604 genes) Pathway Size Genes Identified p-value (FDR)
Visual phototransduction 54 9 6.9× 10−10
Gαs signalling events 48 7 1.6× 10−7
Retinoid metabolism and transport 24 5 1.7× 10−7
Acyl chain remodelling of PS 10 3 6.5× 10−6
Transcriptional regulation of white adipocyte differentiation 51 6 6.5× 10−6
Chemokine receptors bind chemokines 22 4 6.5× 10−6
Signalling by NOTCH4 11 3 6.9× 10−6
Defective EXT2 causes exostoses 2 11 3 6.9× 10−6
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 11 3 6.9× 10−6
Platelet activation, signalling and aggregation 146 12 6.9× 10−6
Phase 1 - Functionalisation of compounds 41 5 1.3× 10−5
Amine ligand-binding receptors 13 3 1.7× 10−5
Acyl chain remodelling of PE 14 3 2.4× 10−5
Signalling by GPCR 300 23 2.4× 10−5
Molecules associated with elastic fibres 29 4 2.6× 10−5
DAP12 interactions 128 10 2.6× 10−5
Cytochrome P450 - arranged by substrate type 30 4 3.2× 10−5
GPCR ligand binding 147 11 3.8× 10−5
Acyl chain remodelling of PC 16 3 4.0× 10−5
Response to elevated platelet cytosolic Ca2+ 66 6 4.2× 10−5
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expression data) and experimentally tested by inhibition with siRNA or drugs (Telford
et al., 2015). However, it is possible that the siRNA screen, that was conducted in an
isolated experimental system of MCF10A cell lines, was pre-disposed to preferentially
detect kinase signalling pathways (which are amenable to pharmacological inhibition
and clinical application). Nevertheless, the other pathways identified by SLIPT may
still be informative of the role of CDH1 loss of function in cancers or mechanisms by
which further gene loss leads to specific inviability.
4.2.5.1 Resampling Genes for Pathway Enrichment
A high number of significantly over-represented pathways were detected between SLIPT
in TCGA expression data and siRNA genes despite relatively few genes being detected
by both approaches. These strongly supported pathways are not unexpected, since syn-
thetic lethal pathways are more robustly conserved (Dixon et al., 2008) and the compu-
tational approach using patient samples from complex tumour micro-environment has
considerably different strengths to an experimental screen (Telford et al., 2015) based
on genetically homogenous cell line models in an isolated laboratory environment. For
instance, it is unlikely for immune signalling to be detected in an isolated cell culture
system.
While many pathways were highly over-represented in the genes detected by both
SLIPT and siRNA, some of these pathways were also highly over-represented in the
siRNA candidate genes and these may not reflect the results of SLIPT in expression
data. A resampling approach (as described in Section 2.3.6) was used to assess whether
SLIPT and the siRNA candidate genes had more frequently over-represented pathways
than expected by chance. This resampling procedure tests whether pathways were
over-represented in the genes detected by both approaches beyond that expected from
any subset of siRNA candidates. Thus resampling can determine whether SLIPT
independently supports these putative synthetic lethal pathways (without assuming
an underlying test statistic distribution).
A resampling approach is also applicable to testing whether the number of genes
detected by each approach significantly intersected. As shown in Figure 4.7, resampling
did not find evidence of significant depletion or over-representation for experimental
synthetic lethal candidate genes in the computationally predicted synthetic lethal part-
ners of CDH1, and thus the observed overlap may be due to chance. This is consistent
with previous findings (as shown in Figure 4.2) and does not preclude pathways rela-
tionships being supported by resampling.
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Figure 4.7: Resampled intersection of SLIPT and siRNA candidate genes. Resam-
pling analysis of intersect size from genes detected by SLIPT and siRNA screening approaches
over 1 million replicates. The proportion of expected intersection sizes for random samples
below or above the observed intersection size respectively, lacking significant over-represent-
ation or depletion of siRNA screen candidates within the SLIPT predictions for CDH1.
A permutation analysis was performed to resample the genes tested by both ap-
proaches to investigate whether the observed pathways over-representation could have
occurred in a randomly selected sample of genes from the experimental candidates,
that is, whether the pathways predictions from SLIPT could be expected by chance
(as described in Sections 2.2.4 and 2.3.6). While the number of siRNA candidate genes
also detected by SLIPT was not statistically significant (p = 0.281), this may be due to
the vastly different limitations of the approaches and the correlation structure of gene
expression not being independent (as assumed for multiple testing procedures). The
intersection may still be functionally relevant to CDH1 -deficient cancers, such as the
pathways data in Table 4.7. The resampling analysis for pathways was compared to
the pathways over-representation for SLIPT predicted synthetic lethal partners in Ta-
ble 4.8. Similarly, the pathways resampling for intersection between SLIPT predictions
115
and experimental screen candidates was compared to pathways over-representation in
Table 4.9 for intersection with siRNA data.
The pathways resampling approach for SLIPT-specific gene candidates (Table 4.8)
largely recapitulates the parametric gene set over-representation analysis for all SLIPT
genes, detecting evidence of synthetic lethal pathways for CDH1 in translational, im-
mune, and cell signalling pathways including Gαi signalling, GPCR downstream sig-
nalling, and chemokine receptor binding. While the immune and signal transduction
pathways were not significantly over-represented in the resampling analysis, the results
for the two approaches were largely consistent for translation and post-transcriptional
gene regulation, supporting gene set over-representation of the SLIPT-specific pathways
Table 4.8: Pathways for CDH1 partners from SLIPT
Reactome Pathway Over-representation Permutation
Eukaryotic Translation Elongation 1.3× 10−207 < 1.241× 10−5
Peptide chain elongation 5.6× 10−201 < 1.241× 10−5
Viral mRNA Translation 1.2× 10−196 < 1.241× 10−5
Eukaryotic Translation Termination 1.2× 10−196 < 1.241× 10−5
Formation of a pool of free 40S subunits 3.7× 10−194 < 1.241× 10−5
Nonsense Mediated Decay independent of the Exon Junction Complex 5.3× 10−187 < 1.241× 10−5
L13a-mediated translational silencing of Ceruloplasmin expression 9.6× 10−183 < 1.241× 10−5
3’ -UTR-mediated translational regulation 9.6× 10−183 < 1.241× 10−5
GTP hydrolysis and joining of the 60S ribosomal subunit 1.9× 10−181 < 1.241× 10−5
Nonsense-Mediated Decay 6.2× 10−176 < 1.241× 10−5
Nonsense Mediated Decay enhanced by the Exon Junction Complex 6.2× 10−176 < 1.241× 10−5
Adaptive Immune System 6.5× 10−174 0.15753
Eukaryotic Translation Initiation 5.7× 10−173 < 1.241× 10−5
Cap-dependent Translation Initiation 5.7× 10−173 < 1.241× 10−5
SRP-dependent cotranslational protein targeting to membrane 2.0× 10−171 < 1.241× 10−5
Translation 6.1× 10−170 < 1.241× 10−5
Infectious disease 1.6× 10−166 0.23231
Influenza Infection 1.9× 10−163 < 1.241× 10−5
Influenza Viral RNA Transcription and Replication 1.9× 10−160 < 1.241× 10−5
Influenza Life Cycle 2.5× 10−156 < 1.241× 10−5
Extracellular matrix organisation 1.1× 10−152 0.071761
GPCR ligand binding 1.1× 10−143 0.55801
Class A/1 (Rhodopsin-like receptors) 1.5× 10−142 0.58901
GPCR downstream signalling 7.6× 10−140 0.098357
Haemostasis 1.9× 10−134 0.27059
Developmental Biology 2.0× 10−123 0.52737
Metabolism of lipids and lipoproteins 3.3× 10−120 0.724
Cytokine Signalling in Immune system 2.6× 10−119 0.39661
Peptide ligand-binding receptors 3.7× 10−109 0.61102
Gαi signalling events 8.9× 10−100 < 1.241× 10−5
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR).
Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).
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Table 4.9: Pathways for CDH1 partners from SLIPT and siRNA primary screen
Reactome Pathway Over-representation Permutation
Visual phototransduction 6.9× 10−10 0.91116
Gαs signalling events 1.6× 10−7 0.012988
Retinoid metabolism and transport 1.7× 10−7 0.20487
Transcriptional regulation of white adipocyte differentiation 6.5× 10−6 0.38197
Acyl chain remodelling of PS 6.5× 10−6 0.58485
Chemokine receptors bind chemokines 6.5× 10−6 0.97255
Defective EXT2 causes exostoses 2 6.9× 10−6 0.056437
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 6.9× 10−6 0.056437
Signalling by NOTCH4 6.9× 10−6 0.15497
Platelet activation, signalling and aggregation 6.9× 10−6 0.53358
Phase 1 - Functionalisation of compounds 1.3× 10−5 0.24836
Amine ligand-binding receptors 1.7× 10−5 0.3195
Acyl chain remodelling of PE 2.4× 10−5 0.7307
Signalling by GPCR 2.4× 10−5 0.9939
Molecules associated with elastic fibres 2.6× 10−5 0.0072929
DAP12 interactions 2.6× 10−5 0.78273
Cytochrome P450 - arranged by substrate type 3.2× 10−5 0.87019
GPCR ligand binding 3.8× 10−5 0.99417
Acyl chain remodelling of PC 4.0× 10−5 0.65415
Response to elevated platelet cytosolic Ca2+ 4.2× 10−5 0.55461
Arachidonic acid metabolism 4.4× 10−5 0.060298
Defective B4GALT7 causes EDS, progeroid type 4.9× 10−5 0.15497
Defective B3GAT3 causes JDSSDHD 4.9× 10−5 0.15497
Elastic fibre formation 4.9× 10−5 0.0019227
HS-GAG degradation 6.2× 10−5 0.017747
Bile acid and bile salt metabolism 6.2× 10−5 0.15497
Netrin-1 signalling 7.1× 10−5 0.95056
Integration of energy metabolism 7.1× 10−5 0.0019287
DAP12 signalling 7.9× 10−5 0.67835
GPCR downstream signalling 8.1× 10−5 0.88678
Diseases associated with glycosaminoglycan metabolism 8.7× 10−5 0.017747
Diseases of glycosylation 8.7× 10−5 0.017747
Signalling by Retinoic Acid 8.7× 10−5 0.13592
Signalling by Leptin 8.7× 10−5 0.15497
Signalling by SCF-KIT 8.7× 10−5 0.73399
Opioid Signalling 8.7× 10−5 0.99417
Signalling by NOTCH 0.0001 0.26453
Platelet homeostasis 0.0001 0.55912
Signalling by NOTCH1 0.00011 0.13797
Class B/2 (Secretin family receptors) 0.00011 0.4659
Diseases of Immune System 0.00013 0.15497
Diseases associated with the TLR signalling cascade 0.00013 0.15497
A tetrasaccharide linker sequence is required for GAG synthesis 0.00013 0.33566
Nuclear Receptor transcription pathways 0.00016 0.22735
Formation of Fibrin Clot (Clotting Cascade) 0.00016 0.0054639
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across
pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).
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in Table 4.8. In particular, some of the most significantly over-represented pathways
had higher observed χ2 values than any of the 1 million random permutations. Similar
pathways were also replicated by permutation analysis for mtSLIPT candidate partners
against CDH1 mutation (shown in Appendix Table C.4). For the genes detected by
SLIPT, the permutation approach detected many of the most strongly over-represented
pathways.
The permutation approach was also applied to the intersection between computa-
tional and experimental candidates. This permutation analysis tested whether detec-
tion of pathways was independent of their pre-existing status as experimental candi-
dates. In contrast to the SLIPT pathways (in Table 4.8), the pathways results for these
candidate partners (in Table 4.9) differed considerably between over-representation and
resampling analyses.
Namely, many of the over-represented pathways were not significant in the resam-
pling analysis, including visual phototransduction and retinoic acid signalling, and were
likely over-represented in the intersection due to over-representation in the siRNA can-
didates rather than additional support from SLIPT. Of the highest over-represented
pathways in the intersection, only Gαs signalling events were supported by both over-
representation and resampling analyses. Other pathways supported by both analy-
ses were cytoplasmic elastic fibre formation, associated HS-GAG protein modification
pathways, energy metabolism, and the fibrin clotting cascade.
Many of the pathways supported in the intersection by permutation analysis were
also replicated in the mtSLIPT analysis of partners tested with CDH1 mutation (in
Table 4.10), including Gαs, elastic fibres, HS-GAG, and energy metabolism. While
there were differences between the pathways identified by over-representation analysis,
those replicated by permutation were highly concordant, supporting the combined use
of these pathways approaches to identify synthetic lethal gene functions and targets.
While this indicates that Gαs and GPCR class A/1 signalling events were signifi-
cantly detected by both approaches, GPCR signalling pathways overall were not. It is
likely that GPCRs were primarily over-represented in the intersection with the experi-
mental candidates due to strong over-representation of these pathways in experimental
candidates, rather than detection by SLIPT, which may be driven by these more spe-
cific constituent pathways.
Several pathways, including some immune functions and neurotransmitters, were
supported by the resampling analysis (in Table 4.9 and Appendix Table 4.10) when the
initial pathways over-representation test was not significant. These functions appear
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Table 4.10: Pathways for CDH1 partners from mtSLIPT and siRNA primary screen
Reactome Pathway Over-representation Permutation
Visual phototransduction 1.2× 10−9 0.86279
Gαs signalling events 2.9× 10−7 0.023066
Retinoid metabolism and transport 2.9× 10−7 0.299
Acyl chain remodelling of PS 1.1× 10−5 0.42584
Transcriptional regulation of white adipocyte differentiation 1.1× 10−5 0.53928
Chemokine receptors bind chemokines 1.1× 10−5 0.95259
Signalling by NOTCH4 1.2× 10−5 0.079229
Defective EXT2 causes exostoses 2 1.2× 10−5 0.22292
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 1.2× 10−5 0.22292
Platelet activation, signalling and aggregation 1.2× 10−5 0.48853
Serotonin receptors 1.4× 10−5 0.34596
Nicotinamide salvaging 1.4× 10−5 0.70881
Phase 1 - Functionalization of compounds 2× 10−5 0.31142
Amine ligand-binding receptors 2.5× 10−5 0.34934
Acyl chain remodelling of PE 3.8× 10−5 0.42615
Signalling by GPCR 3.8× 10−5 0.93888
Molecules associated with elastic fibres 3.9× 10−5 0.017982
DAP12 interactions 3.9× 10−5 0.71983
Beta defensins 3.9× 10−5 0.91458
Cytochrome P450 - arranged by substrate type 4.7× 10−5 0.83493
GPCR ligand binding 5.7× 10−5 0.95258
Acyl chain remodelling of PC 6.1× 10−5 0.42584
Response to elevated platelet cytosolic Ca2+ 6.4× 10−5 0.54046
Arachidonic acid metabolism 6.7× 10−5 0.026696
Defective B4GALT7 causes EDS, progeroid type 7.3× 10−5 0.24921
Defective B3GAT3 causes JDSSDHD 7.3× 10−5 0.24921
Hydrolysis of LPC 7.3× 10−5 0.80663
Elastic fibre formation 7.4× 10−5 0.0058768
HS-GAG degradation 9.4× 10−5 0.0083179
Bile acid and bile salt metabolism 9.4× 10−5 0.079905
Netrin-1 signalling 0.00011 0.92216
Integration of energy metabolism 0.00011 0.011152
Dectin-2 family 0.00012 0.10385
Platelet sensitization by LDL 0.00012 0.34596
DAP12 signalling 0.00012 0.62787
Defensins 0.00012 0.77542
GPCR downstream signalling 0.00012 0.79454
Diseases associated with glycosaminoglycan metabolism 0.00013 0.065927
Diseases of glycosylation 0.00013 0.065927
Signalling by Retinoic Acid 0.00013 0.22292
Signalling by Leptin 0.00013 0.34596
Signalling by SCF-KIT 0.00013 0.70881
Opioid Signalling 0.00013 0.96053
Signalling by NOTCH 0.00015 0.26884
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across
pathways (FDR). Significant pathways were marked in bold (FDR < 0.05) and italics (FDR < 0.1).
119
to have been detected by both approaches more than expected by chance but must be
interpreted with caution since they were still not common enough to be detected in
pathways over-representation analysis.
4.2.6 Integrating Synthetic Lethal Pathways and Screens
Based on these results, it appears that computational and experimental approaches to
synthetic lethal screening for CDH1 lead to a broader functional characterisation, and
many candidate partners, when combined, despite different strengths and limitations.
Compared to candidate gene approaches, experimental genome-wide screens are an
appealing unbiased strategy for identifying synthetic lethal interactions. Since these
screens are costly, laborious, and specific to genetic background, computational analysis
can augment candidate triage to either reduce the initial panel of screened genes or
prioritise validation.
GPCR pathways were detected among both computational and experimental syn-
thetic lethal candidates, with more support in the experimental screen (Table 4.9). The
homogeneous cell line model may be more likely to detect particular pathways. For
instance, SLIPT identified immune pathways, not expected to be detected in isolated
cell culture. GPCR signalling was supported in experimental models Telford et al.
(2015) with some of these pathways replicated in varied genetic backgrounds of patient
samples. These pathways require further investigation such as identification of more
specific pathways, higher-order interactions, and modes of resistance. These investi-
gations would include experimental validation of synthetic lethal relationships, further
testing dosage or combinations of inhibitors for specificity against CDH1 mutant cells,
and expression studies of compensating pathways under synthetic lethal treatment in
resistant cells.
The pathways composition across computational and experimental synthetic lethal
candidates was informative with over-representation (Table 4.7) and was supported by
resampling analysis (Table 4.9), despite a modest intersection of genes between them
(Figure 4.2). Either approach may be significant for a pathway in this intersection
without being supported by the other: resampling analysis may support pathways
that were not over-represented due to small effect sizes, thus both tests are required to
identify candidate pathways. The pathways detected by both over-representation and
resampling are the strongest candidates for further investigation, such as Gαs signalling,
a strong candidate in prior analyses with a role in the regulation of translation in cancer
Gao and Roux (2015), another function supported by SLIPT analysis.
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The predicted synthetic lethal partners occurred across functionally distinct path-
ways, including characterised functions of CDH1. This diversity is consistent with the
wide ranging role of CDH1 in cell-cell adhesion, cell signalling, and the cytoskeletal
structure of epithelial tissues. Pathway structure may be relevant to identifying poten-
tial drug targets from gene expression signatures, indicating downstream effector genes
and mechanisms leading to cell inviability. These distinct synthetic lethal gene clusters
and pathways may further lead to the elucidation of drug resistance mechanisms.
4.3 Synthetic Lethal Pathway Metagenes
Metagenes are a one-dimensional summary of the activity for each biological pathway.
The direction of metagenes (derived by the singular value matrix decomposition as
described in Section 2.2.3) reflects overall activation of the pathways. This has been
verified by examining the expression patterns of previously published gene signatures
(Gatza et al., 2011, 2014) in Appendix D. Pathway metagenes for Reactome pathways
were used for testing synthetic lethal pathways. Since the metagenes values are higher
when the pathways as a whole is activated, they are suitable for SLIPT analysis using
low metagene levels to represent less activated pathways.
The TCGA breast cancer expression data was used to generate pathway metagenes
for each collection of genes in a pathway from the Reactome database (Croft et al.,
2014). These metagenes were tested against the expression of CDH1 by SLIPT to
directly detect synthetic lethal pathways. These synthetic lethal metagenes differed
to the over-represented pathways among synthetic lethal gene candidates. However,
there were some similarities to previous findings, as shown in Table 4.11. In particular,
translational pathways were replicated as observed in Table 4.3. While the specific
pathways differ, immune pathways (e.g., NF-κB) were also supported by metagene
synthetic lethal analysis.
Signalling pathways were more strongly supported by mtSLIPT analysis of meta-
gene pathways expression against CDH1 mutation, as shown in Table D.1, although
these results were generally less statistically significant than expression analyses. Sig-
nalling pathways detected as synthetic lethal metagenes include Gαz, insulin-related
growth factor (IGF), GABA receptor, Gαs, S6K1 and various toxin responses medi-
ated by GPCRs. Metabolic processes including processing of carbohydrates and fatty
acids were also implicated across these analyses.
The metagene analyses differ more between expresssion and CDH1 mutation than
previous analyses, with more specific signalling pathways identified in the mutation
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Table 4.11: Examples of candidate metagenes synthetic lethal for CDH1 from SLIPT
Pathway ID Observed Expected χ2value p-value p-value (FDR)
Glycogen storage diseases 3229121 68 130 176 6.62× 10−37 1.82× 10−34
Myoclonic epilepsy of Lafora 3785653 68 130 176 6.62× 10−37 1.82× 10−34
Diseases of carbohydrate metabolism 5663084 68 130 176 6.62× 10−37 1.82× 10−34
Arachidonic acid metabolism 2142753 81 130 157 8.13× 10−33 1.49× 10−30
Translation initiation complex formation 72649 70 130 152 7.08× 10−32 1.17× 10−29
Synthesis of 5-eicosatetraenoic acids 2142688 68 130 151 1.25× 10−31 1.88× 10−29
SRP-dependent cotranslational protein targeting to membrane 1799339 69 130 150 2.01× 10−31 2.76× 10−29
L13a-mediated translational silencing of Ceruloplasmin expression 156827 72 130 148 5.91× 10−31 6.44× 10−29
3’ -UTR-mediated translational regulation 157279 72 130 148 5.91× 10−31 6.44× 10−29
Activation of the mRNA upon binding of the cap-binding complex and eIFs,
and subsequent binding to 43S
72662 70 130 147 1.14× 10−30 9.28× 10−29
Formation of the ternary complex, and subsequently, the 43S complex 72695 70 130 147 1.14× 10−30 9.28× 10−29
Ribosomal scanning and start codon recognition 72702 70 130 147 1.14× 10−30 9.28× 10−29
Eukaryotic Translation Elongation 156842 72 130 146 1.19× 10−30 9.28× 10−29
Nonsense Mediated Decay independent of the Exon Junction Complex 975956 71 130 146 1.24× 10−30 9.28× 10−29
Viral mRNA Translation 192823 70 130 146 1.51× 10−30 1.04× 10−28
Eukaryotic Translation Termination 72764 70 130 146 1.51× 10−30 1.04× 10−28
NF-kB is activated and signals survival 209560 71 130 145 1.90× 10−30 1.19× 10−28
Peptide chain elongation 156902 72 130 145 1.91× 10−30 1.19× 10−28
Influenza Life Cycle 168255 70 130 145 1.95× 10−30 1.19× 10−28
Formation of a pool of free 40S subunits 72689 73 130 145 2.01× 10−30 1.19× 10−28
Nonsense-Mediated Decay 927802 71 130 145 2.44× 10−30 1.34× 10−28
Nonsense Mediated Decay enhanced by the Exon Junction Complex 975957 71 130 145 2.44× 10−30 1.34× 10−28
GTP hydrolysis and joining of the 60S ribosomal subunit 72706 72 130 145 2.58× 10−30 1.37× 10−28
Influenza Viral RNA Transcription and Replication 168273 72 130 144 4.01× 10−30 2.07× 10−28
Signalling by NOTCH1 HD Domain Mutants in Cancer 2691230 79 130 143 5.99× 10−30 2.82× 10−28
Strongest candidate synthetic lethal partners for CDH1 by SLIPT with observed and expected numbers of TCGA breast cancer samples with low expression of
both CDH1 and the metagene. The most significant 26 pathways are reported to show the diversity of candidate synthetic lethal metagene and demonstrate
the highly significant results of SLIPT when performed on pathway metagenes.
analysis. This supports the usage of a complete null mutant model in experimental
testing for synthetic lethality of signalling pathways against CDH1 inactivation rather
than a knockdown in expression. However, low expression of partners has been used in
either case to be applicable to dose-dependent pharmacological inhibition and across
genes where mutations have different functional consequences, including variants of
unknown significance.
These results show an alternative pathways-based approach to detecting synthetic
lethal gene functions interacting with CDH1. The use of synthetic lethal metagenes
replicates support for these pathways independent of pathways size (as genes are
weighted equally). Having verified that the direction of metagenes recapitulates the
activity of a pathway, these demonstrate that many of the pathways previously iden-
tified (from SLIPT candidate genes) are synthetic lethal pathways, with their activity
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dependent on synthetic lethal genes, rather than containing synthetic lethal genes as
inhibitors or peripheral regulators of the pathways.
The synthetic lethal analysis against low CDH1 expression supports prior findings
in translational and immune pathways even if they were not able to be detected in an
experimental screen (Telford et al., 2015). Together these findings support the role of
CDH1 loss in cancer disrupting cell signalling with wider effects on protein translation
and metabolism necessary for the proliferation of cancer cells. This is consistent with
the GPCR pathways, such as Gαs signalling, being supported by SLIPT gene candidates
and the experimental primary siRNA screen, as shown by resampling in Section 4.2.5.1.
4.4 Application of SLIPT to Stomach Cancer
CDH1 is also important in stomach cancer biology as a driver tumour suppressor gene,
including as a germline mutation in many cases of hereditary diffuse gastric cancer.
The synthetic lethal analysis of genes and pathways (previously identified for TCGA
breast cancer data) was replicated in TCGA stomach cancer.
While the sample size was lower for TCGA stomach cancer (particularly for mu-
tations), the results serve to support the findings in breast cancer in an independent
patient cohort and tissue samples. The molecular profiling, including RNA-Seq expres-
sion, were performed by TCGA using the sample procedures as for breast cancer and
the findings reported here were performed using data analysis techniques identical to
those presented previously. These procedures should ensure as close a comparison as
feasible across both of the cancer types most relevant to HDGC and recurrent CDH1
mutations.
The strongest SLIPT genes for stomach cancer (shown in Table 4.12) did not nec-
essarily directly correspond to those observed in breast cancer (shown in Table 4.1).
However, several gene functions were replicated in stomach cancer. Together, these
gene candidates indicate widespread functions of CDH1 and strongly detectable syn-
thetic lethality with many genes, using a strategy that can be applied across cancer
types. More specifically, the signalling genes included GPCR signalling genes, which
was one of the most supported synthetic lethal pathways in breast cancer analysis
and the experimental screen (Telford et al., 2015). These findings were further sup-
ported by the pathways over-represented in SLIPT candidates from TCGA stomach
cancer (shown in Appendix Table 4.13) which replicated the translational and immune
pathways observed in TCGA breast cancer (shown in Table 4.3) and further supported
GCPR signalling pathways, including the class A/1 receptors. The extracellular matrix
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was also detected at the pathway level in stomach cancer, including elastic fibres, gly-
cosylation, collagen, and integrin cell-surface interactions. While fewer pathways were
supported by resampling for the intersection of SLIPT and experimental screen can-
didate partners in stomach cancer than breast cancer, many of those detected (shown
in Appendix Table 4.17) were consistent with those detected in breast cancer (shown
in Table 4.9). The pathways detected by both permutation and over-representation
analysis were more likely to be replicated across stomach and breast cancer than those
detected by over-representation alone, supporting the use of this procedure to detect
synthetic lethal pathways applicable across cancer types. These pathways include Gαs
signalling and elastic fibre formation as discussed for breast cancer (in Section 4.2.5.1).
4.4.1 Synthetic Lethal Genes and Pathways
The strongest of the 4365 SLIPT candidate genes detected in stomach cancer (shown in
Table 4.12) did not necessarily directly correspond to those observed in breast cancer
(shown in Table 4.1). However, several gene functions were replicated in stomach can-
cer. Cell membrane genes including EMP3, GYPC, LGALS1, PRR24, and FUNCD2
were among the strongest SL candidates. Similarly, cell signalling genes including
PLEKHO1, RARRES2, VEGFB, HSPB2, and CREM were detected in stomach can-
cers. It is notable that several of these genes (EMP3, PLEKHO1, and FUNCD2 ) have
a known role in cancer. Together these genes support the roles of CDH1 in cell mem-
brane and signalling functions (of epithelial tissues) which are perturbed in both breast
and stomach cancers.
These findings were further supported by the pathways over-represented in SLIPT
candidates from TCGA stomach cancer (shown in Table 4.13) which were replicated
the translational and immune pathways observed in TCGA breast cancer (shown in
Table 4.3). There was further support for GCPR signalling pathways including the class
A/1 receptors in CDH1 -deficient stomach cancers, in addition to cell signalling and
translation pathways important in tumour growth across breast and stomach cancer.
4.4.2 Synthetic Lethal Expression Profiles
The expression profiles of candidate synthetic lethal partners detected by SLIPT in
stomach cancer were plotted against clinical characteristics as described for breast
cancer data in Section 4.1.2 (shown in Figure 4.8). As expected the majority of CDH1
mutant samples had low expression of CDH1 and were the diffuse type of stomach
cancer.
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Table 4.12: Synthetic lethal gene partners of CDH1 from SLIPT in stomach cancer
Gene Observed* Expected* χ2 value p-value p-value (FDR)
PRAF2 17 50.4 121 3.54× 10−25 1.45× 10−21
EMP3 17 50.4 115 5.06× 10−24 1.48× 10−20
PLEKHO1 22 50.4 112 2.14× 10−23 4.75× 10−20
SELM 20 50.4 111 5.13× 10−23 8.09× 10−20
GYPC 20 50.4 110 5.77× 10−23 8.45× 10−20
COX7A1 18 50.4 109 1.15× 10−22 1.39× 10−19
TNFSF12 20 50.4 106 4.06× 10−22 4.38× 10−19
SEPT4 17 50.4 106 6.58× 10−22 5.91× 10−19
LGALS1 19 50.4 105 6.64× 10−22 5.91× 10−19
RARRES2 27 50.4 105 8.02× 10−22 6.85× 10−19
VEGFB 16 50.4 104 1.19× 10−21 9.74× 10−19
PRR24 22 50.4 102 2.96× 10−21 2.02× 10−18
SYNC 19 50.4 102 3.73× 10−21 2.39× 10−18
MAGEH1 17 50.4 100 9.52× 10−21 5.01× 10−18
HSPB2 23 50.4 99.6 1.19× 10−20 5.82× 10−18
SMARCD3 19 50.4 99 1.59× 10−20 7.57× 10−18
CREM 13 50.4 98.1 2.48× 10−20 1.13× 10−17
GNG11 20 50.4 97.3 3.68× 10−20 1.59× 10−17
GNAI2 17 50.4 96.4 5.75× 10−20 2.36× 10−17
FUNDC2 22 50.4 95.9 7.39× 10−20 2.91× 10−17
CNRIP1 21 50.4 95.3 1.0× 10−19 3.66× 10−17
CALHM2 22 50.4 93.1 2.94× 10−19 1.06× 10−16
ARID5A 18 50.4 92.7 3.47× 10−19 1.22× 10−16
ST3GAL3 27 50.4 92.2 4.49× 10−19 1.56× 10−16
LOC339524 21 50.4 92.1 4.8× 10−19 1.59× 10−16
Strongest candidate synthetic lethal partners for CDH1 of 4365 genes detected by
SLIPT (with FDR p-value < 0.05) in TCGA stomach cancer expression data
* Observed and expected numbers of samples which had low expression of both genes
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Table 4.13: Pathways for CDH1 partners from SLIPT in stomach cancer
Pathways Over-represented Pathway Size SL Genes p-value (FDR)
Extracellular matrix organization 241 104 7.5× 10−140
Hemostasis 445 138 1.8× 10−121
Developmental Biology 432 125 9.2× 10−107
Axon guidance 289 94 1.5× 10−102
Eukaryotic Translation Termination 84 49 1.9× 10−99
GPCR ligand binding 373 108 3.8× 10−99
Viral mRNA Translation 82 48 3.3× 10−98
Formation of a pool of free 40S subunits 94 51 3.3× 10−98
Eukaryotic Translation Elongation 87 49 1.6× 10−97
Peptide chain elongation 84 48 7.2× 10−97
Class A/1 (Rhodopsin-like receptors) 289 90 2.7× 10−96
Nonsense Mediated Decay independent of the Exon Junction Complex 89 49 3.0× 10−96
Infectious disease 349 100 2.6× 10−94
GTP hydrolysis and joining of the 60S ribosomal subunit 105 52 3.4× 10−94
L13a-mediated translational silencing of Ceruloplasmin expression 104 51 2.8× 10−92
3’ -UTR-mediated translational regulation 104 51 2.8× 10−92
Neuronal System 272 84 8.4× 10−92
SRP-dependent cotranslational protein targeting to membrane 105 51 9.5× 10−92
Eukaryotic Translation Initiation 112 52 2.0× 10−90
Cap-dependent Translation Initiation 112 52 2.0× 10−90
The most significant pathways from gene set over-representation analysis (hypergeometric test) for Reactome pathways in
SLIPT partners for CDH1.
The SLIPT partners of CDH1 exhibited similar clustering in staomch cancer to
breast cancer, replicating the diverse roles of elevated partner genes in different clinical
samples. Specifically (as shown in Figure 4.8), the diffuse type stomach cancers had
higher expression of the candidate synthetic lethal partners (where CDH1 has a role as a
driver mutation), despite an unbiased clustering. This is consistent with compensating
expression of synthetic lethal partners under loss of CDH1, as suggested by Lu et al.
(2015). The pathways composition of gene clusters for stomach cancer (shown in
Table 4.14) was also highly concordant with breast cancer findings (shown in Table 4.4).
These included replicated of translation (Cluster 1), immune functions (Cluster 2), Gαs
signalling (Cluster 3), and further support for the roles of GPCRs and the extracellular
matrix (Cluster 4) in the synthetic lethal partners and functions of CDH1, replicated
across stomach and breast cancers. Clusters 1 and 4, which had particularly high
expression of SLIPT candidate partner genes in the diffuse subtype, also had the most
significant over-representation of pathways.
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Figure 4.8: Synthetic lethal expression profiles of analysed samples. Gene expression
profile heatmap (correlation distance) of all samples (separated by the 1/3 quantile of CDH1
expression) analysed in TCGA stomach cancer dataset for gene expression of 4365 candidate
partners of E-cadherin (CDH1 ) from SLIPT prediction (with significant FDR adjusted p <
0.05). Deeply clustered, inter-correlated genes form several main groups, each containing
genes that were SL candidates or toxic in an siRNA screen Telford et al. (2015). Clusters
had different sample groups highly expressing the synthetic lethal candidates in CDH1 low
samples. Notably, diffuse and CDH1 mutant samples had elevated expression in one or more
distinct clusters, although there was less complexity and variation among candidate synthetic
lethal partners than in breast data. CDH1 low samples also contained most of samples with
CDH1 mutations.
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Table 4.14: Pathways for clusters of CDH1 partners in stomach SLIPT
Pathways Over-represented in Cluster 1 Pathway Size Cluster Genes p-value (FDR)
Viral mRNA Translation 82 48 1.3× 10−97
Formation of a pool of free 40S subunits 94 51 1.3× 10−97
Eukaryotic Translation Elongation 87 49 4.8× 10−97
Peptide chain elongation 84 48 1.4× 10−96
Eukaryotic Translation Termination 84 48 1.4× 10−96
GTP hydrolysis and joining of the 60S ribosomal subunit 105 52 7.9× 10−94
Nonsense Mediated Decay independent of the Exon Junction Complex 89 48 3.1× 10−93
L13a-mediated translational silencing of Ceruloplasmin expression 104 51 5.1× 10−92
3’ -UTR-mediated translational regulation 104 51 5.1× 10−92
SRP-dependent cotranslational protein targeting to membrane 105 51 1.7× 10−91
Eukaryotic Translation Initiation 112 52 3.3× 10−90
Cap-dependent Translation Initiation 112 52 3.3× 10−90
Translation 142 56 3.6× 10−85
Nonsense-Mediated Decay 104 48 1.2× 10−84
Nonsense Mediated Decay enhanced by the Exon Junction Complex 104 48 1.2× 10−84
Influenza Viral RNA Transcription and Replication 109 48 4.1× 10−82
Influenza Life Cycle 113 48 3.4× 10−80
Influenza Infection 118 48 6.4× 10−78
Pathways Over-represented in Cluster 2 Pathway Size Cluster Genes p-value (FDR)
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65 12 1.3× 10−15
Phosphorylation of CD3 and TCR zeta chains 18 6 1.7× 10−12
Generation of second messenger molecules 29 7 2.7× 10−12
PD-1 signalling 21 6 7.4 ×10−12
TCR signalling 62 9 4.3 ×10−11
Translocation of ZAP-70 to Immunological synapse 16 5 1.1 ×10−10
Interferon alpha/beta signalling 68 9 1.6 ×10−10
Initial triggering of complement 17 5 1.6 ×10−10
IKK complex recruitment mediated by RIP1 19 5 5.1 ×10−10
TRIF-mediated programmed cell death 10 4 6.2 ×10−10
Creation of C4 and C2 activators 11 4 1.3 ×10−9
RHO GTPases Activate NADPH Oxidases 11 4 1.3 ×10−9
Interferon Signalling 175 15 2.3× 10−9
Chemokine receptors bind chemokines 52 7 4.0× 10−9
Interferon gamma signalling 74 8 1.6× 10−8
TRAF6 mediated induction of TAK1 complex 15 4 1.6× 10−8
Activation of IRF3/IRF7 mediated by TBK1/IKK ε 16 4 2.7× 10−8
Downstream TCR signalling 45 6 3.5× 10−8
Pathways Over-represented in Cluster 3 Pathway Size Cluster Genes p-value (FDR)
Uptake and actions of bacterial toxins 22 4 3.5× 10−6
Neurotoxicity of clostridium toxins 10 3 3.5× 10−6
Activation of PPARGC1A (PGC-1alpha) by phosphorylation 10 3 3.5× 10−6
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription 28 4 1.4× 10−5
Assembly of the primary cilium 149 10 2.5× 10−5
Serotonin Neurotransmitter Release Cycle 15 3 2.5× 10−5
Glycosaminoglycan metabolism 114 8 3.3× 10−5
Platelet homeostasis 54 5 3.3× 10−5
Norepinephrine Neurotransmitter Release Cycle 17 3 3.3× 10−5
Acetylcholine Neurotransmitter Release Cycle 17 3 3.3× 10−5
Gαs signalling events 100 7 5.5× 10−5
GABA synthesis, release, reuptake and degradation 19 3 5.6× 10−5
deactivation of the beta-catenin transactivating complex 39 4 6.7× 10−5
Dopamine Neurotransmitter Release Cycle 20 3 6.7× 10−5
IRS-related events triggered by IGF1R 83 6 7.1× 10−5
Generic Transcription Pathway 186 11 7.1× 10−5
Termination of O-glycan biosynthesis 21 3 7.4× 10−5
Kinesins 22 3 8.5× 10−5
Pathway over-representation analysis for Reactome pathways with the number of genes in each pathway (Pathway Size), number of genes within
the pathway identified (Cluster Genes), and the pathway over-representation p-value (adjusted by FDR) from the hypergeometric test.
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Table 4.14: Pathways for clusters of CDH1 partners in stomach SLIPT
Pathways Over-represented in Cluster 4 Pathway Size Cluster Genes p-value (FDR)
Extracellular matrix organization 241 97 8.8× 10−126
Axon guidance 289 75 8.3× 10−72
Hemostasis 445 101 8.3× 10−72
Developmental Biology 432 95 3.0× 10−67
Response to elevated platelet cytosolic Ca2+ 84 37 5.8× 10−67
Platelet degranulation 79 36 5.8× 10−67
Degradation of the extracellular matrix 104 39 6.7× 10−63
Platelet activation, signalling and aggregation 186 52 6.6× 10−62
ECM proteoglycans 66 31 8.1× 10−61
Neuronal System 272 64 5.1× 10−60
Signalling by PDGF 173 47 9.7× 10−57
Integrin cell surface interactions 82 31 1.9× 10−53
Collagen biosynthesis and modifying enzymes 56 26 1.1× 10−52
Collagen formation 67 28 1.4× 10−52
Class A/1 (Rhodopsin-like receptors) 289 61 2.3× 10−52
GPCR ligand binding 373 73 2.8× 10−52
Elastic fibre formation 38 22 4.7× 10−52
Non-integrin membrane-ECM interactions 53 24 7.0× 10−49
Pathway over-representation analysis for Reactome pathways with the number of genes in each pathway (Pathway Size),
number of genes within the pathway identified (Cluster Genes), and the pathway over-representation p-value (adjusted by
FDR) from the hypergeometric test.
4.4.3 Comparison to Primary Screen
The number of genes detected by both SLIPT in TCGA stomach cancer data and
siRNA in breast cell lines (shown in Figure 4.9) was also not a significant overlap (as
observed for breast cancer in Figure 4.2). SLIPT against CDH1 in stomach cancer
detected fewer genes due to low sample size and mutation frequency compared to the
breast cancer analysis. This smaller overlap can also be attributed to the tissue-specific
differences between the stomach cancers and the breast cells used for the experimental
model (Chen et al., 2014). Nevertheless, many genes were detected across SLIPT in
stomach cancers and the experimental screen (Telford et al., 2015) and the pathways
detected were consistent with prior observations in breast cancer. Despite differences
in the specific genes detected, the functions of CDH1 were conserved across epithetial
cancers in different tissues and synthetic lethal inhibition of interacting pathways may
be effective against molecular targets such as CDH1 inactivation across tissue types.
However, the pathways composition of SLIPT-specific genes and those replicated
with the siRNA primary screen (Telford et al., 2015) were highly concordant between
the pathways identified by SLIPT in TCGA stomach cancer (shown in Table 4.15)
and pathways previously identified in TCGA breast cancer (shown in Table 4.7). In
both cases, translation and immune pathways were highly over-represented in SLIPT-
specific genes, which I would not expect to be detected by siRNA screening in cell
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Figure 4.9: Comparison of SLIPT in stomach to siRNA. The overlap of gene candi-
dates for E-cadherin synthetic lethal partners between computational (SLIPT) and experi-
mental screening (siRNA) approaches. The χ2 test suggests that the overlap is no more than
would be expected by chance (p = 0.281).
lines, as discussed in Section 4.2.5. In addition, the extracellular matrix was supported
by in stomach cancer. While the pathways identified by specifically by SLIPT in
stomach cancer or siRNA screening were similar to those observed for breast cancer
(in Table 4.7), the pathways over-represented in the intersection for stomach cancer
SLIPT candidates and the siRNA primary screen (Telford et al., 2015) also had a clear
over-representation of signalling pathways, although they differed from those observed
in breast cancer SLIPT candidates. GPCR signalling was supported in genes detected
in both TCGA stomach cancer and screening, including Gαq, Gαs, serotonin receptors,
and class A signalling (shown in more detail in Table 4.17). In addition MAPK and
NOTCH signalling pathways were detected. These replicate the findings in breast
cancer and show consistent detection of signalling pathways in stomach cancer despite
less genes being detected by SLIPT and patient samples differing from the tissue in
which the experiments were conducted.
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Table 4.15: Pathways for CDH1 partners from SLIPT and siRNA
Predicted only by SLIPT (3392 genes) Pathway Size Genes Identified p-value (FDR)
Extracellular matrix organization 238 90 3.4× 10−107
Eukaryotic Translation Termination 79 46 7.6× 10−91
Viral mRNA Translation 77 45 1.2× 10−89
Eukaryotic Translation Elongation 82 46 5.8× 10−89
Peptide chain elongation 79 45 2.1× 10−88
Nonsense Mediated Decay independent of the Exon Junction Complex 84 46 9.4× 10−88
Formation of a pool of free 40S subunits 89 47 3.3× 10−87
GTP hydrolysis and joining of the 60S ribosomal subunit 100 48 3.2× 10−83
Axon guidance 284 84 3.9× 10−82
Developmental Biology 426 111 4.2× 10−82
L13a-mediated translational silencing of Ceruloplasmin expression 99 47 1.4× 10−81
3’ -UTR-mediated translational regulation 99 47 1.4× 10−81
SRP-dependent cotranslational protein targeting to membrane 99 47 1.4× 10−81
Nonsense-Mediated Decay 99 47 1.4× 10−81
Nonsense Mediated Decay enhanced by the Exon Junction Complex 99 47 1.4× 10−81
Hemostasis 438 112 1.2× 10−80
Eukaryotic Translation Initiation 107 48 8.0× 10−80
Cap-dependent Translation Initiation 107 48 8.0× 10−80
Infectious disease 338 90 1.6× 10−76
Neuronal System 267 77 1.6× 10−76
Detected only by siRNA screen (1803 genes) Pathway Size Genes Identified p-value (FDR)
Class A/1 (Rhodopsin-like receptors) 282 62 8.1× 10−50
GPCR ligand binding 363 71 4.9× 10−46
Peptide ligand-binding receptors 175 38 7.9× 10−38
Gαi signalling events 184 37 1.1× 10−34
Gastrin-CREB signalling pathway via PKC and MAPK 180 35 1.4× 10−32
Gαq signalling events 159 32 4.8× 10−32
DAP12 interactions 159 29 1.4× 10−27
Downstream signal transduction 146 26 2.4× 10−25
DAP12 signalling 149 26 6.4× 10−25
VEGFA-VEGFR2 Pathway 91 19 8.1× 10−24
Signalling by PDGF 172 27 5.7× 10−23
Signalling by ERBB2 146 24 1.4× 10−22
Signalling by VEGF 99 19 2.0× 10−22
Visual phototransduction 85 17 1.3× 10−21
Downstream signalling of activated FGFR1 134 22 1.3× 10−21
Downstream signalling of activated FGFR2 134 22 1.3× 10−21
Downstream signalling of activated FGFR3 134 22 1.3× 10−21
Downstream signalling of activated FGFR4 134 22 1.3× 10−21
Signalling by FGFR 146 23 2.0× 10−21
Signalling by FGFR1 146 23 2.0× 10−21
Intersection of SLIPT and siRNA screen (547 genes) Pathway Size Genes Identified p-value (FDR)
Class A/1 (Rhodopsin-like receptors) 282 25 3.9× 10−9
Platelet activation, signalling and aggregation 182 17 3.9× 10−9
Response to elevated platelet cytosolic Ca2+ 82 9 5.5× 10−8
Platelet homeostasis 53 7 5.7× 10−8
Nucleotide-like (purinergic) receptors 16 4 1.8× 10−7
Platelet degranulation 77 8 2.8× 10−7
Peptide ligand-binding receptors 175 14 3.8× 10−7
Molecules associated with elastic fibres 34 5 7.1× 10−7
Amine ligand-binding receptors 35 5 8.6× 10−7
Gαi signalling events 184 14 9.8× 10−7
GPCR ligand binding 363 27 1.1× 10−6
Elastic fibre formation 38 5 1.5× 10−6
Gαq signalling events 159 12 1.9× 10−6
Serotonin receptors 12 3 3.8× 10−6
P2Y receptors 12 3 3.8× 10−6
Signal amplification 16 3 2.3× 10−5
Gastrin-CREB signalling pathway via PKC and MAPK 180 12 2.3× 10−5
Complement cascade 33 4 2.4× 10−5
Glycosaminoglycan metabolism 110 8 2.5× 10−5
Glycogen breakdown (glycogenolysis) 17 3 2.7× 10−5
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4.4.3.1 Resampling Analysis
Similarly, resampling for SLIPT specific candidates (shown in Table 4.16) replicated
many of the most highly over-represented pathways in stomach cancer. These include
translational, immune, GPCR signalling, and elastic fibres, consistent with previous
analyses in breast cancer (shown in Tables 4.8 and C.4).
While fewer pathways were supported by resampling for the intersection of SLIPT
and experimental screen (Telford et al., 2015) candidate partners in stomach cancer
than breast cancer, many of those detected (shown in Table 4.17) replicate those de-
tected in breast cancer (shown in Table 4.9). The pathways detected by both permu-
tation and over-representation were more likely to be replicated across stomach and
breast cancer than those detected by over-representation alone, supporting the use of
this procedure to detect synthetic lethal pathways applicable across cancer types. The
include Gαs signalling and elastic fibre formation as discussed for breast cancer (in
Section 4.2.5.1).
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Table 4.16: Pathways for CDH1 partners from SLIPT in stomach cancer
Reactome Pathway Over-representation Permutation
Extracellular matrix organization 7.5× 10−140 0.070215
Hemostasis 1.8× 10−121 0.25804
Developmental Biology 9.2× 10−107 0.53032
Axon guidance 1.5× 10−102 0.6704
Eukaryotic Translation Termination 1.9× 10−99 > 1.031× 10−5
GPCR ligand binding 3.8× 10−99 0.54914
Viral mRNA Translation 3.3× 10−98 > 1.031× 10−5
Formation of a pool of free 40S subunits 3.3× 10−98 > 1.031× 10−5
Eukaryotic Translation Elongation 1.6× 10−97 > 1.031× 10−5
Peptide chain elongation 7.2× 10−97 > 1.031× 10−5
Class A/1 (Rhodopsin-like receptors) 2.7× 10−96 0.58174
Nonsense Mediated Decay independent of the Exon Junction Complex 3× 10−96 > 1.031× 10−5
Infectious disease 2.6× 10−94 0.25484
GTP hydrolysis and joining of the 60S ribosomal subunit 3.4× 10−94 > 1.031× 10−5
L13a-mediated translational silencing of Ceruloplasmin expression 2.8× 10−92 > 1.031× 10−5
3’ -UTR-mediated translational regulation 2.8× 10−92 > 1.031× 10−5
Neuronal System 8.4× 10−92 0.53433
SRP-dependent cotranslational protein targeting to membrane 9.5× 10−92 > 1.031× 10−5
Eukaryotic Translation Initiation 2.0× 10−90 > 1.031× 10−5
Cap-dependent Translation Initiation 2.0× 10−90 > 1.031× 10−5
Nonsense-Mediated Decay 7.4× 10−90 > 1.031× 10−5
Nonsense Mediated Decay enhanced by the Exon Junction Complex 7.4× 10−90 > 1.031× 10−5
Adaptive Immune System 8.1× 10−88 0.14116
Translation 1.3× 10−87 > 1.031× 10−5
Platelet activation, signalling and aggregation 1.3× 10−86 0.28959
Influenza Infection 1× 10−82 > 1.031× 10−5
Influenza Viral RNA Transcription and Replication 2.4× 10−82 > 1.031× 10−5
Influenza Life Cycle 2× 10−80 > 1.031× 10−5
Response to elevated platelet cytosolic Ca2+ 4.9× 10−78 0.50817
Signalling by NGF 1.6× 10−75 0.38518
Rho GTPase cycle 5.1× 10−75 0.14864
Signalling by PDGF 7.4× 10−74 0.40493
Signalling by Rho GTPases 5.1× 10−73 0.077217
Glycosaminoglycan metabolism 1.4× 10−68 0.52984
Gαi signalling events 1.8× 10−66 0.9254
Metabolism of carbohydrates 1.1× 10−65 0.39501
Gαs signalling events 2.7× 10−65 0.0050293
Potassium Channels 2.7× 10−65 0.53359
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR).
Significant pathways were marked in bold (FDR < 0.05) and italics (FDR < 0.1).
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Table 4.17: Pathways for CDH1 partners from SLIPT in stomach and siRNA
Reactome Pathway Over-representation Permutation
Platelet activation, signalling and aggregation 3.9× 10−9 0.49557
Class A/1 (Rhodopsin-like receptors) 3.9× 10−9 0.98432
Response to elevated platelet cytosolic Ca2+ 5.5× 10−8 0.54349
Platelet homeostasis 5.7× 10−8 0.45017
Nucleotide-like (purinergic) receptors 1.8× 10−7 0.36966
Peptide ligand-binding receptors 3.8× 10−7 0.91294
Molecules associated with elastic fibres 7.1× 10−7 0.0025868
Amine ligand-binding receptors 8.6× 10−7 0.43303
Gαi signalling events 9.8× 10−7 0.99626
GPCR ligand binding 1.1× 10−6 0.97733
Elastic fibre formation 1.5× 10−6 0.0025868
Gαq signalling events 1.9× 10−6 0.86089
P2Y receptors 3.8× 10−6 0.18795
Serotonin receptors 3.8× 10−6 0.37853
Signal amplification 2.3× 10−5 0.47856
Gastrin-CREB signalling pathway via PKC and MAPK 2.3× 10−5 0.98567
Complement cascade 2.4× 10−5 > 3.4628× 10−6
Glycosaminoglycan metabolism 2.5× 10−5 0.38953
Glycogen breakdown (glycogenolysis) 2.7× 10−5 0.83772
Defective B4GALT7 causes EDS, progeroid type 4.9× 10−5 0.10792
Defective B3GAT3 causes JDSSDHD 4.9× 10−5 0.10792
Role of LAT2/NTAL/LAB on calcium mobilization 5.6× 10−5 0.35373
Cell surface interactions at the vascular wall 5.6× 10−5 0.47642
Gαs signalling events 6× 10−5 0.019858
Signalling by NOTCH 6× 10−5 0.19008
A tetrasaccharide linker sequence is required for GAG synthesis 0.00017 0.47642
Extracellular matrix organization 0.00018 0.0047308
Collagen formation 0.00018 0.19245
Effects of PIP2 hydrolysis 0.0002 0.37779
Syndecan interactions 0.0002 0.37779
Diseases associated with glycosaminoglycan metabolism 0.00023 0.01028
Diseases of glycosylation 0.00023 0.01028
Chondroitin sulfate/dermatan sulfate metabolism 0.00023 0.085541
Integrin alphaIIb beta3 signalling 0.00028 0.76936
Keratan sulfate biosynthesis 0.00034 0.68744
Rho GTPase cycle 0.00034 0.15675
Creation of C4 and C2 activators 0.00035 0.12275
Abacavir transport and metabolism 0.00035 0.12443
Amine compound SLC transporters 0.00037 0.69773
FCERI mediated NF-kB activation 0.00037 0.69846
Fc ε receptor (FCERI) signalling 0.00056 0.43303
Defective EXT2 causes exostoses 2 0.00067 0.16053
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 0.00067 0.16053
Collagen biosynthesis and modifying enzymes 0.00071 0.052911
Keratan sulfate/keratin metabolism 0.00073 0.46533
G α (12/13) signalling events 0.00078 0.59164
SEMA3A-Plexin repulsion signalling by inhibiting Integrin adhesion 0.00084 0.038504
Signal attenuation 0.00084 0.37779
Eicosanoid ligand-binding receptors 0.0011 0.11117
SOS-mediated signalling 0.0011 0.25387
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR).
Significant pathways were marked in bold (FDR < 0.05) and italics (FDR < 0.1).
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4.4.4 Metagene Analysis
Metagene analysis (as conducted in Section 4.3) was also performed for TCGA stom-
ach cancer expression data, using Reactome pathways. These results (as shown in Ta-
ble 4.18) provided further support for signalling and extracellular processes as synthetic
lethal pathways across stomach and breast cancer. Namely, cell-cell communication,
VEGF signalling, and various GPCR pathways were detected. These results support
the role of extracellular processes in proliferation of CDH1 -deficient cancers and in-
teractions of CDH1 with the extracellular environment that was not tested in the cell
line experimental screen in addition to the signalling pathways that were identified.
Table 4.18: Synthetic lethal metagenes against CDH1 in stomach cancer
Pathway ID Observed Expected χ2value p-value p-value (FDR)
Cell-Cell communication 1500931 18 50.4 110 7.43× 10−23 1.53× 10−20
VEGFR2 mediated vascular permeability 5218920 19 50.4 109 1.36× 10−22 2.49× 10−20
Sema4D in semaphorin signalling 400685 20 50.4 104 1.62× 10−21 2.12× 10−19
Ion transport by P-type ATPases 936837 17 50.4 100 8.29× 10−21 8.06× 10−19
Sialic acid metabolism 4085001 19 50.4 95.3 9.95× 10−20 7.82× 10−18
Synthesis of pyrophosphates in the cytosol 1855167 26 50.4 94 1.86× 10−19 1.23× 10−17
Keratan sulfate/keratin metabolism 1638074 25 50.4 93.5 2.36× 10−19 1.44× 10−17
Ion channel transport 983712 19 50.4 92.8 3.37× 10−19 1.99× 10−17
Keratan sulfate biosynthesis 2022854 26 50.4 91.4 6.79× 10−19 3.62× 10−17
Arachidonic acid metabolism 2142753 22 50.4 90.6 9.81× 10−19 5.07× 10−17
RHO GTPases activate CIT 5625900 22 50.4 87 5.80× 10−18 2.66× 10−16
Stimuli-sensing channels 2672351 25 50.4 85.8 1.03× 10−17 4.58× 10−16
Synthesis of PI 1483226 19 50.4 85.6 1.15× 10−17 4.89× 10−16
G-protein activation 202040 19 50.4 85.3 1.34× 10−17 5.53× 10−16
NrCAM interactions 447038 22 50.4 84.3 2.1× 10−17 8.27× 10−16
Inwardly rectifying K+ channels 1296065 24 50.4 83.5 3.19× 10−17 1.22× 10−15
Calcitonin-like ligand receptors 419812 20 50.4 82.2 6.07× 10−17 2.13× 10−15
Prostacyclin signalling through prostacyclin receptor 392851 24 50.4 81.8 7.27× 10−17 2.5× 10−15
Presynaptic function of Kainate receptors 500657 26 50.4 79.7 2.00× 10−16 6.34× 10−15
ADP signalling through P2Y purinoceptor 12 392170 23 50.4 79.2 2.57× 10−16 7.71× 10−15
regulation of FZD by ubiquitination 4641263 22 50.4 78.8 3.15× 10−16 9.3× 10−15
Toxicity of tetanus toxin (TeNT) 5250982 27 50.4 78.7 3.36× 10−16 9.75× 10−15
Gap junction degradation 190873 21 50.4 78.5 3.66× 10−16 1.04× 10−14
Nephrin interactions 373753 25 50.4 78.2 4.21× 10−16 1.14× 10−14
GABA synthesis, release, reuptake and degradation 888590 26 50.4 77 7.69× 10−16 1.95× 10−14
Strongest candidate synthetic lethal partners for CDH1 by SLIPT with observed and expected numbers of TCGA stomach cancer
samples with low expression of both genes.
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4.5 Discussion
4.5.1 Strengths of the SLIPT Methodology
Synthetic lethal discovery with SLIPT applied statistical procedures to identify pu-
tative partner genes from gene expression data. The χ2-values were also used for
pathways or permutation analyses. This approach could be applied to other disease
genes or pair-wise across the genomes, although previous genome-wide approaches were
unable to find informative candidate genes for E-cadherin (Lu et al., 2015). Synthetic
lethal discovery in cancer has focused on genes with severe cellular mutant pheno-
types, such as essential genes or the oncogenes TP53 and AKT (Lu et al., 2015; Tiong
et al., 2014; Wang and Simon, 2013). Other cancer genes, such as CDH1, required
more focused investigations (Srihari et al., 2015; Telford et al., 2015). Prior computa-
tional approaches for synthetic lethal discovery, in cancer, vary widely (Jerby-Arnon
et al., 2014; Lu et al., 2015; Tiong et al., 2014; Wappett et al., 2016). There is no
consensus as to which approach is more appropriate, and the methods are difficult to
compare, as many do not make predictions from similar data or have a released code
implementation.
The query-based approach demonstrated by SLIPT analysis is suitable for wider
application on expression data in concert with experimental screens. This approach
has identified biologically plausible synthetic lethal pathways for CDH1, triaged can-
didates from experimental screening (Telford et al., 2015), and replicates genes and
pathways across breast and stomach cancer datasets. SLIPT avoids the assumptions
underlying the design of some approaches, such as co-expression of synthetic candi-
dates or that interacting gene pairs will have known (annotated) similarities in func-
tion. Since functional redundancy does not require genes to be expressed together (Lu
et al., 2015), the SLIPT approach does not assume co-expression of synthetic lethal
genes which may enrich for synthetic lethal genes in established coregulated pathways.
The interpretation of synthetic lethality for SLIPT was similar to methods based on
‘co-loss under-representation’, ‘compensation’, or ‘simultaneous differential expression’
(Lu et al., 2015; Tiong et al., 2014; Wang and Simon, 2013). As such, SLIPT detects
genes positively and negatively correlated with CDH1 in contrast to methods which
require co-expression. This is biologically plausible as functionally redundant genes
do not need to be expressed at the same time or in the same cell. Furthermore the
majority of correlation between genes are relatively weak.
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Genomic analyses are prone to false-positives and require statistical caution, par-
ticularly with gene-pairs which scale up the number of multiple tests drastically. Thus
analyses throughout this thesis have focused on querying for partners of a particular
gene of interest. Experimental screens for synthetic lethality are also error-prone (Fece
de la Cruz et al., 2015; Lord et al., 2015; Lu et al., 2015), especially with false-positives,
raising the need for integrated analyis of genetic interactions in the genomes, or statis-
tical modelling of the discovery of synthetic lethal partners of a particular query gene
(in Section 3.3 and Chapter 6). Simulations based on the model also supported the
design decisions underlying SLIPT analysis and its strengths over other approaches. In
particular, the categorisation of expression data during the SLIPT procedure is subject
to loss of information which could impact on the statistical performance of synthetic
lethal detection. This has been tested by simulation analysis in Section 6.1.1 and will
be discussed further in Section 6.4.3.
4.5.2 Synthetic Lethal Pathways for E-cadherin
Specific genes were difficult to replicate across experiments. This is consistent with gene
expression profiles for synthetic lethal partners reflecting the complexity of biological
pathways (Perou et al., 2000), which are subject to higher-order interactions and do
not consistently compensate for loss of gene function across all samples (Jerby-Arnon
et al., 2014; Lu et al., 2015). The large number of synthetic lethal partners detected may
stem from synthetic lethal detection being error-prone, and indicates that identifying
genes relevant for clinical application could be difficult without a supporting biological
pathway rationale. As such, investigations into the genes identified by SLIPT, the
correlation structure between them, and those which were validated by experimental
screening (Telford et al., 2015), focused at the pathway level throughout this chapter
and comparisons across analyses were mainly made at the pathway level.
The Reactome (Croft et al., 2014) database was selected for analysis of biological
pathways and functions of gene sets. This database provides a balance between wide
coverage of many human genes in the analysis and more careful curation of literature
and experimental evidence for pathways. While the Reactome pathways are not in-
dependent as they overlap considerably (as shown in Appendix Figure A.1), this is
a recurrent issue with heirarchically organised pathway databases. The smallest and
largest pathways have been removed from pathway analyses to avoid multiple testing
for subsets and supersets of many pathways (as performed by others such as Araki
et al., 2012). The results were sufficient to make biological inferences about synthetic
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lethality in HDGC and functions of CDH1 in cancers. Similar results were obtained
for WikiPathways, Gene Ontology (GO), and the Kyoto Encyclopaedia of Genes and
Genomes (KEGG) which supports that the results reported were not specific to Reac-
tome. Reactome also has the advantage of pathway structures being available which
have been used in Chapters 5 and 6 in addition to gene sets.
The synthetic lethal partners identified by SLIPT had many distinct functions and
were highly expressed in different patient subgroups (Figure 4.1). Ductal breast can-
cers had higher expression of synthetic lethal partners, suggesting treatment may be
more effective in these tumours. Conversely, there was consistently low expression of
SL partners in ER negative tumours, that have poor prognosis, which could inform
other treatment strategies. Synthetic lethal partner expression varies between patients
which suggests that these different tumour classes could react differently to the same
treatment and that the expression of synthetic lethal partners could be a clinically im-
portant biomarker. Treatment of different pathway and gene combinations in different
patients is likely to be the most effective approach to target genes compensating for
CDH1 gene loss without acquired resistance as well (Lord et al., 2015).
The synthetic lethal partners of CDH1 identified by SLIPT were involved in a di-
verse range of biological functions and differed to those detected experimentally. This
discrepancy may be accounted for by gene expression analyses detecting both synthetic
lethal partners, as screened for experimentally by Telford et al. (2015), and their up-
stream regulators or downstream targets (that were not detected by siRNA). Hence
SLIPT may be capturing the wider pathways and mechanisms involved in synthetic
lethality with CDH1 inactivation. In particular, GPCR phosphorylation cascades,
which regulate gene expression and translation in cancers (Gao and Roux, 2015), were
predicted to be synthetic lethal with CDH1. The most consistently supported pathways
included elastic fibres in the extracelullar matrix, GPCR signalling, and translation,
which present vulnerabilities for CDH1 -deficient cancer cells from extracellular stimuli
to the core growth mechanisms of a cell.
The diversity in synthetic lethal functions is consistent with the wide ranging role of
CDH1 in cell-cell adhesion, cell signalling, and the cytoskeletal structure of epithelial
tissues. Pathway structure may be relevant to identifying potential drug targets from
gene expression signatures, indicating downstream effector genes and mechanisms lead-
ing to cell inviability. Identification of distinct synthetic lethal gene clusters may lead
to the elucidation of drug resistance mechanisms. While these pathways are indicative
of the main functions of E-cadherin and synthetic lethal partners, it remains to iden-
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tify the genes within these pathways that are the most actionable or supported across
SLIPT analysis in patient samples and detected by experiments in preclinical models
(Chen et al., 2014; Telford et al., 2015). The specific genes within key pathways will be
be discussed in Chapter 5, along with further investigations in the context of pathway
structure. These synthetic lethal pathways have potential clinical implications, partic-
ularly those supported in pre-clinical models and in patient expression data. However,
further validation of gene candidates will be necessary to ensure that these are able to
reproduced in further pre-clinical studies, they are applicable to tumours in vivo, and
that effective inhibitory agents can be repurposed or designed against them. While
these pathways have important clinical implications, the synthetic lethal predictions
also need statistical modelling and simulation of synthetic lethality in genomics expres-
sion data to ensure that the candidates detected are reliable.
4.5.3 Replication and Validation
4.5.3.1 Integration with siRNA Screening
The pathways composition across computational and experimental synthetic lethal can-
didates was identified by over-representation (Table 4.7), and supported by resampling
analysis (Table 4.9), despite a modest intersection of genes between them (Figure 4.2).
Either approach may identify a pathway without being supported by the other: resam-
pling analysis may support pathways that were not over-represented due to small effect
sizes, thus both tests are required for a candidate pathway. The pathways detected by
both over-representation and resampling are the strongest candidates for further inves-
tigation. The pathway structure analyses in Chapter 5 will focus on these pathways
detected by both over-representation and resampling. Particularly, those replicated
across datasets or with pathway metagenes.
The SLIPT approach was shown to be predictive of which siRNA primary screen
candidate partners of CDH1 were validated in a secondary screen (as shown in Sec-
tion 4.2.4). These results further support SLIPT for identifying robust synthetic lethal
candidates which can be validated and as a triage approach for interpreting screening
experiments (O’Neil et al., 2017).
4.5.3.2 Comparison across Tissues
Some of the synthetic lethal partners identified by SLIPT in breast cancer were also
detected in stomach cancer. These were particularly concordant at the pathway level,
as expected between tissues, since synthetic lethal pathways have higher conservation
139
between species (Dixon et al., 2008). These findings support gene functions conserved
across CDH1 -deficient cancers in breast and stomach tissues, presenting vulnerabilities
that could be applied against molecular targets in both cancers. In addition, these
analyses serve as a replication across independent patient cohorts from breast and
stomach cancers, decreasing the likelihood of the synthetic lethal pathways detected
being false positives or artifacts of either dataset.
These are very distinct diseases involving different tissues and molecular pathways.
Breast cancer involves more varied pathways and this likely stems from sampling of
both lobular and ductal tissues are highly distinct in cell types with different molecular
profiles and patient outcomes. The similarities in synthetic lethal pathways between
these tissues despite of these biological differences is important for exploiting vulner-
abilities of CDH1 -deficient cancers and finding common pathways between cancers in
epithelial tissues. Thus it is plausible that there remain molecular targets common be-
tween cancers of different tissue types such as breast and stomach cancers and supports
the rationale to target molecular differences between cancers and normal cells (such as
mutations) rather than the tissue (Hanahan and Weinberg, 2000; Parker et al., 2009;
Perou et al., 2000; Vogelstein et al., 2013).
Synthetic lethal pathways were also replicated across expression analyses of TCGA
patient samples in heterogeneous tumours and homogeneous cell line isolates. This
further suggests that the subset of synthetic lethal functions detectable in experimen-
tal models (Chen et al., 2014; Telford et al., 2015) would be applicable to tumours
of patients with CDH1 -deficient cancers. There are many gene functions replicated
across breast cancer gene expression analyses. Many of these were also replicated with
mutation analysis and with stomach cancer or cell line expression data.
4.6 Summary
I have developed a simple, interpretable, computational approach to predict synthetic
lethal partners from gene expression data. This approach has been applied to robustly
detect synthetic lethal pathways for E-cadherin (the CDH1 gene) in TCGA breast
cancer molecular profiles. Comparisons were made to experimental screening (Telford
et al., 2015) in cell lines and the analysis was replicated in TCGA stomach cancer
molecular profiles. The pathways replicated across several analyses included extracel-
lular matrix pathways (e.g., elastic fibres formation), cell signalling (including GPCRs),
and core gene regulation and translational processes crucial for the growth and pro-
liferation of cancer cells. These pathways are subject to non-oncogene addiction for
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CDH1 -deficient cells, which presents vulnerabilities that could be exploited for specific
treatment against CDH1 mutations in cancers. There was also support for synthetic
lethality with CDH1 in cell adhesion and cytoskeletal processes, supporting the finding
that synthetic lethality occurs within biological pathways (Boone et al., 2007; Kelley
and Ideker, 2005).
While translational and immune pathways detected by SLIPT were not supported
by primary siRNA screening (Telford et al., 2015), these were replicated across various
analyses. Due to the differences between an experimental cell line model (Chen et al.,
2014; Fece de la Cruz et al., 2015) and patient molecular profiles (Bass et al., 2014;
Koboldt et al., 2012), these would not be expected to be completely concordant as some
pathways are difficult to test in an isolated experimental system. Nevertheless, many of
the genes and pathways detected by SLIPT are suitable to inform further investigations
and to triage potential therapeutic targets against CDH1 -deficient tumours.
Thus synthetic lethal pathways have been identified using TCGA patient molecular
profiles and experimental screening results. Some of these were robustly replicated
across these datasets and against CDH1 mutation or expression analysis. However,
there remains the need to identify actionable genes within these pathways, relationships
with experimental candidates, and how these pathways may affect viability when lost.
The results of the TCGA breast cancer analysis will be further examined in the context




Synthetic Lethal Pathway Structure
Having identified key pathways implicated in synthetic lethal genetic interactions with
CDH1 (in Chapter 4), the synthetic lethal genes within these pathways were inves-
tigated for their relationships with respect to pathway structure. This chapter will
focus on the Reactome biological pathways detected across analyses in Chapter 4.
Specifically, investigations were performed to determine whether synthetic lethal can-
didates, detected by SLIPT or siRNA, exhibited differences with respect to metrics
of pathway structure of network connectivity and importance (as described in Sec-
tions 2.4.4 and 3.5.3). The relationships between synthetic lethal candidates, detected
by either approach, were also examined to determine whether SLIPT candidate genes
were upstream or downstream siRNA candidate genes by resampling (as described in
Sections 3.4.1 and 3.4.1.1). Together these investigations into structural relationships
demonstrate how a combination of network biology and statistical techniques can be
performed with genes identified by a bioinformatics analysis.
5.1 Synthetic Lethal Genes in Reactome Pathways
The graph structure for Reactome pathways was obtained from Pathway Commons
via BioPAX (as described in Section 2.4.2). The pathways describe the (directional)
relationships between biomolecules, including genes that encode proteins in biologi-
cal pathways. These relationships include cell signalling (e.g., kinase phosphorylation
cascades), gene regulation (e.g., transcription factors, chromatin modifiers, RNA bind-
ing proteins), and metabolism (e.g., the product of an enzyme being the substrate of
another). Together these relationships describe the known functional pathways in a
human cell with a reasonable resolution, from a curated database supported by publi-
cations documenting pathway relationships.
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Pathway structures from the Reactome network (as described in Section 2.4.3)
were used to derive the graph structure of each biological pathway. The synthetic
lethal candidate genes for notable pathways discussed in Chapter 4, including candidate
synthetic lethal pathways of CDH1, were examined to show the SLIPT and siRNA
candidates within these pathways. The synthetic lethal genes considered here are those
candidates detected by SLIPT (as described in Section 3.1) in TCGA breast cancer
expression and mutation data (Koboldt et al., 2012) in comparison to the candidate
gene partners from the siRNA screening in breast cell lines (Telford et al., 2015).
5.1.1 The PI3K/AKT Pathway
The phosphoinositide 3-kinase (PI3K) cascade signalling pathway is important in can-
cer because it is involved in mediating signals between the GPCRs and regulation of
protein translation, which have both been strongly implicated to be synthetic lethal
pathways with loss of CDH1 function (Chapter 4). These pathways are all subject to
dysregulation in cancer (Courtney et al., 2010; Dorsam and Gutkind, 2007; Gao and
Roux, 2015). Thus the PI3K cascade will be examined along with the most supported
synthetic lethal pathways (as identified in Chapter 4).
The PI3K pathway is well characterised and has an established direction of signal
transduction from extracellular stimuli (and membrane bound receptors) to the inner
mechanisms of the cell, namely, the regulation of protein translation. The production
of proteins is necessary for the growth of the cell so it is reasonable to suggest that these
processes may be subject to (non-oncogene) addiction in some cancer cells which rely
upon them for sustained protein production and cell growth. This is also supported
by the oncogenes PIK3CA and AKT1 being involved with the PI3K cascade and the
related PI3K/AKT pathway, which may be subject to oncogene addiction when these
proto-oncogenes are activated.
The PI3K cascade was not supported across SLIPT in TCGA breast expression data
and the siRNA primary screen by over-representation (in Section 4.2.5) or resampling
(in Section 4.2.5.1) but genes within this pathway were detectable by either approach
(as shown in Figure 5.1). While few genes were identified by both approaches, they
include genes that are highly connected in the PI3K cascade and are hubs to information
transmission such as FGF9,PDE3B, and PDE4A. The key upstream genes PIK3CA and
PIK3CG were detected by siRNA whereas the downstream PIK3R1 and AKT2 genes
were detected by SLIPT. Genes detected by either method were also prevalent in the






Figure 5.1: Synthetic lethality in the PI3K cascade. The Reactome PI3K Cascade
pathway with synthetic lethal candidates coloured as shown in the legend. The genes in this
pathway are detailed in Appendix Table F.1.
and ribosomal genes (EIF4B, EEF2K, and RPS6 ). Together these suggest that there
may be further structure between the SLIPT and siRNA candidate partners of CDH1
in pathways as illustrated by PI3K. As such, pathway structure will be investigated to
detect differences in the upstream and downstream gene candidates detected by either
method. Pathway structure may account for the disparity between SLIPT and siRNA
genes, even in pathways such as PI3K where they did not significantly intersect. For
instance, SLIPT gene partners may be downstream of siRNA candidates rather than
replicating them directly.
This disparity between SLIPT and siRNA gene candidates synthetic lethal partners
of CDH1 (i.e., a high number of genes detected by either approach with few detected by
both) was replicated in the related PI3K/AKT pathway and the “PI3K/AKT in can-
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cer” pathway (shown in Appendix Figures F.1 and F.2). Many synthetic lethal candi-
dates were at the upstream core of these pathway networks and the downstream extrem-
ities. It is particularly notable that many genes important in cell signalling and gene
regulation were detected by either synthetic lethal detection approach. These include
AKT1, AKT2, and AKT3, the Calmodulin signalling genes CALM1 and CAMK4, and
the forkhead family transcription factors FOXO1 (a tumour suppressor) and FOXO4
(an inhibitor of EMT).
5.1.2 The Extracellular Matrix
The extracellular pathways “elastic fibre formation” and “fibrin clot formation” (shown
in Appendix Figures F.3 and F.4 respectively) were both supported across analyses (in
Chapter 4). These pathways were identified by both SLIPT (for TCGA breast cancer)
and siRNA gene candidates as they had significant over-representation and resampling
analyses.
Particularly for elastic fibres (Appendix Figure F.3), the vast majority of genes
were detected by either approach, in addition to a significant proportion of genes de-
tected by both approaches (as determined in Section 4.2.5). The genes detected by
both approaches also appeared to have a non-random distribution in the network, with
TFGB1, ITGB8, and MFAP2 exhibiting high connectivity, and having a central role in
their respective pathway modules. In addition to a structural role in the extracellular
matrix and connective tissue (including the tumour microenvironment), these proteins
including Furin, TGFβ, and BMP, are also involved in responses to endocrine signals
and interact with the cellular receptors for signalling pathways. Therefore it is plau-
sible that CDH1 -deficient tumours will be subject to non-oncogene addiction to the
extracellular environment and growth signals arising from this pathway. The pathway
structure also indicated that the genes detected by siRNA (or by both approaches) may
be be downstream of those detected by SLIPT, in addition to whether connectivity or
centrality is higher for synthetic lethal candidates than other genes in the pathway.
Genes detected as synthetic lethal partners of CDH1 by SLIPT or siRNA screening
were also common in the Fibrin clot formation pathway (shown in Appendix Fig-
ure F.4). This is consistent with the established pleiotropic role of CDH1 in regulating
fibrin clotting. It is also notable that the genes detected by either method appear to be
highly connected such as C1QBP KNG1, F8, F10, F12, F13A, and PROC (including
many of the coagulation factors). Synthetic lethal candidates also include SERPINE2
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and PRCP, which only affect downstream genes, in addition to PROCR and VWF,
which are only affected by upstream genes.
Many of these genes are involved in the Extracellular Matrix pathway (shown in
Appendix Figure F.5), including many of the synthetic lethal candidates discussed for
elastic fibres. The number of SLIPT candidate genes outnumbers those identified by
siRNA, as expected from an isolated cell model. However, the endocrine response
genes (e.g., TGFB1 and LTBP4 ) which are potentially artifacts of the cell line growth
process were replicated with SLIPT analysis in patient tumours (TCGA breast cancer
data). There is also additional support for synthetic lethal genes (e.g., ITGB2, MFAP2,
and SPARC ) being highly connected networks hubs of the pathway. The complexity
of the extracellular matrix pathway lends credence to the need for formal network
analysis approaches to interpret the pathway structure of synthetic lethal candidates.
Furthermore, statistical approaches are needed to determine whether the apparent
structural relationships between synthetic lethal candidates could have occurred by
chance
5.1.3 G Protein Coupled Receptors
G protein coupled receptor (GPCR) pathways are highly complex (as shown in Fig-
ure 5.2 and Appendix Figure F.6). Many genes in these pathways were synthetic lethal
as detected by either SLIPT or siRNA screening, including genes frequently detected by
both approaches, consistent with these pathways being supported by prior analyses (in
Sections 4.2.5 and 4.2.5.1). Synthetic lethal candidates include the Phosphodiesterase
(PDE) and Calmodulin genes (as discussed in Section 5.1.3) in addition to others such
as the regulators of RGS, chemokine receptors (CXCR), Janus Kinase (JAK), and the
Ras Homolog Family (RHO) genes. These are important regulatory signalling path-
ways necessary for cellular growth and cancer proliferation. Thus the GPCR pathways
(and downstream PI3K/AKT signals) are a potentially actionable vulnerability against
CDH1 -deficient cancers, particularly since many existing drug targets are in these sig-
nalling pathways, some of which have been experimentally validated (Telford et al.,
2015). While statistically significant numbers of genes in pathways were detected by
both approaches (in Sections 4.2.5 and 4.2.5.1), the complexity of GPCR networks
(containing hundreds of genes) further support the needs for a rational network-based
approach to the relationships between SLIPT and experimental candidates.
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Figure 5.2: Synthetic lethality in the GPCRs. The Reactome Gαi pathway with syn-
thetic lethal candidates, coloured as shown in the legend. The genes in this pathway are
detailed in Appendix Table F.5.
5.1.4 Gene Regulation and Translation
While very few synthetic lethal genes were detected in translational pathways in an
experimental screen against CDH1 (Telford et al., 2015), these were highly over-
represented in translational elongation (as shown in Appendix Figure F.7). These
SLIPT genes include many ribosomal proteins and the regulatory “elongation factors”
which may be subject to responses in the upstream signalling pathways. This obser-
vation further indicates that pathway structure may be used to identify relationships
between synthetic lethal candidates detected by SLIPT and siRNA. The computa-
tional approach with SLIPT may exhibit the ability to detect downstream genes in
the core translational processes, which experimental screening did not identify. The
experimental screening may similarly detect upstream regulatory genes less sensitive
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to inactivation, that is, genes that are less likely to be indiscriminately lethal to both
genotypes at high doses of inactivation.
Many of these SLIPT candidate genes are also among the nonsense-mediated de-
cay (NMD) pathway (shown in Appendix Figure F.8) or 3′ untranslated region (UTR)
mediated translational regulation (shown in Appendix Figure F.9). While genes in
these pathways were also supported by experimental screening with siRNA, there were
differences in which genes were detected within the pathway structures. In particular,
UPF1 was detected in the siRNA screen and is the focal downstream gene for the en-
tire NMD pathway showing that (in this case) siRNA genes are downstream effectors
of those detected by SLIPT. 3′ UTR mediated translational regulation has a similar
structure with two modules connected solely by RPL13A, giving an example of SLIPT
candidate genes with high connectivity, although there were many ribosomal proteins
detected by SLIPT. However, the detection of EIF3K, a regulatory elongation factor
(not essential to ribosomal function) was replicated across SLIPT and siRNA screen-
ing, while the majority of the elongation factors were not detected by either approach.
The SLIPT candidates may support experimental candidates in biological pathways
by detecting downstream genes, which may not be detectable by experimental screen-
ing with high dose inhibitors. This difference between the approaches may explain
the greater number of SLIPT candidate partners of CDH1 than those experimentally
identified.
Regulatory genes may be more amenable to experimental validation since their
function varies depending on whether they are active. Therefore regulatory genes
may better exhibit synthetic lethality when inhibited at the mRNA or protein level.
Transcription and translational genes also have upstream regulators and downstream
targets which would be suitable for further investigation into pathway structure. These
upstream regulators, such as GPCRs or kinase cascades also have well-characterised di-
rectional pathways and existing RNAi or compound inhibitors for further experimental
testing.
5.2 Network Analysis of Synthetic Lethal Genes
To demonstrate the network properties of synthetic lethal candidates in a pathway,
a network analysis was performed on the genes detected as synthetic lethal partners
of CDH1 with the SLIPT computational approach and the siRNA screen (Telford
et al., 2015) in Gαi signalling, a GPCR pathway. This pathway was used to demon-
strate deeper network analysis approaches to synthetic lethal candidates within com-
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Table 5.1: ANOVA for synthetic lethality and vertex degree
DF Sum Squares Mean Squares F-value p-value
siRNA 1 21 20.8 0.0030 0.9561
SLIPT 1 16215 16215 2.3722 0.1246
siRNA×SLIPT 1 17 17 0.0025 0.9603
Analysis of variance for vertex degree against synthetic lethal detection
approaches (with an interaction term)
plex pathways, as it was supported across analyses (in Chapter 4), with significant
over-representation in both SLIPT and siRNA screening, and the genes differed con-
siderably between synthetic lethal detection methods (shown in Appendix Figure 5.2).
These network metrics were used to measure whether the network properties differed
between groups of genes detected by either or both approaches. These analyses serve
to test both whether synthetic lethal gene candidates had higher connectivity or im-
portance in a network and whether either detection approach is biased towards genes
with different network properties.
5.2.1 Gene Connectivity and Vertex Degree
Vertex degree (the number of connections) for each gene is a fundamental property of
a network. The vast majority of genes had a relatively modest number of connections,
each with only a few genes in the Gαi pathway (shown in Figure 5.3) having pathway
relationships with a high number of genes, consistent with the scale-free property of
biological networks (Barabási and Oltvai, 2004). The number of connections was similar
between gene groups (by synthetic lethal detection). Genes detected by siRNA included
those with the fewest connections, despite there being fewer genes that were detected
by either approach. There was no statistically significant effect of either computational
or experimental synthetic lethal detection method on vertex degree, as determined by















































































Figure 5.3: Synthetic lethality and vertex degree. The number of connected genes
(vertex degree) was compared (on a log-scale) across genes detected by SLIPT and siRNA
screening in the Reactome Gαi signalling pathway. There were no differences in vertex degree
between the groups (shown in Table 5.1), although genes detected by siRNA included those
with the fewest connections.
The results for the Gαi pathway were very similar when testing synthetic lethality
against CDH1 mutation (mtSLIPT). In either case, there was no significant evidence
that SLIPT or mtSLIPT-specific genes had higher connectivity than those detected
by siRNA screening (shown in Appendix Figure G.1 and Appendix Table G.1). Thus
synthetic lethal detection does not discriminate among genes by their connectivity in
this pathway network, nor is either approach constrained to detecting highly connected
genes. Both approaches have been demonstrated to detect genes with many and very
few connections in the Gαi signalling pathway.
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Table 5.2: ANOVA for synthetic lethality and information centrality
DF Sum Squares Mean Squares F-value p-value
siRNA 1 0.00000000 2.7000× 10−9 0.0016 0.96783
SLIPT 1 0.00000548 5.4831× 10−6 3.3253 0.06926
siRNA×SLIPT 1 0.00000002 1.8800× 10−8 0.0114 0.91511
Analysis of variance for information centrality against synthetic lethal detection
approaches (with an interaction term)
5.2.2 Gene Importance and Centrality
5.2.2.1 Information Centrality
Information centrality is a measure of the importance of nodes in a network in terms
of how vital they are to the transmission of information throughout the network. This
applies well to biological pathways, partcularly gene regulation and cell signalling. The
nodes with the highest information centrality are not necessarily the most connected, as
they may also include nodes that pass signals between highly connected network hubs.
Information centrality therefore provides a distinct metric for the connectivity of a gene
in a pathway, which has the added benefit of being directly related to the disruption
of pathway function were it to be inactivated or removed. Information centrality has
also been suggested to be indicative of the essentiality of genes or proteins (Kranthi
et al., 2013).
Within the Gαi pathway, the information centrality across gene groups detected by
either synthetic lethal approach did not differ significantly (shown by Figure 5.4 and
Table 5.2). Genes detected by SLIPT span the complete range of PageRank centrality
values for this pathway. These findings were very similar for mtSLIPT against CDH1
mutation (shown in Appendix Figure G.2 and Appendix Table G.2). Thus neither
method was unable to detect synthetic lethal genes in the Gαi pathway with particular
centrality constraints but they were also not detecting genes with higher centrality















































































Figure 5.4: Synthetic lethality and centrality. The information centrality was compared
(on a log-scale) across genes detected by SLIPT and siRNA screening in the Reactome Gαi
pathway. Genes detected by SLIPT or siRNA did not have higher centrality than other genes
(shown in Table 5.2). Genes detected by SLIPT spanned the range of centrality values.
5.2.2.2 PageRank Centrality
PageRank centrality is another network analysis procedure to infer a hierarchy of gene
importance from a network using connections and structure (Brin and Page, 1998). In
contrast to the information centrality approach of removing nodes, PageRank uses the
eigenvalue properties of the adjacency matrix to rank genes according to the number
of connections and paths they are involved in.
This distinction is immediately clear within the Gαi pathway (shown in Figure 5.5),
which differs considerably from the information centrality scores (as shown in Fig-
ure 5.4). Genes detected by either synthetic lethal approach did not include those with
the highest PageRank centrality. There was a significant association between genes
detected by SLIPT (which had a lower median) with PageRank centrality (shown by
Table 5.3).
The genes detected by SLIPT span the range of centrality values of siRNA showing
that both approaches were capable of detecting genes of moderately high centrality (as
shown for information centrality) and that the lower centrality of SLIPT candidates
in the Gαi pathway may be due to synthetic lethal partners being less critical to the







































































































































































Figure 5.5: Synthetic lethality and PageRank. The PageRank centrality was compared
(on a log-scale) across genes detected by SLIPT and siRNA screening in the Reactome Gαi
pathway. Genes detected by either synthetic lethal detection approach had a more restricted
range of centrality values but only SLIPT genes had a significant association with centrality
(shown in Table 5.3).
synthetic lethal genes will be important to the function of the pathway, it is possible
that genes with high centrality were avoided if they are essential to cellular viability.
Essential genes, which are known to have high information centrality (Kranthi et al.,
2013), can not be synthetic lethal nor can they be detected by SLIPT as they must
expressed in all samples, not just those deficient in CDH1.
There was not a significant association between siRNA candidates and PageRank
centrality. The significant result for SLIPT was not replicated when testing synthetic
lethality against CDH1 mutation (shown in Appendix Figure G.3 and Appendix Ta-
ble G.3). However, this may be due to fewer genes being detected by mtSLIPT and
siRNA.
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Table 5.3: ANOVA for synthetic lethality and PageRank centrality
DF Sum Squares Mean Squares F-value p-value
siRNA 1 0.0001059 1.0589× 10−4 2.1021 0.14818
SLIPT 1 0.0002881 2.8808× 10−4 5.7188 0.01743
siRNA×SLIPT 1 0.0000477 4.7704× 10−5 0.9470 0.33131
Analysis of variance for PageRank centrality against synthetic lethal detection
approaches (with an interaction term)
5.3 Relationships between Synthetic Lethal Genes
The network analyses so far have tested whether synthetic lethal candidate genes
were more connected or important within a pathway structure, such as the Gαi path-
way. However these metrics do not ascertain whether there were relationships between
SLIPT and siRNA candidate partners of CDH1. In particular, it is plausible that they
may be upstream or downstream of one another within a pathway.
The direction of a biological pathway is important, particularly those involved in
cell signalling which respond to extracellular stimuli and transmit these signals via
intermediary proteins to regulate core functions and responses of the cell. These path-
ways regulate processes such as gene expression and protein translation, which are
important in the proliferation of cancers (Gao and Roux, 2015). Therefore it is impor-
tant to determine which synthetic lethal candidates were upstream or downstream in
the context of a biological pathway. In particular, pathway structure may be used to
identify relationships between SLIPT and siRNA gene candidates.
A pathway structure method was devised to use network structures to identify
directional relationships between individual SLIPT and siRNA genes. This pathway
structure methodology was applied (as described in Section 3.4.1) to detect the direc-
tion of shortest paths between SLIPT and siRNA gene candidates. This is used to
demonstrate the methodology on the PI3K and Gαi pathways, to develop a statistical
test for pathway structure between SLIPT and siRNA gene candidates using resam-
pling (as described in Section 3.4.1.1), and to apply this test for pathway structure
among synthetic lethal gene candidates to the pathways identified in Chapter 4 and
discussed in Section 5.1.
5.3.1 Detecting Upstream or Downstream Synthetic Lethality
Shortest paths in a pathway network were used to devise a strategy to detect pathway
structure between SLIPT and siRNA gene candidates partners of CDH1 (as described
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in Section 3.4.1). Thus I can determine whether individual SLIPT genes have upstream
or downstream siRNA candidates (scored as “up” or “down” events respectively). This
procedure enables the detection of directional relationships between SLIPT and siRNA
gene candidates (e.g., if genes detected by siRNA are more likely to be downstream of
genes detected by SLIPT in the same pathway).
The total number of gene candidate pairs in either direction can be compared within
a pathway network to assess the overall directional relationships in a pathway. This
directionality is detectable by the difference between the number of SLIPT candidate
genes with upstream and downstream siRNA gene partners. However, this measure
alone is not sufficient to determine whether there is evidence of pathway structure
between SLIPT and siRNA gene candidates partners of CDH1 in a pathway network.
Nevertheless, it does serve to measure the magnitude (and direction) of the consensus
of directional relationships (upstream and downstream) between SLIPT and siRNA
gene candidates partners. This measure of pathway structure can be used for testing
for statistical significance of pathway structure by resampling, using a permutation
procedure to test whether these relationships are detectable among randomly selected
gene groups rather than the detected SLIPT and siRNA gene candidates partners (as
described in Sections 2.3.6 and 3.4.1.1).
This resampling procedure was performed for the Gαi and PI3K pathways to gen-
erate a null distribution for the difference in the number of “up events” and “down
events” for these pathway structures (as shown in Figures 5.1 and 5.2). The resulting
null distributions (as shown in Figure 5.6) were used to detect whether genes detected
by SLIPT had significantly more upstream or downstream siRNA candidates in either
pathway. It can be seen that siRNA genes were significantly downstream of SLIPT
candidate genes by resampling for the Gαi signalling pathway (Figure 5.6a). This
demonstrates that pathway relationships can be detected between synthetic lethal can-
didates by this procedure and that siRNA genes were downstream of gene detected by
SLIPT in an example of GPCR signalling expanding on support for synthetic lethal-
ity in this pathway (as shown in Chapter 4). These structural relationships may also
account for why each of the computational and experimental approaches did not de-
tect many of the same specific genes because they are detecting different parts of the
pathway.
In contrast, there was no significant evidence of such pathway structure between
siRNA and SLIPT candidate genes when resampling within the PI3K cascade pathway



























(a) Resampling in Gαi signalling






















(b) Resampling in the PI3K cascade
Figure 5.6: Structure of synthetic lethality resampling. A null distribution with 10,000
iterations of the number of siRNA genes upstream or downstream of SLIPT genes (depicted
as the difference of these) in each pathway. To assess significance, the observed events (with
shortest paths) were compared to the 90% and 95% intervals for the null distribution (shown in
blue). Genes detected by both methods were not fixed to the same number as observed for the
alternative null distribution (shown in red), although the significance of the observed number
of events (red) was changed in either case. The genes detected by both approaches were
included in computing the number of shortest paths (in either direction) between SLIPT and
siRNA genes. The permutations show (a) significant pathway relationships for Gαi signalling
and (b) and non-significant relationships for the PI3K cascade.
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cific rather than a general property of these synthetic lethal detection methods. These
results were robustly reproducible, with similar findings (as shown in Appendix Fig-
ure H.1) for each pathway when testing for synthetic lethality against CDH1 mutation
(mtSLIPT).
The number of genes detected by both approaches was fixed (to the number ob-
served) for deriving p-values for pathway relationships (as described in Section 3.4.1.1).
These genes were included in the analysis because they can be disproportionately up-
stream (or downstream) of more siRNA genes than SLIPT genes, which may lead to
them having different proportions of genes detected by either approach upstream (or
downstream) of them. However, allowing the number of jointly detected genes to vary
during resampling (as shown in Figure 5.6 and Appendix Figure H.1) or excluding
these jointly detected genes did not alter the findings of this approach. Furthermore,
expanding the range of shortest paths to consider links in related pathways (using the
“meta-pathways” constructed in Section 2.4.3) also had little effect on the null distri-
bution generated, despite increasing the computational complexity of the procedure.
5.3.2 Resampling for Synthetic Lethal Pathway Structure
The permutation procedure (as described in Section 3.4.1.1) that was performed in Sec-
tion 5.3.1 for the Gαi and PI3K pathways was also applied to other pathways identified
in Chapter 4 and discussed in Section 5.1. In addition to the cell signalling path-
ways (PI3K/AKT and GCPRs demonstrated in Section 5.3.1), the pathways tested
include extracellular matrix (with constituent elastic fibre and fibrin pathways), and
translational pathways (with NMD and 3′UTR regulation).
The resampling results across these pathways (as shown in Table 5.4) had limited
support for association between pathway structure and detection of synthetic lethal
genes, with the majority of these being non-significant (as shown for PI3K in Fig-
ure 5.6b), with the exception of Gαi signalling (as shown in Figure 5.6a). However,
the exact distribution for these pathways will differ depending on their structure, the
number of genes they contain, and the proportion of synthetic lethal candidates among
them (including a higher frequency of genes detected by both methods for the pathways
identified in Section 4.2.5.1). This resampling is therefore an appropriate procedure
to use to detect structural relationships across pathways as it does not assume an
underlying test statistic distribution.
Pathway structure was supported for the NMD pathway (which is consistent with
siRNA being downstream in Appendix Figure F.8). However, this observation rests
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upon a single gene (UPF1 which was downstream of all the other genes) detected by
siRNA when the pathway had poor support in the siRNA screen. This relationship was
not replicated when testing synthetic lethality (mtSLIPT) against CDH1 mutation (as
shown in Appendix Table H.1) nor was it supported by the related 3′UTR regulation
and translational elongation pathways. This may be due to these pathways functioning
as protein complexes which is poorly represented by Reactome graph structures.
Table 5.4: Resampling for pathway structure of synthetic lethal detection methods
Graph Candidates Observed Down−Up Permutation
Pathway Nodes Edges SLIPT siRNA Up1 Down2 Down−Up p-value FDR adj.
Gαi signalling 292 22003 95 58 836 1546 710 0.0029 0.0087
GPCR downstream 1270 142071 312 160 9755 9261 -494 0.6305 0.6636
Elastic fibre formation 42 175 24 7 1 2 1 0.3865 0.5798
Extracellular matrix 299 3677 127 29 547 455 -92 0.6636 0.6636
Formation of fibrin 52 243 18 5 12 17 5 0.3564 0.5798
Nonsense-mediated decay 103 102 74 2 0 74 74 < 0.0001 < 0.0006
Pathways in the Reactome network tested for structural relationships between SLIPT and siRNA genes by resampling. The raw
p-value (computed without adjusting for multiple comparisons over pathways) is given for the difference in upstream and
downstream paths from SLIPT to siRNA gene candidate partners of CDH1 with significant pathways highlighted in bold.
Sampling was performed only in the target pathway and shortest paths were computed within it. Loops or paths in either
direction that could not be resolved were excluded from the analysis. The genes detected by both SLIPT and siRNA (or
resampling for them) were included in the analysis and the number of these were fixed to the number observed.
1 The number of paths where the siRNA candidate was upstream of a SLIPT candidate
2 The number of paths where the siRNA candidate was downstream of a SLIPT candidate
There does not appear to be a consensus on the directionality of SLIPT and siRNA
candidates across pathways as distinct pathways showed stronger tendency for siRNA
genes to be either upstream or downstream. Even related pathways such as PI3K and
PI3K/AKT signalling showed directional events in opposite directions. The strongest
pathway (among those tested) with support for directional pathways structure is Gαi
signalling (as shown in Figure 5.6a). In contrast to the other pathwayss Gαi signalling
showed significant downstream siRNA genes for SLIPT from a large number of shortest
paths (in Table 5.4). This would indicate that SLIPT detects upstream regulators
of genes experimentally validated by siRNA in this pathway. This result was also
the strongest result in mtSLIPT results (Appendix Table H.1), although it was not
significant after adjusting for multiple testing in this case.
There is insufficient evidence to determine whether there is pathway structure, that
genes were detected upstream or downstream by either method, between the SLIPT
and siRNA candidates in many of the synthetic lethal pathways (identified in Chap-
ter 4). In particular, directional structure among synthetic lethal candidates for CDH1
was not strongly supported in most of the signalling pathways (with the exception of
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Gαi signalling) upon which the rationale for pathway structure hypotheses were based.
While there is statistically significant over-representation of many of these pathways
in genes detected by both SLIPT and siRNA (as described in Chapter 4), many of
these did not show relationships with respect to pathway structure. Despite the de-
sign of a robust resampling approach to test relationships between gene groups, the
detection of structural relationships between SLIPT and siRNA gene candidates did
not generalise across pathways (and was specific to a few). Such structural relation-
ships may apply more broadly to gene networkss as different biological pathways were
more over-represented among SLIPT and siRNA gene candidates. Furthermore, path-
way structure did not account for the discrepancy between SLIPT and siRNA gene
candidates which did not significantly intersect, such as the PI3K cascade.
5.4 Discussion
These investigations used a pathway network that encapsulates protein complexes and
functional modules. The Reactome network uses curated, experimentally identified
pathways to map relationships between genes and does not have the limitation of re-
lying solely on protein binding or text-mining which are prone to false positives (Croft
et al., 2014). While it is not documented whether these relationships are activating
or inhibiting, the Reactome network (Croft et al., 2014) was sufficient to test path-
way relationships with directional information. However, this database is limited in
that some pathways are better represented as a graph structure with clear directional
relationships (such as kinase signalling, transcription factor regulation, and metabolic
pathways) whereas others are not as well defined where protein complexes act together
(such as 3′-UTR-mediated translational regulation or translational elongation). The
network analysis may be less applicable to these pathways and may explain why the
conclusions were weaker for them. This does not detract from the conclusions based on
well-defined pathways such as Gαi signalling or the methodology demonstrated which
could be applied graph structures from any biological pathway database that provides
them.
Synthetic lethal genes and pathways (for CDH1 loss in cancer) were identified across
gene expression and mutation datasets in Chapter 4. The investigations in this chap-
ter considered synthetic lethal gene candidates within pathway structures, including
whether the discrepancy between individual SLIPT and siRNA candidate genes could
be accounted for, within a synthetic lethal pathway. Pathways with replicated syn-
thetic lethal genes across SLIPT and siRNA candidates in breast and stomach cancer
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data, were investigated, including pathways from the extracellular microenvironment
to core translational pathways and the signalling pathways between them.
Examining synthetic lethal gene candidates in the context of pathway structures
may provide additional mechanisms by which the function of particular genes is subject
to induced essentiality and support for them belonging to a synthetic lethal pathway.
Gene candidates with characterised functions important to cellular viability are ideal
for triage of targets specific to CDH1 -deficient tumours and for further experimental
validation in preclinical models. This chapter presents computational methods using
pathway structure to detect genes with importance in a pathway and to compare the dif-
ferences between SLIPT and siRNA candidate genes with pathway relationships (e.g.,
one group being downstream of the other). The differences between these computa-
tional and experimental screening approaches could feasibly lead to differences in which
genes within a synthetic lethal pathway are identified. Genes detected by synthetic
lethal detection strategies included those of biological importance within synthetic
lethal pathways, those which are actionable drug targets, and those with functional
implications for the biological growth mechanisms or vulnerabilities of CDH1 -deficient
tumours. It appeared that genes detected by both approaches were highly connected
(or of importance) in the network structure of some pathways, and that there may
be some structure with SLIPT and siRNA candidates tending to appear upstream or
downstream of each other.
The complexity of biological pathways meant that relationships between gene can-
didates were difficult to discern without formal mathematical and computational ap-
proaches, which were used to analyse these networks. Network analysis techniques
were applied to formalise and quantify the connectivity or importance of genes within
pathways in the Gαi pathway. These network metrics support the application of syn-
thetic lethal detection across pathways (and the findings using pathways as gene sets
in Chapter 4) as neither synthetic lethal detection approach was pre-disposed towards
genes of higher importance or connectivity and neither approach was insensitive to
genes of lower importance or connectivity. SLIPT did not detect genes with a signifi-
cantly more crucial role in the Gαi pathway, as inferred by pathway connectivity and
centrality measures. However, SLIPT genes had significantly lower centrality in the
Gαi pathway by PageRank centrality (as shown in Section 5.2.2.2), and so the highest
scoring genes may be essential to cellular viability rather than synthetic lethal.
Pathway structure between individual SLIPT and siRNA candidate genes within
a pathway was measured with the direction of shortest paths in graph structures.
161
This enabled the detection of a consensus of directionality for the pathway across
pairs of genes detected by either method. This pathway structure methodology is
generally applicable to comparison of node groups (which may intersect), including
genes in biological pathways and their detection by different methodologies. While
the pathway structure measure alone was not able to detect structural relationships
between gene groups (e.g., SLIPT and siRNA gene candidates), it was able to determine
whether these relationships were statistically significant by resampling. This approach
successfully detected a relationship between SLIPT and siRNA candidate genes in the
Gαi signalling pathway, despite there being few differences between these genes with
respect to other network metrics.
5.5 Summary
Analyses of biological pathways, network metrics, and statistical procedures devised
specifically for this purpose were applied to Reactome pathway structures to test
whether structural relationships existed between synthetic lethal candidates. In par-
ticular, the differences between the computational (SLIPT) and experimental (siRNA)
synthetic lethal candidate partners of CDH1 were examined (in the pathways discussed
in Chapter 4).
There were few detectable structural relationships between SLIPT and siRNA gene
candidates, with respect to network connectivity or centrality measures with the no-
table exception of Gαi signalling. Since network analyses were unable to ascertain
whether the candidates detected by either method stratified into upstream and down-
stream genes, a statistical resampling procedure was applied for shortest path analysis
between pairs of SLIPT and siRNA gene candidates. This approach did not detect
many structural relationships in the synthetic lethal pathways identified in Chapter 4.
Overall, support for pathway structure between SLIPT and siRNA gene candidates was
weak and the direction was inconsistent across pathways. Therefore pathway structure
does not appear to generally account for the differences between the SLIPT and siRNA
gene candidates. However, it may apply in specific pathways, as demonstrated with
Gαi signalling. It was possible to detect some pathway relationships between candi-
date genes in synthetic lethal pathways, in addition to the significantly over-represented
genes shared between SLIPT and siRNA (as identified in Chapter 4).
The resampling procedure demonstrated in this chapter is more widely applicable
to gene states in network structures and may be of further utility in the analysis
of biological pathways or networks. This approach was able to quantify structural
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relationships that were otherwise difficult to interpret and to conclusively exclude many
potential relationships. In this respect, the network resampling methodology may also




Simulation and Modelling of
Synthetic Lethal Pathways
Simulation and modelling of synthetic lethality in gene expression was revisited in
greater detail in this chapter, building upon the results which supported the use of
SLIPT (in Section 3.3). In Chapter 3, a procedure for generating simulated data with
underlying (known) synthetic lethal partners of a query gene, such as CDH1, was
developed (as described in Section 3.2.2) by sampling from a multivariate normal dis-
tribution based on a statistical model of synthetic lethality in gene expression data (as
described in Section 3.2.1). This simulation framework was applied to simulated data
(in Section 3.3), including simple correlation structures to assess the statistical perfor-
mance of the SLIPT methodology and support its use as a computational approach
for detecting synthetic lethal candidates from expression data throughout this thesis
(Chapters 4 and 5).
While this basic framework provided some support for the use of SLIPT, further
investigations with simulations were conducted to assess the strengths and limitations
of the SLIPT methodology, compare it to alternative statistical approaches to synthetic
lethal detection, and assess its performance under more complex correlation structures.
Together these simulation investigations assess the performance of the SLIPT method-
ology, including on pathway graph structures (e.g., those discussed in Chapter 5).
These results can indicate whether the SLIPT methodology robustly detects known
synthetic lethal partners (and how it compares to other bioinformatics strategies) or is
suitable for wider genomics applications.
These simulation investigations continued to utilise the multivariate normal sim-
ulation procedure (as applied in Section 3.3) with further refinements. The SLIPT
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methodology (and the χ2 test) were applied across a range of parameters (including
altering the quantiles for detecting synthetic lethal direction) and compared to cor-
relation as a predictor of synthetic lethality. These simulations included thousands
of non-synthetic lethal genes and correlations with the query gene (as performed in
Section 3.3).
A refined simulation procedure was developed specifically to extend the method-
ology described in Section 3.2 to utilise pathway graph structures for the correlation
structures of simulated datasets (as described in Section 3.4.2). This methodology can
be applied to simulated correlation structures across simple graph structures to test
specific network modules or use pathway structures based on biological pathways. Thus
graph structure and simulation approaches were combined to test whether a gene locus
in a pathway affects detection by SLIPT and whether SLIPT performance is affected by
pathway structure. The simulation procedure based on graph structures was applied in
a computational pipeline across many parameter combinations using high-performance
computing resources (as discussed in Section 2.5.3) and the core simulation functions
have been released as a software package for wider use to test bioinformatics and sta-
tistical methods on graph structures (as described in Section 3.5.3).
6.1 Synthetic Lethal Detection Methods
The SLIPT methodology (as it has been applied throughout Chapters 4 and 5) was com-
pared to alternative computational approaches for detecting synthetic lethality in sim-
ulated gene expression data. As discussed in Section 3.3, this procedure enabled testing
the ability of SLIPT to detect known synthetic lethal partner genes by sampling from
a statistical model of synthetic lethality. While comprehensive benchmarking has not
been performed, several approaches to synthetic lethal detection are considered (e.g.,
Pearson correlation, the χ2 test, and testing for bimodality) to evaluate the strengths
of the SLIPT methodology, including modifications to the parameters of SLIPT. The
following comparisons of simulations of computational detection of synthetic lethality
with different statistical rationales were perfomed to show the strengths of SLIPT,
evaluate whether it is appropriate for further application in genomics research, and
identify limitations which may be addressed with further developments.
6.1.1 Performance of SLIPT and χ2 across Quantiles
Simulated datasets with synthetic lethal partner genes were generated using the multi-
variate normal simulation procedure (as described in Section 3.2.2) with performance
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assessed using AUROC analysis (as described in Section 2.3.5). Synthetic lethal de-
tection was compared for modifications to the SLIPT methodology (as described in
Section 3.1), namely that the quantiles used to define low and high expression were
varied. Rather, than 1/3 (as used throughout this thesis) the samples below the lowest
1/n quantile and above the highest 1/n quantile were used for SLIPT (and the χ2-test)
to detect samples that exhibited low and high expression levels respectively. The quan-
tiles tested ranged from two, splitting at the 1/2 quantile (the median), to 100, using
the lowest (1%) and highest (99%) percentiles.
This enabled testing of the threshold for low expression of genes which is most
able to distinguish synthetic lethal genes, even with higher-order synthetic lethal in-
teractions (as discussed in Section 3.2.1). Both SLIPT with the directional criteria for
synthetic lethality and significance of the equivalent χ2 test were performed for each
quantile. Pearson correlation was also tested on simulated continuous expression data
for synthetic lethal detection. Both positive and negative correlations were considered
separately as predictors of synthetic lethality for comparison with χ2 based approaches,
using discrete categories of gene function deriving from quantiles.
The results presented throughout this Section use the example of five synthetic
lethal partners to illustrate the differences in performance between the standard SLIPT
procedure (slipt-3) to n quantiles (slipt-n), the χ2-test on the same quantiles, and posi-
tive or negative correlation. However, similar results across different numbers of known
synthetic lethal genes are shown in Appendix I. The synthetic lethal detection proce-
dures were compared with 10,000 simulations of a small dataset of 100 genes and 1000
samples without correlation structure between genes (as performed in Section 3.3.2).
As shown in Figure 6.1, the 1/3-quantiles previously used have optimal performance
and SLIPT has a comparable or higher performance than the χ2-test alone across
quantiles. Pearson correlation was also tested as a predictor of synthetic lethality (i.e.,
whether highly positive or negative correlations with the query gene detected synthetic
lethal partners). Positive correlation performed worse than random (with an AUROC
lower than 0.5) as thus coexpression of genes was not predictive of synthetic lethality
in simulated data. Conversely, negative correlation was predictive of synthetic lethal-
ity, consistent with synthetic lethal gene activity being mutually exclusive. However,
neither correlation approach performed as well as the optimal quantiles for the SLIPT
procedure or the χ2-test.
These results are shown in both a bargraph and lineplot to show the individual
results of each parameter, and to compare SLIPT with the χ2-test side-by-side across
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(a) Barplot of χ2, SLIPT, and correlation (b) Lineplot of χ2, SLIPT, and correlation
Figure 6.1: Performance of χ2 and SLIPT across quantiles. Synthetic lethal
detection (of 5 genes) with quantiles as on the axes. The barplot uses the same hues
for each quantile (grey for correlation) and darker for χ2 (and positive correlation). The
line plot (with log-scale quantiles) is coloured according to the legend. SLIPT and χ2
perform similarly, peaking at 1/3-quantiles and converging to random (0.5). Negative
correlation had higher performance than positive correlation but not optimal quantiles
for SLIPT or χ2.
quantiles. Similarly, these plots are given for detecting a range of known synthetic lethal
partners in the simulations in Appendix Figures I.1 and I.2. These demonstrate that
the findings shown for five synthetic lethal genes are robust across different numbers
of underlying synthetic lethal genes.
The synthetic lethal detection procedures were also tested with 1000 simulations of
a larger dataset of 20,000 genes and 1000 samples. While fewer simulations gives a less
accurate ROC result, this is sufficient to replicate the above findings with a feasible
number of genes in a human gene expression dataset and assess the impact of a higher
proportion of non-synthetic lethal genes (potential false positives). Simulated datasets
of this size were also used in Section 3.3.2 to test the specificity in a number of genes
similar to that in experimental datasets for cancer genomes. As shown in Figure 6.2,
the above findings were replicated in simulations of a larger dataset with 20,000 genes.
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Figure 6.2: Performance of χ2 and SLIPT across quantiles with more genes.
Synthetic lethal detection (of 5 genes in 20,000) with quantiles as in axis labels. The
line plot (with log-scale quantiles) is coloured according to the legend. As for simula-
tions with fewer genes, SLIPT and χ2 perform similarly, peaking at 1/3-quantiles and
converging to random (0.5). Negative correlation had higher performance than positive
correlation but not optimal quantiles for SLIPT or χ2.
These were also robustly replicated across varying numbers of underlying synthetic
lethal genes (as shown in Appendix Figure I.3).
6.1.1.1 Correlated Query Genes affects Specificity
As discussed in Section 3.3.2.2, positively correlated genes (with the query gene) have
an impact on the performance of synthetic lethal detection. SLIPT was able to distin-
guish these correlated genes from synthetic lethal partners and hence is likely to have a
higher specificity in datasets which include positively correlated genes with the query
gene (as expected in gene expression data). The synthetic lethal detection procedures
were compared with 10,000 simulations of a small dataset of 100 genes (with 5 corre-
lated with the query gene) and 1000 samples otherwise without correlation structure
between genes. As shown in Figure 6.3a, this specificity is reflected in the increased
AUROC performance values for SLIPT (in contrast to Figure 6.1). This specificity can
be attributed to the directional criteria (as described in Section 3.1) since the χ2-test
alone performs comparatively poorly with positively correlated genes.
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(a) Performance in 100 genes (b) Performance in 20,000 genes
Figure 6.3: Performance of χ2 and SLIPT across quantiles with query correla-
tion. Synthetic lethal detection (of 5 genes with query correlated genes) with quantiles
as in axis labels. Query correlated genes composed 5% of the dataset: (a) 5 out of 100
genes and (b) 1000 out of 20,000. The line plot (with log-scale quantiles) is coloured
according to the legend. SLIPT performs consistently higher than χ2 due to higher
specificity. Negative correlation performed modestly.
The synthetic lethal detection procedures were also compared with 1000 simula-
tions of a larger dataset of 20,000 genes (with 1000 correlated with the query gene)
and 1000 samples otherwise without correlation structure between genes. This sim-
ulation increases the number of genes (and proportion of negative genes) to those
comparable with a human gene expression dataset while maintaining a comparable 5%
of positively correlated genes. As shown in Figure 6.3b, SLIPT outperformed χ2 or
negative correlation and was optimal at the 1/3-quantile. The difference between SLIPT
and χ2 was less pronounced in a larger dataset, with many weakly correlated genes.
The greater specificity of SLIPT than the χ2-test, to distinguish positively correlated
non-synthetic lethal genes, was not as evident with a large number of negative genes
(as potential false positives). However, specificity is important in large-scale genomics
analysis with many potential false positives. SLIPT with 1/3-quantiles (as performed
throughout Chapters 4 and 5), had higher performance than other quantile thresholds,
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particularly with positive correlations (replicating the Section 3.3.2.2), across different
numbers of underlying synthetic lethal genes (as shown in Figures I.5 and I.6).
Together these results support the use of SLIPT, particularly the use of quantiles as
thresholds for gene function and specific use of 1/3-quantiles which performed well com-
pared to other quantiles. Of particular concern in the design of SLIPT for expression
data is whether the samples sizes are sufficient when the data are divided into quan-
tiles. The SLIPT methodology further performed better for 1/3-quantiles (and other
moderate values) than χ2 or correlation as a predictor of synthetic lethality. These
results were irrespective of sample size or p-value threshold since the results replicated
across sample sizes and the AUROC values were independent significance thresholds.
Using a moderate number of quantiles for SLIPT ensures that there are a sufficient
number of samples expected below and above them so that deviations from these are
statistically detectable. These quantiles were also optimal for the χ2 test which uses
the same expected values as the SLIPT directional conditions.
6.1.2 Alternative Synthetic Lethal Detection Strategies
The SLIPT approach (and χ2) to detect synthetic lethality from partitioning expres-
sion to estimate gene function also outperformed correlations, which use continuous
data directly. Correlation performing poorly as a synthetic lethal detection strategy
is consistent with there not necessarily being a relationship between synthetic lethal
partners, which can be in distinct biological pathways, expressed at different times
or in different cell types. Nevertheless, correlation is among the alternative detection
methods considered in further detail as it represents a method that is not subject to
loss of information. Co-expression was among the criteria required by other synthetic
lethal approaches, most notably DAISY (Jerby-Arnon et al., 2014), for which it has
been critiqued (Lu et al., 2015). While DAISY does not have released software to
tested with simulated data for direction comparison, the assumption of co-expression
can be tested in this manner.
The BiSEp R package (Wappett, 2014) for using bimodality to detect synthetic
lethality (Wappett et al., 2016) was also considered, along with a linear regression
approach. These statistical methods span a range of computational approaches to
detecting synthetic lethality and serve to compare alternatives to SLIPT, supporting its
design and application. However, these comparisons are able to provide supporting data
from statistical modelling and simulations for the viability of the SLIPT methodology
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for synthetic lethal discovery in cancer (as demonstrated in Chapter 4) and further
applications.
6.1.2.1 Correlation for Synthetic Lethal Detection
As expected from prior results, negative (Pearson) correlation performed better than
positive correlation at detecting synthetic lethality (shown in Section 6.1.1). However,
neither correlation approach performed as well as SLIPT or the χ2 test as a predictor
of synthetic lethal gene partners. It is notable that negative correlation still often
performed considerably better than random chance.
Negative correlation was compared directly to the SLIPT methodology (as de-
scribed in Section 3.1) across numbers of known synthetic lethal partners and sample
size (ranging from 500 to 5000). This comparison used 1000 simulations of a dataset
with 20,000 genes and synthetic lethal genes from within a network (sampled as in
Section 3.4.2) with a 0.8 correlation between adjacent genes. In a direct comparison of
SLIPT and negative correlation (shown in Figure 6.4), SLIPT consistently has higher
performance in simulated data across parameter values and (inverse) correlation-based
approaches perform modestly in comparison. Thus using thresholds to categorise ex-
pression data (as performed by SLIPT and χ2) does not compromise the performance
of these methods by losing continuous data that would be used for calculating correla-
tions.
Both SLIPT and correlation had poorer performance with increasing numbers of the
synthetic lethal genes to detect, while they had higher performance in higher sample
sizes, as expected (as previously observed for SLIPT in Section 3.3). Thus the issue
with detection of greater numbers of synthetic lethal genes is not specific to SLIPT
but occurs across computational methods of synthetic lethal discovery in (simulated)
expression data and likely stems from cryptic higher-order synthetic lethal interactions
(as conservatively assumed in Section 3.2.1).
6.1.2.2 Testing for Bimodality with BiSEp
Extensive attempts were also made to compare SLIPT to the BiSEp methodology
(Wappett et al., 2016), a statistical approach to identify synthetic lethal gene pairs
from mutually exclusive relationships using bimodal distributions. This synthetic lethal
detection methodology is also designed for expression analysis in cancer and is readily
available as an (open-source) R package (Wappett, 2014), a practice which facilitates
adoption and testing of the methodology on the same datasets and simulations proce-
dures as previously used for SLIPT.
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Figure 6.4: Performance of negative correlation and SLIPT. Synthetic lethal de-
tection with SLIPT was compared to negative (Pearson) correlation across parameters.
SLIPT consistently outperformed correlation. Both approaches had lower performance
for more synthetic lethal partners and for lower sample sizes. 10,000 simulations were
performed with correlation structure.
The BiSEp package is designed for global testing of all potential gene pairs in the
genomes for synthetic lethality rather than focusing on the search space of potential
partners of the query gene. This approach was unable to detect synthetic lethal gene
pairs in the TCGA breast cancer expression dataset (Koboldt et al., 2012). How-
ever, this may be due to stringent thresholds under the multiple testing of millions of
potential gene pairs.
For a direct comparison with the query-based SLIPT approach, the source code of
the BiSEp R functions was modified to test solely for the partners of a specific gene.
This approach was still unable to detect synthetic lethal partners of CDH1 in TCGA
breast cancer expression data (Koboldt et al., 2012), even with the detection thresholds
for bimodality and significance greatly relaxed from those the package defaults to.
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To circumvent multiple testing issues, BiSEp only tests gene pairs for synthetic
lethality between genes with a detectable bimodal distribution. However, even with
relaxed thresholds, bimodal distributions were not detectable in the normalised TCGA
data (Koboldt et al., 2012). Such normalisation Ritchie et al. (2015) is standard prac-
tice for expression datasets generated from microarrays or RNA-Seq and therefore
BiSEp may not be appropriate to apply to this data. However, it is noted that BiSEp
may also use other data types such as DNA copy number or cell line data for which it
may be more applicable (Wappett et al., 2016).
Nevertheless, attempts were made to test BiSEp on simulated datasets with under-
lying synthetic lethal genes (using the procedures described in Sections 3.2.2 and 3.4.2).
However, BiSEp was also unable to detect genes with bimodal distributions of genes
(and thus unable to detect synthetic lethality) in a limited number of computationally
intensive simulations. Therefore investigations on a wider range of parameters were
not performed.
6.2 Simulations with Graph structures
The simulations of synthetic lethality performed in Section 3.3 included correlated
blocks of genes as a rudimentary representation of pathway structure and co-regulated
genes. The simulation procedure was enhanced here to account for more complex
pathway structures by sampling from multivariate normal distributions with correlation
structure derived from graph structures (as described in Section 3.4.2). This approach
enabled the simulation of synthetic lethal pathways with known correlation structure
and synthetic lethal partners (of a gene not in the pathway). Using this procedure,
the performance of SLIPT was evaluated under simple controlled correlation structures
and complex correlations, such as those derived from biological networks (e.g., those
described in Chapter 5). The SLIPT methodology was tested in artificially constructed
networks to evaluate the effect of pathway structure on synthetic lethal detection These
included large biologically feasible pathways to ensure that the SLIPT methodology is
robust under complex correlation structures and applicable to such complex genomics
data.
These simulations combine the approach of prior simulation analyses (in Sections 3.3
and 6.1) with the graph structures for biological pathways (as used in Chapter 5).
This enabled testing whether subtle or large differences in pathway structure affect
synthetic lethal detection, whether inhibiting relationships (or inverse correlations) be-
tween genes affects synthetic lethal detection, and whether synthetic lethal detection
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varies by which gene is synthetic lethal and which genes are closely linked within the
pathway structure. In addition, large numbers of synthetic lethal genes and biologically
feasible numbers of genes (with many non-synthetic lethal genes) were tested to repli-
cate the findings of Sections 3.3 and 6.1 in correlated structures derived from pathway
graphs, including examples of biological pathways from Reactome (Croft et al., 2014).
Simple and more complex constructed graph structures were used to demonstrate
the impact of pathway structure on the performance of SLIPT for synthetic lethal
detection in simulations. In addition, more complex constructed graph structures were
compared to the PI3K and Gαi signalling pathways derived from Reactome which
were used for simulation of pathway structures of biological complexity (as shown in
Figure 5.1 and Appendix Figure 5.2).
6.2.1 Performance over Graph structures
6.2.1.1 Simple Graph structures
Simple pathway modules were used to test the effect of pathway structure on the
performance of detecting synthetic lethal partners within graph structures. For an intial
comparison, the graph structures (shown by Figure 6.5) were used where a gene has
one upstream regulator and two downstream (Figure 6.5a) or a gene has two upstream
regulators and one downstream gene (Figure 6.5b). SLIPT had a high performance
in these simulations, detecting randomly selected synthetic lethal partners in both of
these small simple networks (shown in Figure 6.6 and Appendix Figure J.1).
As previously observed (in Section 3.3), performance declined with higher numbers
of synthetic lethal genes and lower sample sizes. However, the sensitivity of SLIPT as a
binary classifier was high. Synthetic lethal partners are often distinguishable from non-
synthetic lethal genes, even in simple highly correlated networks. The small number of
genes and their high correlation has an impact on the ROC curves for higher numbers
of synthetic lethal partners which are skewed compared to those observed previously.
Specificity cannot be tested if all potential partner genes are synthetic lethal, which
limits the number of synthetic lethal genes that can be tested.
These results were consistent between the pathway modules of diverging (as shown
in Figure 6.7a) and converging signals (as shown in Figure 6.7b). The AUROC per-
formance and underlying curves were strikingly similar between these graph structures
(as shown in Figure 6.6 and Appendix Figure J.1). Thus the performance of SLIPT
was not perturbed by pathway structure, specifically the direction of pathway relation-












Figure 6.5: Simple graph structures. These simple graph structures were used to demon-
strate the simulation procedure. These are examples of a pathway diverging (a) or converging
(b) which enabled testing the importance of direction in pathway structures. These are used
with both activating and inhibiting relationships as shown.
a direct comparison (shown in Figure 6.7c), the performance of simulations did not
differ across parameter values in these simple graphs and therefore SLIPT is robust to
pathway direction.
6.2.1.2 Constructed Graph structures
A more complex graph structure was used to examine the performance of detecting
synthetic lethal partners with SLIPT in simulated expression data with pathway cor-
relation structures. For a simple chain of genes representing a very linear pathway
(shown in Figure 6.8), the above findings were generally replicated. SLIPT had high
performance across parameter values in small networks but was still lower for higher
numbers of synthetic lethal genes and lower sample sizes.
When detecting synthetic lethal genes with SLIPT as a binary classifier, the perfor-
mance differences were primarily due to changes in specificity, as the small numbers of
synthetic lethal genes still had highly significant p-values. Despite lower specificity and
performance in ROC curves, the accuracy increased and false positive rate decreased
desirably with higher numbers of synthetic lethal genes due to the high sensitivity and
the high proportion of synthetic lethal genes detected. Therefore the use of adjusted p-
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values for SLIPT as a binary classifier appears to be appropriate for detecting synthetic
lethal partners, even in strongly correlated pathways, at least in these small-scale test
cases.
An artifact of these small test cases led to the skewed ROC curves (as discussed
in Section 6.2.1.1), which may be the result of the low number of non-synthetic lethal
genes to identify as true negatives, affecting the accuracy of specificity. This issue does
not occur in larger, more complex graph structures, even with modest total numbers of
genes and high correlations (as shown in Section 6.3). This issue is unlikely to occur in
large expression datasets with many non-synthetic lethal genes, as shown previously (in
Section 3.3 and 6.2.1.1) and with graph structures in larger datasets (in Section 6.2.4).
6.2.2 Performance with Inhibitions
Simulations of synthetic lethality in expression data were also performed with corre-
lation structures derived from graphs containing inhibiting relationships (as are com-
monplace in biological pathways) which produce negative correlations. As shown in
Figure 6.9, these were not an issue for detection by SLIPT. Rather, the SLIPT proce-
dure performs well on simple graph modules with highly negative correlations. With
SLIPT as a binary classifier, it had higher specificity, higher accuracy, and lower false
positive rate in an inhibitory graph than the same graph with activating relationships
(as shown by Figure 6.6).
The ROC curves for an inhibiting graph also showed consistently high specificity,
irrespective of detection threshold, with only the upper extreme of the curve exhibit-
ing a skew below random performance (as shown in Figure 6.9). Nevertheless, SLIPT
had high performance across parameter values, particularly avoiding issues with higher
numbers of synthetic lethal partners (as observed in Section 6.2.1.1). However, perfor-
mance was marginally lower for higher numbers of synthetic lethal genes to detect and
lower sample sizes, consistent with previously observations. Negatively correlated sim-
ulated datasets are also unperturbed by minor differences in graph structure, such as
changing in the direction of the graph module. As observed for activating relationships
in these graph modules, the performance was highly concordant between the graph
modules (shown by similar results in Figures 6.9 and J.2).
Detection of synthetic lethality by SLIPT in simulated data with inhibiting relation-
ships outperforms simulations with activating relationships in the same graph structure
(as shown in Figure 6.10). Thus SLIPT was robust in gene expression datasets with
inverse correlations and performed well in them, at least in simple test cases. These
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relationships occur frequently in biological pathways and therefore the findings inferred
from graph structures without inhibiting relationships are a conservative estimate of
performance.
The SLIPT methodology appears to perform better in biological pathways (which
contain negative correlations) than the graph structures discussed previously (in Sec-
tion 6.2.1). This may be due to negative correlations which lead to synthetic lethal
partners and inversely correlated genes which are positively correlated with the query
gene. As previously shown, the SLIPT methodology performed well with specificity
against positively correlated query genes (in Sections 3.3.2.2 and 6.1.2.1).
Similarly, more complex graph structures with entirely inhibiting relationships (neg-
ative correlations) also perform desirably with SLIPT as a binary classifier and had
high performance across increasing numbers of synthetic lethal genes, particularly for
sufficiently high sample sizes (as shown by Appendix Figure J.3). However, this was
not necessarily the case for graph structures with a combination of activating and in-
hibiting relationships (i.e., containing positive and negative correlations). As shown
by Appendix Figure J.4, such a mixed network structure did not necessarily have high
performance across parameters as observed for purely inhibiting networks.
These still appeared to have desirably high sensitivity, high accuracy, and low false
positive rate for detecting more synthetic lethal genes, despite poor specificity. The
ROC curves were particularly skewed for high proportions of the network being syn-
thetic lethal and may stem from low numbers of true negative genes to detect (as
discussed in Section 6.2.1.1). In a direct comparison of performance (shown in Fig-
ure 6.12), the purely inhibiting graph had consistently higher performance than the
activating one, as observed for simpler graphs (as shown in Figure 6.10).
In contrast, the combination of activating and inhibiting relationships had slightly
lower performance across parameters compared to the same graph structure with ac-
tivating relationships. Therefore correlation structure (e.g., the addition of negative
correlations) can impact on the performance of SLIPT in a graph network in either
direction. However, this may be an artifact of the simulation procedure as synthetic
lethal genes from the correlation structure were randomly selected (without regard to
the relationships between them), with the query gene added to ensure that conditions
for synthetic lethal relationships were met.
This system for simulating inhibitory pathways is not ideal since it can lead to
synthetic lethal gene combinations, by randomly selecting them, which are unlikely
to occur in biological pathways. These randomly selected synthetic lethal genes may
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account for the detection results being suboptimal (i.e., difficult to detect synthetic
lethal partners) compared to previous investigations. It is expected that inversely
correlated synthetic partner genes will be highly expressed in a mutually exclusive
manner such that at least one of them will be compensating for loss of the query gene
in most samples, leading to a weak synthetic lethal signature in expression data in this
case. Furthermore, this case may not be representative of biological data with synthetic
lethal partners of tumour suppressor genes which are commonly inversely correlated
to the query gene (to some extent) and therefore it is unlikely that they are strongly
negative correlated with each other, unless they are synthetic lethal partners of each
other as well.
It is plausible that many synthetic lethal partner genes will serve to separately
compensate for the loss of query gene function and be positively correlated with each
other. Nonetheless, these simulations demonstrate that correlation structure (partic-
ularly negative correlations) have an impact on the detection of synthetic lethality.
However, SLIPT was still able to perform well across graphs with different activat-
ing and inhibiting relationships, and the perturbations in performance were marginal,
particularly those reducing performance compared to an activating network.
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(c) Graph structure (d) Statistical performance
Figure 6.6: Performance of simulations on a simple graph. Simulation of synthetic
lethality was performed by sampling from a multivariate normal distribution generated from
a diverging graph structure. Performance of SLIPT declined for more synthetic partners but
this was lower sample sizes (in darker colours). This manifests as a decline in specificity and
the false positive rate. For each parameter value, 10,000 simulations were used. Colours of












































(c) Performance between graph structures
Figure 6.7: Performance of simulations is similar in simple graphs. The AUROC
values for simulations of multivariate normal distributions based on each graph structure
yielded indistinguishable performance across parameter values in 10,000 simulations.
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(c) Graph structure (d) Statistical performance
Figure 6.8: Performance of simulations on a pathway. Simulation of synthetic lethality
was performed by sampling from a multivariate normal distribution generated from a pathway
structure. Performance of SLIPT declines for more synthetic partners and lower sample sizes
(in darker colours). For each parameter value, 10,000 simulations were used. Colours of the
ROC curves in Figure 6.8b correspond to the parameters in Figure 6.8d.
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(c) Graph structure (d) Statistical performance
Figure 6.9: Performance of simulations on a simple graph with inhibition. Simula-
tion of synthetic lethality was performed by sampling from a multivariate normal distribution
generated from an inhibiting graph. Performance of SLIPT declined for more synthetic part-
ners and lower sample sizes. For each parameter value, 10,000 simulations were used. Colours












































(c) Performance between graph structures
Figure 6.10: Performance is higher on a simple inhibiting graph. The AUROC values
for simulations of multivariate normal distributions based on inhibitions in the graph structure
yielded consistently higher performance across parameter values in 10,000 simulations.
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(c) Graph structure (d) Statistical performance
Figure 6.11: Performance of simulations on a constructed graph with inhibition.
Simulation of synthetic lethality was performed by sampling from a multivariate normal dis-
tribution generated from pathway structure with a combination of inhibitions. Performance
of SLIPT declines for more synthetic partners and lower sample sizes. For each parameter





























































(d) Performance between graphs (a) and (b)
































(e) Performance between graphs (a) and (c)
Figure 6.12: Performance is affected by inhibition in graphs. The AUROC values
for simulations of multivariate normal distributions based on graph structure containing only
inhibitions in the graph structure yielded consistently higher performance across parameter
values in 10,000 simulations. A combination of activating and inhibiting relationships had
lower performance but was more similar to the activating graph.
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6.2.3 Synthetic Lethality across Graph structures
Synthetic lethal genes were distinguishable from highly correlated genes in simple cases
(as shown by ROC analysis). However, correlated genes may lead to low specificity and
high false positive rates. Negative correlations do not affect specificity this way but they
may perturb the correlation structure between synthetic lethal partner genes, making
it difficult to detect many of them with high sensitivity. Synthetic lethal genes have
been selected randomly in simulations so far, which is a limited approach. To examine
the impact of pathway relationships in more detail, specific genes were selected to be
synthetic lethal within a network over replicate simulations. These simulations with a
fixed synthetic lethal gene were performed to demonstrate their impact on the detection
of other genes in the network.
For detection of a synthetic lethal gene in an activating graph structure (as shown
in Figure 6.13a), the χ2 values were clearly distinguishable from other genes (shown in
Figure 6.13c). Simulations were performed for each gene being the synthetic lethal part-
ner. For each synthetic lethal gene, it had the highest χ2 value amongst 20,000 genes,
including the highly correlated graph network (as shown in Appendix Figure J.5). De-
spite optimal performance for SLIPT detecting one synthetic lethal gene in a ROC
curve (as shown in Figure 6.8), irrespective of detection threshold, the highly corre-
lated genes would be detected as false positives by SLIPT as a binary classifier (as
described in Section 3.1). In particular, the genes that were adjacent in the pathway to
the synthetic lethal gene “D” had high test statistics which could be false positives (as
shown in Figure 6.13c). This was not specific to example of gene “D”, with the neigh-
bouring genes of each synthetic lethal having higher χ2 values (as shown in Appendix
Figure J.5).
The synthetic lethal signal propagates from the true synthetic lethal gene through-
out the network. As such, the genes nearer to (i.e., more highly correlated with) the
true synthetic lethal gene had higher test statistics and were more likely to be detected
by SLIPT as false positives. The adjacent genes of synthetic lethal partners being false
positives may account for the higher concordance of synthetic lethal pathways than
genes between SLIPT in TCGA data (Koboldt et al., 2012) and the siRNA screen
(Telford et al., 2015) than individual gene results (in Chapter 4). False positive genes
are more likely to be involved in a synthetic lethal pathway, being correlated with a
true synthetic lethal gene. Synthetic lethal pathways are likely to contain many genes
detected by SLIPT, giving a consensus in the pathway over-representation analysis.




































































(d) χ2 distribution for inhibiting graph
Figure 6.13: Detection of synthetic lethality within a graph structure. The gene
“D” was designated to be synthetic lethal and the χ2 value from SLIPT was computed for
each gene across each graph structure. The χ2 values were computed in 100 simulations of
datasets of 20,000 genes including the graph structure and 1000 samples. Adjacent genes
exhibited lower χ2 values with inhibiting relationships.
likely to be experimentally validated. Genes with the strongest support (i.e, higher χ2
values and more significant p-values) are more likely to be the underlying synthetic
lethal gene.
The immediately adjacent genes in an inhibiting graph (Figure 6.13b) did not have
elevated χ2 test statistics or a significant inverse effect (as shown in Figure 6.13d).
Therefore true synthetic lethal partners were highly distinguishable from other genes
with inhibiting relationships. This was shown for each gene in the graph structure as
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the synthetic lethal partner (shown in Appendix Figure J.6). These results support
SLIPT as an appropriate approach to distinguish synthetic lethal partners in biological
pathways (which frequently have inhibitions), including those relevant to cancer growth
and inhibition.
The 2nd degree neighbours of the synthetic lethal gene still exhibited moderate
χ2 values (and are moderately correlated with the synthetic lethal gene). These genes
could be false positives, as shown for an activating graph structure, although inhibitory
relationships (i.e., negative correlations) lead to more differences in test statistics be-
tween correlated genes and underlying synthetic lethal partners (as shown in Appendix
Figure J.6). Simulations in a graph containing a combination of activating and inhibit-
ing relationships exhibits either of these χ2 profiles, depending on which gene is syn-
thetic lethal and the relationships between genes (as shown in Appendix Figure J.7).
In this case, the synthetic lethal gene is distinguishable and inhibitory relationships
make it easier to detect with SLIPT.
These results contrast with randomly selecting multiple synthetic lethal genes (as
shown in Figure 6.12), where the performance of SLIPT was impeded by the inhibitory
relationships between synthetic lethal partners. The randomly selected synthetic lethal
genes, with negative correlations between them, which had poor performance due to an
artifact in the simulation process resulting in biologically implausible synthetic lethal
genes. The results with one synthetic lethal partner were sufficient to show the impact
of synthetic lethal partners on neighbouring (correlated) genes. It is plausible that
the synthetic lethal signatures in expression data would propagate similarly through a
network from multiple synthetic lethal partners.
6.2.4 Performance within a Large Simulated Dataset
The performance of SLIPT with higher numbers of true partners to detect may have
been affected by the high proportion of synthetic lethal partners (i.e., fewer true neg-
atives) in small networks (as noted in Section 6.2.1.1). The performance of SLIPT
increased with the addition of more non-synthetic lethal genes, particularly the speci-
ficity (as shown in Sections 3.3 and 6.1). Therefore, correlated genes from graph struc-
tures (as used in Section 6.2.1) were included in a larger simulated dataset to assess
the performance of SLIPT for a synthetic lethal pathway in the context of thousands
of genes, as occurs in expression datasets.
The simulations performed in Section 6.2.1.1 were replicated within a dataset of
20,000 genes with the remainder being composed of non-synthetic lethal genes without
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correlation structure. The specificity in a higher number of synthetic lethal genes did
not affect performance in a simple graph structure (as shown in Appendix Figure J.8).
For a graph of highly correlated genes within a gene expression dataset, SLIPT had
high performance detecting of synthetic lethal genes in the network within a larger
dataset. In this case, a reduction in sensitivity resulted in poorer performance. A high
number of non-synthetic lethal genes were correctly identified, with a low false positive
rate and high accuracy. Thus the use of stringent χ2 p-value thresholds (adjusted by
FDR) are suitable for testing for synthetic lethality in gene expression data across the
number of genes in human and cancer data.
In a direct comparison with simulations in the graph structure alone (as performed
in Section 6.2.1.1), detection of synthetic lethality with SLIPT performed consistently
better in a larger dataset with many true negative genes to detect (as shown in Fig-
ure 6.14). The SLIPT methodology had a high specificity and low false positive rate,
which is desirable. SLIPT is therefore applicable to large gene expression datasets,
where these are important considerations since the number of negative genes often
vastly outnumbers the number of positive genes to detect.
Performance was not necessarily higher with more non-synthetic lethal genes in an
inhibiting graph structure. The performance of simulations of an entirely inhibiting
graph structure did not improve within a larger dataset. Rather, the performance
in the inhibiting graph structure was similar to simulations of the graph structure in
isolation. Biological pathways commonly contain inhibiting relationships (and inverse
correlations), although they are unlikely to occur across an entire pathway. In graph
structures with inhibitions included in a larger dataset, the performance of synthetic
lethal detection by SLIPT was sometimes higher than in graph structure simulated
alone (as shown in Figure 6.15). However, these did not perform as well as the equiv-
alent graph structures without inhibitory relationships within a similar dataset. It is
expected that the findings based on these simulations of genes with pathway structures
in smaller datasets (as described in Section 6.2.1) will be relevant to larger datasets.
The simulation results in these inhibiting graph structures perform comparably or bet-
ter with more non-synthetic lethal genes to distinguish from them even with inhibitory
relationships within the graph structure
This poorer performance of inhibitory graph structures may be due to highly neg-
atively correlated genes being false positives. These genes will be positively correlated
with the query gene if they are negatively correlated with a synthetic lethal partner












































(c) Performance in Diverging module
































(d) Performance in Converging module
Figure 6.14: Performance on a simple graph improves with more genes. Simulations
were performed with each of the graph structures to detect synthetic lethal partners within
them. In either structure, performance of detection in a dataset containing on the graph
structure (in colour) was lower than testing the graph structure within a larger dataset of
non-synthetic lethal genes (without correlations).
tinguishing these positively correlated genes, as previously shown (in Sections 3.3.2.2
and 6.1.1.1). These false positives will also be a minority amongst a larger dataset of
non-synthetic lethal genes without correlation to the query or synthetic lethal genes.
It is more likely that the poorer performance stems from negative correlations be-
tween synthetic lethal genes which makes them more difficult to individually detect (as
observed in Section 6.2.2). As discussed in Section 6.2.3, this is likely an artifact of the




















































(c) Performance in Graph
































(d) Performance with Inhibitions
Figure 6.15: Performance on an inhibiting graph improves with more genes. Sim-
ulations were performed in a graph structure with activating and inhibiting relationships to
detect synthetic lethal partners within them. In contrast to an activating graph, performance
of detection in a dataset containing only the graph structure (in colour) was as much lower
than testing the graph structure within a larger dataset of non-synthetic lethal genes (without
correlations) in an inhibiting graph structure with negative correlations.
relationships between them. Therefore the poorer performance for inhibiting graphs
within larger datasets is not cause for concern because the cases where SLIPT performs
poorly are likely to be combinations of simulated synthetic lethal genes that are not
likely to occur within biological pathways. This simulation procedure has included
higher-order synthetic lethal to produce the weakest signal of synthetic lethality for
individual partner genes which are still detectable by SLIPT.
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6.3 Simulations in More Complex Graph structures
Investigations with simulations based on graph structures were extended to larger
graphs, enabling more synthetic lethal genes within a pathway and modelling the
complexity of a biological pathway. Sensitivity declines over a greater range for the
number of synthetic lethal partners in a larger network with a trade-off with specificity
(as shown in Appendix Figures J.9–J.11). However, the accuracy declined for greater
numbers of synthetic lethal partners and the false positive rate peaks at intermediate
values. In this range, differencse between simulations varied with greater sample size.
The AUROC results were similar between these more complex graph structures, al-
though the larger graph (Appendix Figure J.11) differed in sensitivity and specificity
for SLIPT as a binary classifier. This difference be due to different proportions of
synthetic lethal and non-synthetic lethal genes to detect, since these graphs (as shown
in Appendix Figures J.9 and J.10) had fewer genes.
While the graph structures (of similar size) were highly distinct, they had simi-
lar performance profiles across parameters. SLIPT is therefore robust across pathway
structures and is more affected by the number or proportion of genes to detect. Find-
ings from previous simulations in similar correlation structures (in Section 3.3) should
be applicable to expression data with more complex correlation structures, such as
those occurring in biological pathways. Specifically, synthetic lethal partners are dis-
tinguishable from closely correlated genes in the context of biological pathway networks,
irrespective of thresholds (shown by ROC) and with the sensitivity and specificity of
SLIPT as a binary classifier (as used in Chapters 4 and 5).
The findings for inhibitory graph structures were replicated with larger more com-
plex graph structures with inhibiting relationships and more synthetic lethal genes to
detect (shown in Appendix Figures J.12–J.15). In each graph structure, simulations en-
tirely with inhibiting relationships (Appendix Figures J.12, J.14, and J.16) had higher
performance than the equivalent graph with entirely activating relationships (Appendix
Figures J.9, J.10, and J.11) or a combination of activating and inhibiting relationships
(Appendix Figures J.13, J.15, and J.17). While the presence of negative correlations
subtly affects the performance of SLIPT, the methodology is robust across the exact
structures of genes and is therefore applicable to detecting synthetic lethal genes in a
range of (synthetic lethal) biological pathways with different structural relationships.
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6.3.1 Simulations over Pathway-based Graphs
Simulations of synthetic lethality in gene expression with correlation structures thus
far have used simple blocks of correlated genes (as used in Section 3.3) or have ben de-
rived from constructed graph structures (as used in Section 6.2). These have been used
to make inferences on the impact of correlation structure but it remains to be shown
whether these findings are reproducible in the complexity of the biological network
structure. Specifically, SLIPT was tested on simulated data with known underlying
simulated synthetic lethal partners (as described in Section 3.2.2) with multivariate
normal correlation structure derived from biological pathways (as described in Sec-
tion 3.4.2).
The Reactome pathway structure for the PI3K cascade (as used in Chapter 5) was
used to demonstrate the simulation procedure for detecting synthetic lethality in the
graph structure of a biological pathway. This pathway has clear directionality, with
related signalling pathways among those identified to be synthetic lethal candidates
(in Chapter 4). The PI3K pathway has a relatively moderate size (138 genes) and
complexity. It is therefore suitable for comparison to previous graph structures of a
similar scale (50–100 genes) with the complexity of a biological pathway.
The performance of synthetic lethal detection with SLIPT, in simulated expression
data based on the Reactome PI3K pathway (as shown in Figure 6.16), was concordant
with previous findings. SLIPT had high performance when detecting a low number of
synthetic lethal genes which decreased for high numbers of synthetic lethal genes or
lower sample sizes. In particular, the performance of simulations in the PI3K pathway
closely resembled the simulation results for constructed graphs of similar scale and
complexity (as shown in Appendix Figures J.9 and J.10). Using thresholds based on
the χ2 p-value (adjusted by FDR), simulations in the biological PI3K pathway had
a higher sensitivity and lower specificity. While the performance decreased for more
synthetic lethal genes to detect within the simulated PI3K pathway, this primarily
involved a reduction in sensitivity to detect synthetic lethal genes rather than false
positives, as the false positive rate decreased, the accuracy increased, and the specificity
was relatively unperturbed (being more dependent on sample size). Thus SLIPT was
stringent in an example of a biological graph structure and is appropriate for detection
of synthetic lethal genes in complex correlation structures in gene expression data
involving biological pathways.
These simulations were replicated in the more complex Gαi signalling pathway
(of 292 genes), which was one of the most well supported synthetic lethal pathways
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(a) Statistical evaluation (b) ROC curves
(c) Graph structure (d) Statistical performance
Figure 6.16: Performance of simulations on the PI3K cascade. Simulation of synthetic
lethality was performed by sampling from a multivariate normal distribution based on the
Reactome PI3K cascade. Performance of SLIPT was high across parameters for detecting
synthetic lethality in the graph structure within a larger dataset. The performance decreased
for a greater number of true positives to detect but the accuracy increased with a low false
positive rate.
with loss of CDH1 in cancer (in Chapters 4 and 5). This pathway showed similar
relationships between sensitivity, specificity, and false positive rate with number of
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synthetic lethal partners and sample size (as shown in Appendix Figure J.18). While
the overall performance was lower than for smaller networks structures, many of the
findings from previous networks were replicated in a larger more complex biological
network. In the Gαi signalling pathway, SLIPT had high performance for detecting
low numbers of synthetic lethal genes and was highly stringent against false positives
for higher numbers of synthetic lethal genes.
6.3.2 Pathway Structures in a Large Simulated Dataset
Simulations were also performed with graph structures from biological pathways in-
cluded in a larger dataset to simulate gene expression data of the scale typical for
human and cancer studies. These simulations (as discussed in Section 6.2.4) showed a
higher specificity and therefore SLIPT had higher performance. The simulated PI3K
pathway (as shown in Appendix Figure J.19) was no exception, with high performance
across parameter values, which remained high up to many genes. While the sensi-
tivity decreased for high numbers of synthetic lethal genes to detect within the PI3K
pathway, the SLIPT methodology remained accurate, with high specificity in a large
simulated gene expression dataset.
Therefore the SLIPT methodology is a highly stringent approach suitable to be ap-
plied for detecting synthetic lethal genes and pathways within highly complex expres-
sion data with biological pathway structure. Even the poorly performing simulations
were highly stringent, with low false positive rates, which are an important considera-
tion in gene expression data with many non-synthetic lethal genes. The enrichment of
true synthetic lethal partners among detected genes makes SLIPT valuable for triage
of candidate synthetic lethal partners for further validation and for pathway analysis.
The performance of SLIPT in simulations of synthetic lethality within biological
pathways was markedly higher in the context of a larger dataset of thousands of genes.
As shown in a direct comparison with the graph structures alone (as shown in Fig-
ure 6.17c), performance was consistently higher across parameters in pathways of bi-
ological complexity from the Reactome database (Croft et al., 2014) such as PI3K
cascade and the Gαi signalling pathway (shown in Figure 6.17d and Appendix Fig-
ure J.20).
These biologically complex graph structures, based on the Reactome pathways, as-
sumed activating relationships to test synthetic lethal detection with SLIPT in the
context of complex correlation structures. Inhibiting relationships were not distin-
guished in the Reactome database (Croft et al., 2014). However, these investigations
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(a) The PI3K cascade (see Figure 5.1) (b) Gαi signalling (see Figure 5.2)
































(c) Performance in the PI3K cascade
































(d) Performance in Gαi signalling
Figure 6.17: Performance on pathways improves with more genes. Simulations were
performed in a graph structures for the PI3K cascade and Gαi signalling pathways structures
to detect synthetic lethal partners within them. As for constructed graphs, performance
of detection in a dataset containing only the graph structure (in colour) was as much lower
than testing the graph structure within a larger dataset of non-synthetic lethal genes (without
correlations) for both graphs of biological complexity.
with pathway-based graph structures indicate that the findings in constructed graphs
(as used in Section 6.2) are relevant to gene expression data containing real correlated
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pathways. Furthermore, previous comparisons between simulations with inhibiting re-
lationships indicated that the performance of synthetic lethal detection in an equivalent
graph structure with inhibitory relationships will likely be higher.
Non synthetic lethal genes, inversely correlated with the underlying synthetic lethal
partners, were distinguishable by SLIPT with high specificity. Synthetic lethal genes
were detectable with reasonable performance in large scale simulated gene expression
data and highly (positively) correlated genes in pathway structures. These findings
serve as a conservative estimate for the performance of SLIPT to detect synthetic lethal
genes within a synthetic lethal biological pathway in empirical data. Synthetic lethal
genes are distinguishable from correlated genes, to varying extents, in simulations.
False positives are also more likely to occur within the same (synthetic lethal) pathways.
Therefore SLIPT is both effective at triage of synthetic lethal candidates within a




Simulations were performed to assess the performance of the SLIPT methodology (as
described in Section 3.1 and with modifications) when detecting known underlying
synthetic lethal partners of a query gene. The simulation results supported the findings
in empirical data (in Chapters 4 and 5) by addressing whether the methodology used
to generate them was accurate or had desirable statistical performance in controlled
simulated conditions. These investigations included adjusting parameters, such as
the number of synthetic lethal genes that were known in simulated data, to assess
the performance of the SLIPT methodology and characterise the datasets for which
SLIPT performs well. Simulation and statistical modelling also enabled comparison of
the SLIPT methodology to other approaches to synthetic lethal detection in expression
data.
These simulations were based on a statistical model of synthetic lethality (as de-
scribed in Section 3.2.1) which was designed stringently to ensure that if synthetic
lethality was detectable in the simulated datasets, it would also be detectable by the
same methodology in empirical expression data. The model of synthetic lethality made
conservative assumptions, such as the low threshold of expression for gene function or
the inclusion of cryptic higher-order synthetic lethality (when testing pairwise). These
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assumptions decrease the likelihood that synthetic lethality would be detectable in ex-
pression data. If the assumptions used in constructing a model of synthetic lethality
were to be relaxed, such as including pairwise relationships, these would be more clearly
detectable than high-order synthetic lethality. Pairs of genes are rarely completely mu-
tually exclusive and usually have at least some samples which exhibit low expression
of both genes. Thus observed expression data was more consistent with the higher-
order relationships as modelled than there being only gene pairs. Thus it is reassuring
that synthetic lethality was still detectable under many simulation parameters as the
performance of SLIPT would be expected to be higher were these assumptions to be
violated in empirical data.
The simulation procedure (as described in Section 3.2.2) was designed as a com-
putational pipeline with arguments passes to scripts. The SLIPT methodology and
simulation of expression from graph structures were both used as R (R Core Team,
2016) software packages, developed and released for this project (as described in Sec-
tion 3.5). This design ensured that the simulations can be robustly applied across
parameters with consistency between simulations apart from the differences discussed.
The simulation procedure is also flexible to simulating other datasets, including syn-
thetic lethal relationships and pathway correlation structures, should these be rele-
vant to future investigations or bioinformatics tool development. The computational
pipeline is also compatible with parallel computing and made use of High Performance
Computing (HPC) infrastructure provided by the New Zealand eScience Infrastructure
(NeSI) using the Simple Linux Utility for Resource Management (Slurm) submission
system (as described in Section 2.5.3). This parallel computing pipeline enabled exten-
sive investigations into synthetic lethality in simulated data, including approximately
2 million cpu-hours on NeSI.
6.4.2 Comparing Methods with Simulated Data
Attempts were made to implement alternative synthetic lethal detection approaches
such as Pearson correlation and the BiSEp R package (discussed in Section 6.1). How-
ever, these were less effective than SLIPT at detecting synthetic lethality in multivariate
normal simulated data. While some of the published synthetic lethal detection methods
(Jerby-Arnon et al., 2014; Lu et al., 2015) did not provide reproducible software re-
leases for direct comparison, some of the central assumptions used in their design were
tested by the statistical methods considered for synthetic lethal detection in expression
data.
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BiSEp took considerably more time to compute predictions than SLIPT or χ2,
which limited the number of simulations that were feasible and made it difficult to
apply across parameters in the simulation pipeline (even when using supercomputing
infrastructure as discussed in Section 2.5.3). The computationally intensive nature of
the BiSEp procedure does not appear to be the issue for detecting synthetic lethal
genes in TCGA data or simulations, although it has made more extensive simulations
challenging. Rather, BiSEp was not suitable in either case since the TCGA data
was normalised with voom (Ritchie et al., 2015) and simulated data was generated by
sampling from a multivariate normal distribution. In either case, even subtle bimodal
signatures in expression data were not consistently detectable or sufficient to detect
synthetic lethality.
The BiSEp methodology may perform better on other data types but it cannot
be directly compared with the results for SLIPT throughout this thesis which have
used normalised or (multivariate) normally distributed data. Since it requires bimodal
distributions, BiSEp was not suitable for stringently normalised expression data nor
would it be expected to perform on (ranked) pathway metagenes. Thus SLIPT rep-
resents a distinct approach more suitable for these data types whereas BiSEp may be
applicable to other applications in which bimodal distributions are more frequent.
While the DAISY methodology (Jerby-Arnon et al., 2014) could not be entirely
reproduced on a simulated dataset, the weakest assumption of co-expression (Lu et al.,
2015) has been tested by comparison to Pearson correlation. BiSEp and DAISY were
selected for comparison because they have also been designed to analysis expression
data in cancer and represent different approaches to identifying signatures of synthetic
lethality. Details of the methodology was also available in comparison to other stud-
ies which did not release code and instead report the candidates detected or provide
a database of known synthetic lethal genes. These have the additional weakness of
publication bias for those curated from the literature as positive synthetic lethal rela-
tionships will be reported but it is unclear whether those that were not reported were
not detected or were not included in the investigations. The simulation investigations
have the advantage of testing whether genes can be correctly identified without this
bias towards positive results or relying on the validity of previous results. Many of
the existing methods (for which sparse methodological information is available) are
machine learning procedures which may be misrepresented if they were to be imple-
mented poorly. Some of these methods are subject to patent applications and can not
be accessed to test on simulated data.
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The investigation into BiSEp also demonstrated that implementing scientific soft-
ware from other research groups is not a trivial exercise, even when released as an
open-source R package. Therefore, the above results were used to evaluate SLIPT
and compare it to other statistical rationales. A comprehensive comparison to other
synthetic lethal detection approaches or further benchmarking is left to an impartial
researcher to evaluate. Nevertheless, the SLIPT methodology was shown to be able to
detect synthetic lethal genes in simulated data with comparable or better performance
than a range of distinct statistical techniques and was appropriate for use throughout
this thesis. SLIPT has been documented and released as an R package to enable further
use and comparison with other methods.
6.4.3 Design and Performance of SLIPT
The simulation procedure using sampling from a multivariate normal distribution was
used throughout the simulation investigations in this thesis. This approach has the
advantages of emulating the continuous normalised expression data used for gene ex-
pression analysis and enabled the simulation of correlation structures (as discussed in
Section 3.3). These simulations scaled to datasets of comparable size to those used
in gene expression analysis, with thousands of genes. The SLIPT methodology was
shown to perform robustly, across large numbers of genes and simple correlation struc-
tures. This included high specificity against genes positively correlated with the query
gene, for which the directional SLIPT methodology was more suited to distinguishing
synthetic lethal genes than the χ2 test without directional criteria on the number of
samples observed.
The SLIPT and the χ2 test , approaches using threshold-based discrete gene func-
tion, were compared across different quantiles to the Pearson correlation without loss
of the continuous expression data. The 1/3-quantiles for SLIPT (as described in Sec-
tion 3.1) were optimal for both SLIPT and the χ2 alone, being optimal for the signifi-
cance of synthetic lethal interactions and for the directional criteria of SLIPT (since this
method outperformed the χ2 test and was the most different at the 1/3-quantile). This
difference was more pronounced with positively correlated genes (with the query gene),
for which the specificity of SLIPT improved, and was replicated in large datasets with
thousands of genes. These results were not simply due to sufficient samples for signifi-
cant p-values, since the AUROC analysis was independent from significance thresholds.
This indicated that the SLIPT methodology (as it has been used in Chapters 4 and 5)
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was optimal, with the 1/3-quantile having the highest performance, and that the pa-
rameters used to design it were appropriate.
Both discrete functional approaches (SLIPT and χ2) were able to outperform nega-
tive correlation, which addressed the concern that arbitrary thresholds of low and high
gene function (as used by SLIPT) may lose useful data by compressing the spectrum of
gene expression into categorical data. However, this does not impede the performance
of SLIPT if the quantiles used are optimal. The poorer performance of correlation-
based detection of synthetic lethality was consistent with gene function for synthetic
lethality being qualitative, that is expression must be sufficient for cell viability and
higher expression is not necessary for function (as this is not the case for all genes).
Furthermore, the finding that negative correlation outperforms positive correlation
was also consistent with co-expression being a poor predictor of synthetic lethality
compared to other approaches (Jerby-Arnon et al., 2014), supporting the claims of Lu
et al. (2015). Compared with SLIPT correlation approaches were not as suitable for de-
tecting synthetic lethality in expression data. The correlation-based approaches made
assumptions about the relationship between gene expression and function which do not
necessarily hold for all genes. A linear model or regression approach may also be used
to detect synthetic lethality from relationships between expression of genes, which may
be improved with conditioning on known synthetic lethal partners with multivariate
regression or Bayesian priors. Similarly, synthetic lethal detection could be performed
by iteratively conditioning upon the strong candidate from previous analysis. These
approaches may be able to better circumvent the issues of high-order synthetic lethality
and multiple testing.
Nevertheless, the above findings were sufficient to assess the performance of SLIPT
and present an effective straightforward approach to synthetic lethal detection in gene
expression data. Further development with linear models, Bayesian inference ap-
proaches, or comparison to existing synthetic lethal approaches (e.g., machine learning)
remain as future directions. Developing and testing more sophisticated statistical ap-
proaches to synthetic lethal detection may benefit from findings for the relatively sim-
ple SLIPT methodology. Similarly, further comparisons and benchmarking of SLIPT
against other computational approaches to synthetic lethal detection in gene expression
data is more suitable for an independent researcher and the slipt R package has been
released (as described in Section 3.5) for this purpose, in addition to further application
in research.
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6.4.4 Simulations from Graph structures
The simple correlation structures (as used in Section 3.3) were expanded upon using
the multivariate normal simulation procedure to produce correlation structures based
on graph structures (as described in Section 6.2). These simulations enabled further
investigations into the performance of SLIPT in the context of more complex correlation
structures. The simulation of expression from network structures is widely applicable
to simulating pathway expression data and as such the graphsim R package has been
released (as described in Section 3.5).
These investigations show that SLIPT performs robustly across datasets with dif-
ferent correlation structures, including those derived from graphs with the complexity
of biological pathways. The SLIPT methodology was able to detect synthetic lethal
genes within synthetic lethal pathways across many graph structures. This method-
ology performed particularly well with synthetic lethal pathways in the context of a
larger dataset with a high specificity, which supports SLIPT as a stringent approach to
synthetic lethal detection in highly dimensional gene expression data. Together these
results support the use of SLIPT in biological gene expression data, since it was able
to detect synthetic lethal genes in highly complex correlation structures.
Similarly, the inclusion of inhibitory relationships in graph structures was shown
to increase the performance in simple networks, supporting SLIPT being applicable
to biological data in which these relationships are common. While these results were
not replicated in more complex inhibitory graph structures, this is likely an artifact
of the simulation procedure (which randomly selects combinations of synthetic lethal
genes). When the simulations with a synthetic lethal gene were examined in more
detail, the test statistics of the synthetic lethal gene were consistently higher and
distinguishable from nearby genes in the graph structure. These differences were more
pronounced with genes which had inhibitory relationships with synthetic lethal genes.
While distinguishable from nearby genes in a pathway structure, the genes correlated
with synthetic lethal partners had higher test statistics than more distant genes (similar
to observations with correlated genes in Section 3.3).
In addition to being able to detect synthetic lethal genes in a pathway, the proximal
genes in a pathway were most likely to be false positives and therefore SLIPT is also
able to detect synthetic lethal pathways. SLIPT identifies genes which are likely to be
constituent of a synthetic lethal pathway and is more likely to rank underlying synthetic
lethal genes with greater significance. Together these findings support the use of SLIPT
throughout this thesis, further application of SLIPT, and further development of such
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strategies for synthetic lethal detection. Similarly, the simulation procedures developed
and demonstrated for examining synthetic lethal detection in expression data using
graph structures is amenable to further development. Investigations into pathway
structure in expression data, such as predicting biological pathways from expression
data or on the impact of pathways on differential expression analyses, could also be
conducted with simulated data.
6.5 Summary
A statistical model and simulation procedure has been developed to test the perfor-
mance of the SLIPT methodology in controlled conditions, using multivariate normal
distributions. This simulation procedure has been developed into a computational
pipeline which was able to test the statistical performance (using stringent assump-
tions) of SLIPT across many parameters and compare it to alternative synthetic lethal
detection strategies. The SLIPT methodology performed well at detecting small num-
bers of synthetic lethal genes in simple systems. It did not perform as well in more
complex systems but neither did alternative strategies. The SLIPT methodology per-
formed well compared to Pearson correlation and the χ2 test. Thus SLIPT is an
effective detection method for synthetic lethal relationships in expression data despite
its relatively simple design.
Simulations of more complex datasets were performed, including large numbers of
genes, complex correlation structure derived from graph structures, and correlations
with the query gene. SLIPT performed robustly across these, including correlation
structures based on complex biological pathways. The performance of SLIPT improved
in larger datasets, datasets with positive correlations with the query genes, and some
graph structures which included inhibiting relationships, namely those datasets that
were more representative of gene expression in biological data. SLIPT was both capa-
ble of recurrently detecting genes within a synthetic lethal pathway and distinguishing
synthetic lethal genes from those correlated with them, even in highly complex correla-
tion structures. Therefore SLIPT is a stringent synthetic lethal detection strategy and
is applicable to gene expression as previously demonstrated for the partners of CDH1




This thesis combines analysis of gene expression data from TCGA with experimental
screening results (Telford et al., 2015) to demonstrate synthetic lethal discovery for
partners of CDH1. Together these findings further elucidate known and novel func-
tions of CDH1 in the cell, functional redundancy in cancer, and represent potential
therapeutic targets against loss of CDH1 function. Synthetic lethal candidate genes
were further investigated for relationships within synthetic lethal pathways, and in the
process a network-based approach to compare gene sets was developed.
The SLIPT synthetic lethal detection methodology was applied to gene expression
data throughout this thesis and was evaluated with simulated data. A procedure was
developed to stringently generate gene expression data from known synthetic lethal
partners in simulated data. These simulations included simple and complex correla-
tion structures, and modelling synthetic lethal genes within pathways. Together, these
results demonstrate SLIPT as a robust widely applicable gene expression analysis pro-
cedure for discovery of synthetic lethal partner genes (for which an R package has been
made available). The performance of SLIPT on simulated data also highlights the
strengths and limitations of the procedure.
7.1 Synthetic Lethality and CDH1 Biology
The CDH1 tumour suppressor gene was the focus to demonstrate the novel SLIPT
methodology for identifying synthetic lethal partners. This gene is important in spo-
radic breast and stomach cancers, in addition to familial syndromes, such as HDGC.
The analysis of synthetic lethal partners of CDH1 in breast and stomach cancers was
enabled by the availability of molecular data (Bass et al., 2014; Koboldt et al., 2012)
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and a synthetic lethal screen conducted in MCF10A breast cells (Chen et al., 2014;
Telford et al., 2015).
Synthetic lethal interactions arise due to functional redundancy (Boone et al., 2007;
Fece de la Cruz et al., 2015; Kaelin, Jr, 2005) and so the synthetic lethal partners
of CDH1 indicate the wide-ranging biological functions that E-cadherin is involved
in. The diverse synthetic lethal pathways identified support the known pleiotropic
nature of the CDH1 gene (Kroepil et al., 2012), across established functions of CDH1,
candidates from an experimental screen (Telford et al., 2015), and novel interactions
identified for further investigation. The highly pleiotropic functions of E-cadherin was
also consistent with CDH1 being a tumour suppressor gene.
7.1.1 Established Functions of CDH1
CDH1 has established functions in cell-cell communication and maintaining the cy-
toskeleton, specifically with cell-cell adhesion by forming tight junctions and the ad-
herens complex (Jeanes et al., 2008). More recently, functions of CDH1 in the extracel-
lular matrix and fibrin clotting have also been identified (Cardiff et al., 2011; Tunggal
et al., 2005; Wojtukiewicz et al., 2016). Synthetic lethal interactions within the same
biological pathway were expected (Boone et al., 2007; Kelley and Ideker, 2005). Syn-
thetic lethal interactions identified in these pathways are consistent with the known
functions of CDH1, which are also potentially actionable targets against cancers.
7.1.2 The Molecular Role of CDH1 in Cancer
The involvement of CDH1 in the extracellular matrix is important in cancers as it indi-
cates that CDH1 loss may affect the tumour microenvironment, contributing to its role
as a tumour and invasion suppressor. Furthermore, perturbations in the extracellular
matrix and tumour microenvironment present a means by which to specifically inhibit
(cancerous) CDH1 -deficient cells, in addition to those identified by siRNA screening
(Telford et al., 2015). These may be further supported in further investigations with
3D cell culture, “organoid”, or mouse xenograft cancer models.
Many of the pathways involved in cell signalling, including GPCRs, were identified
by SLIPT in addition to the experimental screen, supporting findings in cell line models
(Telford et al., 2015). These pathways are essential to the growth of CDH1 -deficient
cancers and present a potential vulnerability specific to these (cancerous) cells. Fur-
thermore, the replication of synthetic lethality of CDH1 with cell signalling pathways
in TCGA data, across cancer types and genetic backgrounds, robustly supports these
pathways being clinically applicable beyond the genetic background of the model sys-
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tem of CDH1 -/- MCF10A cells (Chen et al., 2014). While specific synthetic lethal
genes were not consistently detected between the SLIPT analyses and siRNA screen
(Telford et al., 2015), they were sufficient to identify synthetic lethal pathways for fur-
ther experimental investigation, which are more likely to be replicated between genetic
backgrounds (Dixon et al., 2008). Together these results demonstrate that computa-
tional methods, such as SLIPT, could be integrated with an experimental screen to
triage potential therapeutic targets for further pre-clinical investigation.
The analysis of expression data with SLIPT is also indicative of biological mech-
anisms of synthetic lethality in pathways beyond those identified in screening experi-
ments (Telford et al., 2015). In particular, translation and regulatory pathways, involv-
ing 3′ UTRs and NMD, were candidate synthetic lethal pathways with CDH1 identified
by SLIPT. These pathways represent downstream targets, regulated by the putative
synthetic lethal signalling pathways, which cancer cells are dependent on to proliferate
and evade host defense processes, such as apoptosis and immune responses (Gao and
Roux, 2015).
It is possible that either the SLIPT methodology or the siRNA screen (Telford
et al., 2015) are biased towards detecting particular pathways. In particular, the pri-
mary siRNA screen (conducted in a cell line model) detected a considerable number of
kinase signalling pathways. The SLIPT methodology could similarly be biased towards
pathways regulating or involved in translation. The pathways detected by both ap-
proaches (as verified by resampling analysis) with distinct limitations are therefore the
strongest candidate synthetic lethal pathways of CDH1. It is still necessary to perform
further experimental validation of the candidate genes and pathways identified by both
of these approaches. Nevertheless, SLIPT is a useful triage utility to identify synthetic
lethal genes and was shown to be effective at predicting genes that would be validated
in the secondary siRNA screen (Telford et al., 2015) and simulation results (presented
in Section 3.3 and Chapter 6).
7.2 Significance
7.2.1 Synthetic Lethality in the Genomic Era
An effective synthetic lethal discovery tool for bioinformatic analysis could have a wide
range of applications in genetics research, including functional genomics, medical and
agricultural applications. The SLIPT approach demonstrated in this thesis is widely
applicable to other genes, cell types, and biological research questions. In addition to
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further query of cancer genes, synthetic lethal gene functions also have implications for
genetic redundancy. Highly redundant genes, and the genetically robust systems they
give rise to, are also relevant to evolutionary, developmental, and systems biology to
understand how these change over time and play a fundamental role in fundamental
development (Boone et al., 2007; Nowak et al., 1997; Tischler et al., 2008).
Developmental genes in particular, are highly evolutionarily conserved and subject
to high rates of redundancy (Fromental-Ramain et al., 1996; Kockel et al., 1997; Nowak
et al., 1997). These genes are often difficult to study with conventional functional ge-
netics techniques since individual knockouts of redundant genes may not have a mutant
phenotype. Identifying genes with a common function is therefore also important to
characterise developmental genes. Synthetic lethal discovery methods, such as SLIPT,
represent a genomic approach to further systematic characterisation of gene function
including highly redundant developmental genes.
Variants of unknown significance and modifier loci are a major concerns in human
genetics, including “monogenic” and “rare” diseases. Many of these variants could be
difficult to characterise individually due to synthetic lethal interactions, where addi-
tional loci contribute to the disease (or only compensate for some variants). Systematic
identification of synthetic lethal interactions therefore also has applications in the study
of these “oligogenic” diseases. There could also be similar applications in the study of
heritability for traits including agricultural genomic selection.
Polypharmacology and network medicine are rationales that account for genetic
redundancy by using drugs with multiple (known and specific) targets (Barabási et al.,
2011; Hopkins, 2008). Further characterisation of synthetic lethal genes could asist
with the design of effective multi-target drugs or combination therapies in a range
of therapeutic applications, including molecular targeted therapies against cancer for
which combination therapies may alleviate acquired resistance against individual tar-
geted therapies. Characterisation of genetic interactions and combination therapies
also has the potential to expand pharmacogenomic investigations. Synthetic lethality
may elucidate the impact of genotypes at multiple loci, which lead to adverse effects
due to variants in synthetic lethal genes.
Redundant functions and synthetic lethal interactions also present a means to ex-
pand upon the concept of the “minimal” genome (Hutchison et al., 2016). It is impor-
tant to account for essential gene functions that are performed by redundant genes (or
in combination with pleiotropic genes), rather than simply those that are perturbed
208
by individual genes. An essential gene approach therefore is likely to produce an un-
derestimate that does not account for synthetic lethal interactions.
Synthetic lethal interactions are fundamentally important throughout genetics.
Further understanding of them in a genomic context, facilitated by methods such as
SLIPT, would contribute towards deeper understanding of gene functions and their
role in traits or diseases in the post-genomic era. Genes do not function in isolation
and understanding them in the context of the complexity of a cell and across genetic
backgrounds is essential to further characterise their functions and ensure that findings
can be validated or applied beyond experimental systems.
7.2.2 Clinical Interventions based on Synthetic Lethality
Synthetic lethal discovery with SLIPT is of particular relevance to cancer for the dis-
covery of synthetic lethal drug targets. The cancer research community relies on cell
line and mouse models for screening and validation experiments (Fece de la Cruz et al.,
2015) which would benefit from integration with gene expression analysis, as demon-
strated for CDH1 and the screen conducted by Telford et al. (2015). Synthetic lethal
drug design against cancer mutations, including gene loss or over-expression, could lead
to a revolution in cancer therapy and chemoprevention. These therapeutics would en-
able personalised treatment for cancer patients and high risk individuals. The synthetic
lethal strategy for cancer treatment has been shown to be clinically effective (Bryant
et al., 2005; Farmer et al., 2005; McLachlan et al., 2016). Many large-scale RNAi
screens have been conducted recently, aiming to discover gene function and drug tar-
gets for similar application with other cancer genes, including cancers in other tissues
(Fece de la Cruz et al., 2015).
While SLIPT analysis and RNAi screens represent a significant step towards anti-
cancer medicines, further validation is required to ensure that the synthetic lethal
candidate genes and pathways identified for CDH1 in breast and stomach cancer are
applicable against CDH1 -deficient cancers in the clinic. Validation with RNAi or phar-
macological inhibitors is needed because false positives may occur in SLIPT analysis
or siRNA screens. These candidates still need to be tested in pre-clinical models (cell
lines and mouse xenografts) before proceeding to clinical trials. A therapeutic inter-
vention will also require a targeted therapeutic to be developed or repurposed against
a synthetic lethal partner. Drug targets could be triaged from synthetic lethal genes
by functions known to be amenable to drugs, having protein structures with conserved
specific sites that are not homologous to other genes, or those with existing drugs.
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Both structure-aided drug design and compound screening are viable ways to target
synthetic lethal partners.
Targeted therapeutics designed based on synthetic lethal interactions could expand
the applications of “precision medicine” against molecular targets. Synthetic lethality
expands the range of cancer genes which can be (indirectly) targeted to include tumour
suppressor genes with loss of function, such as CDH1. Oncogenes with disrupted func-
tions that are over-expressed or highly homologous to non-cancerous proto-oncogenes,
such as MYC, EGFR or KRAS, may also be targeted by synthetic lethality. Appli-
cations against tumour suppressor genes is particularly important, as these cannot be
approached by careful dosing. Synthetic lethal drug design has the benefit of being
highly specific against a particular genotype (e.g., CDH1-/-) with the potential for tar-
geted therapies with a wide therapeutic index and few adverse effects, in contrast to
many cancer treatment regimens (Hopkins, 2008; Kaelin, Jr, 2009). These proper-
ties are highly desirable for chemoprevention applications, such as treatment against
CDH1 -deficient in HDGC patients (Guilford et al., 2010), as an alternative to moni-
toring or surgery.
7.3 Future Directions
While further validation and pre-clinical testing is required to translate the findings
for CDH1 to cancer therapy or prevention, there are also further avenues for research
into the detection of synthetic lethality in gene expression and other genomics data.
The SLIPT methodology is amenable to wider application against a range of genes for
which loss of function is deleterious, including other cancer genes in breast cancer or
other tissues. Synthetic lethal interactions are functionally informative, particularly for
mode-of-action of known drug targets, and are also relevant for identifying functions
of newly characterised genes in genomics studies and designing specific interventions
against cells with loss of function in cancer and other diseases. Thus synthetic lethal
detection using SLIPT in expression data could be further used for many other genes,
including others relevant to human health and disease.
These investigations do not need to be limited to expression data. While expression
as a measure of gene function has been the focus of this thesis, other genomics data
could be used for a similar purpose for SLIPT analysis. These include DNA copy num-
ber, DNA methylation, histone activation, mutation status, protein abundance, and
protein activation state. In particular, DNA copy number and mutations have been
demonstrated by other approaches to synthetic lethal analysis (Jerby-Arnon et al.,
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2014; Lu et al., 2015; Srihari et al., 2015; Wappett et al., 2016), although some of these
have not been released for wider application. This approach lends itself to any molec-
ular data that can be partitioned in to lowly and highly active states such as deletion
and ampliflications for DNA copy number or hypermethylation and hypomethylation
for DNA methylation.
For some applications or genes, these molecular profiles may be more informative
of gene function and synthetic lethal relationships. However, expression was the focus
of the investigations thus far as a widely accepted measure of gene function which has
widely available genomics data. SLIPT is compatible with each of these data types (if
the thresholds are selected appropriately) and may perform better for some applications
with these molecular profiles or a weighted combination of these. As demonstrated,
SLIPT is also suitable for future investigations with pathway metagenes and other
summary data as well.
It may also be possible to improve the performance of SLIPT with refinements to the
statistical or computational approach. This thesis has focused on rational query-based
approach which computes relatively quickly in R (R Core Team, 2016), and is relatively
intuitive to interpret. These computations are compatible with parallel computing and
the computational resources may be further reduced by using a different computing
language. The slipt R package has been documented and released as open-source
software (as described in Section 3.5) to facilitate further development, wider adoption,
or comparison with other scientific software for similar purposes.
Alternative methods may also improve on the statistical performance of SLIPT.
In particular, the sensitivity was generally an issue with higher numbers of synthetic
lethal partners in simulated data. While approaches using continuous data such as
Pearson correlation and linear regression did not perform as well as SLIPT, they could
be improved. A least squares regression approach in particular, enables multiple mea-
sures of relationships such as the coefficients of the fitted curve and significance of the
fit (computed from the residuals). A linear modelling approach using regression is also
amenable to refinement such as extending from fitting a linear relationship to a polyno-
mial or logistic regression. Another benefit to fitting linear models is that these would
enable the conditioning of known synthetic lethal partners to identify subtle signatures
of further interacting partners.
This approach could also be applied iteratively on the strongest candidates from
previous synthetic lethal analyses in further rounds of prediction conditioned upon
them. Similarly, synthetic lethal prediction could also be approached with a Bayesian
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framework (Friedman et al., 2000; Imoto et al., 2004; Jansen et al., 2003) which is also
amenable to Bayesian priors on known or previously predicted synthetic lethal partners.
Either of these approaches has the potential to improve upon the synthetic lethal pre-
dictions which have been demonstrated as possible and biologically relevant by SLIPT.
Another approach to overcome the issue for loss of information from categorisation of
expression data to estimate gene function would be to estimate the underlying hidden
state with a likelihood model instead. The model of synthetic lethality (in Section 3.2.1)
would serve as a good foundation for this approach.
Using another data types, such as DNA methylation, may provide another per-
spective on synthetic lethal candidates from molecular profiles but this wealth of in-
formation becomes difficult to interpret stringently as DAISY has been critiqued for
(Lu et al., 2015). These analysis could be combined to improve the results of the
SLIPT approach: either by using a combination of molecular data to estimate gene
function and partition samples or to perform SLIPT separately for each and weight the
results. These are likely to be subject to diminishing returns for additional computa-
tions required. For instance, DNA methylation influences gene expression and may not
add much information about gene function if expression is already known. However,
a weighting of these results could improve the accuracy of the SLIPT procedure. In
particular, a combination of SLIPT results for different molecular data across different
partitioning thresholds could be optimised with a machine learning approach.
7.4 Conclusions
Synthetic lethal interactions are important for understanding gene function and the
development of highly specific targeted cancer treatments. In particular, synthetic
lethality could expand the repertoire of applications for precision cancer medicine by
indirectly targeting loss of function in tumour suppressor genes. Synthetic lethal dis-
covery with experimental screening is error-prone and limited by the model systems in
which it is performed. Thus there is a need for a bioinformatics tool to predict synthetic
lethal interactions from gene expression data, which would facilitate the rapid iden-
tification of synthetic lethal candidates, and augment functional genetic screens and
triage of cancer drug targets. This thesis develops the Synthetic Lethal Interaction
Prediction Tool (SLIPT) methodology as a statistically robust procedure to perform
this analysis.
The SLIPT methodology has been demonstrated to identify biologically relevant
genes and pathways. A comprehensive analysis of synthetic lethal partners of the
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CDH1 gene was performed in TCGA breast cancer data (Koboldt et al., 2012), with
many of these findings replicated in stomach cancer data (Bass et al., 2014). These
genes clustered into several distinct groups, with distinct biological functions and el-
evated expression in different clinical subtypes. These analyses identified synthetic
lethal candidates in the Gαi signalling, cytoplasmic microfibres, and extracellular fib-
rin clotting pathways. These pathways were supported by an siRNA screen performed
by Telford et al. (2015) and were consistent with the known cytoskeletal and cell sig-
nalling roles of E-cadherin. SLIPT also identified synthetic lethal partners in novel
pathways for CDH1, including the regulation of immune signalling and translational
elongation, which extend the range of established functions of CDH1 and present fur-
ther biological mechanisms that can be investigated to exploit the vulnerabilities of
CDH1 -deficient cancers.
While some of these pathways are not expected to be detected in an isolated exper-
imental cell line model, pathway structure may have accounted for this disparity. Thus
synthetic lethal candidates detected by SLIPT and siRNA were compared within graph
structures of the candidate synthetic lethal pathways. However, this did not generally
account for differences between these approaches. Neither synthetic lethal detection
methodology preferentially detected genes of more importance or connectivity in path-
way structures using established network metrics, nor could it be generally established
that SLIPT gene candidates were upstream or downstream of siRNA gene candidates
in pathway structures across biological pathways. However, it could be shown that
SLIPT genes had lower centrality and were upstream of siRNA candidates, specifically
in the Gαi signalling pathway.
Pathway graph structures were also included in investigations with simulated data
to ascertain whether the SLIPT procedure performed well in data with complex cor-
relation structures derived based on biological pathways. A simulation procedure was
developed based on a statistical model of synthetic lethality which generates multi-
variate normal data with known synthetic lethal partners and correlation structures.
The SLIPT methodology performed well at detecting synthetic lethality in simulated
expression data, particularly when detecting few known synthetic lethal genes, with
large sample sizes, and a background of many non-synthetic lethal genes to distinguish
true partners from. This method had high specificity, performed better than Pearson
correlation or the χ2-test, and had optimal performance across simulation parameter
combinations for the thresholds used throughout this thesis. These findings were robust
across correlation structures, including those derived from complex pathway structures
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containing strong positive and negative correlations between genes. Together, these
findings support the release of the SLIPT software R packages and the application
of the method to identify synthetic lethal genes within pathways and use candidate
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Figure A.1: Pathway overlap between the Reactome pathways. Matrix heatmap
(Euclidean distance) of pathways in the Reactome dataset against each other for their overlap
with each other as proportions of each pathway (on a blue–red scale). The 1050 pathways
consisting of 10–500 genes that were used for over-representation and permutation analysis
were compared. The majority of pathways do not overlap but some do considerably.
239
A.2 Sample Correlation
Figure A.2: Correlation analysis and sample removal. Correlation matrix heatmap
(Euclidean distance) of all samples in TCGA breast cancer dataset against each other an-
notated for sample clinical data: sample type, tissue type, tumour stage, ER and intrinsic
subtype (from the PAM50 method). CDH1 somatic mutation, gene expression, and status
for SLIPT prediction were also annotated. Discrete variables were coloured as displayed in
the legend and continuous variables on a blue–red scale as shown in the colour key. Trimmed
samples cluster at the bottom of the heatmap and the colour bars of the left show which were
removed for quality concerns.
240
Figure A.3: Correlation profiles of removed samples. Heatmap (Euclidean distance)
of samples in TCGA breast cancer dataset (left) clustered for all samples against removed
samples (top): tissue source site (TSS), sample type with reds for tumour and greens for
normal, patient (A2QH in pink), with varied analyte and plate. Excluded samples clustered
at the bottom and annotation (left) show shared properties between samples in the dataset.
241
A.3 Replicate Samples in TCGA Breast Cancer Data
Replicate samples were picked where possible from the TCGA breast cancer gene ex-
pression data to examine for sample quality. Independent samples of the same tumour
were expected to have very high Pearson correlation between their expression profiles
unless there were issues with sample collection or preparation and were thus an indica-
tor of sample quality. The log-transformed raw read counts for replicate samples were
examined in Figures A.4–A.6. These were examined before normalisation which would
be expected to increase sample concordance.
Another consideration was the samples which were removed for quality concerns
(in Section 2.2.2). While these were selected by unbiased hierarchical clustering (See
Figure A.2), many of the excluded (tumour) samples were performed in replicate despite
relatively few replicate samples in the overall dataset. These samples correlate poorly
































































































































































































































































































































































































































































































































































































































































































Figure A.4: Replicate excluded samples. Both tumour samples of patient A2QH were
excluded as they were poorly correlated with other samples, although they were highly similar

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A.5: Replicate samples with all remaining. Patient A26J was sampled 3 times
and compared pairwise. Pairs of samples were also compared for other patients with replicate
samples. In all cases, replicate samples remaining in the dataset were highly concordant, as























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(i) Compare with excluded


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(n) Compare with excluded
Figure A.6: Replicate samples with some excluded. Patients A0DB, A13D, A13E, and
A26E were each sampled 3 times and compared pairwise. Pairs of samples were also compared
for other patients with replicate samples. In all cases, the replicate samples remaining in the
dataset more were highly concordant than those excluded from the analysis, as shown by




Software Used for Thesis
Table B.1: Computers used during thesis















Linux Kernel 3.19.0-65-generic 4.4.0-36-generic 3.10.0-327.36.2.el7.x86 64 2.6.32-504.16.2.el6.x86 64
Shell: Bash 4.3.11(1) 4.3.46(1) 4.2.46(1) 4.2.1(1)
Shell: zsh 5.0.2 5.1.1 5.0.2 5.2
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Table B.2: Linux utilities and applications used during thesis










Linux Kernel 3.19.0-65-generic 4.4.0-36-generic 3.10.0-327.36.2.el7.x86 64 2.6.32-504.16.2.el6.x86 64
Scripting Shell Bash 4.3.11(1) 4.3.46(1) 4.2.46(1) 4.2.1(1)
Shell zsh 5.0.2 5.1.1 5.0.2 5.2
Programming Python 2.7.6 2.7.12 2.7.5
Java 1.8.0 101 9-ea 1.8.0 101
C++ 4.8.4 5.4.0 4.8.5 4.4.7
Text Editor nano 2.2.6 2.5.3 2.3.1 2.0.9
kile (LATEX) 2.1.3 2.1.3
Version Control git 1.9.1 2.11.0 1.7.1 1.8.3.1
Shell Utilities sed 4.4.2 4.4.2 4.4.2 4.4.1
grep 2.16-1 2.25-1 2.20 2.6.3
nohup 8.21 8.25 8.22 8.4
Typesetting TEX 3.1415926 3.14159265
TexLive (LATEX) 2013 2015
PDFTEX 2.5-1 2.6
pandoc 1.12.2.1 1.16.0.2
Remote Computing Slurm scheduler 16.05.6
OpenSSH 7.2p2 7.2p2 6.6.1 5.3p1
OpenSSL 1.0.2g 1.0.2g 1.0.01e-fips 1.0.01e-fips
rsync 3.1.0p31 3.1.1p31 3.0.9p30
Globus Online Transfer 3.1 3.1
Cisco AnyConnect VPN 3.1.05170
Image Processing Inkscape 0.48.4 0.91
GIMP 2.8.10 2.8.16
ImageMagick 6.7.7.10-6
Table B.3: Complete list of R packages used during this thesis
Package Repository Laptop Lab Server NeSI
base base 3.3.2 3.3.2 3.3.1 3.3.0
abind CRAN 1.4-5 1.4-3
acepack CRAN 1.4.1 1.3-3.3
ade4 CRAN 1.7-5
annaffy Bioconductor 1.46.0
AnnotationDbi Bioconductor 1.36.0 1.36.0 1.34.4
apComplex CRAN 2.40.0
ape CRAN 4 3.4
arm CRAN 1.9-3
assertthat CRAN 0.1 0.1 0.1 0.1
backports CRAN 1.0.5 1.0.4 1.0.5 1.0.2
base64 CRAN 2 2
base64enc CRAN 0.1-3 0.1-3
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beanplot CRAN 1.2 1.2 1.2
BH CRAN 1.60.0-2 1.62.0-1 1.62.0-1 1.60.0-2
Biobase Bioconductor 2.34.0 2.34.0 2.32.0
BiocGenerics Bioconductor 0.20.0 0.20.0 0.18.0
BiocInstaller Bioconductor 1.24.0 1.20.3 1.22.3
BiocParallel Bioconductor 1.8.1 1.8.1
Biostrings Bioconductor 2.42.1 2.42.0
BiSEp Bioconductor 2.0.1 2.0.1 2.0.1
bitops CRAN 1.0-6 1.0-6 1.0-6 1.0-6
boot base 1.3-18 1.3-18 1.3-18 1.3-18
brew CRAN 1.0-6 1.0-6 1.0-6 1.0-6
broom CRAN 0.4.1
caTools CRAN 1.17.1 1.17.1 1.17.1 1.17.1
cgdsr CRAN 1.2.5
checkmate CRAN 1.8.2 1.7.4
chron CRAN 2.3-47 2.3-48 2.3-50 2.3-47
class base 7.3-14 7.3-14 7.3-14 7.3-14
cluster base 2.0.5 2.0.5 2.0.5 2.0.4
coda CRAN 0.19-1 0.18-1
codetools base 0.2-15 0.2-15 0.2-15 0.2-14
colorRamps CRAN 2.3
colorspace CRAN 1.2-6 1.3-2 1.3-2 1.2-6
commonmark CRAN 1.1 1.2
compiler base 3.3.2 3.3.2 3.3.1 3.3.0
corpcor CRAN 1.6.8 1.6.8 1.6.8
Cprob CRAN 1.2.4
crayon CRAN 1.3.2 1.3.2 1.3.2 1.3.2
crop CRAN 0.0-2 0.0-2
curl CRAN 1.2 2.3 2.3 0.9.7
d3Network CRAN 0.5.2.1
data.table CRAN 1.9.6 1.10.0 1.10.1 1.9.6
data.tree CRAN 0.7.0 0.7.0
datasets base 3.3.2 3.3.2 3.3.1 3.3.0
DBI CRAN 0.5-1 0.5-1 0.5-1 0.5-1
dendextend CRAN 1.4.0 1.4.0 1.4.0
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DEoptimR CRAN 1.0-8 1.0-8 1.0-8 1.0-4
desc CRAN 1.1.0 1.1.0
devtools CRAN 1.12.0 1.12.0 1.12.0 1.12.0
DiagrammeR CRAN 0.9.0 0.9.0
dichromat CRAN 2.0-0 2.0-0 2.0-0 2.0-0
digest CRAN 0.6.10 0.6.11 0.6.12 0.6.9
diptest CRAN 0.75-7 0.75-7 0.75-7
doParallel CRAN 1.0.10 1.0.10 1.0.10 1.0.10
dplyr CRAN 0.5.0 0.5.0 0.5.0 0.5.0
ellipse CRAN 0.3-8 0.3-8 0.3-8
evaluate CRAN 0.1 0.1 0.9
fdrtool CRAN 1.2.15
fields CRAN 8.1
flexmix CRAN 2.3-13 2.3-13 2.3-13
forcats CRAN 0.2.0
foreach CRAN 1.4.3 1.4.3 1.4.3 1.4.3
foreign base 0.8-67 0.8-67 0.8-67 0.8-66
formatR CRAN 1.4 1.4 1.4
Formula CRAN 1.2-1 1.2-1
fpc CRAN 2.1-10 2.1-10 2.1-10
futile.logger CRAN 1.4.3 1.4.3 1.4.1
futile.options CRAN 1.0.0 1.0.0 1.0.0
gdata CRAN 2.17.0 2.17.0 2.17.0 2.17.0
geepack CRAN 1.2-1
GenomeInfoDb Bioconductor 1.10.2 1.10.1
GenomicAlignments Bioconductor 1.10.0 1.10.0
GenomicRanges Bioconductor 1.26.2 1.26.1
ggm CRAN 2.3
ggplot2 CRAN 2.1.0 2.2.1 2.2.1 2.1.0
git2r CRAN 0.15.0 0.18.0 0.16.0 0.15.0
glasso CRAN 1.8
GO.db Bioconductor 3.4.0 3.2.2 3.3.0
GOSemSim Bioconductor 2.0.3 1.28.2 1.30.3
gplots CRAN 3.0.1 3.0.1 3.0.1 3.0.1
graph Bioconductor 1.52.0
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0.1.0 0.1.0 0.1.0 0.1.0
grDevices base 3.3.2 3.3.2 3.3.1 3.3.0
grid base 3.3.2 3.3.2 3.3.1 3.3.0
gridBase CRAN 0.4-7 0.4-7 0.4-7 0.4-7
gridExtra CRAN 2.2.1 2.2.1 2.2.1 2.2.1
gridGraphics CRAN 0.1-5
gtable CRAN 0.2.0 0.2.0 0.2.0 0.2.0





0.0.0.9000 0.0.0.9000 0.0.0.9000 0.0.0.9000
hgu133plus2.db Bioconductor 3.2.3
highr CRAN 0.6 0.6 0.6
Hmisc CRAN 4.0-2 4.0-2 3.17-4
hms CRAN 0.2 0.3
htmlTable CRAN 1.8 1.9
htmltools CRAN 0.3.5 0.3.5 0.3.5 0.3.5
htmlwidgets CRAN 0.8 0.8
httpuv CRAN 1.3.3 1.3.3
httr CRAN 1.2.1 1.2.1 1.2.1 1.1.0
huge CRAN 1.2.7
hunspell CRAN 2.3 2
hypergraph CRAN 1.46.0




0.1.0.9001 0.1.0.9001 0.1.0.9001 0.1.0.9001




0.1.0 0.1.0 0.1.0 0.1.0
IRanges Bioconductor 2.8.1 2.8.1 2.6.1
irlba CRAN 2.1.1 2.1.2 2.1.2 2.0.0
iterators CRAN 1.0.8 1.0.8 1.0.8 1.0.8
jpeg CRAN 0.1-8
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jsonlite CRAN 1.1 1.2 1.3 0.9.20
KEGG.db Bioconductor 3.2.3
kernlab CRAN 0.9-25 0.9-25 0.9-25
KernSmooth base 2.23-15 2.23-15 2.23-15 2.23-15
knitr CRAN 1.15.1 1.15.1 1.14
labeling CRAN 0.3 0.3 0.3 0.3
lambda.r CRAN 1.1.9 1.1.9 1.1.7
lattice base 0.20-34 0.20-34 0.20-34 0.20-33
latticeExtra CRAN 0.6-28 0.6-28
lava CRAN 1.4.6
lavaan CRAN 0.5-22
lazyeval CRAN 0.2.0 0.2.0 0.2.0 0.2.0
les CRAN 1.24.0
lgtdl CRAN 1.1.3
limma Bioconductor 3.30.7 3.30.3
lme4 CRAN 1.1-12 1.1-12
lubridate CRAN 1.6.0
magrittr CRAN 1.5 1.5 1.5 1.5
maps CRAN 3.1.1
markdown CRAN 0.7.7 0.7.7 0.7.7
MASS base 7.3-45 7.3-45 7.3-45 7.3-45
Matrix base 1.2-7.1 1.2-7.1 1.2-8 1.2-6
matrixcalc CRAN 1.0-3 1.0-3 1.0-3 1.0-3
mclust CRAN 5.2 5.2.1 5.2.2 5.2
memoise CRAN 1.0.0 1.0.0 1.0.0 1.0.0
methods base 3.3.2 3.3.2 3.3.1 3.3.0
mgcv base 1.8-16 1.8-16 1.8-17 1.8-12
mi CRAN 1
mime CRAN 0.5 0.5 0.5 0.4
minqa CRAN 1.2.4 1.2.4
mnormt CRAN 1.5-5 1.5-5 1.5-4
modelr CRAN 0.1.0
modeltools CRAN 0.2-21 0.2-21 0.2-21
multtest Bioconductor 2.30.0 2.30.0
munsell CRAN 0.4.3 0.4.3 0.4.3 0.4.3
252
mvtnorm CRAN 1.0-5 1.0-5 1.0-6 1.0-5
network CRAN 1.13.0
nlme base 3.1-128 3.1-128 3.1-131 3.1-128
nloptr CRAN 1.0.4 1.0.4
NMF CRAN 0.20.6 0.20.6 0.20.6 0.20.6
nnet base 7.3-12 7.3-12 7.3-12 7.3-12
numDeriv CRAN 2016.8-1 2014.2-1
openssl CRAN 0.9.4 0.9.6 0.9.6 0.9.4
org.Hs.eg.db Bioconductor 3.1.2 3.3.0
org.Sc.sgd.db Bioconductor 3.4.0





0.1.0 0.1.0 0.1.0 0.1.0
pbivnorm CRAN 0.6.0
PGSEA Bioconductor 1.48.0
pkgmaker CRAN 0.22 0.22 0.22 0.22
PKI CRAN 0.1-3




0.0.0.9001 0.0.0.9001 0.0.0.9001 0.0.0.9001
plotrix CRAN 3.6-4
plyr CRAN 1.8.4 1.8.4 1.8.4 1.8.3
png CRAN 0.1-7 0.1-7
prabclus CRAN 2.2-6 2.2-6 2.2-6
praise CRAN 1.0.0 1.0.0 1.0.0





psych CRAN 1.6.12 1.6.12
purrr CRAN 0.2.2 0.2.2 0.2.2 0.2.2
qgraph CRAN 1.4.1
quadprog CRAN 1.5-5 1.5-5 1.5-5
R.methodsS3 CRAN 1.7.1 1.7.1
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R.oo CRAN 1.21.0 1.20.0
R.utils CRAN 2.5.0
R6 CRAN 2.1.3 2.2.0 2.2.0 2.1.3
RBGL CRAN 1.50.0
RColorBrewer CRAN 1.1-2 1.1-2 1.1-2 1.1-2
Rcpp CRAN 0.12.7 0.12.9 0.12.9 0.12.7
RcppArmadillo CRAN 0.7.700.0.0 0.6.700.6.0
RcppEigen CRAN 0.3.2.9.0 0.3.2.8.1
RCurl CRAN 1.95-4.8 1.95-4.8 1.95-4.8





readr CRAN 1.0.0 1.0.0
readxl CRAN 0.1.1
registry CRAN 0.3 0.3 0.3 0.3
reshape2 CRAN 1.4.1 1.4.2 1.4.2 1.4.1
rgexf CRAN 0.15.3 0.15.3




rmarkdown CRAN 1.3 1.3 1
Rmpi CRAN 0.6-6 0.6-5
rngtools CRAN 1.2.4 1.2.4 1.2.4 1.2.4
robustbase CRAN 0.92-7 0.92-7 0.92-7 0.92-5
ROCR CRAN 1.0-7 1.0-7 1.0-7 1.0-7
Rook CRAN 1.1-1 1.1-1
roxygen2 CRAN 6.0.1 5.0.1 6.0.1 5.0.1
rpart base 4.1-10 4.1-10 4.1-10 4.1-10
rprojroot CRAN 1.2 1.1 1.2
Rsamtools Bioconductor 1.26.1 1.26.1
rsconnect CRAN 0.7
RSQLite CRAN 1.1-2 1.1-2 1.0.0
rstudioapi CRAN 0.6 0.6 0.6 0.6
rvest CRAN 0.3.2
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S4Vectors Bioconductor 0.12.1 0.12.0 0.10.3
safe Bioconductor 3.14.0 3.10.0
scales CRAN 0.4.0 0.4.1 0.4.1 0.4.0
selectr CRAN 0.3-1
sem CRAN 3.1-8




0.1.0 0.1.0 0.1.0 0.1.0
sm CRAN 2.2-5.4 2.2-5.4
sna CRAN 2.4
snow CRAN 0.4-1 0.4-2 0.4-2 0.3-13
sourcetools CRAN 0.1.5 0.1.5
SparseM CRAN 1.74 1.7
spatial base 7.3-11 7.3-11 7.3-11 7.3-11
splines base 3.3.2 3.3.2 3.3.1 3.3.0
statnet.common CRAN 3.3.0
stats base 3.3.2 3.3.2 3.3.1 3.3.0
stats4 base 3.3.2 3.3.2 3.3.1 3.3.0
stringi CRAN 1.1.1 1.1.2 1.1.2 1.0-1




survival base 2.39-4 2.40-1 2.40-1 2.39-4
tcltk base 3.3.2 3.3.2 3.3.1 3.3.0
testthat CRAN 1.0.2 1.0.2 1.0.2
tibble CRAN 1.2 1.2 1.2 1.2






tools base 3.3.2 3.3.2 3.3.1 3.3.0
tpr CRAN 0.3-1
trimcluster CRAN 0.1-2 0.1-2 0.1-2
Unicode CRAN 9.0.0-1 9.0.0-1 9.0.0-1







viridis CRAN 0.3.4 0.3.4 0.3.4
visNetwork CRAN 1.0.3 1.0.3
whisker CRAN 0.3-2 0.3-2 0.3-2 0.3-2
withr CRAN 1.0.2 1.0.2 1.0.2 1.0.2
XML base 3.98-1.3 3.98-1.1 3.98-1.5 3.98-1.4
xml2 CRAN 1.1.1 1.1.1 1.0.0
xtable CRAN 1.8-2 1.8-2 1.8-2 1.8-2
XVector Bioconductor 0.14.0 0.14.0
yaml CRAN 2.1.14 2.1.14 2.1.13
zlibbioc CRAN 1.20.0 1.20.0
zoo CRAN 1.7-13 1.7-14 1.7-13
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Appendix C
Mutation Analysis in Breast Cancer
C.1 Synthetic Lethal Genes and Pathways
SLIPT expression analysis (described in Section 3.1) on TCGA breast cancer data
(n = 969) found the following genes and pathways, described in Sections 4.1 and 4.1.1.
Table C.1: Pathways for CDH1 partners from mtSLIPT
Pathways Over-represented Pathway Size SL Genes p-value (FDR)
Eukaryotic Translation Elongation 86 60 2.0× 10−128
Peptide chain elongation 83 59 2.0× 10−128
Eukaryotic Translation Termination 83 58 2.3× 10−125
Viral mRNA Translation 81 57 2.5× 10−124
Nonsense Mediated Decay independent of the Exon Junction Complex 88 59 8.6× 10−124
Nonsense-Mediated Decay 103 61 5.2× 10−117
Nonsense Mediated Decay enhanced by the Exon Junction Complex 103 61 5.2× 10−117
Formation of a pool of free 40S subunits 93 58 1.6× 10−116
L13a-mediated translational silencing of Ceruloplasmin expression 103 59 1.3× 10−111
3’ -UTR-mediated translational regulation 103 59 1.3× 10−111
GTP hydrolysis and joining of the 60S ribosomal subunit 104 59 6.2× 10−111
SRP-dependent cotranslational protein targeting to membrane 104 58 2.9× 10−108
Eukaryotic Translation Initiation 111 59 3.0× 10−106
Cap-dependent Translation Initiation 111 59 3.0× 10−106
Influenza Viral RNA Transcription and Replication 108 57 5.1× 10−103
Influenza Infection 117 59 1.5× 10−102
Translation 141 64 3.7× 10−101
Influenza Life Cycle 112 57 1.4× 10−100
GPCR downstream signalling 472 116 1.0× 10−80
Hemostasis 422 105 1.4× 10−78
The most significant pathways from gene set over-representation analysis (hypergeometric test) for Reactome pathways in
mtSLIPT partners for CDH1.
The genes and pathways identified in Tables 4.2 and C.1 were derived from com-
paring the expression profiles of potential partners to the mutation status of CDH1
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(as shown in Figure 3.2). The following analysis was limited to the samples for which
both expression and somatic mutation data were available from TCGA.
C.2 Synthetic Lethal Expression Profiles
Similar to the analysis of synthetic lethal partners against low CDH1 expression in
Section 4.1.2, the partners detected from CDH1 mutation were also examined for
their expression profiles and the pathway composition of gene clusters. Hierachical
clustering was performed on mtSLIPT partners for CDH1 as shown in Figure C.1.
Over-representation for Reactome pathways for each of the gene clusters identified is
given in Table C.2.
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Figure C.1: Synthetic lethal expression profiles of analysed samples. Gene expres-
sion profile heatmap (correlation distance) of all samples (separated by CDH1 somatic mu-
tation status) analysed in TCGA breast cancer dataset for gene expression of 3743 candidate
partners of E-cadherin (CDH1 ) from mtSLIPT prediction (with significant FDR adjusted
p < 0.05). Deeply clustered, inter-correlated genes form several main groups, each containing
genes that were SL candidates or toxic in an siRNA screen Telford et al. (2015). Clusters
had different sample groups highly expressing the synthetic lethal candidates in CDH1 mu-
tant samples and often lowly expressing CDH1wild-type samples (which were not tested
for), although many of the CDH1 mutant samples had among the lowest CDH1 expression.
In contrast to the expression analysis the (predominantly CDH1wild-type) basal subtype
and ER negative samples have depleted expression among most candidate synthetic lethal
partners.
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Table C.2: Pathways for clusters of CDH1 partners from mtSLIPT
Pathways Over-represented in Cluster 1 Pathway Size Cluster Genes p-value (FDR)
Olfactory Signalling Pathway 57 8 7.1× 10−9
Assembly of the primary cilium 149 14 8.0× 10−9
Sphingolipid metabolism 62 8 9.6× 10−9
Signalling by ERBB4 133 12 5.1× 10−8
PI3K Cascade 65 7 4.9× 10−7
Circadian Clock 33 5 4.9× 10−7
Nuclear signalling by ERBB4 34 5 4.9× 10−7
Intraflagellar transport 35 5 4.9× 10−7
PI3K events in ERBB4 signalling 87 8 4.9× 10−7
PIP3 activates AKT signalling 87 8 4.9× 10−7
PI3K events in ERBB2 signalling 87 8 4.9× 10−7
PI-3K cascade:FGFR1 87 8 4.9× 10−7
PI-3K cascade:FGFR2 87 8 4.9× 10−7
PI-3K cascade:FGFR3 87 8 4.9× 10−7
PI-3K cascade:FGFR4 87 8 4.9× 10−7
Deadenylation of mRNA 22 4 5.6× 10−7
PI3K/AKT activation 90 8 5.6× 10−7
Cargo trafficking to the periciliary membrane 38 5 5.6× 10−7
Pathways Over-represented in Cluster 2 Pathway Size Cluster Genes p-value (FDR)
Gαs signalling events 83 19 5.1× 10−25
Extracellular matrix organization 238 30 1.4× 10−18
Hemostasis 422 46 2.7× 10−16
Aquaporin-mediated transport 32 9 2.7× 10−16
Transcriptional regulation of white adipocyte differentiation 56 11 1.7× 10−15
Degradation of the extracellular matrix 102 15 1.7× 10−15
Integration of energy metabolism 84 13 8.8× 10−15
GPCR downstream signalling 472 48 2.8× 10−14
Gαz signalling events 15 6 5.0× 10−14
Molecules associated with elastic fibres 33 8 5.4× 10−14
Phase 1 - Functionalization of compounds 67 11 5.6× 10−14
Platelet activation, signalling and aggregation 179 20 5.6× 10−14
Vasopressin regulates renal water homeostasis via Aquaporins 24 7 6.1× 10−14
Elastic fibre formation 37 8 .03× 10−13
Calmodulin induced events 27 7 3.3× 10−13
CaM pathway 27 7 3.3× 10−13
cGMP effects 18 6 3.6× 10−13
Gαi signalling events 167 18 6.3× 10−13
Pathway over-representation analysis for Reactome pathways with the number of genes in each pathway (Pathway Size), number
of genes within the pathway identified (Cluster Genes), and the pathway over-representation p-value (adjusted by FDR) from the
hypergeometric test.
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Table C.2: Pathways for clusters of CDH1 partners from mtSLIPT
Pathways Over-represented in Cluster 3 Pathway Size Cluster Genes p-value (FDR)
Eukaryotic Translation Elongation 86 55 1.1× 10−112
Peptide chain elongation 83 54 1.3× 10−112
Viral mRNA Translation 81 53 1.6× 10−111
Eukaryotic Translation Termination 83 53 7.1× 10−110
Nonsense Mediated Decay independent of the Exon Junction Complex 88 54 1.0× 10−108
Formation of a pool of free 40S subunits 93 53 4.1× 10−102
Nonsense-Mediated Decay 103 54 3.9× 10−98
Nonsense Mediated Decay enhanced by the Exon Junction Complex 103 54 3.9× 10−98
L13a-mediated translational silencing of Ceruloplasmin expression 103 53 1.2× 10−95
3’ -UTR-mediated translational regulation 103 53 1.2× 10−95
SRP-dependent cotranslational protein targeting to membrane 104 53 4.3× 10−95
GTP hydrolysis and joining of the 60S ribosomal subunit 104 53 4.3× 10−95
Influenza Viral RNA Transcription and Replication 108 53 9.6× 10−93
Eukaryotic Translation Initiation 111 53 4.2× 10−91
Cap-dependent Translation Initiation 111 53 4.2× 10−91
Influenza Life Cycle 112 53 1.4× 10−90
Influenza Infection 117 53 6.2× 10−88
Translation 141 55 3.0× 10−81
Pathways Over-represented in Cluster 4 Pathway Size Cluster Genes p-value (FDR)
ECM proteoglycans 66 10 2.9× 10−11
deactivation of the beta-catenin transactivating complex 38 7 5.1× 10−10
Arachidonic acid metabolism 41 7 1.1× 10−9
Gαq signalling events 149 14 4.0× 10−9
HS-GAG degradation 21 5 4.5× 10−9
Uptake and actions of bacterial toxins 22 5 6.1× 10−9
Gastrin-CREB signalling pathway via PKC and MAPK 170 15 6.1× 10−9
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription ll 64 8 6.1× 10−9
Non-integrin membrane-ECM interactions 53 7 1.5× 10−8
Syndecan interactions 25 5 1.5× 10−8
NOTCH1 Intracellular Domain Regulates Transcription 40 6 2.3× 10−8
Synthesis of Leukotrienes and Eoxins 15 4 3.2× 10−8
Signalling by NOTCH1 59 7 5.3× 10−8
Regulation of insulin secretion 44 6 6.0× 10−8
Metabolism of lipids and lipoproteins 471 37 8.2× 10−8
Signalling by NOTCH 80 8 1.2× 10−7
Platelet activation, signalling and aggregation 179 14 1.2× 10−7
Recruitment of mitotic centrosome proteins and complexes 64 7 1.2× 10−7
Pathway over-representation analysis for Reactome pathways with the number of genes in each pathway (Pathway Size), number of genes within
the pathway identified (Cluster Genes), and the pathway over-representation p-value (adjusted by FDR) from the hypergeometric test.
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C.3 Comparison to Primary Screen
The mutation synthetic lethal partners with CDH1 were also compared to siRNA
primary screen data (Telford et al., 2015), as performed in Section 4.2.1. These were
expected to be more concordant with the experimental results performed on a null
mutant, however this was not the case at the gene level: less genes overlapped with
experimental candidates in Figure C.2. This discrepancy was may be due to lower
sample size for mutations in TCGA data or lower frequency (expected value) of CDH1
mutations compared to low expression.
Figure C.2: Comparison of mtSLIPT to siRNA. Testing the overlap of gene candidates
for E-cadherin synthetic lethal partners between computational (SLIPT) and experimental
screening (siRNA) approaches. The χ2 test suggests that the overlap is no more than would
be expected by chance (p = 0.281).
Despite a lower sample size (and low number of a predicted partners) for mutation
analysis, the pathway composition (Tables C.1 and C.3) was similar to expression analy-
sis, as described in Section 4.2.5. In particular, the resampling analysis (Section C.3.1)
supported many of the results of expression analysis (Section 4.2.5.1). Tables C.4
and 4.10 detected many of the same or functionally-related pathways.
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Table C.3: Pathways for CDH1 partners from mtSLIPT and siRNA
Predicted only by SLIPT (2901 genes) Pathway Size Genes Identified p-value (FDR)
Eukaryotic Translation Elongation 87 57 2.8× 10−120
Peptide chain elongation 84 56 3.1× 10−120
Eukaryotic Translation Termination 84 55 2.8× 10−117
Viral mRNA Translation 82 54 4.1× 10−116
Nonsense Mediated Decay independent of the Exon Junction Complex 89 55 3.7× 10−113
Formation of a pool of free 40S subunits 94 55 2.8× 10−109
Nonsense-Mediated Decay 104 57 8.4× 10−108
Nonsense Mediated Decay enhanced by the Exon Junction Complex 104 57 8.4× 10−108
L13a-mediated translational silencing of Ceruloplasmin expression 104 56 3.4× 10−105
3’ -UTR-mediated translational regulation 104 56 3.4× 10−105
GTP hydrolysis and joining of the 60S ribosomal subunit 105 56 1.4× 10−104
Eukaryotic Translation Initiation 112 56 2.8× 10−100
Cap-dependent Translation Initiation 112 56 2.8× 10−100
SRP-dependent cotranslational protein targeting to membrane 105 54 2.2× 10−99
Influenza Viral RNA Transcription and Replication 109 54 5.3× 10−97
Influenza Life Cycle 113 54 9.6× 10−95
Influenza Infection 118 55 1.7× 10−94
Translation 142 60 3.5× 10−94
Infectious disease 349 77 5.9× 10−62
Extracellular matrix organization 241 54 3.0× 10−52
Detected only by siRNA screen (1752 genes) Pathway Size Genes Identified p-value (FDR)
Class A/1 (Rhodopsin-like receptors) 282 69 1.9× 10−59
GPCR ligand binding 363 78 2.7× 10−54
Peptide ligand-binding receptors 175 41 1.5× 10−42
Gαi signalling events 184 41 1.1× 10−40
Gastrin-CREB signalling pathway via PKC and MAPK 180 37 1.5× 10−35
Gαq signalling events 159 34 3.7× 10−35
DAP12 interactions 159 27 1.1× 10−24
VEGFA-VEGFR2 Pathway 91 19 1.0× 10−23
Downstream signal transduction 146 24 1.9× 10−22
Signalling by VEGF 99 19 2.6× 10−22
DAP12 signalling 149 24 4.2× 10−22
Organelle biogenesis and maintenance 264 34 4.3× 10−20
Downstream signalling of activated FGFR1 134 21 4.3× 10−20
Downstream signalling of activated FGFR2 134 21 4.3× 10−20
Downstream signalling of activated FGFR3 134 21 4.3× 10−20
Downstream signalling of activated FGFR4 134 21 4.3× 10−20
Signalling by ERBB2 146 22 5.3× 10−20
Signalling by FGFR 146 22 5.3× 10−20
Signalling by FGFR1 146 22 5.3× 10−20
Signalling by FGFR2 146 22 5.3× 10−20
Intersection of SLIPT and siRNA screen (450 genes) Pathway Size Genes Identified p-value (FDR)
HS-GAG degradation 21 4 4.9× 10−6
Retinoid metabolism and transport 39 5 4.9× 10−6
Platelet activation, signalling and aggregation 186 13 4.9× 10−6
Signalling by NOTCH4 11 3 4.9× 10−6
Gαs signalling events 100 8 5.0× 10−6
Defective EXT2 causes exostoses 2 12 3 5.0× 10−6
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 12 3 5.0× 10−6
Class A/1 (Rhodopsin-like receptors) 289 18 2.2× 10−5
Signalling by PDGF 173 11 2.9× 10−5
Circadian Clock 34 4 2.9× 10−5
Signalling by ERBB4 139 9 4.3× 10−5
Role of LAT2/NTAL/LAB on calcium mobilization 99 7 4.4× 10−5
Peptide ligand-binding receptors 181 11 4.5× 10−5
Defective B4GALT7 causes EDS, progeroid type 19 3 4.5× 10−5
Defective B3GAT3 causes JDSSDHD 19 3 4.5× 10−5
Signalling by NOTCH 80 6 4.5× 10−5
Gαq signalling events 164 10 5.1× 10−5
Response to elevated platelet cytosolic Ca2+ 84 6 7.1× 10−5
Signalling by ERBB2 148 9 7.1× 10−5
Signalling by SCF-KIT 129 8 8.3× 10−5
263
C.3.1 Resampling Analysis
Table C.4: Pathways for CDH1 partners from mtSLIPT
Reactome Pathway Over-representation Permutation
Eukaryotic Translation Elongation 3.2× 10−128 < 7.035× 10−4
Peptide chain elongation 3.2× 10−128 < 7.035× 10−4
Eukaryotic Translation Termination 3.7× 10−125 < 7.035× 10−4
Viral mRNA Translation 4.1× 10−124 < 7.035× 10−4
Nonsense Mediated Decay independent of the Exon Junction Complex 1.4× 10−123 < 7.035× 10−4
Nonsense-Mediated Decay 8.4× 10−117 < 7.035× 10−4
Nonsense Mediated Decay enhanced by the Exon Junction Complex 8.4× 10−117 < 7.035× 10−4
Formation of a pool of free 40S subunits 2.6× 10−116 < 7.035× 10−4
L13a-mediated translational silencing of Ceruloplasmin expression 2.0× 10−111 < 7.035× 10−4
3’ -UTR-mediated translational regulation 2.0× 10−111 < 7.035× 10−4
GTP hydrolysis and joining of the 60S ribosomal subunit 9.9× 10−111 < 7.035× 10−4
SRP-dependent cotranslational protein targeting to membrane 4.7× 10−108 < 7.035× 10−4
Eukaryotic Translation Initiation 4.8× 10−106 < 7.035× 10−4
Cap-dependent Translation Initiation 4.8× 10−106 < 7.035× 10−4
Influenza Viral RNA Transcription and Replication 8.1× 10−103 < 7.035× 10−4
Influenza Infection 2.4× 10−102 < 7.035× 10−4
Translation 6.0× 10−101 < 7.035× 10−4
Influenza Life Cycle 2.2× 10−100 < 7.035× 10−4
Disease 2.1× 10−90 0.013347
GPCR downstream signalling 1.6× 10−80 0.095478
Hemostasis 2.1× 10−78 0.2671
Signalling by GPCR 1.2× 10−73 0.44939
Extracellular matrix organization 2.2× 10−67 0.054008
Metabolism of proteins 1.4× 10−66 0.9607
Signal Transduction 2.1× 10−66 0.48184
Developmental Biology 2.5× 10−66 0.54075
Innate Immune System 5.3× 10−66 0.9589
Infectious disease 9.6× 10−66 0.21075
Signalling by NGF 1.1× 10−62 0.43356
Immune System 2.8× 10−62 0.23052
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR).
Significant pathways were marked in bold (FDR < 0.05) and italics (FDR < 0.1).
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C.4 Compare SLIPT genes
The mutation synthetic lethal partners with CDH1 were also compared to siRNA pri-
mary screen data (Telford et al., 2015), by correlation and siRNA viability as described
in Sections 4.2.2 and 4.2.3.
Figure C.3: Compare mtSLIPT and siRNA genes with correlation. The mtSLIPT p-
values were compared against Pearson correlation of expression with CDH1. Genes detected
















siRNA− SLIPT− siRNA+ SLIPT− siRNA− SLIPT+ siRNA+ SLIPT+












Figure C.4: Compare mtSLIPT and siRNA genes with correlation. Genes detected
by mtSLIPT against CDH1 mutation and siRNA screening were compared against Pearson






























Figure C.5: Compare mtSLIPT and siRNA genes with siRNA viability. Genes de-
tected as candidate synthetic lethal partners by mtSLIPT (in TCGA breast cancer) expression
analysis against CDH1 mutation and experimental screening (with siRNA) were compared
against the viability ratio of CDH1 mutant andwild-type cells in the primary siRNA screen.
There were clear no differences in viability between genes detected by mtSLIPT and those
not with the differences being primarily due to viability thresholds that were used to detect




Well characterised gene signatures from previous publications in breast cancer (Gatza
et al., 2011, 2014) were used to demonstrate to utility of the metagene approach for use
on a wider range of pathways as was performed with the Reactome (Croft et al., 2014)
pathways as an alternative approach to identification of synthetic lethal pathways. The
direction of metagenes is arbitrary but they have been corrected to ensure the metagene
increases in a direction which reflects overall activation of the pathways (as described in
Section 2.2.3) which was verfied by examining in the pathway signatures in breast can-
cer. Metagenes were derived for these pathways signatures (Gatza et al., 2011, 2014),
which were expected to have particular molecular properties in clinical and molecular
subtypes (Parker et al., 2009; Perou et al., 2000). This was performed by examining
the pathways expression of breast cancer gene signatures in TCGA expression data.
These gene signatures were used to establish that metagenes generated with this
procedure reflect gene activity. The same metagene procedure (in Section 2.2.3) was
applied to the Reactome pathways (Croft et al., 2014). These Reactome metagenes
were used for synthetic lethal analysis of pathways with SLIPT, directly using pathways
activity for identifying synthetic lethal pathways with CDH1.
D.1 Pathway Signature Expression
Pathway metagenes (generated as described in Section 2.2.3) for gene signatures of
key processes in breast cancer (Gatza et al., 2011) were used to check that metagenes
were generated in the correct direction to indicate pathways activation. Some of these
gene signatures are plotted in Figure D.1 for comparison with clinical factors and
somatic mutations. The “intrinsic subtypes” was computed by performing the PAM50
procedure Parker et al. (2009) for RNA-Seq data which was highly concordant (χ2 =
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1305.9, p = 2.73 × 10−268) with the subtypes provided by University of California,
Santa Cruz (UCSC) (UCSC, 2012) for TCGA samples (Koboldt et al., 2012) previously
analysed by microarrays (as shown in Appendix E). Somatic mutations were reported
for glslinkrecurrent mutationrecurrently mutated genes in breast cancer, as reported
by TCGA (Koboldt et al., 2012), related genes, and those previously discussed to be
important in hereditary breast cancers (BRCA1, BRCA2, and CDH1 ).
These gene signatures reflect intrinsic subtypes as expected. In particular, the
estrogen and progesterone receptor signatures are low in the predominantly ER− and
Progesterone receptor (PR)− basal-like subtype tumours. These tumours also had the
highest frequency of TP53 mutations and a corresponding reduction of p53 metagene
activity, as expected for loss of a tumour suppressor. The luminal A and luminal B
tumour subtypes are the most similar, which is reflected in these metagenes signatures,
although they are distinguishable molecular subtypes as shown by elevated PI3K, AKT,
RAS, and β-catenin signalling in luminal B tumours. However, these pathways were
also elevated in basal-like and HER2-enriched subtypes and lowly expressed in the
“normal-like” subtype (which contained the normal samples).
The direction of each metagene was consistent with the clinical characteristics,
which formed a consensus of gene activity as shown for the PI3K and ER signatures
(Gatza et al., 2011) in Figure D.2. The expression of the majority of the genes were
highly concordant with the metagene, being either positively or negatively correlated.
These were generally consistent with established clinical and molecular subtypes of
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Somatic Mutation (Gene 1)
Somatic Mutation (Gene 2)
Somatic Mutation (Gene 3)
Somatic Mutation (Gene 1 Silent)
Somatic Mutation (Gene 2 Silent)
Somatic Mutation (Gene 3 Silent)
Somatic Mutation (Gene 1 and 2)
CDH1 Low
CDH1 High
Figure D.1: Pathway metagene expression profiles. Expression profiles for metagene
signatures from Gatza et al. (2011) in TCGA breast data, annotated for clinical factors
(with sample types and histological results coloured according to the legend) and cancer
gene mutations (Negative values for mutation are light grey with missing data in white).
Intrinsic subtypes are shown as derived from microarray (UCSC) and RNA-Seq (PAM50)
data (Koboldt et al., 2012; Parker et al., 2009). Samples were clustered independently for
each intrinsic subtypes and by CDH1 expression status. Pathway expression signatures are
consistent with mutations and clinical subgroups.
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Figure D.2: Expression profiles for estrogen receptor related genes. Expression profiles the genes
contained in the estrogen receptor (ER) gene signature from Gatza et al. (2011) in TCGA breast data,
annotated for clinical factors and cancer gene mutations. Samples are separated by CDH1 expression status
and sorted by the metagene. In both cases, the majority of genes were consistent with the direction of the
metagene, with very few exceptions being inversely correlated. Estrogen receptor (by antibody staining)
negative samples had low metagene expression, as expected. These were more likely to be ductal and basal
subtypes, lacking CDH1 or PIK3CA mutations.
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D.2 Synthetic Lethal Reactome Metagenes
Metagene analysis was performed for synthetic lethal pathways against CDH1 muta-
tion. These were described and compared to expression analysis in Section 4.3.
Table D.1: Candidate synthetic lethal metagenes against CDH1 from mtSLIPT
Pathway ID Observed Expected χ2value p-value p-value (FDR)
Neurotoxicity of clostridium toxins 168799 8 36.7 79.4 5.71× 10−18 3.14× 10−15
Aquaporin-mediated transport 445717 8 36.7 76.3 2.73× 10−17 9.01× 10−15
Toxicity of botulinum toxin type G (BoNT/G) 5250989 8 36.7 76.3 2.73× 10−17 9.01× 10−15
ABC-family proteins mediated transport 382556 10 36.7 68.2 1.58× 10−15 1.86× 10−13
Gαz signalling events 418597 10 36.7 59.9 9.97× 10−14 5.48× 10−12
Regulation of IGF transport and uptake by IGFBPs 381426 9 36.7 56.3 5.88× 10−13 2.11× 10−11
GP1b-IX-V activation signalling 430116 8 36.7 55.7 8.20× 10−13 2.76× 10−11
GABA receptor activation 977443 12 36.7 55.1 1.07× 10−12 3.26× 10−11
Vasopressin regulates renal water homeostasis via Aquaporins 432040 9 36.7 54.1 1.77× 10−12 4.88× 10−11
Toxicity of botulinum toxin type D (BoNT/D) 5250955 14 36.7 53.4 2.54× 10−12 6.64× 10−11
Toxicity of botulinum toxin type F (BoNT/F) 5250981 14 36.7 53.4 2.54× 10−12 6.64× 10−11
STAT6-mediated induction of chemokines 3249367 16 36.7 52.2 4.72× 10−12 1.13× 10−10
Toxicity of botulinum toxin type B (BoNT/B) 5250958 14 36.7 50.8 9.5× 10−12 1.98× 10−10
S6K1 signalling 165720 12 36.7 50.2 1.24× 10−11 2.5× 10−10
Gαs signalling events 418555 11 36.7 49.2 2.08× 10−11 3.85× 10−10
RHO GTPases activate CIT 5625900 14 36.7 48.2 3.34× 10−11 5.9× 10−10
NADE modulates death signalling 205025 15 36.7 47.4 5.00× 10−11 8.32× 10−10
Keratan sulfate degradation 2022857 10 36.7 46.6 7.5× 10−11 1.15× 10−9
Signalling by Retinoic Acid 5362517 10 36.7 46.6 7.5× 10−11 1.15× 10−9
Adenylate cyclase inhibitory pathway 170670 14 36.7 45.9 1.11× 10−10 1.59× 10−9
Inhibition of adenylate cyclase pathway 997269 14 36.7 45.9 1.11× 10−10 1.59× 10−9
Fatty acids 211935 6 36.7 45.7 1.21× 10−10 1.72× 10−9
Ionotropic activity of Kainate Receptors 451306 13 36.7 44.6 2.03× 10−10 2.58× 10−9
Activation of Ca-permeable Kainate Receptor 451308 13 36.7 44.6 2.03× 10−10 2.58× 10−9
RA biosynthesis pathway 5365859 13 36.7 44.6 2.03× 10−10 2.58× 10−9
Strongest candidate synthetic lethal partners for CDH1 by mtSLIPT with observed and expected numbers of mutant CDH1 TCGA breast





The intrinsic subtypes for TCGA breast cancer samples provided by UCSC (Koboldt
et al., 2012; UCSC, 2012) that were derived from microarray analysis have been com-
pared to the PAM50 results for performing subtyping from RNA-Seq data (Parker et al.,
2009). As shown in Table E.1, these subtypes were highly concordant for samples which
had both procedures performed upon them (χ2 = 1305.9, p = 2.73×10−268). The main
exception were the luminal A samples some of which were reclassified as luminal B or
“normal-like”.
Table E.1: Comparison of intrinsic subtypes
UCSC Subtype
Basal-like HER2-enriched Luminal A Luminal B Normal-like
100 58 232 128 30
PAM50 Subtype
Basal-like HER2-enriched Luminal A Luminal B Normal-like
208 94 314 334 227
UCSC Subtype
PAM50 Subtype Basal-like HER2-enriched Luminal A Luminal B Normal-like
Basal-like 96 4 2 2 1
HER2-enriched 0 47 5 3 0
Luminal A 1 0 141 1 0
Luminal B 2 7 49 121 0
Normal-like 1 0 35 1 29
The intrinsic subtypes of TCGA breast samples were compared between those provided by
UCSC (Koboldt et al., 2012) from microarray expression to those derived from RNA-Seq
data (Parker et al., 2009). Comparisons between these were limited to samples for which
both data types were available.
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The PAM50 subtypes could be more accurate given similarity of these subtypes and
that the remainder of the subtypes were accurately recapitulated with RNA-Seq data.
Furthermore, UCSC subtypes correctly identified 22/22 normal samples as “normal-like”
and PAM50 subtyping in RNA-Seq data had a success rate of 112/113 (including all of
those identified from microarrays). Therefore the PAM50 subtypes (performed on a
larger cohort of samples) are appropriate to use for further interpretation, superseding
the UCSC subtypes available for a limited set of samples.
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Appendix F
Synthetic Lethal Genes in Pathways
Table F.1: Synthetic lethal candidate genes in the PI3K cascade
Predicted only by SLIPT
CAMK2B CAMK2D CUX1 FGF10 FGF23 FGF9
FGFR1OP2 FGFR2 FRS2 FYN GNG10 HSP90AA1
IRS2 KITLG KLRK1 MLST8 MOV10 PIK3CB
PIP4K2B SRC SYK ZMYM2 FOXO4 ABI2
INPP5J INPPL1 LAT PLCG1 PLCG2 WASF2
EPHB1 EPHB4 GNA11 GNAI3 INPP5B INPP5E
PLCH2 TRIO
Detected only by siRNA screen
AGO4 AKT1 AKT2 CALM1 CAMK4 CD19
CD247 CD86 CDC37 DVL3 ERBB4 EREG
FGF19 FGF1 FGF3 GAB1 GNB1 GNB5
GNG11 GNG5 GUSB IRS1 KDR KLRC2
LAT2 NRG1 PDGFRB PHLPP2 PIK3R5 PIK3R6
PIP5K1A PIP5K1C PRKACG PTEN PTPN11 RPS6KA6
TNRC6A TNRC6B TNRC6C TRIM24 TYROBP CDKN1B
CHUK NR4A1 RPS6KB2 BRK1 RAC1 TEC
WASF1 WASF3 CD79B EFNB1 EPHB3 EPHB6
GNAI1 GNAO1 NTN1 PLCB4 PLCD4 SH3KBP1
SYNJ1 WASL
Intersection of SLIPT and siRNA screen
B2M FCGR1A FGFR1 GNB3 GNB4 PIP2
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RPS6KA2 CREB1 INPP5K VAV2 VAV3 SYNJ2
Not detected by SLIPT or siRNA screen
AGO1 AGO2 AGO3 AGO4 BCR BTC
CALM3 CAMK2A CAMK2B CAMK2G CD3G CD80
CNTRL CPSF6 CUX1 DVL3 EGF ERBB2
ERBB4 FGF10 FGF16 FGF19 FGF1 FGF22
FGF23 FGF3 FGF4 FGF5 FGF6 FGFR1
FGFR1OP2 FGFR1OP FGFR2 FGFR4 FRS2 GAB1
GNB1 GNB2 GNB4 GNB5 GNG10 GNG13
GNG3 GNG4 GNGT1 GRB2 GUSB HSP90AA1
NULL KDR KITLG KLB KLRC2 LCK
MAPKAPK2 MOV10 MTOR NRG3 NRG4 PDGFA
PDGFB PDGFRB PDPK1 PHLPP1 PIK3CB PIK3R2
PIK3R3 PIP2 PIP3 PIP4K2B PIP5K1C PIP5KL1
PRKACB PRKACG PTEN PTPN11 RICTOR RPS6KA1
RPS6KA2 RPS6KA5 RPS6KA6 SOS1 SRC TNRC6A
TNRC6B TRIB3 TRIM24 VEGFA CASP9 CDKN1A
CDKN1B CHUK FOXO3 GSK3A MDM2 RPS6KB2
TSC2 ABI1 ABI2 BAIAP2 BRK1 CYFIP2
INPP5A INPP5J INPPL1 TEC VAV2 VAV3
WASF1 WASF3 BLNK CBLB CBL CDC42
DCC DOCK1 EFNB2 EFNB3 EZR GNA11
GNA14 GNAI3 GNAO1 GNAQ GNAT2 GNAZ
ITSN1 OCRL PIK3C3 PLCB1 PLCB3 PLCB4
PLCD4 PLCH1 PLCH2 PLCZ1 SDC4 SYNJ2
SYNJ2 TIRAP TRIO WASL WAS
Table F.2: Synthetic lethal candidate genes in the PI3K/AKT pathway
Predicted only by SLIPT
AKT1 B2M CALM1 CALM2 CAMK4 ERBB3
EREG FCGR3A FGF20 FGFR3 IRS1 KL
LRRFIP1 MLST8 MYO18A NRG1 PHLPP2 PIK3CA
PIK3CG PIP5K1A TNRC6C ZMYM2 CREB1 GSK3B
NCKAP1 PLCG1 RAC1 EPHB4 GNAT1 PIK3R4
PTK2
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Detected only by siRNA screen
AKT2 AKT3 CAMK2D CD19 CD247 CD28
CD86 DVL1 DVL2 EGFR FCGR1A FCGR2A
FGF17 FGF18 FGF2 FGF7 FGF8 FYN
GAB2 GNB3 GNG11 GNG12 GNG7 GNG8
GNGT2 HBEGF KIT KLRD1 KLRK1 LAT2
MAPKAP1 NGF NRG2 NTRK1 PDGFRA PIK3AP1
PIK3CD PIK3R1 PIK3R5 PIK3R6 PIP4K2A PIP5K1B
PRKACA RPS6KA3 SH2D2A SHC1 SYK THEM4
TRAT1 TYROBP AKT1S1 BAD FOXO1 FOXO4
BTK GRAP2 INPP5D INPP5K ITK LAT
LCP2 PLCG2 RHOA TXK WASF2 APBB1IP
CD79A CD79B DAPP1 DOK1 EFNB1 EPHB1
EPHB2 EPHB6 GNA15 GNAI1 GNAI2 INPP5B
INPP5E NTN1 PLCB2 PLCD3 PLCE1 RAP1A
RAP1B SH3KBP1 TLR9
Intersection of SLIPT and siRNA screen
AXL CDC37 FGF9 GNG2 GNG5 HLA-E
IRS2 TREM2 VAV1 NR4A1 EPHB3 NCK1
PLCD1
Not detected by SLIPT or siRNA screen
AGO1 AGO2 AGO3 AGO4 BCR BTC
CALM3 CAMK2A CAMK2B CAMK2G CD3G CD80
CNTRL CPSF6 CUX1 DVL3 EGF ERBB2
ERBB4 FGF10 FGF16 FGF19 FGF1 FGF22
FGF23 FGF3 FGF4 FGF5 FGF6 FGFR1
FGFR1OP2 FGFR1OP FGFR2 FGFR4 FRS2 GAB1
GNB1 GNB2 GNB4 GNB5 GNG10 GNG13
GNG3 GNG4 GNGT1 GRB2 GUSB HSP90AA1
NULL KDR KITLG KLB KLRC2 LCK
MAPKAPK2 MOV10 MTOR NRG3 NRG4 PDGFA
PDGFB PDGFRB PDPK1 PHLPP1 PIK3CB PIK3R2
PIK3R3 PIP2 PIP3 PIP4K2B PIP5K1C PIP5KL1
PRKACB PRKACG PTEN PTPN11 RICTOR RPS6KA1
RPS6KA2 RPS6KA5 RPS6KA6 SOS1 SRC TNRC6A
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TNRC6B TRIB3 TRIM24 VEGFA CASP9 CDKN1A
CDKN1B CHUK FOXO3 GSK3A MDM2 RPS6KB2
TSC2 ABI1 ABI2 BAIAP2 BRK1 CYFIP2
INPP5A INPP5J INPPL1 TEC VAV2 VAV3
WASF1 WASF3 BLNK CBLB CBL CDC42
DCC DOCK1 EFNB2 EFNB3 EZR GNA11
GNA14 GNAI3 GNAO1 GNAQ GNAT2 GNAZ
ITSN1 OCRL PIK3C3 PLCB1 PLCB3 PLCB4
PLCD4 PLCH1 PLCH2 PLCZ1 SDC4 SYNJ1
SYNJ2 TIRAP TRIO WASL WAS
Table F.3: Synthetic lethal candidate genes in the PI3K/AKT pathway in cancer
Predicted only by SLIPT
AKT1 B2M CALM1 CALM2 CAMK4 CREB1
ERBB3 EREG FCGR3A FGF20 FGFR3 IRS1
KL LRRFIP1 MLST8 MYO18A NRG1 PHLPP2
PIK3CA PIK3CG PIP5K1A TNRC6C ZMYM2 GSK3B
NCKAP1 PLCG1 RAC1 EPHB4 GNAT1 PIK3R4
PTK2
Detected only by siRNA screen
AXL CDC37 FGF9 GNG2 GNG5 HLA-E
IRS2 TREM2 VAV1 NR4A1 EPHB3 NCK1
PLCD1
Intersection of SLIPT and siRNA screen
AXL CDC37 FGF9 GNG2 GNG5 HLA-E
IRS2 TREM2 VAV1 NR4A1 EPHB3 NCK1
PLCD1
Not detected by SLIPT or siRNA screen
AGO1 AGO2 AGO3 AGO4 BCR BTC
CALM3 CAMK2A CAMK2B CAMK2G CD3G CD80
CDKN1A CNTRL CPSF6 CUX1 DVL3 EGF
ERBB2 ERBB4 FGF10 FGF16 FGF19 FGF1
FGF22 FGF23 FGF3 FGF4 FGF5 FGF6
FGFR1 FGFR1OP2 FGFR1OP FGFR2 FGFR4 FOXO3
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FRS2 GAB1 GNB1 GNB2 GNB4 GNB5
GNG10 GNG13 GNG3 GNG4 GNGT1 GRB2
GSK3A GUSB HSP90AA1 NULL KDR KITLG
KLB KLRC2 LCK MAPKAPK2 MOV10 MTOR
NRG3 NRG4 PDGFA PDGFB PDGFRB PDPK1
PHLPP1 PIK3CB PIK3R2 PIK3R3 PIP2 PIP3
PIP4K2B PIP5K1C PIP5KL1 PRKACB PRKACG PTEN
PTPN11 RICTOR RPS6KA1 RPS6KA2 RPS6KA5 RPS6KA6
SOS1 SRC TNRC6A TNRC6B TRIB3 TRIM24
VEGFA CASP9 CDKN1B CHUK MDM2 RPS6KB2
TSC2 ABI1 ABI2 BAIAP2 BRK1 CYFIP2
INPP5A INPP5J INPPL1 TEC VAV2 VAV3
WASF1 WASF3 BLNK CBLB CBL CDC42
DCC DOCK1 EFNB2 EFNB3 EZR GNA11
GNA14 GNAI3 GNAO1 GNAQ GNAT2 GNAZ
ITSN1 OCRL PIK3C3 PLCB1 PLCB3 PLCB4
PLCD4 PLCH1 PLCH2 PLCZ1 SDC4 SYNJ1
SYNJ2 TIRAP TRIO WASL WAS
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Figure F.1: Synthetic lethality in the PI3K/AKT pathway. The Reactome
PI3K/AKT pathway with synthetic lethal candidates, coloured as shown in the legend. The
genes in this pathway are detailed in Appendix Table F.2.
280
Figure F.2: Synthetic lethality in the PI3K/AKT pathway in cancer. The Reactome
PI3K/AKT in cancer pathway with synthetic lethal candidates, coloured as shown in the















































Figure F.3: Synthetic lethality in Elastic Fibre Formation. The Reactome Elastic

















































Figure F.4: Synthetic lethality in Fibrin Clot Formation. The Reactome Fibrin Clot






Figure F.5: Synthetic lethality in the Extracellular Matrix. The Reactome Extracel-
lular Matrix pathway with synthetic lethal candidates, coloured as shown in the legend. The
genes in this pathway are detailed in Appendix Table F.4.
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Table F.4: Synthetic lethality in the Extracellular Matrix
Predicted only by SLIPT
BSG COL12A1 COL17A1 COL28A1 FBN1 FBN3
FN1 IBSP ITGB4 ITGB6 LAMC2 PIP5K1A
PLOD2 SLC8A2 VCAN NID2
Detected only by siRNA screen
A2M ADAM15 ADAMTS16 ADAMTS1 ADAMTS3 ADAMTS4
ADAMTS5 ADAMTS8 ADAMTS9 ASPN BGN BMP1
BMP2 CMA1 COL11A2 COL14A1 COL15A1 COL16A1
COL18A1 COL19A1 COL20A1 COL25A1 COL4A2 COL4A3
COL4A4 COL5A3 COL6A1 COL6A2 COL9A2 COL9A3
CRTAP CTSD CTSG CTSK CTSL1 CTSS
DCN DMD DVL1 DVL2 EFEMP1 EFEMP2
ELANE ELN FBLN1 FBLN2 FBLN5 FGF2
FMOD FURIN GNAI1 GNAI2 ICAM1 ICAM2
ICAM3 ICAM4 ITGA10 ITGA5 ITGA7 ITGA9
ITGAE ITGAM ITGAX ITGB2 ITGB5 ITGB7
JAM2 KLK7 LAMA4 LAMB1 LAMB3 LOXL1
LOXL3 LOXL4 LOX LTBP2 LTBP3 MFAP4
MFAP5 MMP19 MMP20 MMP2 MMP3 MMP7
MMP8 NCAM1 PCOLCE2 PCOLCE PIP4K2A PIP5K1B
PLOD1 PLOD3 PPIB SDC2 SLC24A4 SLC8A3
TGFB2 TIMP2 TLL1 TNC TNXB TPSAB1
MATN4 MUSK PTPRS GDF5 SPARC SERPINH1
NRXN1 JAM3 MADCAM1 VCAM1 NTN4 TIMP1
Intersection of SLIPT and siRNA screen
CD151 COL23A1 COL27A1 COL9A1 HSPG2 ITGB8
LTBP4 MFAP2 PRKCA SDC3 TGFB1 TNN
PECAM1
Not detected by SLIPT or siRNA screen
ACAN ACTN1 ADAM10 ADAM17 ADAM9 ADAMTS14
ADAMTS18 ADAMTS2 AGRN BCAN BMP10 BMP4
BMP7 CACNA1C CACNA1D CACNA2D2 CACNB2 CACNB3
CAPN1 CAPNS1 CASK CASP3 CD44 CD47
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CDH1 CEACAM1 CEACAM6 CEACAM8 COL10A1 COL11A1
COL13A1 COL1A1 COL1A2 COL21A1 COL22A1 COL24A1
COL26A1 COL2A1 COL3A1 COL4A1 COL4A5 COL4A6
COL5A1 COL5A2 COL6A3 COL7A1 COL8A1 COL8A2
COLGALT1 COLGALT2 COMP NULL CTRB2 CTSB
CTSL2 DAG1 DMP1 DSPP DST DVL3
F11R FBN2 FGA FGB FGG GRIA1
GRIA2 GRIA3 GRIA4 ITGA11 ITGA1 ITGA2B
ITGA2 ITGA3 ITGA4 ITGA6 ITGA8 ITGAD
ITGAL ITGAV ITGB1 ITGB3 KLK2 KLKB1
LAMA1 LAMA2 LAMA3 LAMA5 LAMB2 LAMC1
LAMC3 P3H1 P3H2 P3H3 LOXL2 LRP4
LTBP1 LUM MATN1 MATN3 MFAP1 MFAP3
MMP10 MMP11 MMP12 MMP13 MMP14 MMP15
MMP16 MMP17 MMP1 MMP24 MMP9 NCAN
NCSTN NID1 P4HB PDGFA PDGFB PIP4K2B
PIP5K1C PIP5KL1 PLG PRSS1 PRSS2 PSEN1
PTEN SDC1 SDC4 SERPINE1 SLC24A1 SLC24A2
SLC24A3 SLC24A5 SLC8B1 SLC8A1 TLL2 TNR
HAPLN1 TGFB3 PLEC SPP1 VTN TTR
MMP25 KDR THBS1 TRAPPC4
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Table F.5: Synthetic lethality in the Gαi signalling Pathway
Predicted only by SLIPT
ADORA1 ADORA3 CALM1 CALM2 CASR CCR8
CXCR1 FPR3 GABBR2 GALR1 GALR2 GNAS
GNAT1 GPR18 GRM2 GRM4 HRH3 HTR1E
KNG1 LPAR2 NPY1R OPN5 OPRL1 PMCH
PTGER3 PYY RGS12 RHO RRH SSTR1
SSTR2 SUCNR1 TAS2R19 TTC21B AKAP5 PDE11A
PDE1A PDE4C
Detected only by siRNA screen
ADCY2 ADCY3 ADCY4 ADRA2A ADRA2B AGT
AGTR2 AK1 ANXA1 C3AR1 C3 C5AR1
CCL19 CCL20 CCL21 CCL23 CCL5 CCR10
CCR2 CCR5 CCR7 CXCL12 CXCL16 CXCL2
CXCL3 CXCL5 CXCL6 CXCR5 CXCR6 DRD4
FPR1 GABBR1 GAL GNAI1 GNAI2 GNB3
GNG11 GNG12 GNG7 GNG8 GNGT2 GPR161
GPR17 GPR55 GRM6 IL8 LPAR1 NMUR1
NPY2R NPY OPN3 OPRK1 OXER1 P2RY14
PENK PF4 PNOC POMC RGS10 RGS14
RGS18 RGS1 RGS6 S1PR1 S1PR2 S1PR4
SLC25A6 SSTR3 PDE1B PDE2A PDE4B PDE4D
PDE6G PDE9A PRKAR1B
Intersection of SLIPT and siRNA screen
ADCY7 APLNR CCL16 CCR1 CCR6 CCR9
CXCL1 CXCR3 CXCR4 GNG2 GNG5 NPY5R
OXGR1 P2RY12 P2RY13 PPBP RGR PDE3B
PDE4A RAPGEF3
Not detected by SLIPT or siRNA screen
ADCY10 ADCY1 ADCY5 ADCY6 ADCY8 ADCY9
ADRA2C APLN APP ATP BDKRB1 BDKRB2
C5 CALM3 CCL25 CCL27 CCL28 CCR3
CCR4 CHRM2 CHRM4 CMPK1 CMPK2 CNR1
CNR2 CXCL10 CXCL11 CXCL13 CXCL9 CXCR2
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ACKR3 DRD2 DRD3 FPR2 GALR3 GNAI3
GNAL GNAT2 GNAZ GNB1 GNB2 GNB4
GNB5 GNG10 GNG13 GNG3 GNG4 GNGT1
GPER1 GRM3 GRM7 GRM8 HCAR1 HCAR2
HCAR3 HEBP1 HRH4 HTR1A HTR1B HTR1D
HTR1F HTR5A IFT122 IFT140 INSL5 LPAR3
LPAR5 MCHR1 MCHR2 NULL MTNR1A MTNR1B
NMS NMU NMUR2 NPB NPBWR1 NPBWR2
NPW NPY4R OPN1LW OPN1MW2 OPN1MW OPN1SW
OPRD1 OPRM1 P2RY4 PDYN PKLR PKM
PPY PTGDR2 RGS11 RGS19 RGS20 RGS21
RGS4 RGS7 RGS8 RGS9 RLN3 RXFP3
RXFP4 S1PR3 S1PR5 SAA1 SLC25A4 SLC25A5
SSTR4 SSTR5 SST TAS2R10 TAS2R13 TAS2R14
TAS2R16 TAS2R1 TAS2R20 TAS2R30 TAS2R31 TAS2R38
TAS2R39 TAS2R3 TAS2R40 TAS2R41 TAS2R43 TAS2R46
TAS2R4 TAS2R50 TAS2R5 TAS2R60 TAS2R7 TAS2R8
TULP3 WDR19 WDR35 HCN1 HCN2 HCN3
HCN4 IQGAP1 PDE10A PDE1C PDE3A PDE5A
PDE6A PDE6B PDE6C PDE6D PDE6H PDE7A
PDE7B PDE8A PDE8B PRKAR1A PRKAR2A PRKAR2B
RAPGEF4 TAS2R9
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Figure F.6: Synthetic lethality in the GPCR Downstream pathway. The Reactome
GPCR Downstream pathway with synthetic lethal candidates, coloured as shown in the
legend. The genes in this pathway are detailed in Appendix Table F.6.
289
Table F.6: Synthetic lethal candidate genes in the GPCR Downstream pathway
Predicted only by SLIPT
ADORA1 ADORA3 ADRBK1 AGTR1 AKAP13 AKT1
ARHGEF11 ARHGEF7 AVPR1B B2M CALM1 CALM2
CASR CCR8 CRHR2 CXCR1 CYSLTR2 DGKD
DRD1 DRD5 ERBB3 EREG F2RL1 FCGR3A
FFAR2 FGD4 FGF20 FGFR3 FPR3 GABBR2
GALR1 GALR2 GNAS GNAT1 GPR18 GRM1
GRM2 GRM4 GRPR HRH3 HTR1E HTR2C
IRS1 KL KNG1 LPAR2 LPAR4 LRRFIP1
MLNR MYO18A NMBR NPY1R NRG1 OPN5
OPRL1 OR10H1 OR13J1 OR1J4 OR2AE1 OR2L13
OR5K2 P2RY10 P2RY1 PDE11A PDE1A PDE4C
PIK3CA PIK3CG PIP5K1A PLCG1 PMCH PRKCH
PROKR1 PROKR2 PTGER3 PYY QRFPR RAC1
RGS12 RHOB RHOC RHO RRH SSTR1
SSTR2 SUCNR1 TAS2R19 TBXA2R TIAM1 TTC21B
VIPR1 ZMYM2 AKAP5 XCR1 NCKAP1 PXN
SLC8A2 TCAP TTN
Detected only by siRNA screen
ADCY2 ADCY3 ADCY4 ADCYAP1 ADM ADRA1D
ADRA2A ADRA2B ADRB1 ADRB2 ADRB3 AGT
AGTR2 AK1 AKT2 AKT3 ANXA1 ARHGAP4
ARHGEF18 ARHGEF1 ARHGEF2 ARHGEF4 AVPR2 BTK
C3AR1 C3 C5AR1 CACNA1A CACNA2D3 CATSPER1
CCL19 CCL20 CCL21 CCL23 CCL5 CCR10
CCR2 CCR5 CCR7 CD19 CD247 CD28
CD79A CD79B CD86 CHRM1 CLIC2 CNGA1
CRHR1 CSF2 CSF2RB CXCL12 CXCL16 CXCL2
CXCL3 CXCL5 CXCL6 CXCR5 CXCR6 CYSLTR1
DAPP1 DGKA DGKZ DRD4 DVL1 DVL2
EDN1 EDN2 EGFR FCGR1A FCGR2A FGD2
FGF17 FGF18 FGF2 FGF7 FGF8 FPR1
FYN GAB2 GABBR1 GAL GHRL GNA15
GNAI1 GNAI2 GNB3 GNG11 GNG12 GNG7
GNG8 GNGT2 GNRH1 GPBAR1 GPR161 GPR17
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GPR55 GRAP2 GRM5 GRM6 HBEGF HTR2A
IL2 IL2RA IL2RG IL3RA IL5RA IL8
INSL3 ITK JAK3 KIT KLRD1 KLRK1
LAT2 LAT LCP2 LHCGR LPAR1 LPAR6
LTB4R MCOLN1 NMB NMUR1 NPFF NPY2R
NPY NRG2 OBSCN OPN3 OPN4 OPRK1
OR2B11 OR2S2 OR52N4 OR7A5 OR7C1 OXER1
P2RX1 P2RY11 P2RY14 PDE1B PDE2A PDE4B
PDE4D PDE6G PDE9A PDGFRA PENK PF4
PIK3AP1 PIK3CD PIK3R1 PIK3R5 PIK3R6 PIP4K2A
PIP5K1B PLCB2 PLCD3 PLCE1 PLCG2 PLD4
PLEKHG5 PNOC POMC PROK2 PTGDR PTGER4
PTGFR PTGIR PTH1R RAC2 RAMP2 RAMP3
RGS10 RGS14 RGS18 RGS1 RGS2 RGS6
RHOA RHOG RYR1 RYR2 RYR3 S1PR1
S1PR2 S1PR4 SH2D2A SH3KBP1 SHC1 SLC25A6
SRI SSTR3 SYK TIAM2 TRAT1 TRPC3
TRPM3 TRPM8 TRPV2 TXK TYROBP UTS2
PRKAR1B INPP5D INPP5K WASF2 INPP5B INPP5E
ITPKC GRK5 ACTA2 ACTN3 CALD1 CAMK2D
DES DMD GRIN2B ITGB5 LMOD1 MYBPC1
MYBPC2 MYBPC3 MYH11 MYH3 MYL2 MYL3
MYL6B MYL6 MYL9 NEFL NFATC1 PYGL
RASGRP4 SLC17A7 SLC24A4 SLC8A3 SORBS1 TMOD1
TNNI2 TNNT2 TNNT3 TPM2 VAMP2 VIM
PLD1 PLD2 PLD3 AK2 AMPD1
Intersection of SLIPT and siRNA screen
ADCY7 APLNR AXL CCL16 CCR1 CCR6
CCR9 CDC37 CSF2RA CXCL1 CXCR3 CXCR4
EDN3 FFAR3 FGF9 GNG2 GNG5 GPR132
GPR65 HCRTR1 HLA-E HRH1 HTR2B HTR7
IRS2 JAK2 NCK1 NPFFR1 NPY5R OXGR1
OXT P2RY12 P2RY13 PDE3B PDE4A PLCD1
PLEKHG2 PLXNB1 PPBP PRKCA PRKCB PRKCQ
PROK1 PTGER2 RGR TACR1 TREM2 VAV1
VIP XCL2 RAPGEF3 VIPR2 RASGRP2 ITPKB
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DLG4 PLA2G4A PYGM SORBS3 TLN1 TNNC1
AMPD2
Not detected by SLIPT or siRNA screen
ABR ADCY10 ADCY1 ADCY5 ADCY6 ADCY8
ADCY9 ADCYAP1R1 ADM2 ADORA2A ADORA2B ADRA1A
ADRA1B ADRA2C APLN APP ARHGEF12 ARHGEF16
ARHGEF17 ARHGEF25 ARHGEF3 ARHGEF6 ARHGEF9 ATP2B1
ATP2B2 ATP2B3 ATP2B4 ATP AVP AVPR1A
BCR BDKRB1 BDKRB2 BLNK BRS3 BTC
C5 CACNA1B CACNA1C CACNA1D CACNA1E CACNA2D2
CACNB1 CACNB2 CACNB3 CACNB4 CACNG2 CACNG4
CALCA CALCB CALCR CALCRL CALM3 CATSPER2
CATSPER3 CATSPER4 CATSPERB CATSPERD CATSPERG CBL
CBLB CCKAR CCKBR CCK CCL25 CCL27
CCL28 CCR3 CCR4 CD3G CD80 CDC42
CGA CHRM2 CHRM3 CHRM4 CHRM5 CMPK1
CMPK2 CNGB1 CNR1 CNR2 CNTRL CPSF6
CRH CUX1 CXCL10 CXCL11 CXCL13 CXCL9
CXCR2 ACKR3 DAGLA DAGLB DGKB DGKE
DGKG DGKH DGKI DGKK DGKQ DRD2
DRD3 DVL3 ECT2 EDNRA EDNRB EGF
ERBB2 ERBB4 F2 F2R F2RL2 F2RL3
FFAR1 FGD1 FGD3 FGF10 FGF16 FGF19
FGF1 FGF22 FGF23 FGF3 FGF4 FGF5
FGF6 FGFR1 FGFR1OP2 FGFR1OP FGFR2 FGFR4
FKBP1B FPR2 FRS2 FSHB FSHR GAB1
GALR3 GAST GCG GCGR GHRH GHRHR
GHSR GIP GIPR GLP1R GLP2R GNA11
GNA12 GNA13 GNA14 GNAI3 GNAL GNAO1
GNAQ GNAT2 GNAZ GNB1 GNB2 GNB4
GNB5 GNG10 GNG13 GNG3 GNG4 GNGT1
GNRH2 GNRHR2 GNRHR GPER1 GPR4 GPR68
GPRC6A GRB2 GRM3 GRM7 GRM8 GRP
GUSB HCAR1 HCAR2 HCAR3 HCRT HCRTR2
HEBP1 HRH2 HRH4 HSP90AA1 HTR1A HTR1B
HTR1D HTR1F HTR3A HTR3B HTR3C HTR3D
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HTR4 HTR5A HTR6 IAPP IFT122 IFT140
NULL IL2RB IL3 IL5 INSL5 ITPR1
ITPR2 ITPR3 ITSN1 JAK1 KALRN KDR
KISS1 KISS1R KITLG KLB KLRC2 LCK
LHB LPAR3 LPAR5 LTB4R2 MC1R MC2R
MC3R MC4R MC5R MCF2L MCF2 MCHR1
MCHR2 MCOLN2 MCOLN3 MGLL MLN MTNR1A
MTNR1B NET1 NGEF NMS NMU NMUR2
NPB NPBWR1 NPBWR2 NPFFR2 NPS NPSR1
NPW NPY4R NRG3 NRG4 NTS NTSR1
NTSR2 OPN1LW OPN1MW2 OPN1MW OPN1SW OPRD1
OPRM1 OR10A2 OR10A3 OR10A4 OR10A5 OR10A6
OR10A7 OR10AD1 OR10AG1 OR10C1 OR10G3 OR10G4
OR10G7 OR10G8 OR10G9 OR10H2 OR10H3 OR10H4
OR10H5 OR10J1 OR10J3 OR10J5 OR10K1 OR10K2
OR10P1 OR10Q1 OR10R2 OR10S1 OR10T2 OR10V1
OR10W1 OR10X1 OR10Z1 OR11A1 OR11G2 OR11H1
OR11H2 OR11H4 OR11H6 OR11L1 OR12D2 OR12D3
OR13A1 OR13C2 OR13C3 OR13C4 OR13C5 OR13C8
OR13C9 OR13D1 OR13F1 OR13G1 OR13H1 OR14A16
OR14C36 OR14J1 OR1A1 OR1A2 OR1B1 OR1C1
OR1D2 OR1D5 OR1E1 OR1E2 OR1F1 OR1G1
OR1I1 OR1J1 OR1J2 OR1K1 OR1L1 OR1L3
OR1L4 OR1L6 OR1L8 OR1M1 OR1N1 OR1N2
OR1Q1 OR1S1 OR1S2 OR2A12 OR2A14 OR2A1
OR2A2 OR2A42 OR2A4 OR2A5 OR2A7 OR2AG1
OR2AK2 OR2AP1 OR2B2 OR2B3 OR2B6 OR2C1
OR2C3 OR2D2 OR2D3 OR2F1 OR2F2 OR2G2
OR2G3 OR2G6 OR2H1 OR2H2 OR2J2 OR2J3
OR2K2 OR2L2 OR2L3 OR2L5 OR2L8 OR2M2
OR2M3 OR2M4 OR2M7 OR2T10 OR2T11 OR2T12
OR2T1 OR2T27 OR2T29 OR2T2 OR2T33 OR2T34
OR2T35 OR2T3 OR2T4 OR2T5 OR2T6 OR2V1
OR2V2 OR2W1 OR2W3 OR2Y1 OR2Z1 OR3A1
OR3A2 OR3A3 OR4A15 OR4A16 OR4A47 OR4A5
OR4B1 OR4C11 OR4C12 OR4C13 OR4C15 OR4C16
OR4C3 OR4C6 OR4D10 OR4D11 OR4D1 OR4D2
293
OR4D5 OR4D6 OR4D9 OR4F15 OR4F16 OR4F17
OR4F21 OR4F29 OR4F3 OR4F4 OR4F5 OR4F6
OR4K13 OR4K14 OR4K15 OR4K17 OR4K1 OR4K2
OR4K5 OR4L1 OR4M1 OR4M2 OR4N2 OR4N4
OR4N5 OR4P4 OR4Q3 OR4S1 OR4S2 OR4X1
OR4X2 OR51A2 OR51A4 OR51A7 OR51B2 OR51B4
OR51B5 OR51B6 OR51D1 OR51E1 OR51E2 OR51F2
OR51G1 OR51G2 OR51I1 OR51I2 OR51L1 OR51M1
OR51Q1 OR51S1 OR51T1 OR51V1 OR52A1 OR52A5
OR52B2 OR52B4 OR52B6 OR52D1 OR52E2 OR52E4
OR52E6 OR52E8 OR52H1 OR52I1 OR52I2 OR52J3
OR52K1 OR52K2 OR52L1 OR52M1 OR52N1 OR52N2
OR52N5 OR52R1 OR52W1 OR56A1 OR56A3 OR56A4
OR56A5 OR56B1 OR56B4 OR5A1 OR5A2 OR5AC2
OR5AK2 OR5AN1 OR5AP2 OR5AR1 OR5AS1 OR5AU1
OR5B12 OR5B17 OR5B2 OR5B3 OR5C1 OR5D13
OR5D14 OR5D16 OR5D18 OR5F1 OR5H2 OR5H6
OR5I1 OR5J2 OR5K1 OR5L1 OR5L2 OR5M10
OR5M11 OR5M1 OR5M3 OR5M8 OR5M9 OR5P2
OR5P3 OR5R1 OR5T1 OR5T2 OR5T3 OR5V1
OR5W2 OR6A2 OR6B1 OR6B2 OR6B3 OR6C1
OR6C2 OR6C3 OR6C4 OR6F1 OR6K2 OR6K3
OR6K6 OR6M1 OR6N1 OR6N2 OR6P1 OR6Q1
OR6S1 OR6T1 OR6V1 OR6X1 OR6Y1 OR7A10
OR7A17 OR7C2 OR7D2 OR7D4 OR7E24 OR7G1
OR7G2 OR7G3 OR8A1 OR8B12 OR8B2 OR8B3
OR8B4 OR8B8 OR8D1 OR8D2 OR8D4 OR8G1
OR8G5 OR8H1 OR8H2 OR8H3 OR8I2 OR8J1
OR8J3 OR8K1 OR8K3 OR8K5 OR8S1 OR8U1
OR8U9 OR9A2 OR9A4 OR9G1 OR9G4 OR9I1
OR9K2 OR9Q1 ORAI1 OXTR P2RY2 P2RY4
P2RY6 PDE10A PDE1C PDE3A PDE5A PDE6A
PDE6B PDE6C PDE6D PDE6H PDE7A PDE7B
PDE8A PDE8B PDGFA PDGFB PDGFRB PDPK1
PDYN PIK3CB PIK3R2 PIK3R3 PIP2 PIP4K2B
PIP5K1C PIP5KL1 PKLR PKM PLCB1 PLCB3
PLCB4 PLCD4 PLCH1 PLCH2 PLCZ1 PPY
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PRKCD PRKCE PRKCG PTAFR PTEN PTGDR2
PTGER1 PTH2 PTH2R PTHLH PTH PTPN11
QRFP RAMP1 RASGRF2 RASGRP1 RGS11 RGS17
RGS19 RGS20 RGS21 RGS4 RGS7 RGS8
RGS9 RLN2 RLN3 RND1 ROCK1 RXFP1
RXFP2 RXFP3 RXFP4 S1PR3 S1PR5 SAA1
SCTR SCT SEMA4D SLC25A4 SLC25A5 SOS1
SOS2 SRC SSTR4 SSTR5 SST STIM1
TAAR1 TAAR2 TAAR5 TAAR6 TAAR8 TAAR9
TAC1 TAC3 TACR2 TACR3 TAS2R10 TAS2R13
TAS2R14 TAS2R16 TAS2R1 TAS2R20 TAS2R30 TAS2R31
TAS2R38 TAS2R39 TAS2R3 TAS2R40 TAS2R41 TAS2R43
TAS2R46 TAS2R4 TAS2R50 TAS2R5 TAS2R60 TAS2R7
TAS2R8 TEC TPCN1 TPCN2 TRDN TRHR
TRH TRIM24 TRIO TRPA1 TRPC1 TRPC4AP
TRPC4 TRPC5 TRPC6 TRPC7 TRPM1 TRPM2
TRPM6 TRPM7 TRPV1 TRPV3 TRPV4 TRPV5
TRPV6 TSHB TSHR TULP3 UTS2B UTS2R
VAV2 VAV3 VEGFA WDR19 WDR35 XCL1
AMP HCN1 HCN2 HCN3 HCN4 IQGAP1
PRKAR1A PRKAR2A PRKAR2B RAPGEF4 TAS2R9 ABI1
ABI2 BAIAP2 BRK1 CYFIP2 INPP5A INPP5J
INPPL1 PIP3 WASF1 WASF3 ITPKA OCRL
SYNJ1 SYNJ2 LPIN1 LPIN2 LPIN3 OR9Q2
ACTG2 ACTN2 AKAP9 ATP2A1 ATP2A2 ATP2A3
ATP2C1 ATP2C2 BZRAP1 CAMK2A CAMK2B CAMK2G
CPLX1 GRIN1 GRIN2A GRIN2C GRIN2D ITGA1
MYH6 MYH8 MYL12B MYL1 MYL4 NEB
NFATC2 NFATC3 PLN PPFIA1 PPFIA2 PPFIA3
PPFIA4 PPP3CA PPP3CB PPP3R1 PRKCZ PYGB
RAB3A RASGRF1 RIMS1 SLC24A1 SLC24A2 SLC24A3
SLC24A5 SLC8B1 SLC8A1 SNAP25 STX1A STXBP1
SYT1 SYT5 TNNC2 TNNI1 TNNI3 TNNT1
TPM1 TPM3 TPM4 UNC13B VCL GK2
GK PLD6 AMPD3 NT5C1B ROCK2
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Figure F.7: Synthetic lethality in the Translation Elongation. The Reactome Trans-











































































































Figure F.8: Synthetic lethality in the Nonsense-mediated Decay. The Reactome
NMD pathway with synthetic lethal candidates, coloured as shown in the legend.
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Figure F.9: Synthetic lethality in the 3′ UTR. The Reactome 3′ UTR pathway with
synthetic lethal candidates, coloured as shown in the legend.
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Appendix G















































































Figure G.1: Synthetic lethality and vertex degree. The number of connected genes
(vertex degree) was compared (on a log-scale) across genes detected by mtSLIPT and siRNA
screening in the Reactome Gαi pathway. There were no differences in vertex degree between



















































































Figure G.2: Synthetic lethality and centrality. The information centrality was compared
(on a log-scale) across genes detected by SLIPT and siRNA screening in the Reactome Gαi
pathway. Genes detected by SLIPT or siRNA did not have higher centrality than other genes

























































































































































Figure G.3: Synthetic lethality and PageRank. The PageRank centrality was compared
(on a log-scale) across genes detected by mtSLIPT and siRNA screening in the Reactome Gαi
pathway. Genes detected by with either synthetic lethal detection approach had a more re-
stricted range of centrality values neither of these had a significant association with centrality
(shown in Table G.3).
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Table G.1: ANOVA for synthetic lethality and vertex degree
DF Sum Squares Mean Squares F-value p-value
siRNA 1 15 15.50 0.0134 0.9084
mtSLIPT 1 196 195.94 0.1689 0.6825
siRNA×mtSLIPT 1 9 9.17 0.0079 0.9294
Analysis of variance for vertex degree against synthetic lethal detection
approaches (with an interaction term)
Table G.2: ANOVA for synthetic lethality and information centrality
DF Sum Squares Mean Squares F-value p-value
siRNA 1 0.000256 0.0002561 0.1851 0.6685
mtSLIPT 1 0.003225 0.0032247 2.3308 0.1318
siRNA×mtSLIPT 1 0.001238 0.0012385 0.8952 0.3476
Analysis of variance for information centrality against synthetic lethal detection
approaches (with an interaction term)
Table G.3: ANOVA for synthetic lethality and PageRank centrality
DF Sum Squares Mean Squares F-value p-value
siRNA 1 0.0002038 2.0385× 10−4 1.1423 0.2892
mtSLIPT 1 0.0000208 2.0752× 10−5 0.1163 0.7342
siRNA×mtSLIPT 1 0.0000137 1.3743× 10−5 0.0770 0.7823
Analysis of variance for PageRank centrality against synthetic lethal detection































(a) Resampling in Gαi signalling




























(b) Resampling in the PI3K cascade
Figure H.1: Structure of synthetic lethality resampling. A null distribution with
10,000 iterations of the number of siRNA genes upstream or downstream of mtSLIPT genes
(depicted as the difference of these) in each pathway. To assess significance, the observed
events (with shortest paths) were compared to the 90% and 95% intervals for the null distri-
bution (shown in blue). Genes detected by both methods were not fixed to the same number
as observed for the alternative null distribution (shown in red), although the significance
of the observed number of events (red) was changed in either case. The genes detected by
both approaches were included in computing the number of shortest paths (in either direc-
tion) between SLIPT and siRNA genes. The permutations show (a) a significant pathway
relationship for Gαi signalling and (b) and non-significant relationship for the PI3K cascade.
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Table H.1: Resampling for pathway structure of synthetic lethal detection methods
Graph Candidates Observed Permutation p-value p-value (FDR)
Pathway Nodes Edges SLIPT siRNA Up1 Down2 Up−Down Up/Down Up−Down Down−Up Down−Up
PI3K Cascade 138 1495 42 25 131 123 8 1.065 0.4473 0.5466 0.7263
PI3K/AKT Signalling in Cancer 275 12882 56 44 478 440 38 1.086 0.4163 0.5810 0.7263
Gαi Signalling 292 22003 57 58 543 866 -323 0.627 0.9507 0.0488 0.488
GPCR downstream 1270 142071 218 160 7632 6500 1132 1.174 0.1707 0.8291 0.8751
Elastic fibre formation 42 175 16 7 6 7 -1 0.857 0.5512 0.3681 0.7263
Extracellular matrix 299 3677 81 29 313 347 -34 0.902 0.5762 0.4215 0.7263
Formation of Fibrin 52 243 11 5 8 19 -11 0.421 0.7993 0.1800 0.6000
Nonsense-Mediated Decay 103 102 56 2 0 0 0 0.197 0.1373 0.6000
3′-UTR-mediated translational regulation 107 2860 56 1 52 1 51 52 0.1210 0.8751 0.8751
Eukaryotic Translation Elongation 92 3746 57 0 0 0 0 0.4952 0.4892 0.7263
Pathways in the Reactome network tested for structural relationships between mtSLIPT and siRNA genes by resampling. The raw p-value (computed without adjusting for multiple
comparisons over pathways) is given for the difference in upstream and downstream paths from mtSLIPT to siRNA gene candidate partners of CDH1 with significant pathways highlighted
in bold. Sampling was performed only in the target pathway and shortest paths were computed within it. Loops or paths in either direction that could not be resolved were excluded from
the analysis. The genes detected by both mtSLIPT and siRNA (or resampling for them) were included in the analysis and the number of these were fixed to the number observed.
1 The number of paths where the siRNA candidate was upstream of a mtSLIPT candidate
2 The number of paths where the siRNA candidate was downstream of a mtSLIPT candidate
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Appendix I
Performance of SLIPT and χ2
(a) 1 SL partner (b) 2 SL partners (c) 3 SL partners
(d) 4 SL partners (e) 5 SL partners (f) 6 SL partners
Figure I.1: Performance of χ2 and SLIPT across quantiles. (continued on next
page)
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(g) 7 SL partners (h) 8 SL partners (i) 9 SL partners
(j) 10 SL partners (k) 15 SL partners (l) 20 SL partners
(m) 30 SL partners (n) 40 SL partners (o) 50 SL partners
Figure I.1: Performance of χ2 and SLIPT across quantiles. Synthetic lethal
detection with quantiles as in axis labels. The barplots have the same hue for each
quantile (grey for correlation) and darker for χ2 (and positive correlation). SLIPT
and χ2 performed similarly, peaking at 1/3-quantiles and converging to random (0.5).
Negative correlation was higher than positive but not optimal quantiles for SLIPT or
χ2. These findings were robust across different numbers of underlying synthetic lethal
genes in 10,000 simulations of 100 genes and 1000 samples. SLIPT performed better
than χ2 for higher numbers of synthetic lethal genes and finer quantiles.
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(a) 1 SL partner (b) 2 SL partners (c) 3 SL partners
(d) 4 SL partners (e) 5 SL partners (f) 6 SL partners
(g) 7 SL partners (h) 8 SL partners (i) 9 SL partners
Figure I.2: Performance of χ2 and SLIPT across quantiles. (continued on next
page)
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(j) 10 SL partners (k) 15 SL partners (l) 20 SL partners
(m) 30 SL partners (n) 40 SL partners (o) 50 SL partners
Figure I.2: Performance of χ2 and SLIPT across quantiles. Synthetic lethal
detection with quantiles as in axis labels. The line plots are coloured for SLIPT (red),
χ2 (blue) and correlation (grey), according to the legend. SLIPT and χ2 performed
similarly, peaking at 1/3-quantiles and converging to random (0.5). Negative correlation
was higher than positive but not optimal quantiles for SLIPT or χ2. These findings
were robust across different numbers of underlying synthetic lethal genes in 10,000
simulations of 100 genes and 1000 samples. SLIPT performed better than χ2 for higher
numbers of synthetic lethal genes and finer quantiles.
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(a) 1 SL partner (b) 2 SL partners (c) 3 SL partners
(d) 4 SL partners (e) 5 SL partners (f) 6 SL partners
(g) 7 SL partners (h) 8 SL partners (i) 9 SL partners
Figure I.3: Performance of χ2 and SLIPT across quantiles with more genes.
(continued on next page)
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(j) 10 SL partners (k) 15 SL partners (l) 20 SL partners
(m) 30 SL partners (n) 40 SL partners (o) 50 SL partners
Figure I.3: Performance of χ2 and SLIPT across quantiles with more genes.
Synthetic lethal detection with quantiles as in axis labels. The line plots are coloured
for SLIPT (red), χ2 (blue) and correlation (grey), according to the legend. SLIPT
and χ2 performed similarly, peaking at 1/3-quantiles and converging to random (0.5).
Negative correlation was higher than positive but not optimal quantiles for SLIPT or
χ2. These findings were robust across different numbers of underlying synthetic lethal
genes in 1000 simulations of 20,000 genes and 1000 samples. SLIPT performed better
than χ2 for higher numbers of synthetic lethal genes and finer quantiles.
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I.1 Correlated Query Genes affects Specificity
(a) 1 SL partner (b) 2 SL partners (c) 3 SL partners
(d) 4 SL partners (e) 5 SL partners (f) 6 SL partners
(g) 7 SL partners (h) 8 SL partners (i) 9 SL partners
Figure I.4: Performance of χ2 and SLIPT across quantiles with query corre-
lation. (continued on next page)
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(j) 10 SL partners (k) 15 SL partners (l) 20 SL partners
(m) 30 SL partners (n) 40 SL partners (o) 50 SL partners
Figure I.4: Performance of χ2 and SLIPT across quantiles with query corre-
lation. Synthetic lethal detection with quantiles as in axis labels. The barplots have
the same hue for each quantile (grey for correlation) and darker for χ2 (and positive
correlation). SLIPT and χ2 performed similarly, peaking at 1/3-quantiles and converg-
ing to random (0.5). Negative correlation was higher than positive but not optimal
quantiles for SLIPT or χ2. These findings were robust across different numbers of
underlying synthetic lethal genes in 10,000 simulations of 100 genes (including 10 cor-
related with the query) and 1000 samples. SLIPT performed consistently better than
χ2 with positively correlated genes.
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(a) 1 SL partner (b) 2 SL partners (c) 3 SL partners
(d) 4 SL partners (e) 5 SL partners (f) 6 SL partners
(g) 7 SL partners (h) 8 SL partners (i) 9 SL partners
Figure I.5: Performance of χ2 and SLIPT across quantiles with query corre-
lation. (continued on next page)
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(j) 10 SL partners (k) 15 SL partners (l) 20 SL partners
(m) 30 SL partners (n) 40 SL partners (o) 50 SL partners
Figure I.5: Performance of χ2 and SLIPT across quantiles with query corre-
lation. Synthetic lethal detection with quantiles as in axis labels. The line plots are
coloured for SLIPT (red), χ2 (blue) and correlation (grey), according to the legend.
SLIPT and χ2 performed similarly, peaking at 1/3-quantiles and converging to ran-
dom (0.5). Negative correlation was higher than positive but not optimal quantiles for
SLIPT or χ2. These findings were robust across different numbers of underlying syn-
thetic lethal genes in 10,000 simulations of 100 genes (including 10 correlated with the
query) and 1000 samples. SLIPT performed consistently better than χ2 with positively
correlated genes.
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(a) 1 SL partner (b) 2 SL partners (c) 3 SL partners
(d) 4 SL partners (e) 5 SL partners (f) 6 SL partners
(g) 7 SL partners (h) 8 SL partners (i) 9 SL partners
Figure I.6: Performance of χ2 and SLIPT across quantiles with query corre-
lation and more genes. (continued on next page)
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(j) 10 SL partners (k) 15 SL partners (l) 20 SL partners
(m) 30 SL partners (n) 40 SL partners (o) 50 SL partners
Figure I.6: Performance of χ2 and SLIPT across quantiles with query corre-
lation and more genes. Synthetic lethal detection with quantiles as in axis labels.
The line plots are coloured for SLIPT (red), χ2 (blue) and correlation (grey), according
to the legend. SLIPT and χ2 performed similarly, peaking at 1/3-quantiles and converg-
ing to random (0.5). Negative correlation was higher than positive but not optimal
quantiles for SLIPT or χ2. These findings were robust across different numbers of
underlying synthetic lethal genes in 1000 simulations of 20,000 genes (including 1000
correlated with the query) and 1000 samples. SLIPT performed consistently better
than χ2 with positively correlated genes.
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Appendix J
Simulations on Graph Structures





(c) Graph (d) Statistical performance
Figure J.1: Performance of simulations on a simple graph. Simulation of synthetic
lethality was performed using a multivariate normal distribution from a converging graph.
For each parameter, 10,000 simulations were used. Colours in Figure J.1b match Figure J.1d.
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J.1 Simulations from Inhibiting Graph Structures





(c) Graph Structure (d) Statistical performance
Figure J.2: Performance of simulations on an inhibiting graph. Simulation of syn-
thetic lethality used a multivariate normal distribution from a converging graph. For each
parameter, 10,000 simulations were used. Colours in Figure J.2b match Figure J.2d.
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(c) Graph Structure (d) Statistical performance
Figure J.3: Performance of simulations on a constructed graph with inhibition.
Simulation of synthetic lethality used a multivariate normal distribution from a pathway with
only inhibitions. For each parameter, 10,000 simulations were used. Colours in Figure J.3b
match Figure J.3d.
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(c) Graph Structure (d) Statistical performance
Figure J.4: Performance of simulations on a constructed graph with inhibition.
Simulation of synthetic lethality used a multivariate normal distribution from a pathway with
a combination of inhibitions. For each parameter, 10,000 simulations were used. Colours in
Figure J.4b match Figure J.4d.
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(f) Gene “E” SL


































































































(j) Gene “I” SL
Figure J.5: Detection of synthetic lethality within a graph structure. Each gene
was designated to be synthetic lethal separately and the χ2 value from SLIPT was computed
for each gene across the graph. For each synthetic lethal gene (highlighted in the respective
colours), the χ2 values were computed in 100 simulations of datasets of 20,000 genes including
the graph structure and 1000 samples. For each synthetic lethal gene, the adjacent genes in











































































































































































































































(j) Gene “I” SL
Figure J.6: Detection of synthetic lethality within an inhibiting graph. Each gene
was designated to be synthetic lethal separately and the χ2 value from SLIPT was computed
for each gene across the graph structure with inhibiting relationships. For each synthetic
lethal gene (highlighted in the respective colours), the χ2 values were computed in 100 simu-
lations of datasets of 20,000 genes including the graph structure and 1000 samples. For each



































































































































































































































(j) Gene “I” SL
Figure J.7: Detection of synthetic lethality within an inhibiting graph. Each gene
was designated to be synthetic lethal separately and the χ2 value from SLIPT was computed
for each gene across the graph structure with inhibiting and relationships. For each syn-
thetic lethal gene (highlighted in the respective colours), the χ2 values were computed in 100
simulations of datasets of 20,000 genes including the graph structure and 1000 samples.
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J.3 Simulations within a Large Simulated Dataset





(c) Graph Structure (d) Statistical performance
Figure J.8: Performance of simulations including a simple graph. Simulation of syn-
thetic lethality was performed by sampling from a multivariate normal distribution (without
correlation structure apart from the graph shown). Performance of SLIPT was high across
parameters for detecting synthetic lethality in the graph structure within a larger dataset.
The sensitivity decreased for a greater number of true positives to detect but the specificity
remained high with a low false positive rate.
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J.4 Simulations from Complex Graph Structures






















































(c) Graph Structure (d) Statistical performance
Figure J.9: Performance of simulations on a branching graph. Simulation of synthetic
lethality used a multivariate normal distribution from a branching graph. For each parameter,
10,000 simulations were used. Colours in Figure J.9b match Figure J.9d.
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(c) Graph Structure (d) Statistical performance
Figure J.10: Performance of simulations on a complex graph. Simulation of synthetic
lethality used a multivariate normal distribution from a complex graph. For each parameter,
10,000 simulations were used. Colours in Figure J.10b match Figure J.10d.
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(a) Statistical evaluation (b) ROC
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(c) Graph Structure (d) Statistical performance
Figure J.11: Performance of simulations on a large graph. Simulation of synthetic
lethality used a multivariate normal distribution from a large graph. For each parameter,
10,000 simulations were used. Colours in Figure J.11b match Figure J.11d.
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J.5 Simulations from Complex Inhibiting Graphs






















































(c) Graph Structure (d) Statistical performance
Figure J.12: Performance of simulations on a branching graph with inhibition.
Simulation of synthetic lethality used a multivariate normal distribution from a branching
graph with only inhibitions. For each parameter, 10,000 simulations were used. Colours in
Figure J.12b match Figure J.12d.
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(c) Graph Structure (d) Statistical performance
Figure J.13: Performance of simulations on a branching graph with inhibition.
Simulation of synthetic lethality used a multivariate normal distribution from a branch-
ing graph with alternating inhibitions. For each parameter, 10,000 simulations were used.
Colours in Figure J.13b match Figure J.13d.
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(c) Graph Structure (d) Statistical performance
Figure J.14: Performance of simulations on a complex graph with inhibition.
Simulation of synthetic lethality used a multivariate normal distribution from a complex
graph with only inhibitions. For each parameter, 10,000 simulations were used. Colours in
Figure J.14b match Figure J.14d.
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(c) Graph Structure (d) Statistical performance
Figure J.15: Performance of simulations on a complex graph with inhibition.
Simulation of synthetic lethality used a multivariate normal distribution from a complex
graph with a combination of relationships. For each parameter, 10,000 simulations were
used. Colours in Figure J.15b match Figure J.15d.
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(a) Statistical evaluation (b) ROC
























(c) Graph Structure (d) Statistical performance
Figure J.16: Performance of simulations on a large constructed graph with inhibi-
tion. Simulation of synthetic lethality used a multivariate normal distribution from a large
graph with only inhibitions. For each parameter, 10,000 simulations were used. Colours in
Figure J.16b match Figure J.16d.
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(a) Statistical evaluation (b) ROC
























(c) Graph Structure (d) Statistical performance
Figure J.17: Performance of simulations on a large constructed graph with in-
hibition. Simulation of synthetic lethality used a multivariate normal distribution from a
large graph with alternating inhibitions. For each parameter, 10,000 simulations were used.
Colours in Figure J.17b match Figure J.17d.
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J.6 Simulations from Pathway Graph Structures
(a) Statistical evaluation (b) ROC
(c) Graph Structure (d) Statistical performance
Figure J.18: Performance of simulations on the Gαi signalling pathway. Simulation
of synthetic lethality used a multivariate normal distribution based on the Reactome Gαi
signalling pathway. Performance of SLIPT was high across parameters for detecting synthetic
lethality in the graph structure within a larger dataset. The performance decreased for
a greater number of true positives to detect but the accuracy increased with a low false
positive rate.
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(a) Statistical evaluation (b) ROC curves
(c) Graph structure (d) Statistical performance
Figure J.19: Performance of simulations including the PI3K cascade. Simulation
of synthetic lethality was performed by sampling from a multivariate normal distribution
(without correlation structure apart from the Reactome PI3K cascade). Performance of
SLIPT was high across parameters for detecting synthetic lethality in the graph structure
within a larger dataset. The sensitivity decreases for a greater number of true positives to
detect but the specificity remains high with a low false positive rate.
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(a) Statistical evaluation (b) ROC
(c) Graph Structure (d) Statistical performance
Figure J.20: Performance of simulations including the Gαi signalling pathway.
Simulation of synthetic lethality used a multivariate normal distribution (without correlation
structure apart from the Reactome Gαi signalling pathway. Performance of SLIPT was high
across parameters for detecting synthetic lethality in the graph structure within a larger
dataset. The sensitivity decreased for a greater number of true positives to detect but the
specificity remained high with a low false positive rate.
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